The role of wild-type SOD1 in SOD1 mouse models of ALS by Bunton-Stasyshyn, RKA
1 
 
 
 
The role of wild-type SOD1 in SOD1 
mouse models of ALS 
 
 
 
 
 
 
A thesis presented in partial fulfilment of the requirements for the 
degree of Doctor of Philosophy to the University of London 
 
Rosie Kate Anna Bunton-Stasyshyn 
 
 
Department of Neurodegenerative Disease 
UCL Institute of Neurology 
University College London 
 
2 
Declaration 
I, Rosie Kate Anna Bunton-Stasyshyn, confirm that the work presented in this thesis is my own. 
Where information has been derived from other sources, I confirm that this has been indicated 
in the thesis 
  
3 
Abstract 
Amyotrophic lateral sclerosis (ALS) is the most common form of adult onset motor neuron 
disease. It is primarily sporadic, however a proportion of cases are inherited and of these ~10% 
are caused by mutations in the gene SOD1. Recent research points to a possible role for wild-
type (WT) SOD1 in ALS. This thesis addresses questions about the role of WT-SOD1 in ALS in 
the context of mouse models of ALS.  
The first set of experiments address whether pathogenically misfolded SOD1 can act in a 
“prion-like” way, recruiting WT-SOD1 into a pathogenic conformation in vivo. SOD1 transgenic 
mice were intracerebrally inoculated with homogenates prepared from central nervous system 
tissue from mouse or human which contains pathogenic SOD1. Pathology was assessed at a 
number of post-inoculation time-points to determine whether misfolding of transgenically 
expressed SOD1G93A was increased, or misfolding of transgenically expressed WT-SOD1 was 
induced.  
The project described above used transgenic mice bred onto an endogenous Sod1 null 
background because evidence from the prion field suggests that the endogenous protein could 
interfere with transmission of human misfolded SOD1. The effect of endogenous SOD1 on the 
disease phenotype of SOD1G93A transgenic mice was not known, therefore mice of 4 genotypes 
were examined: WT, Sod1-/-, Tg SOD1G93A and Sod1-/-;Tg SOD1G93A. Grip-strength and survival 
was measured. Muscle and spinal cord pathology were also examined at two time-points.  
Finally, a project to create a new mouse model of SOD1-fALS is described; a genomically 
humanised mouse with an inducible LoxP-Cre mutant/WT allele. Cloning of the targeting 
constructs was carried out using a combination of traditional restriction endonuclease cloning 
and recombineering. Finalising the constructs and embryonic stem cell targeting is underway. 
This work aims to increase our understanding of how WT-SOD1 may be involved in both 
familial and sporadic ALS and provide more accurate models SOD1-fALS.  
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Chapter 1. Introduction  
1.1 AMYOTROPHIC LATERAL SCLEROSIS  
1.1.1 Clinical Disease Course  
Amyotrophic lateral sclerosis (ALS) is the most common adult onset motor neuron disease, 
with an average onset at 62 and diagnosis at 64 (Chiò et al., 2013). It is a devastating and fatal 
disease, with patients surviving on average only 3-5-years after diagnosis with the majority of 
patients dying from respiratory failure or related complications (Valdmanis et al., 2008).  
Initial symptoms of disease include a progressive weakness of the voluntary muscles. This can 
be accompanied by, or later develop to include, upper motor neuron (UMN) signs, such as 
spasticity and increased reflex reactions, and lower motor neuron (LMN) signs, such as muscle 
wasting, reduced tone and fasciculations. In the majority of cases, ~ 70%, the first signs of the 
disease occur in the limbs, often asymmetrically. In ~25% of cases bulbar muscles are the first 
affected, causing difficulty with speech and swallowing. In a minority of cases, ~5%, the first 
symptoms are in the muscles of the trunk, often affecting breathing (Kiernan et al., 2011). In 
almost all cases (with the occasional exception of those with a very short disease course) 
symptoms of the disease progress both in terms of their severity, developing from initial 
weakness to paralysis, and also their location, spreading out from an initial focal site of onset 
through contiguous regions of the body (Fujimura-Kiyono et al., 2011). Muscles controlling 
voluntary movement are primarily affected, with those involved in functions such as eye 
movement and bladder and bowel control typically being spared (Kiernan et al., 2011).  
The hallmark of ALS is a progressive motor weakness that involves symptoms of both UMN and 
LMN dysfunction with the sparing of sensory function. There can, however, be heterogeneity 
in clinical presentation, with some cases predominating with UMN or LMN signs (Burrell et al., 
2011). Age at onset can range from mid-teens to over 90-years of age (Andersen et al., 1996; 
Gouveia et al., 2007) and although 50% of patients die within 2.5-years of onset, 15-20% will 
survive past 5-years (Talbot, 2009) and in rare cases survival has exceeded 40-years (Grohme 
et al., 2001). On the other hand, shorter disease course has been found to correlate with older 
age and body mass at onset, bulbar onset, and faster progression from the initial site of onset 
or to respiratory dysfunction (Traxinger et al., 2013; Fujimura-Kiyono et al., 2011; Chiò et al., 
2002; Magnus et al., 2002).  
While once considered a pure motor system disorder (Strong et al., 1996), it is increasingly 
apparent that ALS often includes a component of cognitive dysfunction. Recent investigation 
suggests that 51% of ALS cases also have some component of cognitive impairment, with 15% 
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reaching the diagnostic criteria for frontotemporal dementia (FTD) (Ringholz et al., 2005). 
There are several forms of FTD, but broadly it is a dementia affecting the frontal lobe function 
producing changes to personality and behaviour including disinhibition, and problems with 
fluency of speech or language comprehension (Talbot et al., 2006; Giordana et al., 2011). It is 
now clear that the ALS and FTD are often comorbid, and, as shall be discussed further in 
Section 1.1.3, they also share both genetic and neuropathological characteristics (Orr, 2011; 
Giordana et al., 2011). 
Population statistics vary, but meta-analysis of global data provides a median incidence (per 
100,000) of 1.90 and prevalence of 4.48, with incidence peaking at between 60 and 75-years of 
age (Chiò et al., 2013). Men are 1.2-1.5 times more likely to be diagnosed with ALS than 
women, although this difference decreases with age (Manjaly et al., 2010). Many attempts 
have been made to identify possible environmental risk factors for ALS; exercise, smoking, 
certain occupations, and exposure to a range of chemical have all been associated with 
increased risk of developing ALS, although definitive replicable evidence for such associations 
is currently lacking (Al Chalabi et al., 2013).  
There is no diagnostic laboratory test for ALS, nor a definitive clinical test. The Revised El 
Escorial Criteria is the standard diagnostic protocol. It involves both positive inclusion and 
negative exclusion criteria resulting in a range of diagnostic categories as summarised in Table 
1.1 (Brooks et al., 2000).  
Despite a large number of clinical trials examining the effect of over 50 compounds (Turner et 
al., 2001) there is currently only one drug treatment available for ALS, Riluzole, which can 
increase survival by only 2-3 months on average (Miller et al., 2012). Symptomatic treatment 
and palliative care are the main methods for managing the disease, with a multidisciplinary 
approach covering nutrition, physiotherapy, respiratory and pain management all being 
important to help improve and maintain quality of life (Kiernan et al., 2011; Miller et al., 
2009a; Miller et al., 2009b).  
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1.1.2 Pathophysiological Disease Course 
Underlying the progressive weakness and paralysis seen in ALS is the degeneration and death 
of both UMNs and LMNs causing denervation of skeletal muscles (Figure 1.1) (Ota et al., 2005; 
Mendonça et al., 2005; Miki et al., 2010).  
Examination of the spinal cord (SC) and brain of ALS patients using scanning technologies such 
as magnetic resonance imaging (MRI) and diffusion tensor tomography (DTI) have revealed in 
vivo correlations between the severity of atrophy and the severity of clinical disease with the 
regional distribution of atrophy also mirroring the clinical presentation disease (Branco et al., 
2013; Valsasina et al., 2007; Cohen-Adad et al., 2012; Thorns et al., 2013; Schuster et al., 
2013).  
Table 1.1 Clinical criteria for El Escorial diagnostic categories 
Clinically definite UMN signs with LMN signs in the bulbar 
region plus at least two other regions OR 
UMN and LMN signs in at least 3 spinal 
regions 
Clinically probable UMN and LMN signs in 2 spinal cord regions 
with some UMN signs rostal to LMN signs 
Clinically probable. Laboratory-
supported 
UMN and LMN signs in 1 region, OR UMN 
signs alone with EMG defined LMN signs in 2 
regions 
Clinically Possible UMN and LMN signs in 1 region OR UMN 
signs in 2 or more regions, OR LMN signs 
rostral to UMN signs 
UMN signs used for diagnosis include:  spasticity, increased muscle tone and clonus 
(rhythmic tremor like reflex in response to 
forced extension or flexion of muscle), 
bilateral facial weakness affecting the lower 
portion of the face, and spastic dysarthria 
(difficulty with speech).  
LMN signs used for diagnosis include:  muscle weakness, atrophy, fasciculations 
(uncontrollable twitching in a single muscle 
group) and flaccid dysarthria  
(Brooks et al., 2000; Economides et al., 2013; Kiernan et al., 2011; Ravits et al., 2007b; 
Wijesekera et al., 2009) 
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Post mortem examination of the LMNs also reveals a gradation of MN loss along the axis of the 
SC mirroring the spread of disease symptoms, with an average of 55% loss ranging from 8-90% 
at different levels of the LMN tract (Ravits et al., 2007a). 
Gliosis is a widespread in ALS, being reported in both dorsal and ventral horns of the SC 
(O'Reilly et al., 1995; Ota et al., 2005; Schiffer et al., 1996; McGeer et al., 2002) and in both 
motor and non-motor regions of the cortical grey and white matter (Sugiyama et al., 2013; 
 
Figure 1.1 Neuromuscular system and neuromuscular junctions 
Left panel: Upper motor neurons (UMNs), whose cell bodies reside in the motor cortex, 
synapse in the spinal cord with lower motor neurons (LMN). The axons of LMNs project 
out of the spinal cord to synapse with the muscle at the neuromuscular junction (NMJ). 
Degeneration or loss of either UMNs or LMNs results in the loss of connection between 
the motor cortex and the muscle.  
Right panel: Once inside the muscle, the LMN axon branches and each branch innervates a 
single muscle fibre. The foot plate of the axon is the pre-synaptic terminal from which 
acetylcholine is released. The end plate of the muscle fibre is the post-synaptic terminal 
and is populated with nicotinic acetylcholine receptors.  
In a healthy NMJ, the foot plate and end plate are closely aligned to ensure efficient signal 
transduction. In a degenerating NMJ the foot plate and the axon degenerate and retract, 
reducing the efficiency of signal transduction and eventually losing contact altogether.  
UMN= upper motor neuron. LMN= lower motor neuron. NMJ= Neuromuscular junction 
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Nagy et al., 1994; Kushner et al., 1991). Astrocytosis has also been detected in vivo using 
positron emission tomography (PET) techniques (Johansson et al., 2007).  
Inclusions containing TDP43 are very consistently reported in MNs and astrocytes in the 
ventral horns (Nishihira et al., 2008) and have been reported in oligodendrocytes in the SC 
(Mackenzie et al., 2007) as well as both motor and non-motor regions of the brain stem (Miki 
et al., 2010). Ubiquitin and TDP43 often co-localise in LMN inclusions (Mackenzie et al., 2007). 
Ubiquitin positive cytoplasmic, intra-neuronal inclusions are commonly reported in the MNs of 
the brain stem and SC and can take the form of compact, round inclusions or filamentous 
“skein like” inclusions (Ota et al., 2005; Mackenzie et al., 2007; Leigh et al., 1991). p62 
immunoreactivity is also present in many ubiquitinated inclusions (Mizuno et al., 2006).  
Other neuropathological inclusions of note include: neurofilament heavy chain (NFh) 
accumulations in spinal MN cell bodies and axons (Mendonça et al., 2005); phosphorylated 
neurofilament (PNF) inclusions, often co-localising with ubiquitin (Troost et al., 1992; 
Takahashi et al., 1997); Lewy body-like hyaline inclusions (LBHI), which are round eosinophilic 
inclusions, often ubiquitin positive and found in the LMNs (Sasaki et al., 2010); astrocytic 
hyaline-inclusions, of a similar nature to LBHI but present in astrocytes particularly in long 
surviving ALS patients (Kato et al., 1997); Bunina bodies, which are small (1-5 µm) eosinophilic 
granules occasionally co-localising with TDP43 (Mori et al., 2010; Ota et al., 2005).  
1.1.3 Genetics 
When Charcot first described ALS in 1873, he stated that it was never an inherited disease and 
even used this as a way of differentiating between ALS and spinal muscular atrophy (cited in 
(Andersen et al., 2011)). It is now, however, firmly established that although the majority of 
cases of ALS are sporadic (sALS) a significant percentage is heritable or familial (fALS). This 
percentage has been reported from as low as 0.8% up to 23%, with suggestion that even this 
may be an underestimate (Andersen et al., 2011). The disease phenotype of fALS and sALS are 
often reported as being indistinguishable (e.g. (Lattante et al., 2012)).  
SOD1 was the first gene in which ALS causing mutations were identified, in 1993 (Rosen et al., 
1993). Mutations in SOD1 cause 12-24% of fALS, typically showing an autosomal dominant 
pattern of inheritance, and are also present in up to 7% of sALS (Valdmanis et al., 2008; 
Pasinelli et al., 2006). Many other genes have subsequently been identified as causative of ALS 
when mutated, with varying levels of prevalence, and are summarised in Table 1.2. Several risk 
loci have also been identified and it was calculated that genetic determinants are responsible 
for 60% of the risk of developing ALS with the remaining 40% being environmental (Al Chalabi 
et al., 2010).  
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In many cases mutation specific neuropathologies are seen in fALS patients. For example in 
mutant SOD1 cases, proteinaceous SOD1 aggregates are often present (Kato et al., 2000) or 
when TARDBP or FUS are mutated their protein products are found to mislocalise away from 
the nucleus and into the cytoplasm (as reviewed by (Blokhuis et al., 2013)). In the case of 
repeat expansions in C9orf72, RNA aggregates and proteinaceous aggregates containing 
atypical transcription/translation products occur (Mackenzie et al., 2014).  
The previously mentioned link between ALS and FTD is further cemented when considering the 
genetics behind these disorders. As is summarised in Table 1.2, many of the genes mutated in 
ALS are also mutated in FTD. In some families mutation carriers may be diagnosed with ALS, 
FTD or comorbid ALS-FTD, and although the diseases affect different areas of the nervous 
system, the pathologies are similar (Fecto et al., 2011; Ferrari et al., 2011).  
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Table 1.2 Genes causative of ALS 
The table is arranged by date of publication. AD= autosomal dominant. AR= autosomal recessive. * Year gene (or linkage) was published 
Gene 
symbol 
Protein name 
Year 
* 
Chromosomal 
locus 
Inheritance 
Links to 
FTD?  
Frequency Main pathway implicated Ref 
SOD1 
Superoxide dismutase 1 / 
Cu,Zn superoxide dismutase 
1993 21q22 AD no 20% FALS Oxidative stress 1 
ALS2 Alsin 2001 2q33 AR no Rare- juvenile 
Endosomal trafficking and cell 
signalling 
2 
  Unknown 2003 20ptel–p13 AD no Rare Unknown gene 3 
SETX Senataxin 2004 9q34 AD no Rare- juvenile RNA processing 4 
VAPB 
Vesicle-associated membrane 
protein-associated protein B 
2004 20q13.3 AD no Rare 
Endosomal trafficking and cell 
signalling 
5 
TARDBP 
TAR DNA-binding protein 43 
(TDP43) 
2008 1p36.2 AD yes 
5% FALS, more in 
some groups 
RNA processing 6 
FUS Fused in sarcoma  2009 16p11.2 AD yes 
4–5% FALS- 
juvenile 
RNA processing 7, 8 
DAO D-amino acid oxidase 2010 12q24 AD no Rare Glutamate excitotoxicity 9 
OPTN Optineurin 2010 10p13 AD and AR no Rare 
Endosomal trafficking and cell 
signalling 
10 
VCP Valosin-containing protein 2010 9p13–p12 AD yes 1% of FALS  Ubiquitin/protein degradation 11 
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Gene 
symbol 
Protein name 
Year 
* 
Chromosomal 
locus 
Inheritance 
Links to 
FTD?  
Frequency Main pathway implicated Ref 
SIGMAR1 σ Non-opioid receptor 1 2010 9p13.3 AD and AR yes 
Rare- adult and 
juvenile 
  12, 13 
SPG11 Spatacsin 2010 15q15–q21 AR no Rare- juvenile   14 
UBQLN2 Ubiquilin 2 2011 Xp11 X-linked yes   Ubiquitin/protein degradation 15 
C9orf72 
Chromosome 9 open reading 
frame 72 
2011 9q21–q22 AD yes 
22.5-46% FALS, 
21% of SALS 
  16, 17 
PFN1 Profilin 1 2012 17p13.2 AD no Rare Cytoskeleton/ transport 18 
hnRNPA1 
Heterogenous nuclear 
ribonucleoprotein A1 
2013 12q13.3 AD no Rare RNA processing 19 
1- (Rosen et al., 1993); 2- (Yang et al., 2001); 3-(Sapp et al., 2003); 4- (Chen et al., 2004); 5- (Nishimura et al., 2004); 6- (Sreedharan et al., 2008); 7- (Kwiatkowski et 
al., 2009); 8- (Vance et al., 2009); 9- (Mitchell et al., 2010); 10- (Maruyama et al., 2010); 11- (Johnson et al., 2010a); 12- (Luty et al., 2010); 13- (Al-Saif et al., 2011); 
14- (Orlacchio et al., 2010); 15- (Deng et al., 2011); 16- (Renton et al., 2011); 17- (DeJesus-Hernandez et al., 2011); 18- (Wu et al., 2012); 19- (Kim et al., 2013) 
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1.2 SOD1-FALS  
Over 150 mutations in SOD1 have now been identified in ALS cases (ALS Online Database, 
ALSOD. http://alsod.iop.kcl.ac.uk/). As illustrated in Figure 1.2, mutations are distributed 
throughout the protein sequence. The majority of the mutations are missense point mutations 
(Turner et al., 2008), however silent point mutations, deletions, insertions and mutations in 
non-coding sequence have all been identified (e.g. (Hu et al., 2011; Zinman et al., 2009; 
Valdmanis et al., 2009; Birve et al., 2010; Zu et al., 1997)).  
Mutations in SOD1 are thought to cause disease via an as yet undefined dominant gain of 
function rather than a loss of function; although some mutations reduce the function of SOD1, 
many have little or no effect and some have even been found to increase the activity of the 
enzyme (reviewed by (Saccon et al., 2013)) and mice expressing the mutant human protein 
develop an ALS like disease phenotype, while Sod1 null mice do not recapitulate the disease 
(Shefner et al., 1999).  
SOD1-fALS has been described as very similar to sALS in terms of site of onset, progression, 
duration and cause of death (Synofzik et al., 2010). It has been suggested that SOD1-fALS cases 
are less likely to develop the cognitive deficits sometimes seen in sALS (Wicks et al., 2009) 
however cases of SOD1-fALS concurrent with both cognitive decline and diagnosis with ALS-
FTD have been reported in the literature (e.g. (Masè et al., 2001; Battistini et al., 2005; Katz et 
al., 2012)).  
The neuropathology seen in SOD1-fALS is also similar to that of sALS (Nakamura et al., 2014; 
Kato, 2008; Hineno et al., 2012; Hineno et al., 2012; Kato et al., 1996; Tan et al., 2007), 
although some distinctions have been made; neuronal and astrocytic SOD1 pathology is 
ubiquitously reported in SOD1-fALS but often reported as absent in non-SOD1-fALS and sALS 
(Kato et al., 1996; Kato, 1999; Bruijn et al., 1998; Hineno et al., 2012; Kato et al., 2000; Kato et 
al., 2001b; Shibata et al., 1996b; Shibata et al., 1996a). Bunina bodies are also reported as 
absent in SOD1-fALS (e.g. (Nakamura et al., 2014; Shibata et al., 1996a; Tan et al., 2007)). The 
absence of TDP43 pathology in SOD1-fALS has been described as a defining difference 
between SOD1-fALS and non-SOD1-fALS/sALS (Mackenzie et al., 2007; Tan et al., 2007), 
although cases of TDP43 pathology in SOD1-fALS cases have been reported (Okamoto et al., 
2011; Maekawa et al., 2009; Sumi et al., 2009).  
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Figure 1.2 ALS SOD1 mutations 
The amino acid sequence of SOD1 is shown, with exons and introns of the corresponding gDNA sequence indicated. ALS causing disease mutations are annotated.  
Only variations that are predicted to affect the amino acid sequence of the protein are included and pathogenicity has not been shown for all. ALSOD mutations, 
InsAexon2 and E133del are the same as mutations V29insA and E133delGAA, respectively, and so have not been annotated separately. Similarly, we believe 
D125TT to be L126delTT and E133insTT to be E132inTT. Information about highlighted structural elements is from (Wang et al., 2006a). Mutations were collected 
from ALS online database (ALSOD, http://alsod.iop.kcl.ac.uk), and additional references (Pramatarova et al., 1994) and (Kobayashi et al., 2012).  
†= Locations where two nucleotide changes results in the same amino acid substitution; *= Frame shift mutations which result in a premature stop codon; §= 
compound heterozygotes. Modified from Saccon et al., (2013). 
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1.2.1 SOD1 
The human SOD1 gene is 9,310 base pairs (bp) long and resides on human chromosome 21, 
q22.11. The gene has 5 exons and is transcribed into a 966 bp mRNA transcript which is 
translated into a 154 amino acid (aa) protein (Figure 1.3). The protein is highly conserved 
sharing 73% aa sequence across mammals (Wang et al., 2006a).  
A broad range of transcription factor binding sites have been mapped to between -1,200 and 
+1 bp from the transcriptional start site of the SOD1 gene (Miao et al., 2009; Park et al., 2002; 
Yoo et al., 1999a; Romanuik et al., 2009; Yoo et al., 1999b). There are also 2 functional 
transcripts differing in their 3’ untranslated regions (UTR), with the longer transcript directing 
higher expression levels (Sherman et al., 1983; Kilk et al., 1995). Protein expression levels in 
vivo, however, appear remarkably stable within tissues across time and in response to 
environmental insult (Miao et al., 2009; Radyuk et al., 2004).  
SOD1 is ubiquitously expressed in all cell types (Leitch et al., 2009; Bordo et al., 1994) and 
within the central nervous system (CNS) it is particularly abundant in the MNs of the SC 
(Lindenau et al., 2000). Within the cell SOD1 is primarily located in the cytosol (Crapo et al., 
1992) but is also found on the outer membrane and inter-membrane space (IMS) of the 
mitochondria (Sturtz et al., 2001; Kawamata et al., 2010).  
Its canonical role in the cell, where it functions as a 32 kilodalton (kDa) homodimer, is as an 
anti-oxidant enzyme, catalysing the conversion of toxic reactive oxygen species (ROS) to 
hydrogen peroxide and oxygen, guarding the cell against oxidative stress (Zelko et al., 2002). 
Several post-translational modifications (highlighted in Figure 1.3d) are needed for SOD1 to 
become functional; the nascent protein must bind a structurally important zinc ion and then, 
interacting with copper chaperon for SOD1 (CCS), bind an enzymatically important copper ion 
and form an intra-subunit disulphide bond before dimerising (Banci et al., 2012). Once in its 
fully mature dimeric state, SOD1 is a remarkably stable protein with a half-life of unfolding of 
approximately 200-years (Rumfeldt et al., 2009).  
Additional functions of SOD1 have also been proposed; Reddi and Culotta (2013) have 
suggested that SOD1 may act as an O2/glucose dependent regulator of respiration via 
hydrogen peroxide (H2O2) dependent stabilisation of casein kinase 1 gamma (CK1γ). Homma et 
al., (2013) have suggested that SOD1 may act as a zinc sensitive endoplasmic reticulum (ER) 
stress activator, by binding to Derlin-1 when zinc levels are reduced. Zhu et al., (2008) have 
also proposed that SOD1 may have a role in nitrotyrosine production in the liver.  
The effects of ALS mutations on the biological function and biophysical properties of SOD1 
along with posited pathogenic mechanisms will be discussed in more detail later in Section 1.5.  
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1.3 MODELLING GENETIC DISEASES IN MICE  
1.3.1 Why Mice?  
Mice are currently the most genetically pliable organism available to researchers and have 
often been the species in which techniques to manipulate the genome have been pioneered. 
They were the first mammalian species into which researchers introduced exogenous genetic 
sequence (Jaenisch et al., 1974), and the first species with embryonic stem cells (ESC) 
successfully cultured in vitro, in 1981 (Martin, 1981; Evans et al., 1981). It would not be until 
2008 that another species of ESCs, that of the rat, would be successfully cultured (Buehr et al., 
2008; Li et al., 2008). As shall be discussed, the availability of mouse ESCs (mESCs) was 
essential in the development of targeted genetic engineering technologies.  
While it is now possible to genetically manipulate other mammalian model organisms, such as 
rats, pigs and even non-human primates (e.g. (Niu et al., 2014; Prather et al., 2008; Huang et 
al., 2011)), the mouse is still the most genetically tractable of mammalian models and is 
relatively cheap and fast to work with. Compared to some even cheaper and faster model 
organisms, such as the fruit fly or zebra fish, the genetic and physiological similarities between 
 
Figure 1.3 SOD1 chromosomal location, genomic, mRNA and protein structure 
(a) Chromosomal location of SOD1 on human chromosome 21 q22.11. (b) Structure of the 
9,310 bp SOD1 gene including a 1.2 kb upstream encompassing the promoter region. Exons 
are red, URTs are yellow. (c) Structure of the 966 bp SOD1 mRNA. Coding regions are red 
and UTRs are yellow.  
(d) 3-dimensional structure of dimeric SOD1. Cysteines 6 and 146 which form the intra-
subunit bond are highlighted in purple. Residues involved in copper binding are orange and 
zinc binding are yellow. Histidine 63, involved in both copper and zinc binding is shown in 
magenta. Zinc and copper ions are grey and orange respectively. Information about 
highlighted structural elements is from Wang et al., (2006a).  
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humans and mice make the mouse a more attractive model for many diseases, particularly 
those effecting complex systems such as the nervous system.  
The genetic mouse resources now available to researchers is vast: over 1,200 human diseases 
have at least 1 mouse model available for them and there are over 35,500 searchable mutant 
alleles listed on the Jackson Laboratories Mouse Genome Informatics website 
(www.informatics.jax.org Feb 2014).  
The following section will describe some of the main techniques in the ever expanding tool box 
for manipulating the mouse genome.  
1.3.2 Tool Box for Manipulating the Mouse Genome 
1.3.2.1 RANDOM MUTAGENESIS AND TRANSGENE INSERTIONS  
One of the earlier techniques for manipulating the mouse genome was the use of random 
mutagenic agents, such as N-ethyl-N-nitrosourea (ENU), to mutagenize a male mouse resulting 
in point mutations at a near random distribution every 1-1.5 kb within the sperm produced by 
the male (Acevedo-Arozena et al., 2008). The offspring of such mutagenized males can then 
either be screened phenotypically or sperm banks can be made from the male offspring which 
can then be screened for mutations in a particular gene of interest and the sperm used for in 
vitro fertilisation. Although these techniques have been highly useful in analysing gene 
function and producing novel disease models there is no control over the site or sequence of 
the mutations.  
Insertional transgenesis allows a specific genetic sequence of interest to be introduced into the 
mouse genome. In 1980, Gordon et al., created the first transgenic mice using pronuclear 
injection of purified DNA into oocytes, which were then re-implanted into pseudo-pregnant 
females. The exogenous DNA was stably integrated into the genomes of a number of the 
resultant pups. Although previously transgenic mice had been produced by injecting viruses 
into mouse blastocysts (Jaenisch et al., 1974; Jaenisch, 1976) this was the first example of 
confirmed integration of purified DNA. The following year a number of papers revealed that 
the techniques could produce transgenic mice not only capable of germ-line transmission of 
the transgenic DNA to their offspring (Gordon et al., 1981; Costantini et al., 1981) but also that 
transgenes constructed from exogenous mammalian genes were expressed, producing 
functional proteins, and could be carried through successive generations (Wagner et al., 
1981a; Wagner et al., 1981b).  
Theoretically, any DNA sequence that can be cloned can be used as a transgene vector, the 
main limiting factor being the amount of DNA that can be maintained in a plasmid. Because of 
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the size limit of traditional plasmid backbones transgenes have often been constructed using a 
promoter sequence followed by the coding DNA (cDNA) sequence of the gene of interest, into 
which desired mutations can be added using in vitro mutagenesis .  
Using this technique the injected DNA is integrated into the genome of a number of the pups 
at a random genomic locus. If the injection is carried out at the ideal developmental stage, the 
single cell oocyte, every cell in the resultant pups should contain the insertion, including the 
germ-cells, however in practice, not every pup may be capable of germ-line transmission. 
Concatemerisation of the transgene often occurs, resulting in transgene arrays of up to 1000 
copies (Lo, 1986), which can effect expression levels, although a direct correlation between 
transgene copy number and expression level is not always apparent (Epstein et al., 1987). 
Bacterial artificial chromosome (BAC) and yeast artificial chromosome (YAC) transgenes go 
some way to alleviate this potential problem as BAC/YACs are more likely to integrate as a 
relatively low copy transgene array (Chandler et al., 2007). The integration site of random 
insertional transgenics will also differ between different lines and this can affect the resultant 
phenotype due to the chromatin environment of the transgene and the potential of disrupting 
genes around the site of insertion (e.g. (Epstein et al., 1987; Nishioka et al., 2005)).  
1.3.2.2 THE ADVENT OF GENE TARGETING 
The convergence of in vitro mESC culture and two further discoveries opened the gateway to 
new techniques for targeted manipulation of the mouse genome (Martin, 1981; Evans et al., 
1981). The first discovery was that homologous recombination (HR) between exogenous DNAs 
happens at a relatively high frequency in mammalian cells (e.g. (Folger et al., 1982; 
Kucherlapati et al., 1984; Lin et al., 1984; Miller et al., 1983; de Saint Vincent et al., 1983; 
Subramani et al., 1983)) and that this property can be harnessed to recombine exogenous 
plasmid DNA with an endogenous chromosomal locus in a targeted fashion, called “gene 
targeting” (e.g. (Folger et al., 1984; Lin et al., 1985; Smith et al., 1984; Smithies et al., 1984; 
Thomas et al., 1986)). The second was that cultured mESCs could be introduced into 
blastocysts to produce chimeric pups composed of a mixture of host and injected donor cells 
(Bradley et al., 1984) and crucially, mESCs that have undergone genetic manipulation could 
retain their pluripotency and participate in the formation of chimeric pups (Robertson et al., 
1986; Gossler et al., 1986). In 1989 these technological advances were brought together and 
the first gene targeted mice were born (Thompson et al., 1989; Zijlstra et al., 1989; 
Schwartzberg et al., 1989).  
Using in vitro recombinant DNA engineering, a targeting construct can be made with homology 
arms (regions of homology to the targeted chromosomal loci) flanking a cassette containing 
the desired modification, as shown in Figure 1.4. The targeting construct is introduced into the 
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mESCs, typically by electroporation, and cells are selected by antibiotic resistance conferred by 
a cassette included in the construct. In the majority of cases the targeting construct will be 
integrated randomly, as in random integration transgenesis, however in some cells the innate 
HR machinery facilitates the targeted integration of the construct. Once correctly targeted 
mESC clones have been identified they can be used for blastocysts injection. The chimeric 
offspring then need to be mated to check for integration of the donor mESCs into the germ-
cells, thus producing a new line of germ-line gene targeted mice.  
This method of gene targeting can be used to create replacements (Figure 1.4a), insertions 
(Figure 1.4b), deletions (Figure 1.4c) and point mutations (Figure 1.4d). Depending on the 
design of the targeting construct, such mutations are classed as knock-outs (KO) or knock-ins 
(KI); KOs disrupt a gene’s function either by disrupting its transcription or by changing the 
sequence such that the mRNA is not transcribed into a functional protein. This can be done by 
deleting a portion of the gene, or by inserting sequence to disrupt it. KIs change the gene 
product and can range from single point mutations to entire gene replacements (e.g. 
(Rathinam et al., 2011)). These strategies have an advantage over traditional random 
integration transgenesis as the inserted/edited sequence will reside in the endogenous locus 
within the natural chromatin environment of the gene and under the influence of the 
endogenous promoters and other cis factors.  
HR targeting has also been used for the targeted insertion of transgenes into surrogate 
genomic loci. Loci with an open chromatin structure where disruption is known to cause 
minimal unwanted secondary effects are used as surrogates, helping to overcome some of the 
potential pitfalls of traditional transgenesis. The Rosa26 and Hprt (hypoxanthineguanine 
phosphoribosyltransferase) loci are two common examples (e.g. (Freyer et al., 2013; D'Acunzo 
et al., 2014; Heaney et al., 2004)).  
1.3.2.1 SITE SPECIFIC RECOMBINASES 
Site specific recombinases (SSR) encompass a number of enzymes that facilitate the 
recombination of DNA at specific SSR recognition motifs (SSR-RM). There are several classes of 
SSRs, and the most commonly used in mouse genetic engineering, both in vitro and in vivo, are 
the tyrosine simple/bidirectional recombinases (for brevity, simply referred to as SSRs in the 
following text) (Hirano et al., 2011). The 2 most widely used SSRs are Cre (causes 
recombination), which recognises LoxP (locus for crossing over (x), P1) sites (Austin et al., 
1981; Sternberg et al., 1981), and FLP (flippase), which recognises FRT (FLP recombination 
target) sites (McLeod et al., 1986).  
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As illustrated in Figure 1.5, SSRs facilitate directional recombination between SSR-RMs. 
Excision/insertion and inversion reactions (Figure 1.5 a and b) are achieved by the 
recombination of 2 SSR-RMs. For cassette exchange (Figure 1.5c), 4 SSR-RMs are used; 2 
flanking the target locus and 2 flanking the donor cassette. Two cross-over events, one at 
either side of the target and donor are required for successful cassette exchange (Bouhassira 
et al., 1997; Economides et al., 2013; Oberdoerffer et al., 2003; Seibler et al., 1997; Wallace et 
al., 2007).  
 
Figure 1.4 Homologous recombination gene targeting 
Targeting strategies are shown for making replacements (a), insertions (b) and deletions (c) 
and creating point mutations (c) (a variation on replacements) by homologous 
recombination based gene targeting. Upstream and downstream homology arms are 
shown in red and blue, respectively. Original sequence to be changed is yellow. Exogenous 
sequence is green.  
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Figure 1.5 Site-specific recombinase systems 
Site specific recombinases (SSR) recognise a specific SSR-recognition motif (SSR-RM) 
facilitating recombination between SSR-RMs.  
(a) For excision (downward reaction) 2 SSR-RMs arranged in the same orientation flanking 
the cassette. Recombination between SSRs excises the cassette, leaving a single SSR-RM in 
its place and a circularisation of the excised cassette with a single SSR-RM. In the reverse 
(upward) reaction, insertion results from the recombination of a single SSR-RM at the 
target location and the SSR-RM present on the circular donor. In this case an excess of the 
donor vector is required to push the balance of the reaction towards integration and away 
from excision (Seibler et al., 1997).  
(b) For inversion 2 SSR-RMs are arranged in opposing orientation, directing the inversion 
of the flanked cassette within the original locus. Using normal SSR-RMs this reaction is 
reciprocal, however, asymmetrical mutant SSR-RMs have been designed which strongly 
favour unidirectional recombination. Two mutant SSR-RMs, m1 and m2, will recombine to 
produce one wild-type (purple) and one double mutant (pink m1/2) SSR-RM, which have 
reduced recombination efficiency, reducing the likelihood of a reciprocal, upward, 
recombination (Oberdoerffer et al., 2003; Turan et al., 2011; Economides et al., 2013).  
(c) For cassette exchange the genomic locus to be replaced is flanked by 2 SSR-RMs, as is a 
donor cassette and 2 cross-over events, one on either side, are required for successful 
exchange.  
(Continued.... ) 
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In order to use SSR systems for targeting in mESCs it is first necessary to introduce the SSR-
RMs into the genome of the mESC using HR gene-targeting. Once in place however, SSR 
systems are more efficient than HR in mESC targeting, particularly when large stretches of DNA 
(>100 kb) are manipulated (Wallace et al., 2007) and mESC lines with LoxP or FRT sites at the 
Rosa26 locus are also available for streamlined targeted insertional transgenesis (Tchorz et al., 
2012; Sandhu et al., 2011). The construction of targeting vectors is also easier for SSR targeting 
as rather than long homology arms, the short (~34 bp) SSR-RMs are all that is needed for 
targeting. One drawback of this system is that SSR-RMs are left within the mouse genome, 
either at the site of excision, or flanking the region which has been 
inserted/inverted/exchanged. For this reason care needs to be taken with their positioning to 
ensure that off target effects are not caused by their presence within coding/regulatory 
sequence.  
1.3.2.2 CONDITIONAL AND INDUCIBLE CASSETTES  
Conditional expression of a transgene can be achieved by engineering the transgene vector to 
contain the coding sequence of a gene under the control of a tissue specific promoter. Using 
this technique mutant SOD1 transgenic mice have been made with expression directed 
specifically to muscle, using the myosin light chain or the chicken skeletal muscle α-actin 
promoter (Dobrowolny et al., 2008; Wong et al., 2010), or specifically to neurons, using the 
Thy1.2 promoter (Jaarsma et al., 2008).  
Inducible transgene expression is also possible. For example, promoter systems have been 
designed which require a small molecule, such as tetracycline, to dimerise with the 
transcription factor elements to allow transcription, or the reverse, where small molecules 
block transcription (Pollock et al., 2002; Rivera, 1998). Animals can be dosed with these 
molecules in their drinking water and thus expression can be induced or halted at any time.  
Conditional or inducible transgenes directing the expression of SSRs can be combined with 
mice with engineered genomes containing SSR-RM driven “DNA machinery” to allow 
conditional/inducible editing of the mouse genome in vivo. As an illustrative example of how 
such machinery works, a Knock-Out Mouse Project (KOMP) KO-first strategy as illustrated in 
Using normal SSR-RMs, the likelihood of recombination between any pair of SSR-RMs 
would be equally likely, potentially resulting in excisions as shown in a. The use of 
heterospecific SSR-RMs, which have been mutated such that they will only recombine with 
a matching mutant (labelled A (dark blue) and B (light blue)) allows recombination to be 
directed specifically to exchange of the cassettes (Wallace et al., 2007).  
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Figure 1.6. KOMP is currently attempting to produce KO alleles for all known mouse genes, and 
a number of these are being produced using this strategy. Homologous recombination gene 
targeting is used to insert LoxP sites flanking a “critical exon” without which the gene product 
will become non-functional. Upstream of the 5’ LoxP site is an FRT flanked cassette containing 
a reporter and antibiotic selection, for use when targeting the mESCs, with a strong stop signal 
to halt further transcription. In its initial state, Figure 1.6a, the allele is a functional KO as the 
normal coding sequence of the gene is disrupted by the reporter/selection cassette. Upon 
expression of FLP, the reporter/selection cassette is excised, restoring normal transcription of 
the gene as shown in Figure 1.6b. Upon subsequent expression of Cre, the “critical exon” is 
excised disrupting the normal coding sequence of the gene and resulting in a function KO as 
illustrated in Figure 1.6c. Other examples of how SSR-RMs can be used for in vivo excision or 
inversion to switch alleles are shown in Figure 1.7.  
 
 
 
 
Figure 1.6 Knock-Out Mouse Project (KOMP) conditional knock-out first allele 
LoxP sites flank a critical exon which is essential for the production of a functional gene 
transcript and an FRT flanked reporter cassette with a stop signal is positioned upstream. 
In the initial configuration (a) the allele is a functional KO as expression is halted after the 
reporter. Upon expression of FLP recombinase the reporter cassette is excised (b) restoring 
gene function. Subsequence expression of Cre recombinase excises the critical exon (c) 
resulting in a non-functional transcript and a functional KO allele. (KOMP allele information 
was from https://www.komp.org/alleles.php).  
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Figure 1.7 Allele switching 
Two alternative methods for allele switching are described.  
Allele switching by excision: Two alternative alleles (a and b) are arranged in series in the 
same orientation downstream of a promoter, permitting transcription of allele a. Allele a is 
flanked by site-specific recombinase recognition motifs (SSR-RMs) also in the same 
orientation. Upon expression of the appropriate site-specific recombinase (SSR) the first 
allele is excised, permitting expression of allele b.  
Allele switching by inversion: Two alternative alleles (a and b), arranged in series in reverse 
orientation and flanked by 2 SSR-RMs, also in reverse orientation, are positioned 
downstream of a promoter allowing transcription of allele a. Upon expression of the 
appropriate SSR, the flanked sequence is inverted, positioning allele b downstream of the 
promoter and permitting its expression.  
SSR= site-specific recombinase; SSR-RM= site-specific recombinase recognition motif.  
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1.3.2.1 ENHANCING TARGETING WITH ENGINEERED NUCLEASES 
Engineered nucleases are a new class of tool for genome editing and include zinc finger 
nucleases (ZFN) (Hauschild-Quintern et al., 2013), transcription activator-like effector 
nucleases (TALENS) (Feng et al., 2013), and the clustered regularly interspaced short 
palindromic repeats (CRISPR) –Cas9 systems (Ran et al., 2013).  
There are differences between the various engineered nucleases, however the basic 
methodology and their application is the same; the nucleases are engineered to target a 
specific genomic locus where they produce a double stranded DNA break (DSB). DSBs are 
repaired via 2 major pathways; non-homologous end joining (NHEJ) or HR. Repair via NHEJ 
frequently results in small insertions or deletions (Bogdanove et al., 2011) at the cut site, 
which can result in a functional KO by causing a frame shift in the coding sequence (Jones et 
al., 2014). Alternatively, combining targeted DSBs with HR gene targeting can increase the 
efficiency of targeted integration, for example when used in conjunction with ZFNs, HR 
targeting has been reported at 100,000 times increased efficiency (Gaj et al., 2013; Hauschild-
Quintern et al., 2013).  
1.3.2.2 REFINEMENTS IN IN VITRO DNA ENGINEERING  
The bedrock of molecular cloning is the use of restriction endonucleases (RE) and DNA ligases 
to “cut and paste” fragments of DNA between plasmids and these techniques are now 
standard in labs the world over. A major problem with these techniques is that they depend 
upon the presence of unique RE sites and manipulations are limited by their locations. Because 
of this, it is often necessary to include extraneous sequence when designing a vector and this 
could have unintended/uncontrolled functional repercussions.  
Recombineering (recombination-mediated genetic engineering) harnesses the HR pathway of 
DNA repair, in a similar way to HR gene-targeting, to recombine DNA elements in vivo in 
Escherichia coli (E.coli) allowing precision manipulation of DNA free from the constrains of RE 
site location.  
Recombineering uses short (from ~50 bp) regions of homology between a linear vector and a 
resident plasmid to recombine the two and can be used to mutagenize a plasmid recipient, or 
subclone sequence from a plasmid donor, as shown in Figure 1.8. Recombineering is 
independent of the endogenous HR pathway and instead depends on a set of proteins which 
can be expressed either from a transiently transformed plasmid or a cassette stably integrated 
into the E.coli genome. For illustrative purposes the E. coli λ phage Red/ET system (Gene 
Bridges) will be described and is illustrated in Figure 1.9. Several phage or prophage derived 
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systems have been developed which rely on orthologous sets of proteins, although not all are 
expressed in all systems.  
The protein Redα (also called exo, and equivalent to RecE in prophage systems) is a 5’-3’ 
exonuclease. It digests blunt ended linear double stranded DNA (dsDNA) leaving 3’ single 
stranded DNA (ssDNA) overhangs, as shown in Figure 1.9b, and is required for recombineering 
with dsDNA donors (Hill et al., 1997).  
 
 
Figure 1.8 Recombineering strategies 
Strategies are illustrates for engineering deletions (a), insertions (b) or substitutions (c) in a 
resident target plasmid, or for subcloning out of a resident plasmid (d) by recombineering 
in E.coli. Upstream and downstream homology arms are shown in red and blue, 
respectively.  
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Redβ (also called bet, and is equivalent to RecT in prophage systems) is a ssDNA binding 
protein which binds to these ssDNA overhangs, protecting them from degradation, as shown in 
Figure 1.9c. Redβ also promotes annealing to complementary ssDNA (Karakousis et al., 1998; 
Muniyappa et al., 1986), and in some situations may promote strand exchange between a 
dsDNA target and bound ssDNA (Muniyappa et al., 1986; Karakousis et al., 1998). Thus Redβ 
promotes the recombination between a liner donor vector and its plasmid target.  
A third protein, Gam, blocks the dsDNA exonuclease activity of the endogenous RecBCD 
protein which, if not blocked, would degrade the linear DNA donor. The use of recBCD null 
E.coli is undesirable as these mutants have reduced viability (Friedman et al., 1986).  
The RecA protein is also expressed in the Red/ET system. RecA is an endogenous E.coli protein, 
but RecA null mutants are usually used for propagation of BACs due the high level of unwanted 
background recombination that constitutive expression can cause (Hill et al., 2000; 
Swaminathan et al., 2001). RecA binds ssDNA overhangs, in conjunction with Redβ, and 
facilitates strand invasion into homologous dsDNA increasing the HR efficiency, as shown in 
Figure 1.9d. Targeted HR can also occur in the absence of RecA, however efficiency is reduced 
and thought to depend on plasmid replication for exposing ssDNA on the target plasmid (Court 
et al., 2002; Wang et al., 2006b; Maresca et al., 2010). The exact mechanisms of λ Red 
recombination have not yet been elucidated, but it has been suggested that Redα may 
completely digest dsDNA donors to ssDNA intermediates either before or during the 
complementation to homologous sequence (Mosberg et al., 2010; Maresca et al., 2010).  
The expression of the recombineering proteins must be strictly controlled to reduce unwanted 
recombination events during plasmid/BAC propagation and the Red/ET plasmid (Figure 1.10) 
contains several safeguards against unwanted transcription; the pBAD promoter which 
controls expression of the Red/ET proteins and requires L-arabinose to be added to the culture 
medium to induce expression (Guzman et al., 1995). Secondly, the plasmid replication of 
origin, oriR101, is dependent on the temperature sensitive RepA protein (also expressed from 
pRed/ET) for replication. Temporarily raising the temperature from 30 °C to 37-43 °C makes 
RepA dysfunctional and the plasmid is quickly lost during cell replication (Miller et al., 1995), 
further closing the window of potential expression.  
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Figure 1.9 Red/ET recombineering 
(a) a linear double stranded DNA (dsDNA) donor vector comprised on homology arms (red) 
flanking a desired substitution (green) is introduced into E.coli containing a target plasmid.  
 
44 
 
 
 
(b) Redα creates single stranded DNA (ssDNA) overhangs via its 5-3’ exonuclease activity.  
(c) Redβ binds to the ssDNA overhangs, protecting it from degradation. RacA also binds the 
ssDNA overhangs.  
(d) Redβ promotes annealing if the bound ssDNA to complementary ssDNA during 
replication or when homologous ssDNA is exposed by partial denaturation of dsDNA. RecA 
facilitates strand invasion of its bound ssDNA into homologous dsDNA.  
(e) facilitated by both Redβ and RecA, the donor vector is incorporated into the target 
plasmid.  
(f) upon subsequent replication of the plasmid within the host E.coli, the modified DNA is 
propagated.  
ssDNA= single stranded DNA; dsDNA= double stranded DNA 
 
Figure 1.10 pRed/ET 
The pRed/ET (Gene Bridges) plasmid contains two safeguards against ectopic expression of 
the Red/ET proteins. gam, redβ, redα, and recA are all under transcriptional control of the 
L-arabinose inducible pBAD promoter. The plasmid origin of replication, oriR101, is 
dependent on expression of the temperature sensitive RepA; by raising the temperature to 
37-43°C, RepA becomes dysfunctional and the plasmid can no longer replicate and 
propagate during cell division.  
(Plasmid diagram taken from http://www.genebridges.com/) 
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Oligo recombineering, which uses ssDNA oligonucleotide (oligo) donors, appears to be affected 
primarily by the annealing of the oligo to the lagging strand of the replication fork, with the 
oligo acting as an Okazaki fragment during DNA extension. This process only requires the Redβ 
protein and can occur independent of RecA (Ellis et al., 2001; Maresca et al., 2010; Li et al., 
2003). Oligo recombineering is particularly efficient when the oligo is complementary to the 
lagging strand of the replication fork with reports of point mutations being correctly inserted 
in over 1% of unselected surviving cells and 24 bp insertions having a success rate of over 0.7% 
(Swaminathan et al., 2001).  
For larger modifications or increased efficiency it is desirable to include a selectable marker 
with the modifications in order to reduce the number of clones it is necessary to screen. When 
subcloning, this can be done by selection for the antibiotic resistance present on the backbone 
of the subcloning vector, as shown in Figure 1.8d. When a resident plasmid/BAC is modified, 
an antibiotic resistance cassette may be inserted for selection at the same time as the 
modification is made, however, as shown in Figure 1.11a, this can cause a disruption in the 
desired sequence. Figure 1.11b shows a method using SSRs to remove the selection cassette 
leaving a single SSR-RM in its place and Figure 1.11c shows a 2-step recombineering method 
using a positive/negative selection cassette to produce seamless modifications. 
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Figure 1.11 Methods for removing antibiotic selection cassettes 
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(a) Inclusion of an antibiotic selection cassette for reducing background of un-recombined plasmid during recombineering can potentially disrupt the sequence.  
(b) By flanking the inserted selection cassette with SSR-RMs the cassette can be deleted, once a correctly recombined clone has been identified, by expression 
of an appropriate SSR via either a transformed plasmid (Tuntufye et al., 2011) or a stably incorporated, inducible cassette (Warming et al., 2005). This method 
leaves in place a single SSR-RM which could cause disruption to the desired sequence and precludes further use of this SSR.  
(c) Seamless modifications are possible by using positive/negative antibiotic selection cassettes (+/- cassette). The +/- cassette is first inserted into the target 
location by recombineering and selected for. It is then replaced, again by recombineering, with the desired modification and selected against. In this way it is 
possible to create seamless modifications to the resident target plasmid (Wang et al., 2009d; Warming et al., 2005; Westenberg et al., 2010).  
SSR-RM= with site-specific recombinase recognition motifs; SSR= site-specific recombinase; +/- cassette= positive/negative antibiotic selection cassette 
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1.4 SOD1 MOUSE MODELS 
1.4.1 SOD1 Transgenic Mice  
Just one year after Rosen et al., (1993) discovered the first SOD1 mutations in ALS, Gurney et 
al., (1994) presented the first mutant SOD1 transgenic mice. Table 1.3 summarises a selection 
of the great number of SOD1 transgenic mice which have been subsequently produced (a more 
comprehensive list is presented in Section 7.1, Appendix 1) which includes mice expressing 
tagged proteins (Watanabe et al., 2005), experimental mutations (Wang et al., 2003; Deng et 
al., 2008), mutant mouse Sod1 (Ripps et al., 1995) and conditional/inducible lines (e.g. 
(Pramatarova et al., 2001; Jaarsma et al., 2008; Wang et al., 2008; Wang et al., 2009b)).  
The majority of these mice have been created using an 11.58 kb EcoRI-BamHI fragment of 
human SOD1 genomic DNA (gDNA) which includes sufficient promoter sequence (~500 bp) to 
direct expression of the human SOD1 (huSOD1) in a pattern similar to the endogenous mouse 
SOD1 (moSOD1) (Epstein et al., 1987). Not all of the mutant SOD1 transgenic mice display ALS 
like phenotypes (as summarised in Table 1.3 and Section 7.1, Appendix 1). Those that do have 
varying ages of onset and survival which often correlate with the level of transgene expression 
and/or the number of copies in the transgene array (e.g. (Wong et al., 1995; Watanabe et al., 
2005; Gurney et al., 1994; Tu et al., 1996; Zhang et al., 1997)).  
Two of the SOD1 transgenic lines which are used in the work presented in this thesis will be 
described in more detail in the following subsections.  
1.4.1.1 SOD1G93A TRANSGENIC MOUSE  
One of the first SOD1 mutations to be transgenically expressed in mice was the G93A mutation 
in exon 4 of the SOD1 gene. Four founder lines were originally established (Gurney et al., 
1994). The line used in the work described here, designated as G1H by the original authors 
(current strain definition: Tg(SOD1*G93A)1Gur, referred to as TgG93A in the following text), is 
derived from one of these original lines but has a 40% expansion, resulting in 25 copies in the 
transgene array (Chiu et al., 1995). The transgene, shown in Figure 1.12, was constructed by 
isolating a 0.54 kb HindIII-NsiI fragment of patient genomic DNA (gDNA), which encompassed 
the G93A mutant exon 4. This was then cloned into the matching RE sites of a plasmid 
containing an 11.58 kb EcoRI-BamHI gDNA fragment encompassing the SOD1 locus (9.31 kb) 
and flanking sequence (0.48 kb 5' & 1.79 kb 3'), including promoter sequence as described 
above. The transgene integration site has been mapped to band E of mouse chromosome 12 
(Achilli et al., 2005). 
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Table 1.3 Mutant SOD1 transgenic mice 
Rows are arranged by the location of the mutation used. Lines used in the work presented in this Thesis are highlighted in yellow. Lines which failed to develop ALS 
like phenotypes are highlighted in pink.  
All figures are for hemizygous mice unless specified. Protein expression and dismutase activity were assayed from spinal cord, unless specified.  
(*1) Protein expression is expressed as fold increase relative to endogenous Sod1 level 
(*2) SOD1 activity is expressed as fold difference compared to NTg 
Tg= transgene; Hom= homozygous; nr= not reported; nq= measured but not quantified; yrs= years; ($)= symptoms and survival shown for homozygotes; (#)= 
introduces a stop codon at position 133; ¥ = promoter region 483 bp 3' of exon 1; ¤ = EcoRI-BamHI human gDNA fragment is 11.58 kb and included SOD1 gene plus 
0.5 kb 5' & 1.8 kb 3' 
Mutation Promoter Tg fragment 
Tg 
copy  
Protein 
(*1) 
Activity 
(*2) 
Symptom 
onset 
(weeks) 
Survival 
(weeks) notes Ref 
WT 
Human 
SOD1 (¥) gDNA E-B (¤) 7 
50 (24 
fold in 
ref 19) 8.6 36 (hom) 
367d 
(hom)   
1, 2, 
3, 19 
A4V 
Human 
SOD1 (¥) gDNA E-B (¤) ~5 
nr ~1.4 none   
  2 
G37R (line 106) 
Human 
SOD1 (¥) gDNA E-B (¤) nr 
5.3 7.2 22-30 25–29 
  4 
G37R 
NFL (see 
notes) 
cDNA   
4.3 and 
2.8 
nr 
none (up to 
1.5 yrs) 
none (up 
to 1.5 
yrs) 
Neurofilament light chain (NFL) promoter 
Neuron specific expression. Two lines reported 5 
G37R (see 
notes) 
Mouse 
prion 
promoter  cDNA nr 
nq nq 28-36 (hom) 
onset 
+1-3 
weeks 
Co-integration of SOD1 transgene with construct 
encoding wild-type human presenilin 1 (hPS1) with PrP 
promoter 6 
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Mutation Promoter Tg fragment 
Tg 
copy  
Protein 
(*1) 
Activity 
(*2) 
Symptom 
onset 
(weeks) 
Survival 
(weeks) notes Ref 
H46R/H48Q/H6
3G/H120G (line 
125) 
Human 
SOD1 (¥) 
gDNA E-B (¤) nr 
nq 1 nr 39-52 H46R/H48Q ALS mutations with H63G/H120G 
experimental mutations to disrupt copper binding 7 
E77X (stop) 
Human 
SOD1 (¥) gDNA E-B (¤) nq 
nr nr none normal 
RNA "barely detected" 
Experimental, non-ALS, mutation  8 
G85R (line 148) 
Human 
SOD1 (¥) gDNA E-B (¤) nr 
1 1 33 35 
  9 
G85R (line 74) 
Human 
SOD1 (¥) gDNA E-B (¤) nr 0.2 nr 51-61 
onset +2 
weeks   9 
G85R Thy1.2  cDNA   nq nq 
none (up to 
87)   
Bicistronic expression of SOD1 and EGFP in postnatal 
motor neurons 10 
G85R (floxed) 
nr 
gDNA un-
specified 
fragment nr 
1.5 1 44 50 
LoxP flanked transgene 11 
G86R (mouse) 
nr 
gDNA 
mouse nr 
nr 1 13-17 13-17 
Tg made from gDNA mouse SalI fragment, however SalI 
cuts within intron 3 12 
G93A (line G1) 
Human 
SOD1 (¥) gDNA E-B (¤) 18 
nr ~4 12-16 20 
  2 
G93A (line G1H) 
Human 
SOD1 (¥) 
gDNA E-B (¤) 25 
17 
>4 (8.9 
fold in 
ref 14) 
13 19.4 
Protein expression described as equal to the N1029 line 
in ref 16.  
High transgene copy number derived from G1 line 
13, 
14, 
16 
G93A (line 
G1del) 
Human 
SOD1 (¥) gDNA E-B (¤) 8 
nr 
nr 28 
36 
Low transgene copy number derived from G1 line 
15, 
16 
G93A (line T1 
crossed to line 
T3) 
Thy1.2 
cDNA nr     77-104 84-104 
Postnatal motor neurons specific expression. Double 
transgenic line produced by crossing 2 independent 
Thy1.2 transgenic lines 17 
L126delTT (#) 
(line D1) 
Human 
SOD1 (¥) gDNA E-B (¤) 
1 nr nr none   
  18 
L126delTT (#) 
(line D2) 
Human 
SOD1 (¥) gDNA E-B (¤) 
5 
See 
notes 
1 
63 (34 in 
hom) 
68 (36 in 
hom)  Protein: below western detection threshold 18 
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Mutation Promoter Tg fragment 
Tg 
copy  
Protein 
(*1) 
Activity 
(*2) 
Symptom 
onset 
(weeks) 
Survival 
(weeks) notes Ref 
L126delTT-FLAG 
(#) (line DF2) 
Human 
SOD1 (¥) gDNA E-B (¤) 
3 nr nr none   
FLAG tagged SOD1 18 
L126delTT-FLAG 
(#) (line DF7) 
Human 
SOD1 (¥) gDNA E-B (¤) 
4 nq 1 
49 (17 for 
hom) 
53 (18 
for hom) FLAG tagged SOD1 18 
 
1- (Graffmo et al., 2012); 2- (Gurney et al., 1994); 3- (Jaarsma et al., 2000); 4- (Wong et al., 1995); 5- (Pramatarova et al., 2001); 6- (Wang et al., 2005b); 7- (Wang 
et al., 2003); 8- (Deng et al., 2008); 9- (Bruijn et al., 1997); 10- (Lino et al., 2002); 11- (Wang et al., 2009b); 12- (Ripps et al., 1995); 13- (Chiu et al., 1995); 14- (Tu et 
al., 1996); 15- (Zhang et al., 1997); 16- (Gurney, 1997); 17- (Jaarsma et al., 2008); 18- (Watanabe et al., 2005); 19- (Jonsson et al., 2006b).  
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These mice were described in detail by Chiu et al., (1995) who maintained them on a BL6/SJL 
background. The first sign of disease is a plateau, and then gradual loss, of body weight 
starting at around 75-days of age. A fine tremor in one or more of the limbs is the typical first 
sign of motor disturbance seen in these mice at around 13-weeks of age and spreading to all 
limbs with increasing age. Spasticity (increased resistance of limbs), limb-grasping (crossing of 
limbs in toward the body when held by the tail, rather than the usual splaying of limbs) and 
clonus (a rhythmic tremor in response to forced flexion) develop along with weakness and 
atrophy of the muscles especially evident in the hind limbs. Gait disturbance, in the form of a 
dropped pelvis, becomes apparent and as strength in the hind limbs deteriorates the mouse 
appears to drag the body using the forelimbs. As degeneration proceeds, tremor and spasticity 
are reduced presumably due to decreasing muscle force. The animals reach the end stage, 
defined by Chiu et al., (1995) as an inability to right themselves within 30 seconds when placed 
on their sides, at an average of 136-days when the mice had also lost 10% of their body weight 
and had coarsened fur due to a lack of grooming. Loss of muscle strength can be detected at 
40-days of age using electrophysiological techniques and the pattern of loss is suggestive of a 
preferential loss, or decline in functionality, of larger MNs innervating faster muscle fibres 
(Hegedus et al., 2007; Hegedus et al., 2008), similar to the pattern seen in ALS patients 
(Dengler et al., 1990).  
This mouse line has a progressive loss of spinal MNs apparent from 100-days of age resulting in 
a 50% loss of MNs within the cervical and lumbar SC by end stage (Gould et al., 2006; Fischer 
et al., 2004; Chiu et al., 1995). Vacuolated SC MNs are apparent from ~80-days, later spreading 
to the brain stem (Fischer et al., 2004; Dal Canto et al., 1994). Vacuoles are also present in the 
mitochondria, which are morphologically abnormal, with signs of “unravelling” of the 
membranes (Dal Canto et al., 1994). Denervation and reinnervation of skeletal muscles can be 
 
Figure 1.12 SOD1 transgene 
The 11.58 kb EcoRI-BamHI human gDNA fragment used for transgene construction by 
Gurney et al., (1994) is shown. The 0.54 kb HindIII-NsiI fragment was isolated patient gDNA 
containing exon 4 in which the G93A mutation is located. This was then cloned into the 
matching HindIII-NsiI sites in the full length fragment. The transgene encompasses the 
SOD1 locus (9.31 kb) and is flanked by 0.48 kb 5' and 1.79 kb 3'.  
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detected from 47-days of age and by 80-days axonal degeneration can be detected in the 
ventral roots, with preferential loss of large calibre axons (Chiu et al., 1995; Fischer et al., 
2004). Astrocytosis is also apparent in the SC from 82-days of age (Tu et al., 1996) and swollen 
axons containing spheroid neurofilament inclusions are present in the ventral SC from 82-days 
of age, worsening with age (Tu et al., 1996; Gurney et al., 1994). Inclusions containing SOD1 
are prevalent, especially in the ventral horn MNs (Gurney et al., 1994). p62 staining becomes 
apparent from 35-days of age and ubiquitin aggregation from 60-days, and by 120-days p62, 
ubiquitin and SOD1 are co-localised (Gal et al., 2007). TDP43 pathology is typically reported as 
absent in this and other mutant SOD1 transgenic mice (Robertson et al., 2007), although 
TDP43 mislocalisation has been reported once, at end stage in this mouse line (Shan et al., 
2009).  
1.4.1.2 SOD1WT TRANSGENIC MOUSE  
When the first G93A mutant SOD1 transgenic line was made, 3 wild-type (WT) SOD1 transgenic 
lines were also established (Gurney et al., 1994) one of which (referred to as N1029/N29 in the 
original papers, current strain definition Tg(SOD1)2Gur) is used in the work presented in this 
thesis and referred to as TgWT. This mouse was made using the same EcoRI-BamHI gDNA 
fragment as described above and is thought to carry 7 copies in the transgene array. They are 
reported to have comparable huSOD1 protein expression to the TgG93A line (3.2 vs. 4.3 ng/µg 
total brain protein, G93A vs. WT) and both have 4 times the normal level of huSOD1 activity 
(Tu et al., 1996), although not all reports agree (e.g. (Graffmo et al., 2012; Jaarsma et al., 
2000)). This line is commonly used as a control for the TgG93A mouse. This TgWT line was 
originally reported as free from motor deficits up to 1 year of age (Chiu et al., 1995; Dal Canto 
et al., 1995; Tu et al., 1996) however, elsewhere mild motor deficits have been reported from 
58-weeks of age (Jaarsma et al., 2000).  
Strong SOD1 staining is seen in the lateral ventral horn (Gurney et al., 1994) and throughout 
the SC grey matter in the TgWT mouse. Staining is homogeneously distributed at an early age 
but becomes stronger and less homogeneous from 30-weeks of age when it appears focussed 
within the axons of the MNs (Jaarsma et al., 2000). SOD1 inclusions are present in the ventral 
horn MNs and ventral root by 86-weeks (1.7-years) (Jonsson et al., 2006b). Mild axonal 
degeneration and vacuolisation is seen from 30-35-weeks of age (Jaarsma et al., 2000; Chiu et 
al., 1995; Dal Canto et al., 1995), however no indication of denervation/reinnervation of the 
skeletal muscles was noted when examined at a similar age (Chiu et al., 1995).  
Neurofilament and mitochondrial pathology which is qualitatively similar to that seen in the 
TgG93A line has also been noted, although it is less severe and occurs at a later age, for 
example the neurofilament pathology appears at 18.6-weeks rather than 11.7 (Tu et al., 1996; 
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Dal Canto et al., 1995; Jaarsma et al., 2000). Similarly, MN vacuolisation (Tu et al., 1996), gliosis 
(Jaarsma et al., 2000), MN degeneration and death (Jaarsma et al., 2000) have all been 
reported but to a milder extent and with a later occurrence than in the TgG93A line, as 
summarised in Table 1.4.  
 
Of note, Graffmo et al., (2012) recently examined homozygous TgWT mice and reported the 
same phenotype as TgG93A mice but with a longer time-scale; hind limb weakness occurring 
around 36-weeks (253-days) and end-stage by 52-weeks (367-days). Misfolded SOD1 and 
astrocytosis was detected in the SC from 100-days and 40% loss of MNs in the thoracic SC was 
Table 1.4 Comparison of disease related phenotype seen in TgWT and TgG93A mice 
  WT G93A 
Motor deficits 58-weeks mild (1) 
Onset:13-weeks (91-
days) 
Paralysis: 19.4-weeks 
(136-days) (2) 
Muscle 
denervation/reinnervation not seen upto 38-weeks (2) 6.7-weeks (47-days) (5, 6) 
Axonal degeneration 30-35 weeks(1, 2, 3) 
11.4-weeks (80-days) (5, 
6) 
Neurofilament pathology 18.6- weeks (130-days) (4) 11.7-weeks (82-days) (4) 
Mitochondrial vacuolisation 30-40-weeks (1) 5.3-weeks (37-days) (2) 
MN vacuolisation 28.5-weeks (4) 
11.4-weeks (80-days) (5, 
6) 
Astrocytosis 50-60-weeks (1) 
14.3-weeks (100-days) 
(7) 
Microgliosis 
30-weeks white matter  
75-weeks to 2-years grey 
matter (1) 
14.3-weeks (100-days) 
(7) 
Ubiquitin pathology 2-years (in neurties) (1) 8.6-weeks (60-days) (8) 
Motor neuron loss 20-30% at 2 years (1) 
From 100-days (14.3 
weeks). 50% loss by end 
stage (5) 
1- (Jaarsma et al., 2000); 2- (Chiu et al., 1995); 3- (Dal Canto et al., 1995); 4- (Tu et al., 
1996); 5- (Fischer et al., 2004); 6- (Gould et al., 2006); 7- (Hall et al., 1998); 8- (Gal et al., 
2007) 
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reported at end stage. These homozygous mice were described as expressing huSOD1 at an 
equal level to hemizygous TgG93A mice, contrary to other comparisons (e.g. (Tu et al., 1996)) 
and had been bred onto a different background due to a failure to produce homozygotes on 
the original C57BL/6J background. Effects of background strain will be discussed in Section 
1.4.3.  
1.4.2 Sod1 KO Models  
A third mouse used in the work described in this thesis is a Sod1 KO mouse created by Matzuk 
et al., (1998), designated Sod1tm1Leb. This mouse was created by targeting a PGK-Hprt cassette 
to delete exons 1 and 2 of the endogenous Sod1 gene resulting in a complete absence of the 
protein product in homozygous KO mice (Matzuk et al., 1998). These mice do not develop an 
ALS like phenotype, helping to delineate the gain of function mechanism of mutant SOD1 
toxicity. All of the following phenotypes refer to the homozygous null mice.  
Sod1tm1Leb mice suffer from a range of phenotypes, many related to premature ageing, 
including impaired fertility (Ishii et al., 2005; Matzuk et al., 1998; Noda et al., 2012; Tsunoda et 
al., 2012), vascular dysfunction (Groleau et al., 2011; Didion et al., 2002), impaired 
endothelium vasodilation (Cooke et al., 2003; Morikawa et al., 2003), age related hearing loss 
(Keithley et al., 2005; Johnson et al., 2010b), age-related macular degeneration (Imamura et 
al., 2006; Hashizume et al., 2008), and premature aging of the skin (Murakami et al., 2009).  
These mice also display some phenotypes relevant to MN degeneration, such as accelerated 
denervation of the skeletal muscles appearing to a mild extent at 1.5-months and prominently 
by 10-months (Kostrominova, 2010). This phenotype has been more extensively examined in 
another Sod1 null mouse (Sod1tm1Cje) but findings related from either line are expected to be 
comparable as they are both targeted mutations with a complete absence of moSOD1 protein 
(Huang et al., 1997). Sod1tm1Leb mice have been reported as suffering a more profound muscle 
denervation than the Sod1tm1Cje mice, however the 2 lines were compared on different genetic 
backgrounds which could account for this (Kostrominova, 2009). Effects of background strain 
will be discussed further in Section 1.4.3. Sod1tm1Cje mice show reduced motor coordination at 
13-months of age along with tremor and gait abnormalities. An age related loss of muscle mass 
is detectable from 3-4-months developing to ~50% loss in the hind limbs by 20-months, with 
the decrease in muscle size apparently being due to a preferential loss of fast muscle fibres 
(Muller et al., 2006; Jang et al., 2010). Muscle denervation is also accelerated with 78% of 
neuromuscular junctions (NMJs. See Figure 1.1) denervated by 18-months, whereas no 
denervated NMJs were detected in wild-type mice of the same age (Jang et al., 2010). Similar 
results have also been obtained in another Sod1 KO line (e.g. Sod1tm1Cep)(Shefner et al., 1999; 
Flood et al., 1999). Histological abnormality of the muscle mitochondria is reported from 22-
56 
months and mitochondria isolated from Sod1 KO muscles are dysfunctional, with 75% 
decrease in ATP production and 3-fold increase in hydrogen peroxide production at 20-months 
of age (Jang et al., 2010). Although some of the phenotypes of Sod1 null mice have been 
described as premature aging, evidence suggests that the reduction in muscle strength is 
qualitatively different to that seen in old age (Larkin et al., 2011; Larkin et al., 2013).  
1.4.3 Effects of Background Strain on Phenotypes  
Inbred mouse strains are used in order to minimise background genetic heterogeneity in order 
to isolate the effects of a particular mutation or genetic manipulation. Many strains of inbred 
mice exist and phenotypes related to a particular mutation can differ depending on the 
background strain onto which it is bred. This must be taken into consideration when 
comparing results obtained on different backgrounds.  
The original SOD1G93A transgenic mouse line (Gurney et al., 1994) was produced using F1 
BL6SJL oocytes and bred by crossing to BLSJL F1 mice. This involves mating a C57BL/6 female 
to an SJL male to produce BL6SJL F1 mice which are heterozygous at every genomic locus (e.g. 
one allele is from C57BL/6 and the other is from SJL as illustrated in Figure 1.13). A female 
BL6SJL F1 is then crossed to a male from the transgenic colony, producing BL6SJL F2 offspring. 
As illustrated in Figure 1.13, at this point genetic heterogeneity is introduced. At each genomic 
locus, offspring from this cross will have a 50% chance of being heterozygous and 25% chance 
of being homozygous for either of the original alleles. As genetic variability can result in 
phenotypic variability it is often desirable to use a pure inbred line to produce a congenic to 
this strain. This is achieved by backcrossing the donor line to a recipient inbred line for 10 
generations, resulting in ~99.8% of all genomic loci being homozygous for the recipient allele 
(Silver, 1995).  
In TgG93A mice, Mead et al., (2011) found that the time to reach end stage was significantly 
less variable when mice are congenic to C57BL/6J compared to a B6SJL background. Figure 
1.14 illustrates the variance of survival times measured for TgG93A mice on different 
background strains. Heterogeneity between publications may be due to different humane end 
points or genetic drift (including changes in the transgene copy number), so data are grouped 
by publication. Differences in disease onset, electrophysiological measures of disease 
progression, drug response and both quantitative and qualitative difference in MN 
transcriptome profiles are also seen between TgG93A on different background strains (Wooley 
et al., 2005; Mancuso et al., 2012; Nardo et al., 2013; Pizzasegola et al., 2009; Pan et al., 2012).  
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Figure 1.13 Genetic heterogeneity of F2 hybrids 
The figure illustrates the level of genetic heterogeneity introduced at an F2 cross. The 
proportion of offspring with the genonotype illustrated is labelled. As can be seen, in an F1 
hybrid every animal is heterozygous at every genetic locus (Aa and Bb). In an F2 hybrid 
there is a 50% chance of each locus being heterozygous (Aa or Bb), and a 25% chance of 
each locus being homozygous for either of the original parental strain alleles (AA or aa and 
BB or bb). This example uses just 2 loci, and without recombination, to illustrate the 
considerable heterogeneity present in an F2 hybrid.  
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Figure 1.14 Background strain effects on survival of TgG93A mice 
The figure shows survival time for TgG93A transgenic mice congenic on various inbred 
strains or maintained by mating to an F1 hybrid taken from papers which present data for 
2 or more background strains. Where male and female survival was given separately, the 
average is plotted. Data are colour coded according background strain and grouped by 
publication as variation can arise from differences between end-point definition and due 
variation in the transgene copy number between labs. The paper by Heiman-Patterson 
et.al. (2011) includes data collected in different labs. The full strain ID is given above each 
line along with survival in days.  
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Sexual dimorphism in the onset and survival of TgG93A mice is also reported, and this is itself 
further augmented by background strain (Heiman-Patterson et al., 2005; Mancuso et al., 2012; 
Pan et al., 2012). These background and gender differences are not due to changes in 
expression levels of the transgene (Heiman-Patterson et al., 2011; Mancuso et al., 2012; Nardo 
et al., 2013; Pan et al., 2012) and similar effects have also been reported with other SOD1 
transgenes (e.g. (Kunst et al., 2000; Graffmo et al., 2012; Acevedo-Arozena et al., 2011; Pan et 
al., 2012)).  
As summarised in Table 1.5, there is also significant variation between inbred lines in spinal 
column vertebrae composition and some lines show greater within strain variation than others 
(Green, 1941; Green, 1951; McLaren et al., 1955; Rigaud et al., 2008). Strain differences in the 
underlying SC neuroanatomy are also apparent, for example although the sciatic nerve of both 
DBA/2J and C57BL/6J mice is composed primarily of L3 and L4 nerves, in DBA/2J mice the 
contribution of L3 and L4 is equal, whereas in C57BL/6J mice it is predominantly composed of 
L4 nerves (Rigaud et al., 2008).  
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Table 1.5 Variation in spinal vertebrae in different inbred lines of mice 
The number shown is the percentage of mice identified with the combinations of thoracic and lumbar spinal vertebrae number indicated at the top of the table.  
The table is arranged by strain. Where a single configuration is present more than 75% of the time, these are highlighted in bright green. Where a single 
configuration is present between 74-25% it is highlighted in blue. 
Asym= asymmetrical; na= not analysed 
 
Number of vertebrae 
 Thoracic 13 14 na 13 14 na 12 13 14 na 12 13   
Lumbar 5 5 5 
5 (asym 
6th) 
5 (asym 
6th) 
5 (asym 
6th) 6 6 6 6 7 7 ref 
C57BL 2.1     2.5       95.4         1 
C57BL 0.4     1.7       97.8         1 
C57BL/How     0.5     0.5       98.9     2 
C57BL/6J     6     8       86     3 
C3H 96.5     2.5       1         1 
C3H/Bi (Craigie)     78.7     16       5.3     2 
C3H/Bi (Green)     95.3     2.3       2.3     2 
C3H/St     98.9     1.1             2 
DBA 95.3     2.9       1.8         1 
DBA/2J     97     3             3 
BalbC   54     16.5     11 18.1       4 
C 58.2     7.2       34.6         1 
Bagg albino   56     13.5     17.8 12.5     0.2 1 
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Number of vertebrae 
 Thoracic 13 14 na 13 14 na 12 13 14 na 12 13   
Lumbar 5 5 5 
5 (asym 
6th) 
5 (asym 
6th) 
5 (asym 
6th) 6 6 6 6 7 7 ref 
L   59     11.7     11.3 18       1 
P       8.4     88.1       3.6   1 
A 2.1     4.2       93.7         1 
Leaden 1.1 0.3   2.9       95.7         1 
N 0.6     2.6       96.8         1 
Gates       1.9     2.5 15.3     80.3   1 
 
1- (Green, 1941); 2- (McLaren et al., 1955); 3- (Rigaud et al., 2008); 4- (Green, 1951). 
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1.5 HOW DO MUTATIONS IN SOD1 CAUSE ALS?  
1.5.1 The Effect of Mutations on SOD1 Function  
When mutations in SOD1 were first identified it was suggested that a loss or reduction of 
dismutase activity might be the cause of disease (e.g. (Rosen et al., 1993; Bowling et al., 1993; 
Deng et al., 1993)) and consistent with this idea, reduced activity was identified in reb blood 
cells (RBCs) of SOD1-fALS cases (Deng et al., 1993; Bowling et al., 1993; Robberecht et al., 
1994). This theory was quickly dismissed; in mouse models, rather than reduced SOD1 activity 
producing ALS like symptoms (Reaume et al., 1996), expression of mutant huSOD1 in 
conjunction with endogenous moSOD1 resulted in ALS like symptoms despite often increased 
activity levels (e.g. (Dal Canto et al., 1994; Wong et al., 1995; Ripps et al., 1995; Bruijn et al., 
1998)). Direct assay of a variety of ALS mutants also revealed that many retained full activity 
(Borchelt et al., 1994).  
Derlin-1 binding has been demonstrated as increased in 124 ALS SOD1 mutants, suggesting 
that SOD1’s putative function in ER-stress activation may be pathologically perturbed in SOD1-
fALS (Fujisawa et al., 2012; Homma et al., 2013). Indeed blocking mutant SOD1 – Derlin-1 
interaction attenuated toxicity in primary spinal MN culture lending further credence to this 
proposed mechanism of toxicity (Nishitoh et al., 2008). However, although a CNS specific 
interaction of Derlin-1 and mutant SOD1 has been shown in a transgenic SOD1-fALS mouse 
(Nishitoh et al., 2008), the functional consequence of this interaction have not yet been 
demonstrated outside of cell culture. Also of note, Derlin-1 has not been identified in unbiased 
screens for mutant SOD1 interactors in SOD1-fALS mice (e.g. (Watanabe et al., 2008; 
Zetterström et al., 2011)).  
The effect of ALS mutations on the recently proposed role of SOD1 in glucose/oxygen 
dependent respiration repression have not yet been evaluated, however mutation of copper 
binding residues (resulting in dismutase inactive SOD1) does block this activity (Reddi et al., 
2013).  
1.5.2 The Effect of Mutations on Biochemical Characteristics of 
SOD1 
ALS causing mutations in SOD1 are found throughout the aa sequence, affecting all domains of 
the protein and are sometimes categorised as “wild-type like” (WTL) or “metal binding 
mutants” (MBM) according to their abilities to bind metal ions and form an enzymatically 
active dimer (e.g. (Rodriguez et al., 2002)).  
Decreased thermal stability, increased aggregation propensity and increased dimer 
dissociation have all been associated with ALS mutation of SOD1 (Rodriguez et al., 2002; 
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Vassall et al., 2011; Khare et al., 2004; Khare et al., 2006; Lindberg et al., 2002). Attempts to 
correlate disease severity with enzymatic activity, half-life, proteolysis resistance, mutation 
position, protein charge and aggregation propensity both in vivo and in vitro have generally 
failed to produce convincing associations (e.g. (Prudencio et al., 2009b; Vassall et al., 2011; 
Lindberg et al., 2002; Ratovitski et al., 1999)).  
A correlation between decreased thermal stability of apo (metal free) SOD1 mutants with 
decreased disease duration was proposed but at present, is based on a limited number of 
mutations (Lindberg et al., 2002; Kitamura et al., 2011). A link has also been suggested 
between the propensity of the mutant SOD1 dimer to dissociate into monomers and the 
severity of the disease; specifically, when glutathionylation of SOD1 is taken into consideration 
a correlation is apparent (McAlary et al., 2013).  
1.5.3 Proposed Pathogenic Mechanisms in SOD1-fALS  
Although many ALS disease mechanisms have been proposed, often as a result of investigation 
of SOD1-fALS mice, at present it is unknown which are the primary causes of degeneration and 
which are secondary or downstream consequences of disease. Here a brief description is given 
of some of the main proposed mechanisms with a focus on those directly relevant to 
SOD1-fALS and those elucidated using SOD1-fALS mouse models.  
1.5.3.1 OXIDATIVE STRESS  
There is a trend towards a ~50% reduction in SOD1 activity assayed from SOD1-fALS patient 
tissue, independent of the effect of the same mutation on recombinant SOD1 (Saccon et al., 
2013). Several other lines of evidence also suggest that oxidative stress may be involved in ALS, 
even if it is not caused by loss of SOD1 function as a direct consequence of mutation.  
Oxidative damage of proteins, lipids, DNA and mRNA along with other markers of increased 
oxidative stress are present in the SC of SOD1-fALS, and some sALS cases, post mortem and 
have been detected in peripheral bodily fluids (urine, blood, cerebrospinal fluid) of ALS 
patients (Bowling et al., 1993; Abe et al., 1995; Shaw et al., 1995; Beal et al., 1997; Ferrante et 
al., 1997a; Smith et al., 1998; Tohgi et al., 1999; Bogdanov et al., 2000; Sasaki et al., 2000; 
Shibata et al., 2001; Shibata et al., 2004; Simpson et al., 2004; Babu et al., 2008; Chang et al., 
2008; Murata et al., 2008; Cova et al., 2010) with levels reportedly correlating with disease 
measures in some cases (Bogdanov et al., 2000; Murata et al., 2008; Cova et al., 2010).  
These findings are mirrored in SOD1-fALS mouse models (e.g.(Ferrante et al., 1997b; Andrus et 
al., 1998; Poon et al., 2005; Liu et al., 1998; Liu et al., 1999; Casoni et al., 2005; Liu et al., 2007; 
Cha et al., 2000; Lee et al., 2009)), where SOD1 is itself identified as heavily oxidised (Andrus et 
al., 1998). This is of interest as oxidation is implicated in the monomerisation, misfolding and 
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aggregation of both WT and mutant SOD1 (Rakhit et al., 2002; Ezzi et al., 2007; Wilcox et al., 
2009). Also of note, oxidised mRNA species identified in the SC of SOD1-fALS mice are enriched 
for transcripts involved in mitochondrial function, cytoskeleton and protein synthesis, folding 
and degradation, all of which are implicated in ALS (Chang et al., 2008).  
Increased pro-oxidant activity has actually been demonstrated for some ALS SOD1 mutants 
(Yim et al., 1996; Yim et al., 1997; Wiedau-Pazos et al., 1996; Roe et al., 2002; Elliott, 2001), 
however, this is unlikely to be a primary cause of disease as, just like its anti-oxidant activity, 
this is dependent on copper binding and SOD1 with reduced or ablated copper binding is still 
capable of affecting disease (Subramaniam et al., 2002; Wang et al., 2003).  
1.5.3.2 MITOCHONDRIAL DYSFUNCTION 
Structural abnormalities of the mitochondria are reported in sALS MNs (Sasaki et al., 1996b; 
Siklós et al., 1996) and are highly cited in SOD1-fALS mouse models (e.g. (Dal Canto et al., 
1994; Dal Canto et al., 1995; Wong et al., 1995; Kong et al., 1998; Martin et al., 2007)). 
Furthermore, mitochondrial function is severely impaired in MNs of SOD1-fALS mouse models, 
and in post mortem CNS, blood and muscle biopsy of ALS patients (Mattiazzi et al., 2002; Jung 
et al., 2002; Martin et al., 2007; Fujita et al., 1996; Swerdlow et al., 1998; Wiedemann et al., 
1998; Vielhaber et al., 1999; Crugnola et al., 2010), although muscle abnormalities may not be 
specific to ALS (Krasnianski et al., 2005).  
It has been proposed than an increased propensity to localise to the mitochondrial IMS of 
mutant, compared to WT, SOD1 may result in impaired mitochondrial respiratory capacity 
(Ferri et al., 2006). Mutant SOD1 targeted specifically to the IMS in mice impairs mitochondrial 
respiratory capacity and reproduces some key ALS like symptoms including MN loss and 
muscular weakness and wasting, although muscle denervation is not observed (Igoudjil et al., 
2011). This suggests that mutant SOD1 can affect toxicity at the mitochondria, however 
localisation to other cellular compartments may be required to recapitulate the full ALS 
phenotype.  
1.5.3.3 ENDOPLASMIC RETICULUM-STRESS AND THE UNFOLDED PROTEIN 
RESPONSE (UPR) 
Newly synthesised proteins are guided in their correct folding by chaperones within the ER. 
Overloading of the ER results in ER-stress, eliciting the unfolded protein response (UPR), the 
suppression of protein translation and eventually apoptosis (Schröder, 2008). As described 
above, SOD1 is implicated in the activation of ER-stress with mutations potentially increasing 
its activity in this pathway (Homma et al., 2013; Nishitoh et al., 2008; Fujisawa et al., 2012). 
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Markers of increased ER-stress are present in ALS patient tissue (Atkin et al., 2008; Ito et al., 
2009) and in SOD1-fALS mice (Kikuchi et al., 2006; Saxena et al., 2009; Ito et al., 2009).  
Manipulation of the UPR, by genetic or pharmacological means, has been shown to affect the 
degenerative process of SOD1-fALS mice (Wang et al., 2011b; Kalmar et al., 2008; Kiernan et 
al., 2004). However, distinguishing a specific effect of mutant SOD1 from a non-specific 
overload of the ER potentially cause by the transgenic overexpression of a mutant protein 
makes interpretation challenging.  
1.5.3.4 AXONAL TRANSPORT DEFICITS  
Slow anterograde and fast retrograde axonal transport deficits are apparent in most 
SOD1-fALS mice ((Zhang et al., 1997; Williamson et al., 1999; Bilsland et al., 2010; Warita et al., 
1999), cf (Marinkovic et al., 2012)) and fast anterograde and retrograde transport is disturbed 
in primary MNs expressing mutant SOD1, resulting in a depletion of mitochondria in the axon 
(De Vos et al., 2007). There is also evidence of anterograde transport deficits in post mortem 
ALS SC, including mislocalised mitochondria (Sasaki et al., 1996a).  
A direct physical interaction between mutant SOD1 and the dynein complex (a driver of 
retrograde transport) has been identified in cell, mouse and rat models of SOD1-fALS (Zhang et 
al., 2007), and in a cell model, blocking this interaction can reduce aggregation and, in some 
cases, mutant SOD1 toxicity (Ström et al., 2008). A further link between SOD1, retrograde 
transport and ALS is that a fast retrograde axonal transport deficit caused by a mutation in the 
cytoplasmic dynein heavy chain 1 (Dnchc1) gene in mice results in SOD1 aggregation in 
conjunction with a progressive motor phenotype (Hafezparast et al., 2003). Kinesin based fast 
anterograde transport is also inhibited by mutant and oxidised WT SOD1 (Bosco et al., 2010). 
Deficits in axonal transport can cause multiple toxic effects including cytoskeletal abnormality 
and mitochondrial disturbance, deficits which it has been proposed that spinal MNs may be 
particularly sensitive to given their morphology (Chevalier-Larsen et al., 2006).  
1.5.3.5 SOD1 AND RNA  
The role of RNA metabolism in ALS was brought into focus when mutations in genes encoding 
2 RNA binding proteins, TDP43 and FUS, were identified as relatively common causes of fALS 
(as reviewed (Lattante et al., 2013)), but SOD1 has also been implicated in RNA metabolism.  
Mutant SOD1 may down regulate vascular endothelial growth factor (VEGF) expression by 
directly binding its mRNA transcript, competing with RNA stabilising proteins (Lu et al., 2007; 
Lu et al., 2009; Li et al., 2009). There are several lines of evidence that a reduction in VEGF may 
have pathogenic consequence for example a polymorphism in the VEGF promoter is associated 
with increased risk of ALS and lower age of onset (Su et al., 2014) and a similar deletion in the 
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promoter of the mouse gene results in a late-onset MN degenerative phenotype reminiscent 
of ALS (Oosthuyse et al., 2001). Furthermore, in SOD1-fALS mice increasing VEGF expression 
attenuates the disease phenotype (Keifer et al., 2014).  
Mutant SOD1 also reduces the stability of low molecular weight neurofilament (NFL) mRNA, by 
binding its 3’ UTR (Ge et al., 2005; Volkening et al., 2009; Chen et al., 2014). Reduced NFL 
mRNA is reported in sALS and in SOD1-fALS mouse models (Menzies et al., 2002) and 
disturbance of the balance between different neurofilament subunits can result in 
accumulation of neurofilament in MNs and axonal hypotrophy (Julien, 1999). A similar pattern 
of reduced NFL mRNA and mutant SOD1 binding the 3’ UTR were reported in MNs 
differentiated from SOD1-fALS induced pluripotent stem cells (iPSC) (Chen et al., 2014). Down 
regulation of NFL is however unlikely to be a primary cause of SOD1-fALS however, as 
knocking-out Nfl in a SOD1-fALS mouse attenuated, rather than exacerbated, the disease 
phenotype (Williamson et al., 1998).  
1.5.3.6 NON-CELL AUTONOMOUS MECHANISMS  
Although the degeneration and death of MNs is a defining feature of ALS, other cell types are 
also implicated in disease pathogenesis. The fact that astrocytes expressing mutant SOD1 are 
toxic to neurons has been firmly established in multiple co-culture experiments (Nagai et al., 
2007; Marchetto et al., 2008; Di Giorgio et al., 2008; Fritz et al., 2013; Kunze et al., 2013) and 
mutant SOD1 microglial toxicity also seems likely although the effect may be indirect (Thonhoff 
et al., 2012; Zhao et al., 2010). Mouse models with transgenic expression of mutant SOD1 
directed to specific cell types have helped to elucidate cell-specific roles in disease progression.  
Mice with transgenes directing expression of mutant SOD1 to the MNs have produced greatly 
varying results from a complete absence of behavioural or pathological phenotype 
(Pramatarova et al., 2001; Lino et al., 2002), MN loss with no behavioural motor phenotype 
(Wang et al., 2008) to full pathological and behavioural phenotype similar to the constituent 
transgenic mice (Jaarsma et al., 2008).  
Mice in which LoxP flanked transgenes are excised from particular cell types have provided 
more consistent results. Evidence from mice in which the transgene is excised from neuronal 
lineages suggests that neuronal mutant SOD1 is a key determinant of disease onset and 
influences disease progression (Boillée et al., 2006; Yamanaka et al., 2008a; Wang et al., 
2009c). Experiments using chimeric mice in which all MNs and oligodendrocytes were derived 
from mutant SOD1 progenitors while all other tissues are chimeric gave similar results 
(Yamanaka et al., 2008b).  
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Similar models have been used to examine the role of mutant SOD1 in glial cells and reveal 
that both astrocytic and microglial mutant SOD1 is primarily responsible for determining the 
progression of degeneration with minimal impact on onset (Boillée et al., 2006; Wang et al., 
2009c; Beers et al., 2006; Wang et al., 2011a; Yamanaka et al., 2008a; Gong et al., 2000).  
Transgenic mice with mutant SOD1 expression directed to skeletal muscle reveal a directly 
toxic effect of muscular atrophy and reduced strength (Wong et al., 2010; Dobrowolny et al., 
2008). Whether such expression can affect the innervating MNs however is still unclear, as in 
one line there was no evidence for either proximal or distal MN degeneration (Dobrowolny et 
al., 2008), whereas another line developed motor symptoms, and MN degeneration including 
50% loss of MNs (Wong et al., 2010).  
1.5.4 Protein Misfolding and Aggregation  
1.5.4.1 SOD1 AGGREGATES  
The pathological hallmark of many neurodegenerative diseases is the aggregation of the 
disease specific protein. In SOD1-fALS, non-amyloid SOD1 inclusions are found in the MNs (e.g. 
(Wang et al., 2002b; Kerman et al., 2010; Kato et al., 2000; Kato et al., 1996; Kato et al., 1997; 
Okamoto et al., 1991)). Whether such aggregates are themselves pathogenic or are secondary 
consequences is contentious (Mulligan et al., 2013).  
Correlations between disease phenotype and aggregation pathology in SOD1-fALS mice have 
been cited as supporting a causal link between the two. For example the tissues in which 
aggregates occur are those affected in ALS (Wang et al., 2002b) and aggregate level correlates 
with disease progression (Wang et al., 2002a; Wang et al., 2005b; Cheroni et al., 2005; Turner 
et al., 2003). It has also been suggested that expression level must reach a level sufficient to 
cause aggregation in order for ALS like symptoms to arise (Wang et al., 2005b).  
Double transgenic mice expressing both mutant and WT SOD1 generally develop disease 
earlier with reduced survival times. When examined, an increase in mutant protein and a co-
localisation of WT with mutant SOD1 in aggregates is reported, increasing the total aggregate 
burden (Deng et al., 2006; Prudencio et al., 2010; Wang et al., 2009b; Jaarsma et al., 2000; 
Fukada et al., 2001; Jaarsma et al., 2008). Again this correlates increased aggregation with a 
more aggressive phenotype, however, there are exceptions; when an L126Z mutant SOD1-fALS 
mouse was crossed to 2 different WT SOD1 transgenics with different expression levels, the 
cross to the higher expresser produced a more aggressive phenotype in conjunction with 
aggregated WT SOD1 but with no increase in mutant SOD1 aggregation. With the lower WT 
SOD1 expressing line, no change to the phenotype was detected, although a higher level of 
both WT and mutant SOD1 aggregation was observed (Prudencio et al., 2010). Furthermore, 
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SOD1 aggregate inclusions are not typically reported until after denervation of the muscles has 
commenced and the mouse is symptomatic (Gould et al., 2006; Bruijn et al., 1997; Wang et al., 
2002b; Johnston et al., 2000; Koyama et al., 2006).  
Investigation of aggregate toxicity in cell culture models has yielded evidence suggesting that 
increasing the level of soluble SOD1 increases toxicity, while increasing recruitment of mutant 
SOD1 into insoluble inclusions decreased toxicity (Weisberg et al., 2012; Brotherton et al., 
2013). Similarly, co-expression of WT and mutant SOD1 in cell and Caenorhabditis elegans 
(C.elegans) models slows aggregation concurrent with increasing toxicity when measured 
(Prudencio et al., 2009a; Prudencio et al., 2010; Witan et al., 2008; Witan et al., 2009).  
Misfolded SOD1 can overload the ubiquitin proteasome system (UPS) causing it to become 
dysfunctional (Urushitani et al., 2002) which can cause increased SOD1 aggregation (Bendotti 
et al., 2012). UPS dysfunction is observed in SOD1-fALS mice, but not until after onset (Cheroni 
et al., 2009) and SOD1 aggregation elicited by UPS inhibition isn’t necessarily toxic (Lee et al., 
2002), suggesting that this is not a primary cause of mutant SOD1 toxicity.  
Aggregated SOD1 is therefore unlikely a primary cause of disease. Secondary toxicity may be 
caused for example, by perturbing axonal transport (Sau et al., 2011) or by sequestration of 
essential cellular proteins (Pasinelli et al., 2004; Weisberg et al., 2012; Ligon et al., 2005; Zhang 
et al., 2007; Bergemalm et al., 2010) but a direct causal role for any of these has not been 
demonstrated.  
1.5.4.2 PRE-AGGREGATE SPECIES  
A pre-aggregated soluble form of SOD1, present before phenotypic onset may be the toxic 
form of SOD1 (Karch et al., 2009). Biochemical analysis of symptomatic SOD1-fALS mouse SC 
reveals a huge range of SOD1 species ranging from fully soluble monomers and dimers to 
insoluble and detergent resistant monomers, dimers, oligomers and high-molecular weight 
species. In contrast, in reducing conditions, the SC of TgWT mice at 38-weeks old contains only 
fully soluble or membrane bound monomers (Koyama et al., 2006).  
A common feature of SOD1 mutants is an increased propensity for dimers to monomerise 
(Khare et al., 2006; Rakhit et al., 2004) and impaired folding and dimerisation (Bruns et al., 
2007), suggesting that mutation could result in a shift in the population from dimer towards 
monomer. However, monomerisation is also an essential step towards the formation of higher 
molecular weight species and aggregates (Rakhit et al., 2004; Ray et al., 2004) so this 
propensity towards monomerisation could also hasten the path to aggregation. Zetterström et 
al., (2007; 2013) identified a soluble hydrophobic SOD1 fraction, composed of disordered 
monomers, as enriched in the SC of 4 different mutant SOD1-fALS mice as compared to TgWT 
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mice. Unlike total SOD1, the level of this fraction correlated with survival in the 4 mutant lines 
implicating monomeric SOD1 in disease.  
Other oligomeric species, both soluble and insoluble, have been identified in SOD1-fALS mice 
and are present pre-onset and correlate with phenotypic progression (Johnston et al., 2000; 
Wang et al., 2009a). The SEDI antibody recognises the SOD1 exposed dimer interface, and so 
cannot react with natively dimeric SOD1. In SOD1-fALS mice, MNs are labelled diffusely at pre-
symptomatic age and with inclusion morphology at disease onset (Rakhit et al., 2007) and 
when used for immunotherapy onset is delayed (Liu et al., 2012), implicating a non-native-
dimeric species in pathogenesis.  
How such monomeric or oligomeric species might cause toxicity has not been established. 
Exposure of SOD1’s Derlin-1 binding region and activation of ER-stress could result from 
monomerisation or some non-native oligomeric conformations (Nishitoh et al., 2008; Fujisawa 
et al., 2012). Johnston et al., (2000) suggest that misfolded oligomeric SOD1 could disrupt 
retrograde axonal transport by competing with other transport targets and overwhelm the 
system. Aberrant copper binding of mutant monomeric SOD1 resulting in oxidative stress has 
also been proposed as a potential mode of mutant SOD1 toxicity (Kishigami et al., 2010).  
1.5.4.3 PRION-LIKE PROTEIN MISFOLDING MECHANISM 
The prion diseases are a group of neurodegenerative diseases caused by misfolding of the 
prion protein (PrP). Similar to other neurodegenerative diseases, prion diseases can be 
sporadic or caused by mutation of the PRNP gene. However it can also be caused by infection 
with a misfolded PrP (PrPSc) which can induce the correctly folded “cellular” PrP (PrPC) to 
misfold and take on the characteristics of PrPSc. The disease is transmitted within and between 
cells via conversion of PrPC to PrPSc (Acquatella-Tran Van Ba et al., 2013).  
The misfolded/aggregated proteins which are present in most neurodegenerative diseases 
were thought to arise from a failure to correctly fold, or a de novo misfolding, with misfolding 
events occurring somewhat independently but in response to a shared stressor. A prion-like 
model of misfolding is becoming increasingly prevalent, in which misfolding at a discrete focus 
can act as a seed or template, to recruit and propagate misfolding between cells (Guest et al., 
2011). The term “prion-like” is used here to describe two main concepts, which are illustrated 
in Figure 1.15. Firstly, the ability of a misfolded protein “X” to recruit a correctly folded protein 
“X” to become misfolded, either by a process of templated misfolding or seeded aggregation. 
Secondly, the capacity for such a process to propagate between cells. This model is particularly 
appealing in the case of ALS where the disease is clinically characterised by a focal onset 
spreading to regions innervated by contiguous segments of the SC (e.g. (Fujimura-Kiyono et al., 
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2011)), or, as has also been demonstrated in some cases, several focal sites of onset with 
regional spread (Sekiguchi et al., 2014).  
 
Whether SOD1 displays prion-like properties has been examined in vitro, for example by Chia 
et al., (2010) who used an amyloid fibrillisation assay to measure the aggregation propensity of 
recombinant proteins. Self-seeding was demonstrated by a reduction in the time it took for 
G93A mutant SOD1 to form amyloid fibrils by the addition of either G93A pre-formed fibrils, or 
TgG93A SC lysate. Cross-seeding of WT SOD1 by mutant SOD1 was similarly demonstrated. 
Hwang et al., (2010) also demonstrated both self-seeding and cross-seeding with recombinant 
proteins (but not tissue lysates) using an in vitro assay which produced aggregate species with 
structural properties similar to aggregates seen in SOD1-fALS, such as being non-amyloid and 
recognised by the SEDI antibody. Some SOD1-fALS mice develop amyloid pathology with 
 
Figure 1.15 Prion-like mechanisms 
(a) Templated misfolding and seeded aggregation mechanisms of recruitment of a 
normally folded protein into a misfolded/toxic conformation. Templated misfolding occurs 
when a misfolded protein (red) elicits misfolding of a naïve protein (blue) which can then 
itself recruit further naïve proteins into a misfolded conformation. In seeded aggregation, 
the misfolded seed is an oligomeric aggregate (red) which can recruit naïve proteins (blue) 
into the aggregate causing it to misfold.  
(b) Cell-to-cell propagation of protein misfolding. An exogenous misfolded seed/template 
(red) enters the cell and is able to recruit correctly folded endogenous proteins (blue) into 
a misfolded/toxic conformation. The misfolded endogenous proteins can then transfer to a 
naïve cell where they can act as a seed/template for further misfolding of the endogenous 
protein.  
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thioflavin fluorescence (e.g. mutants G37R, G85R, and G93A (Wang et al., 2002b; Furukawa et 
al., 2008)) however, when assessed, amyloid features are reported as absent in SOD1-fALS and 
sALS patients (e.g. (Wang et al., 2002b; Kerman et al., 2010; Kato et al., 2000; Kato et al., 1996; 
Kato et al., 1997; Okamoto et al., 1991)). Further examination of the in vitro non-amyloid 
seeding potential of SOD1-fALS mice and patient tissue is needed.  
Cellular models have also illuminated prion-like properties of SOD1. In an early example, 
Urushitani et al., (2006) found that transgenic SOD1 primary MNs secreted SOD1 into the 
culture medium and that recombinant mutant SOD1 and high concentrations of apo WT SOD1 
were both highly toxic to non-transgenic primary MNs when applied to the culture medium. 
One year later, Ezzi et al., (2007) confirmed that recombinant extracellular mutant SOD1 was 
toxic to primary MNs and extended this finding to oxidised WT SOD1. 
Extracellular mutant SOD1 aggregates were shown to be efficiently internalised by a mouse 
neuronal like cell line, where they induced the aggregation of stably expressed mutant (but not 
WT) SOD1. These seeded aggregates persisted for up to 1 month and were themselves 
transmitted between cells (Munch et al., 2011) demonstrating aggregated SOD1 self-seeding 
and cell-to-cell propagation. Similar self-seeding was observed by recombinant mutant 
amyloid fibrils in the same cell line expressing a tagged human mutant SOD1 (Furukawa et al., 
2013).  
Transient expression of mutant SOD1 can also induce the sustained misfolding of the 
endogenously expressed WT SOD1 in human cell lines. Furthermore, this misfolded WT SOD1 
can transmit between cells via conditioned media, eliciting further misfolding in naïve cells and 
even in primary neurons from WT SOD1 transgenic mice (Grad et al., 2011; Grad et al., 2014). 
These experiments exemplify cross-seeded templated misfolding and sustained cell-to-cell 
propagation of self-seeded templated misfolding. In another human cell line, exogenously 
applied recombinant mutant SOD1 (both aggregated and non-aggregated) and aggregated WT 
SOD1 not only elicits aggregation of endogenous SOD1, but also activate ER stress and 
apoptotic cell death (Sundaramoorthy et al., 2013), demonstrating ALS relevant toxicity related 
to self-seeded and cross-seeded reactions.  
Also of note is the finding that astrocytes derived from SOD1-fALS mice have increased 
secretion of SOD1 in exosomes, as compared to TgWT mice, and that these mutant SOD1 
containing exosomes are toxic to primary cultures (Basso et al., 2013).  
Together this evidence demonstrates that in cell models, both self-seeded and cross-seeded 
misfolding can be transmitted cell-to-cell and that this process can be self-propagating with 
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previously naïve SOD1 itself acting as a template/seed. Furthermore, some evidence also 
suggests that these processes may have toxic consequences.  
Similar work has been carried out exploring the prion-like properties of other “hallmark” 
neurodegenerative proteins and, as summarised in Table 1.6, has been extended to include in 
vivo examination of prion-like mechanisms in transgenic mouse models of several 
neurodegenerative diseases. The ability of intracerebral inoculation of misfolded proteins to 
induce misfolding and spread of pathology, and even in some cases to induce a disease 
phenotype has been demonstrated, as summarised in Table 1.6. Although in vivo prion-like 
mechanisms of SOD1 have not yet been explicitly examined in animal models, experiments 
using non-human primates commencing in the 1950s to examine a possible viral aetiology of 
ALS are relevant; in 1963, Zil’ber et al., reported the successful induction of ALS in monkeys by 
intracerebral inoculation with CNS homogenates of ALS patients. 2-5-years after the 
inoculation, weight loss, muscle atrophy and paralysis developed, and MN loss was 
demonstrated most mortem. Furthermore, the disease was successfully passaged to 2 
subsequent generations. Subsequent attempts to replicate these results by inoculation into 
non-human primates, small laboratory mammals and birds all failed (Gajdusek et al., 1964; 
Gibbs et al., 1972).  
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Table 1.6 Prion-like proteins in neurodegenerative diseases 
The table summarises evidence available for prion-like properties of several neurodegenerative disease “hallmark” proteins. Positive cases are highlighted in green 
and negative cases are highlighted in pink.  
      Tau α-synuclein Aβ SOD1 TDP43 
Seeded-
aggregation in vitro   Yes (1) Yes (6) Yes (11) 
Yes (14, 15, 
16) Yes (21) 
Seeded-
aggregation 
in cell 
culture   Yes (1, 2, 3) Yes (7)   
Yes (16, 17, 
18, 19, 20) 
Yes (22) and using a 
protein transduction 
reagent (21) 
Cell-to-cell 
spread 
in cell 
culture   Yes (1, 2) Yes (7, 8)   Yes (17, 20) Yes (22) 
Cell-to-cell 
spread in mice recombinant 
Yes, earlier presence 
in mutant tau mouse 
(23) 
Yes, earlier presence 
in mutant α-Syn 
mouse (9) 
Yes, earlier presence in 
mutant APP mice (12)     
Cell-to-cell 
spread in mice lysate 
Yes, in WT Tau mice 
(4, 5) 
Yes, earlier presence 
in mutant α-Syn 
mouse (9) 
Yes, earlier presence in 
mutant APP mice (12, 13)     
Clinical 
disease in mice recombinant   
Yes earlier than in 
mutant α-Syn mouse 
(9) No (13)     
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      Tau α-synuclein Aβ SOD1 TDP43 
Clinical 
disease in mice lysate 
Cell death but no 
symptomatic disease 
in WT Tau mice (4) 
Yes earlier than in 
mutant α-Syn mouse 
(9, 10) 
cell death but no 
symptomatic disease (13)     
 
1- (Frost et al., 2009); 2- (Kfoury et al., 2012); 3- (Santa-Maria et al., 2012); 4- (Clavaguera et al., 2009); 5- (Clavaguera et al., 2013); 6- (Yonetani et al., 2009) 7- 
(Desplats et al., 2009); 8- (Hansen et al., 2011); 9- (Luk et al., 2012); 10- (Mougenot et al., 2012); 11- (Petkova et al., 2005); 12- (Stöhr et al., 2012); 13- (Meyer-
Luehmann et al., 2006); 14- (Chia et al., 2010); 15- (Hwang et al., 2010); 16- (Grad et al., 2011); 17- (Munch et al., 2011); 18- (Sundaramoorthy et al., 2013); 19- 
(Furukawa et al., 2013); 20- (Grad et al., 2014); 21- (Furukawa et al., 2011); 22- (Nonaka et al., 2013); 23- (Iba et al., 2013) 
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1.5.5 Wild-type SOD1 Pathogenicity  
That WT SOD1 can be found in aggregates in SOD1-fALS patients has been known for some 
time (e.g. (Bruijn et al., 1998)) and SOD1 aggregates have been reported in some, but not all, 
sALS cases (Shibata et al., 1994; Shibata et al., 1996a; Matsumoto et al., 1996; Watanabe et al., 
2001a). More recently, misfolded SOD1 antibodies are increasingly revealing misfolded SOD1 
in sALS and non-SOD1 fALS (Bosco et al., 2010; Forsberg et al., 2010; Forsberg et al., 2011; 
Pokrishevsky et al., 2012; Gruzman et al., 2007), although there are exceptions (Furukawa, 
2012; Ling et al., 2013).  
As has been touched upon above, in models of prion-like misfolding, WT SOD1 can take on 
mutant-like properties. Other, non-prion, mechanisms such as oxidative damage, demetalation 
or loss or gain of post-translational modifications can also cause WT SOD1 to misfold and 
become toxic to MNs (e.g. (Ezzi et al., 2007; Redler et al., 2011; Proctor et al., 2011; Rakhit et 
al., 2004; Lindberg et al., 2004; Urushitani et al., 2006; Estévez et al., 1999)). Misfolding and 
oxidisation of WT SOD1 has also been reported to result from expression of either mutant or 
WT TDP43 or WT FUS expression in cellular models (Pokrishevsky et al., 2012).  
In transgenic mice expressing WT SOD1, ALS related pathology is present at a late stage (Dal 
Canto et al., 1995). With higher level of WT SOD1 expression, motor dysfunction and MN loss 
occur in conjunction with misfolded SOD1 detectable by pathology and biochemistry (Graffmo 
et al., 2012; Jaarsma et al., 2000). In cellular and in vitro models, misfolded-oxidised WT SOD1 
can mimic mutant SOD1, disturbing anterograde axonal transport, activating ER-stress and 
interacting with Bcl-2 to cause mitochondrial damage (Bosco et al., 2010; Sundaramoorthy et 
al., 2013; Pasinelli et al., 2004; Guareschi et al., 2012). 
Evidence from SOD1 transgenic mice suggests that the presence of WT SOD1 exacerbates the 
mutant SOD1 toxicity (Deng et al., 2006; Prudencio et al., 2010; Wang et al., 2009b; Jaarsma et 
al., 2000; Jaarsma et al., 2008), possibly by increasing solubility (Fukada et al., 2001). Correctly 
folded and metalated WT SOD1 has also been found to exacerbate the toxicity of zinc deficient 
misfolded WT SOD1 in primary MN (Sahawneh et al., 2010).  
WT SOD1 could potentially increase the toxicity of mutant/misfolded SOD1 by stabilising a pre-
aggregated toxic species which would result in the slowed aggregation reported with co-
expression in cellular models (Weisberg et al., 2012; Brotherton et al., 2012; Prudencio et al., 
2009a; Prudencio et al., 2010; Witan et al., 2008; Witan et al., 2009). Heterodimerisation 
between mutant/misfolded and WT SOD1 monomers has been posited as a possible 
mechanism by which WT SOD1 could affect this (Witan et al., 2009; Witan et al., 2008; 
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Weichert et al., 2014). Thus WT SOD1 has potential to cause toxicity via both prion-like and 
non-prion like pathways.  
1.6 CURRENT QUESTIONS IN MOUSE MODELS OF SOD1-FALS AND 
RESEARCH PROJECT AIMS  
1.6.1 Does SOD1 Have Prion-Like Properties Within the CNS?  
Misfolded SOD1 can act as a seed to promote both amyloid and non-amyloid aggregation in 
vitro and in cell culture misfolded SOD1 is able to transfer between cells and act as a template 
or seed to elicit misfolding via both self-seeding and cross-seeding reactions. In mouse models 
of other neurodegenerative diseases exogenous sources of misfolded hallmark proteins can 
elicit misfolding and pathological changes and in some cases can even produce symptomatic 
disease. It is not yet known whether the prion-like properties of SOD1 revealed by in vitro and 
cellular models can translate in vivo in an animal.  
1.6.1.1 AIM: PROPAGATION OF SOD1 MISFOLDING IN VIVO 
Does SOD1 have prion-like properties in an in vivo model? This work aimed to investigate 
whether exogenous mutant human SOD1 can elicit the aggregation of transgenically expressed 
human SOD1 in mice.  
To assess cross-seeded-aggregation in vivo, SC homogenate of TgG93A mice at a symptomatic 
age were intracerebrally inoculated into young TgG93A mice and the consequences on the 
misfolded SOD1 aggregate pathology were measured to see if an increase resulted, as has 
been reported in similar experiments with mutant α-Synuclein and APP mice (Luk et al., 2012; 
Mougenot et al., 2012; Stöhr et al., 2012; Meyer-Luehmann et al., 2006). A second set of 
experiments was carried out to assess cross-seeded-aggregation of WT SOD1 by mutant SOD1 
in vivo, as has been demonstrated in transgenic Tau mice (Clavaguera et al., 2009; Clavaguera 
et al., 2013). In these experiments, TgWT mice were intracerebrally inoculated with SC 
homogenate from symptomatic TgG93A mice and SOD1-fALS motor cortex.  
The aim of this work was to assess whether some of the prion-like properties of SOD1 which 
have been established in vitro and in cellular models are relevant to SOD1 within the CNS. In 
particular we have aimed to evaluate whether seeded-aggregation of transgenically expressed 
SOD1 can occur and spread through the CNS.  
1.6.2 Does Endogenous Mouse Sod1 Affect the Disease Phenotype 
of the SOD1G93A-fALS Transgenic Mouse?  
The phenotype of transgenic mouse models of some neurodegenerative diseases have been 
found to be affected by the endogenous mouse homologue of the human protein being 
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expressed. In mouse models of infectious human prion disease, for example, the presence of 
the mouse PrP in conjunction with human PrP significantly lengthens the incubation period 
between inoculation and disease onset and produces more variable phenotypes than when 
the mouse gene is knocked-out (Telling et al., 1995; Collinge et al., 1995). Mice expressing WT 
human tau from a genomic transgene remained healthy with no disease pathology when the 
endogenous mouse Mapt gene was functional (Duff et al., 2000), however, when mouse Mapt 
was knocked-out, hyperphosphorylated tau accumulated and a pattern of pathology similar to 
that seen in AD, including neuronal death, developed (Andorfer et al., 2003; Andorfer et al., 
2005). Similarly, in a mutant α-synuclein model which developed only mild late onset motor 
disturbance and rarely any pathology, ablation of the endogenous counterpart resulted in 
reduced survival, progressive motor disturbance and characteristic pathology (Cabin et al., 
2005).  
Two previous publications have touched upon the role of endogenous moSOD1 in SOD1-fALS 
mice; in 1998, Bruijn et al., compared G85R mutant SOD1 transgenic mice, with or without an 
endogenous Sod1 KO. Comparing 5 animals of each genotype revealed no difference in 
survival. Motor axon number was also not significantly different between genotypes, but only 
three Sod1+/+ and two Sod1-/- animals were examined and variance between animals was high. 
In 2006, Deng et al., carried out a similar cross with a G93A mutant SOD1 transgenic and found 
a modest delay in disease onset and longer survival in the Sod1-/- mice.  
WT and mutant huSOD1 appear to interact to exacerbate the disease process, as described 
above, but differences in these interactions are apparent when one of these elements is 
derived from human and one from mouse; while double transgenic mice expressing both 
mutant and WT huSOD1 have a more severe phenotype than single mutant transgenics, the 
addition of WT huSOD1 does not affect the phenotype of the G86R mutant moSOD1 
transgenic mouse (Audet et al., 2010). Both WT huSOD1 and moSOD1 slow the aggregation of 
mutant huSOD1 in a cell culture model (Prudencio et al., 2009a), but when aggregates develop, 
only WT huSOD1, but not WT moSOD1, co-aggregates with mutant huSOD1 (Prudencio et al., 
2009a; Grad et al., 2011). When aggregation of mutant moSOD1 was examined in the presence 
of WT huSOD1, co-aggregation was not detected; whether WT moSOD1 affected the speed of 
aggregation was not assessed (Qualls et al., 2013).  
WT huSOD1 and moSOD1 have a similar aggregation propensity when transiently expressed in 
cells, however the ALS mutation, G85R, produces significantly less aggregation in the context 
of moSOD1 than huSOD1 (Karch et al., 2010). In line with this the moSOD1 dimer is 
significantly more stable than the huSOD1 dimer in terms of resistance to thermal and 
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chemical denaturants (Jonsson et al., 2006a). The functional consequences of these similarities 
and differences in a disease model are not clear.  
1.6.2.1 AIM: ENDOGENOUS SOD1 IN SOD1G93A TRANSGENIC MICE 
The aim of this section of work was to look again at the potential effects of WT moSOD1 in the 
TgG93A mouse model of SOD1-fALS by examining TgG93A mice with and without the 
endogenous protein. Behavioural and histological techniques were used to assess whether 
endogenous WT moSOD1 effects the progression of disease, MN survival and aspects of 
neuromuscular atrophy.  
1.6.3 Can We Improve on Current Mouse Models of SOD1-fALS? 
All currently available mouse models of SOD1-fALS are traditional random integration 
transgenics. A huge amount of information about the disease processes and pathogenic 
mechanisms of mutant SOD1 have been gleaned using these models, however there are draw 
backs to this type of mouse model such as artificially high expression and fast disease 
progression making examination of early disease processes more difficult.  
New tools for genetically engineering mice open the possibility for more refined alterations of 
the mouse genome, allowing us to more precisely mimic the genomic context of human 
disease. Could creating a mouse which more closely reflects the genetic architecture of mutant 
SOD1 in SOD1-fALS patients provide a more accurately model the disease?  
1.6.3.1 AIM: A NEW MOUSE MODEL OF SOD1-FALS 
Using a combination of traditional restriction endonuclease cloning and recombineering, 
targeting constructs were produced to genomically humanise the mouse Sod1 locus. The 
construct was designed to replace the mouse locus with the full SOD1 gDNA sequence, 
including an ALS mutation. The construct design also includes engineered DNA sequence to 
facilitate a Cre dependent switch from expression of mutant to WT SOD1.  
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Chapter 2. Materials and Methods 
2.1 GENERAL MOLECULAR BIOLOGY PROTOCOLS 
2.1.1 Extraction/Purification of Nucleic Acids 
2.1.1.1 EAR/TAIL BIOPSY DNA PREPARATION 
For each ear biopsy/0.5 mm piece of tail tissue 50 µL Extraction Solution (Sigma) and 12.5 µL 
Tissue Prep Solution (Sigma) were added. Samples were incubated at room temperature (r/t) 
for 20 mins and then at 95 °C for 4 mins. Samples were centrifuged at maximum speed in a 
bench top microfuge (see Section 7.2, Appendix 2) for 30 secs and 50 µL Neutralisation 
Solution B (Sigma) added and mixed by vortexing. Samples were then centrifuged at maximum 
speed for 7 mins. For PCR, 1 µL of a 1/10 dilution in ddH2O was used as template.  
2.1.1.2 PURE PLASMID PREPARATIONS 
Qiagen kits were used for preparation of plasmid DNA when removal of bacterial genomic DNA 
was necessary. QIAprep Spin Miniprep Kit, QIAGEN Plasmid Maxi Kit or QIAGEN Large-
Construct Kit was used according to the manufacturer’s instructions.  
2.1.1.3 RAPID PLASMID PREPARATION 
5 mL overnight culture was centrifuged 7000 rcf for 5 mins and supernatant discarded. The 
pellet was resuspended in 250 µL Qiagen buffer P1 by pipetting and transferred to a 1.5 mL 
microfuge tube. 300 µL Qiagen buffer P2 was added and mixed thoroughly but gently by 
inversion, for no longer than 5 mins. 350 µL Qiagen buffer P3 was added and mixed thoroughly 
but gently by inversion. The tube was then centrifuged at full speed for 10 mins in a bench top 
microfuge and the supernatant transferred to a fresh tube. 0.6 volumes isopropanol (roughly 
540 µL) was added to the supernatant and mixed thoroughly but gently by inversion. The tube 
was then centrifuged at full speed for 20 mins and the supernatant aspirated and discarded. 
The pellet was then washed in 500 µL 70% (v/v) ethanol, centrifuged at full power for 5 mins 
and the supernatant aspirated and discarded. The pellet was allowed to air dry for 10 mins 
before resuspension. Typically resuspension was in 20 µL ddH2O.  
2.1.1.4 FAST DNA PREPARATIONS FOR PLASMID SCREENING PCR 
2.1.1.4.1 Individual Colonies  
Using a sterile 20/200 µL pipette tip, an individual colony was picked from a Luria Broth (LB) 
agar base plate. The tip was swirled in 50 µL ddH2O in a 96 well plate or PCR tube strip, and 
then the tip used to streak onto a small area of a fresh LB agar plate.  
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2.1.1.4.2 Liquid Cultures  
100 µL culture was transferred to a 96 well PCR plate, sealed with plastic film and centrifuged 
at full power for 15 mins. The sealing film was then removed and the plate was inverted over 
tissue paper and tapped sharply to remove media. 100 µL ddH2O was added to each well and 
the plate sealed with individual cap strips. Using a PCR thermo-cycler the following programme 
was run: Lid heated to 100 °C. 105 °C for 10 mins, 4 °C for 5 mins. The plate was then 
centrifuged at full power for 15 mins to pellet debris and 1 µL supernatant used as template in 
a 10 µL PCR.  
2.1.1.5 PURIFICATION OF DNAS FROM AGAROSE GEL AND MOLECULAR BIOLOGY 
BUFFERS 
2.1.1.5.1 Gel Extraction 
For extraction of DNA from agarose gel after electrophoresis, bands were visualised using 
ethidium bromide stained gels (see Section 2.1.7) on an ultra violet gel illuminator and excised 
using a clean scalpel blade. Qiagen kits, QIAquick Gel Extraction Kit and QIAEX II Gel Extraction 
Kit were used for purification according to the manufacturer’s guidelines for size of the DNA 
fragment to be purified following the manufacturer’s instructions.  
2.1.1.5.2 DNA Purification from Molecular Biology Buffers 
For purification of PCR products Qiagen QIAquick PCR Purification Kit was used following 
manufacturer’s instructions.  
For purification of DNA fragments from restriction endonuclease (RE) digestions and for 
sequencing reactions, microCLEAN (Microzone) was used following the manufacturer’s 
instructions.  
2.1.1.5.3 Phenol:Chloroform Purification of DNA 
Two volumes phenol:chloroform was added to the DNA sample and mixed thoroughly by 
inversion. The sample was centrifuged at full speed for 5-10 mins in a bench top microfuge. 
The top, aqueous phase was transferred to a fresh tube. Two volumes of chloroform was then 
added and inverted to mix, before repeating the centrifuge and removing the aqueous phase 
to a fresh tube. 2-3 volumes 100% ethanol was added, mixed thoroughly by inversion, and 
incubated at room temperature for 10 mins. The sample was then centrifuged at full speed for 
20 mins and the supernatant aspirated. If not pellet was visible a further incubation at 4 °C or 
at -20 °C was carried out. The sample was washed in 1 volume 70% ethanol before a further 
centrifuge and aspiration step. Pellets were air dried before resuspension in H2O or Tris-EDTA 
buffer pH 8 (TE. Sigma).  
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2.1.2 Polymerase Chain Reaction  
All primers were purchased from Sigma Aldrich as desalted lyophilised pellets. Stocks were 
reconstituted in ddH2O to 100 µM and stored at -20 °C. Working dilutions were made to 5 µM 
with ddH2O and stored at -20 °C.  
For screening and genotyping PCRs where 100% faithful amplification of the target sequence 
was not required, Sigma-Aldrich REDTaq ReadyMix (REDTaq), a 2X mega mix was used. 
Extension was carried out at 72 °C and extension time was calculated based on 1 min per 2 kb 
to be amplified. This mega mix contains gel loading dye and buffer so PCR products were 
loaded directly onto agarose gels.  
For PCR amplification for recombineering products or other applications where faithful 
amplification of the target sequence was required Invitrogen AccuPrime Pfx SuperMix 
(AccuPrime) a 1.1X mega mix was used. Extension was carried out at 68 °C and extension time 
was calculated based on 1 min per 1 kb to be amplified. For gel electrophoresis, an appropriate 
volume of Bioline Crystal 5X DNA Loading Buffer Blue was mixed with the product before 
loading onto the gel.  
2.1.2.1 TOUCHDOWN PCR 
Touchdown PCR was used for amplification of products for sequencing and recombineering 
using AccuPrime Pfx SuperMix. The touchdown PCR master mix is given in Table 2.1.  
 
Cycling conditions for touchdown PCR (unless otherwise specified):  
1 95 °C 5 mins   
2 95 °C 15 secs Denature 
3 68 °C 30 secs Anneal 
    Decrease by 1 °C each cycle   
4 68 °C 1 min per kb Extend 
5   Cycle from step 2, 12 times   
6 95 °C 15 secs Denature 
7 55 °C 30 secs Anneal 
8 68 °C 1 min per kb Extend 
9   Cycle from step 6, 21 times   
Table 2.1 Touchdown PCR master mix 
 n=1 Final concentration 
AccuPrime 1.1X 22 µL  
Template (usually 10 ng/µL) 1 µL 0.4 ng/µL 
Forward primer (5 µM) 1 µL 0.2 µM 
Reverse primer (5 µM) 1 µL 0.2 µM 
 25 µL  
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10 68 °C 1 min per kb Final extension 
11 4 °C Forever   
2.1.2.2 STANDARD PLASMID SCREENING PCR 
Template was 1 µL plasmid DNA prepared by either the “rough” or “rapid” protocol described 
above.  
Two to four primers were used in combination depending upon the particular screening PCR. 
Where possible, multiplex primer combinations were used to include both internal controls 
and test primers in the same PCR. 1 µL each primer (5 µM) was added and an appropriate 
volume of ddH2O added to give a final volume of 10 µL. The screening PCR master mix is given 
in Table 2.2.  
 
Cycling conditions for standard plasmid screening PCR (unless otherwise specified):  
1 95 °C 5 mins  
2 95 °C 30 secs Denature 
3 55 °C 30 secs Anneal 
4 72 °C 30 secs per kb Extension 
  Cycle from step 2, 35 times  
5 72 °C 5 mins Final extension 
6 4 °C Forever  
2.1.2.3 GRADIENT PCR 
The gradient PCR used the same master mix as is given in Table 2.2.  
Cycling conditions were as follows:  
1 95 °C 5 mins   
2 95 °C 30 secs Denature 
3 45-55°C 30 secs Anneal 
4 72°C 30 secs Extend 
5   Cycle from step 2, 35 times   
2.1.2.4 SOD1 TRANSGENE GENOTYPING PCR 
The same PCR protocol was used to genotype both the wild-type (WT) and G93A SOD1 
transgenic mice.  
Table 2.2 Standard plasmid screening PCR master mix 
 n=1 Final concentration 
ddH2O X µL To make up to 10 µL total volume 
REDTaq (2X) 5 µL 1X 
Template 1 µL  
Primer (5 µM) X µL 0.5 µM for each primer 
 10 µL  
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Primers details are given in Table 2.3. A working stock mix of primer was prepared by adding 
20 µL each of the 4 stock primers (100 µM) to 120 µL ddH2O to produce a working stock mix of 
5 µM per primer.  
Template was 1 µL of a 1/10 dilution in ddH2O of genomic DNA prepared as described in 
Section 2.1.1.1. The genotyping master mix is given in Table 2.4.  
 
 
Cycling conditions for SOD1 transgene genotyping PCR:  
1 95 °C 3 mins  
2 95 °C 30 secs Denature 
3 60 °C 30 secs Anneal 
4 72 °C 45 secs Extend 
  Cycle from step 2 35 times  
5 72 °C 2 mins Final extension 
6 4 °C Forever  
 
PCR products were resolved on a 2% agarose 45 mM Tris-borate, 1 mM EDTA 
(ethylenediaminetetraacetic acid) (TBE) gel (see Section 2.1.7 below for details) running at 100 
V (~7 V/cm) for 30 mins.  
A control band of 324 bp amplifies across an intron/exon boundary (exon 3/intron 3) from the 
gene Interleukin 2 (Il2) on chromosome 3. This control fragment should be present in all 
samples and acts as a control to check that the PCR has been successful. A band of 236 bp 
amplifies across exon 4 of the SOD1 transgene, from intron 3 to intron 4.  
2.1.2.5 SOD1 KNOCKOUT GENOTYPING PCR 
Primers details are given in Table 2.5 and were taken from the Jackson Laboratory (Jax) 
website (http://jaxmice.jax.org/). A working stock mix of primer was prepared by adding 20 µL 
Table 2.3 Transgene genotyping primers 
 Forward Reverse 
Control  CTAGGCCACAGAATTGAAAGATCT GTAGGTGGAAATTCTAGCATCATC 
Transgene  CATCAGCCCTAATCCATCTGA CGCGACTAACAATCAAAGTGA 
 
Table 2.4 Genotyping PCR master mix 
 n=1 Final concentration 
ddH2O 3 µL  
REDTaq (2X) 5 µL 1X 
Template 1 µL  
Primer mix (5 µM) 1 µL 0.5 µM per primer 
 10 µL  
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each of the 4 stock primers (100 µM) to 120 µL ddH2O to produce a working stock mix of 5 µM 
per primer.  
Template was 1 µL of a 1/10 dilution in ddH2O of genomic DNA prepared as described above in 
Section 2.1.1.1. The genotyping PCR master mix is given in Table 2.4, above.  
 
Cycling conditions for the Sod1 knockout genotyping PCR:  
1 95 °C 3 mins  
2 95 °C 20 secs Denature 
3 61 °C 1 min Anneal 
4 72 °C 1 min Extend 
  Cycle from step 2 35 times  
5 72 °C 5 mins Final extension 
6 4 °C Forever  
PCR products were resolved on a 2% agarose TBE gel (see Section 2.1.7 below) running at 100 
V (~7 V/cm) for 30 mins.  
In the presence of the wild-type allele a 123 bp band is amplified from exon 2 to intron 2 of 
Sod1 on chromosome 16. In the presence of the knockout (KO) allele a band of 240 bp is 
amplified. This larger band presumably amplifies from the selection cassette which was used 
to replace exon 1 and exon 2, however the sequence of this cassette was not published by 
Matzuk et al., (1998) and details are not given on the Jax website where these primers were 
taken from, so this could not be confirmed.  
2.1.3 Quantitative Real Time PCR (qPCR) SOD1 Transgene Copy 
Number Assay 
The qPCR copy number assay of transgene copy number was developed from the protocol 
published on the Jackson Laboratory website (http://jaxmice.jax.org). The assay used TaqMan 
(Applied Biosystems) reagents and used relative standard curve quantitation of multiplex 
reactions, containing one measure of the transgene (Tg) and one internal endogenous control 
(EC).  
The oligos detailed in Table 2.6 were ordered from Sigma as lyophilised pellets and 
resuspended to 100 µM according to the manufacturer’s instructions.  
Table 2.5 KO genotyping primers 
 Forward Reverse 
Control  TGAACCAGTTGTGTTGTCAGG  TCCATCACTGGTCACTAGCC   
KO  TGTTCTCCTCTTCCTCATCTCC  ACCCTTTCCAAATCCTCAGC   
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The endogenous control primers amplified 74 bp from exon 24 of the Apob gene on mouse 
chromosome 12. The transgene primers amplified 88 bp from intron 4 of the human SOD1 
transgene.  
A 50X master mix of primer and probe (all stocks at 100 µM) was made to reduce variability 
between assays as detailed in Table 2.7.  
 
Experimental templates were extracted as described in Section 2.1.1.1 and a 1/20 dilution in 
ddH2O was used. TaqMan Universal PCR Master Mix with passive internal reference, and 
AmpErase UNG (Applied Biosystems), was used in the master mix detailed in Table 2.8.  
Table 2.6 Primers and probes for SOD1 transgene copy number qPCR assay 
Name 5' label Sequence 3' label 
Endogenous control (EC) 
forward primer 
- CACGTGGGCTCCAGCATT - 
Endogenous control (EC) 
reverse primer 
- TCACCAGTCATTTCTGCCTTTG - 
Transgene (Tg) forward 
primer 
- GGGAAGCTGTTGTCCCAAG - 
Transgene (Tg) reverse 
primer 
- CAAGGGGAGGTAAAAGAGAGC - 
EC probe Cy5 CCAATGGTCGGGCACTGCTCAA Black Hole 
Quencher 2 
Tg probe 6-FAM CTGCATCTGGTTCTTGCAAAACA
CCA 
Black Hole 
Quencher 1 
 
Table 2.7 Prime and probe stock for SOD1 transgene copy number qPCR assay 
  Volume for 100 
µL of 50X stock 
Conc. in 
50X stock 
Final conc. (0.2 µL 
in 10 µL reaction) 
EC forward primer 40 µL 40 µM 0.8 µM 
EC reverse primer 40 µL 40 µM 0.8 µM 
Tg forward primer 5 µL 5 µM 0.1 µM 
Tg reverse primer 5 µL 5 µM 0.1 µM 
EC probe 5 µL 5 µM 0.1 µM 
Tg probe 5 µL 5 µM 0.1 µM 
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A 5 point standard curve was created for each assay plate using a known copy number DNA 
supplied by Jackson Laboratories (JAXref). The 5 DNA concentrations used to create the 
standard curve were 100, 20, 4, 0.8 and 0.16 ng/µL. For each point on the standard curve, 6 
replicate reactions were set up. Three of these replicates were measured for the SOD1 Tg 
standard curve and three were measured for the EC standard curve.  
Each experimental DNA sample was assayed over 4 replicate reactions. Two control DNAs, also 
in 4 replicates, were included in each assay plate; JAXref was used as one reference and a 
second was a known reduced copy number DNA.  
Applied Biosystems 7500 Software v2.0.1 was used to set up a standard (2 hr) run, using 
default baseline and threshold settings and the following cycling conditions:  
1 50 °C 2 mins 
2 95 °C 10 mins 
3 95 °C 15 secs 
4 60 °C 1 min 
  Cycle from 3 another 39 times 
 
At the end of the run, the standard curve was first checked for amplification outliers and to 
ensure that the experimental values fell within the standard curve. Next, experimental outliers 
as identified by the software were excluded and the analysis re-run.  
The delta Ct was calculated by subtracting the mean SOD1 Tg Ct from the mean EC Ct for each 
replicate group. The delta-delta Ct was then calculated by subtracting the replicate group delta 
Ct from the JAXref delta Ct. Relative quantity was then calculated as 2 to the power of the 
negative delta-delta Ct.  
2.1.4 Restriction Endonuclease Digestion 
Restriction endonucleases (RE) were purchased from New England BioLabs (NEB) and digests 
carried out using the supplied buffer and bovine serum albumin (BSA) according to the 
manufacturer’s guidelines. Reaction volumes were between 40 and 100 µL depending on the 
Table 2.8 SOD1 transgene copy number qPCR master mix 
 n=1 
ddH20 3.8 µL 
TaqMan Universal PCR Master Mix (2X) 5 µL 
Primer & probe mix (50X) 0.2 µL 
DNA 1 µL 
 10 µL 
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concentration of the DNA to be digested and to ensure that the concentration of glycerol was 
not above that recommended by the manufacturer. Concentration of glycerol in the final 
reaction should be kept below 10% as levels higher than this can result in the inhibition of 
enzymatic activity or star activity resulting aberrant cutting activity.  
Where possible, enzymes were heat inactivated according to the manufacturer’s instructions. 
RE digests were analysed by agarose gel electrophoresis to check for expected band sizes. 
Digested DNA was purified using MicroCLEAN or QIAquick PCR Purification Kit or bands 
separated by agarose gel electrophoresis and the appropriate band excised and gel extracted 
as described in Section 2.1.1.5.1.  
2.1.5 Restriction Endonuclease Cloning 
1 µg plasmid DNA (vector) or PCR (insert) was digested using 20 U BamHI-HF (NEB) for 4 hrs at 
37 °C in a volume of 10 µL. 1 µL was analysed by agarose gel electrophoresis to check success 
of the digest. The digested vector was de-phosphorylated to stop it re-ligating back on itself. 
10 U alkaline phosphatase calf intestinal (CIP) (NEB) was added to the remaining digest 
reaction and incubated at 37 °C for 2 hrs. QIAquick PCR Purification Kit was used to purify both 
insert and vector.  
Ligations were carried out using roughly a 3:1 ratio of insert:vector, by copy number. ~500 ng 
total DNA was incubated with 400 U T4 DNA ligase (NEB) and 1X ligase buffer in a 20 µL 
volume at 16 °C overnight. The enzyme was then heat deactivated at 65 °C for 15 mins and 
1 µL of the reaction was transformed into chemically competent DH10B E.coli as described in 
Section 2.2.4.  
2.1.6 Sanger Sequencing  
For sequencing directly from BACs or plasmids, 50-100 ng template DNA was used. When 
sequencing template was a PCR product Table 2.9 was referred to for template quantities: 
Sequencing reactions were set up on ice and out of direct light due to the photosensitivity of 
BigDye Terminator v1.1, in a 96 well plate as detailed in Table 2.10. BetterBuffer was used as 
standard as it was found to be more reliable. When longer reads were required, BetterBase 
was used.  
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For sequencing from PCR products the following amplification protocol was followed: 
1 96 °C 1 min  
2 96 °C 30 secs Denature 
3 50 °C 15 secs Anneal 
4 60 °C 3 mins Extension 
  Cycle from step 2, 29 more times  
5 15 °C 5 mins Final extension 
6 4 °C forever  
 
For sequencing directly from BACs and plasmids, the following amplification protocol was 
followed:  
1 96 °C 5 mins  
2 96 °C 30 secs Denature 
3 55 °C 15 secs Anneal 
4 60 °C 6 mins Extension 
  Cycle from step 2, 34 more times  
5 5 °C Forever  
After amplification each reaction was precipitated by addition of 37.5 µL (2.5 X volumes) 100% 
ethanol, 1.5 µL (0.1 X volumes) 125 mM EDTA and 1.5 µL (0.1 X volumes) 3M sodium acetate 
and mixed. The plate was incubated at r/t for 15 mins and then centrifuged for 30 mins at 
2500 x g. The plate was then inverted over tissue and centrifuged for ~10 secs to remove the 
supernatant. 70 µL 70% ethanol was then added, and the plate centrifuged for 15 mins at 
2000 x g. Again, the plate was inverted over tissue and centrifuged for 1 min at 100 x g. Sample 
were allowed to air dry for 10 mins away from direct light and stored at -20 °C if not to be 
Table 2.9 Template quantities used for Sanger sequencing of PCR products 
Template size Quantity 
100-200 bp 1-3 ng 
200-500 bp 3-10 ng 
500-1000 bp 5-20 ng 
1000-2000 bp 10-40 ng 
>2000 bp 20-50 ng 
 
Table 2.10 Sanger sequencing reaction master mix 
 n=1 
ddH2O X µL 
BetterBase/Buffer (MicroZone) 5 µL 
BigDye v1.1 (Applied Biosystems)  1 µL 
Betaine (5M) (Sigma Aldrich) 1 µL 
Template X µL 
Primer (5 µM) 1 µL 
 15 µL 
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processed immediately. 20 µL of formamide was added to each well of the plate and the 
reactions denatured by incubation at 95 °C for 5-10 mins before chilling briefly either on ice or 
on a 4 °C thermal cycler. Reactions were analysed by capillary electrophoresis on an ABI 3730XI 
DNA analyser.  
2.1.7 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was carried out using a horizontal submarine gel tank (Mupid). A 
voltage of ~7v/cm was used for most applications, unless otherwise specified. 10X concentrate 
45 mM Tris-borate, 1 mM EDTA (TBE) was purchased from commercial suppliers and a 1X 
dilution in ddH2O was used as running buffer and for preparation of gels.  
Gels were typically made using 100 mL TBE to produce a gel of approximately 6 mm thickness. 
Invitrogen UltraPure Agarose was dissolved in the TBE by heating in a microwave, taking care 
not to over boil. Ethidium bromide was then added to a concentration of 0.05 µg/mL before 
pouring the gel.  
Once run, gels were visualised, and a digital photograph was taken, using a UV illuminator. 
Quantitative DNA ladders were used to approximate the size of the DNA bands on the gel. For 
expected bands of less than 1 kb, Bioline HyperLadder IV was used and for bands of over 1 kb 
Bioline HyperLadder I was used. 2.5 µL ladder was used for sizing of bands. When the ladder 
was also to be used for quantitation 5 µL of ladder was loaded (see Figure 2.1).  
 
 
Figure 2.1 HyperLadder 
HyperLadder I and HyperLadder IV, respectively 
Picture taken from www.bioline.com 
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2.2 BACTERIAL CULTURE 
All bacterial work was carried out aseptically, under a Bunsen flame.  
Liquid bacterial culture was in Miller’s Modification Luria Broth (LB) unless otherwise stated. 
Miller’s Modification LB is lower in salts than regular LB and so reduces the chance or arching 
when electroporating E.coli that have been cultured using it.  
Volumes of up to 1 mL were contained in 1.5 mL microfuge tubes and incubated in an 
thermomixer (Eppendorf), shaking at 300 rpm. For volumes over 1 mL appropriate size plastic-
ware was used and incubation was in a bench top incubator (see Section 7.2, Appendix 2), 
shaking at 200 rpm.  
Bacteria grown on Luria Agar Base plates (LB plates) were incubated in a stationary bench top 
incubator.  
For details on preparation of plates and media and antibiotic concentrations, see Section 7.2, 
Appendix 2.  
2.2.1 Culture Conditions for Escherichia coli Strains Used 
SW102 E.coli were always cultured at 30 °C unless otherwise specified.  
DH10B E.coli containing high copy plasmids, or no plasmid, were cultured at 37 °C unless 
otherwise stated. DH10B E.coli containing low copy plasmids or BACs were cultured at 30 °C 
unless otherwise stated.  
2.2.2 Overnight Culture 
A 15 mL falcon tube containing 5 mL LB with appropriate antibiotics was inoculated with a 
single colony from an LB agar plate and cultured overnight for ~16 hrs.  
2.2.3 Measurement of E.coli Suspension Concentration 
Concentration of E.coli grown in liquid culture was estimated by spectrophotometry.  
Briefly, 1 mL LB or liquid culture was aliquoted into a disposable cuvette. The LB only aliquot 
was used to blank the equipment after which the OD600 of the culture was measured. 
Concentration was estimated as OD600 of 1 being roughly equal to 1x10
9 cells/mL.  
2.2.4 Transformation of Chemically Competent E.coli 
Chemically competent E.coli were purchased from Invitrogen. MAXefficiency DH10B 
Competent cells and One Shot TOP10 Competent E.coli were used according to the 
manufacturer’s instructions.  
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2.2.5 Preparation and Transformation of Electrocompetent E.coli 
Note- “§” indicates points of deviation from this protocol referenced in Section 2.4 BAC 
Recombineering.  
2.2.5.1 MAKING E.COLI ELECTROCOMPETENT 
500 µL overnight culture was used to inoculate 10 mL LB plus appropriate antibiotics in a 50 
mL Falcon tube and grown for ~3 hrs until OD600 reached 0.5-0.6. At this point 1.5 mL aliquots 
were taken for each planned transformation.  
(§1) Aliquots were transferred to an ice water slurry and chilled for ~5 mins before being 
centrifuged in a pre-chilled, 4 °C bench top microfuge for 15 secs. Supernatant was tipped out 
and the inverted tube tapped sharply on the side of the waste pot to remove as much media 
as possible. 1 mL sterile, ice-cold, 10% glycerol (v/v in ddH2O) was then added to wash the cells 
and the tube inverted to mix. The centrifuge and wash step was repeated once. Samples were 
centrifuged a third time and supernatant tipped out leaving between 50-100 µL. The tubes 
were placed on ice and processed one at a time.  
2.2.5.2 ELECTROPORATION TRANSFORMATION 
(§2) 1 µL of plasmid DNA suspended in ddH2O at 10 ng/µL was added to the tube containing 
the electrocompetent E.coli and the tube was tapped gently to mix. The cell suspension was 
then transferred to a pre-chilled 1 mm gap electroporation cuvette and immediately 
electroporated in a Biorad E.coli Pulser at 1.35 kV, with the time constant set to 5 msecs. The 
actual time constant was noted with readings from 5.3 to 4.8 msecs being acceptable. If 
shorter readings were achieved, DNA was diluted 1:1 in ddH2O to reduce salt content before 
repeating the electroporation on a spare aliquot of electrocompetent E.coli was washed for a 
third time to reduce residual salts from the growing media.  
Immediately after electroporating, 1 mL LB (no antibiotics) was added to the cuvette to 
resuspend the E.coli and the cells were transferred to a fresh 1.5 mL tube. Bacteria were 
cultured for 90 mins without antibiotics to allow time for expression of antibiotic resistance. 
(§3) After this time, an appropriate dilution of the cell suspension was plated onto LB agar 
plates with appropriate antibiotics. Plates were incubated overnight at 30 °C to obtain 
individual colonies.  
2.2.6 Glycerol Stocks 
750 µL overnight culture was added to 750 µL bacterial freezing media (Section 7.2, Appendix 
2) in a 2 mL cryotube and inverted to mix. These were placed in a polystyrene rack in a plastic 
box to slow freeze time and transferred to a -70 °C freezer. Once frozen, tubes were 
transferred into a regular freezer box.  
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When removing glycerol stocks from the freezer to streak LB agar plates, tubes were kept on 
dry ice.  
2.3 PLASMIDS, BACS AND CASSETTES 
2.3.1 BAC Selection  
Human and C57BL/6J (BL/6J) BACs were selected using National Center for Biotechnology 
Information’s (NCBI) CloneDB (http://www.ncbi.nlm.nih.gov/clone/) searching by species and 
gene. BACs were selected based on the position of the SOD1 sequence being central to the 
insert. One human BAC was selected: RP11-535E10 (E10) which resides in the pBACe3.6 
(Frengen et al., 1999) backbone. Two BL/6J BACS were selected: RP24-363N21 (N21) and RP24-
238L18 (L18) both of which reside in the pTARBAC1 (Zeng et al., 2001) backbone. BACs were 
ordered from Children’s Hospital Oakland Research Institute (CHORI) BACPAC Resource Center 
(http://bacpac.chori.org/home.htm).  
The National Institute of Genetics (Japan) (NIG) mouse genome database was used to search 
for an appropriate C57BL/6N (BL/6N) BAC (http://molossinus.lab.nig.ac.jp/msmdb/BacDetail). 
One Sod1 containing BAC was selected: B6Ng01-068O19 (O19) which resides in the pBACe3.6 
(Frengen et al., 1999) backbone. BACs were ordered from Riken Bioresource Center 
(http://dna.brc.riken.jp/en/NBRPB6Nbacen.html).  
Full details of each BAC can be found in Section 7.2.2, Appendix 2.  
2.3.2 Antibiotic Resistance Cassettes  
2.3.2.1 FRT FLANKED NEO CASSETTE 
FRT-PGK-gb2-neo-FRT cassette plasmid was purchased from Gene Bridges. In eukaryotic cells 
the mouse Phosphoglucokinase (PGK) promoter allows for selection with G418/neomycin. In 
Prokaryotic cells, such as E.coli the gb2 promoter, a modified Em7 promoter, allows for 
selection by kanamycin. The cassette is flanked by FRT sites allowing use of FLP recombinase to 
excise the sequence. See Figure 2.2. Primers detailed in Table 2.11 were used for amplification 
of the 1,601 bp cassette. 
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2.3.2.2 RPSL_GEN POSITIVE/NEGATIVE SELECTION 
The rpsL_Gen positive/negative selection cassette was a kind gift from Dr Andrew Smith, and is 
shown in Figure 2.3. The plasmid has a polycistronic operon encoding a gentamicin resistance 
gene (Gen) and an rpsL gene which confers sensitivity to streptomycin. Primer details in Table 
2.12 were used for amplification of the 1,077 bp cassette.  
 
 
Figure 2.2 FRT-PGK-gb2-neo-FRT cassette  
(GeneBridges) 
Table 2.11 Primers for amplification of FRT-PGK-gb2-neo-FRT 
Primer name Primer sequence 
FRT_FOR  CGCGAAGTTCCTATTCTCTAGAAAG 
FRT_REV  CTATAGGGCTCGAGGAAGTTC 
 
Table 2.12 Primers for amplification of rpsL_Gen cassette 
Primer name Primer sequence 
rpsL_ge_F GAGCATGTTTCTGCGTAGTGTCAGC 
rpsL_ge_R CATCCTGTAGGTGTAGACGACGACG 
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2.3.3 Custom Plasmids 
In order to speed up the construction process of our BAC targeting vector custom plasmids 
were purchased from GeneArt.  
Plasmids were supplied as 5 µg lyophilised DNA and resuspended in 50 µL ddH2O to give a 
concentration of 100 ng/µL. Long terms stocks were stored at -70 °C, working stocks were 
stored at -20 °C.  
2.3.3.1 SOD1_HSUBARMS_PMS 
The SOD1_hSUBarms_pMS plasmid was designed for subcloning the human SOD1 sequence 
out of a BAC, and cloning this subclone into a Sod1 containing mouse BAC. It is illustrated in 
Figure 2.4.  
For the purpose of subcloning human SOD1 into the plasmid, the construct contains is a 172 bp 
region of homology to the 5’ sequence of SOD1 from the start codon in exon 1, through to 100 
bp of intron 1. After a 98 bp polylinker there is a 499 bp homology region to the 3’ human 
SOD1 sequence including all of exon 5 and 36 bp of intron 4.  
For the purpose of cloning the SOD1 sequence into a Sod1 containing mouse BAC the construct 
contains 500 bp of mouse sequence 5’ to the mouse Sod1 sequence including exon 1 up to the 
start codon (at which point the sequence becomes that of human) and 436 bp of 5’ sequence. 
There are also 502 bp of sequence matching sequence 3’ of the mouse Sod1 sequence.  
 
 
Figure 2.3 rpsL_Gen plasmid 
Diagram created in Geneious (Drummond et al., 2010) 
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2.3.3.2 SOD1_EXON4+5_PMA 
The purpose of the SOD1_Exon4-5_pMA was for introduction of a repeat section of human 
exons 4-5 as part of the selectable mutation machinery. It contains a 3,046 bp cassette with 
human genomic sequence running from 356 bp of intron 3 to the end of exon 5, continuing 
with 1 kb of mouse genomic sequence 3’ of exon 5’. Flanking this 3,046 bp repeat cassette is 
200 bp of mouse and engineered sequence to target the cassette to the desired location in the 
humanising construct (Figure 2.5). 
 
 
 
Figure 2.4 SOD1_hSUBarms_pMS 
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2.4 BAC RECOMBINEERING  
2.4.1 Red/ET Recombineering System 
Red/ET recombineering was carried out using Gene Bridges Quick & Easy BAC Modification Kit.  
Using the Red/ET system, Redα, Redβ and Redγ recombinase proteins are expressed in E.coli 
via a transiently transformed plasmid, pRed/ET (illustrated in Figure 2.6). A polycistronic 
operon encodes the recombinase proteins under a temperature sensitive and L-arabinose 
inducible promoter. Redα, Redβ and Redγ are equivalent to exo, bet and gam (as described 
above in Section 1.3.2). The plasmid is lost after each heat induction and must be re-
transformed for each round of recombineering.  
2.4.1.1 TRANSFORMATION OF PRED/ET PLASMID 
20 ng pRed/ET plasmid was transformed by electroporation into DH10B E.coli, already 
containing the target BAC or plasmid as described in Section 2.2.5 Preparation and 
Transformation of Electrocompetent E.coli. After electroporation, E.coli were cultured at 30 °C 
for 1 hr in LB (no antibiotics). 100 µL cell suspension was then spread onto an LB agar plate 
containing tetracycline (tet) and appropriate antibiotics to maintain the target BAC or plasmid, 
protected from light in a cardboard box because tet is light sensitive, and incubated at 30 °C 
overnight (~16 hrs). The following day, plates should be populated with individual colonies. 
Plates were stored at 4 °C for up to 1 week.  
 
Figure 2.5 SOD1_Exon4+5_pMA 
hI= human intron. hE=human exon 
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2.4.1.2 INDUCTION OF RED/ET RECOMBINASE EXPRESSION 
1 mL LB with tet and appropriate antibiotics to maintain the target BAC or plasmid was 
inoculated with a single colony and cultured overnight at 30 °C, protected from light.  
For each recombineering experiment, one induced and one un-induced control was prepared 
as follows. 1.4 mL LB with the same antibiotics was inoculated with 40 µL overnight culture 
and cultured at 30 °C for around 2 hrs until OD600 reached ~0.3.  
The experimental culture was induced by adding 50 µL 10% (w/v) L-arabinose. The control 
culture was left un-induced by not adding L-arabinose. Both I and UI cultures were then 
incubated at 37 °C for 45 mins to 1 hr. Cultures were then transferred to an ice water slurry.  
The protocol described in Section 2.4.3 General Recombineering Protocol, was then followed.  
2.4.2 SW102 Recombineering System 
SW102 E.coli are derived from DH10B E.coli. They have been modified to express exo, bet and 
gam from a stably integrated defective λ prophage which is under control of a temperature 
sensitive repressor. Thus SW102 E.coli can be used directly for recombineering following 
induction at 42 °C, rather than re-transforming the expression plasmid for each round of 
recombineering (Warming et al., 2005).  
 
Figure 2.6 RedET plasmid 
Picture taken from www.GeneBridges.com 
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2.4.2.1 INDUCTION OF SW102 RECOMBINASE EXPRESSION 
500 µL overnight culture of SW102 E.coli harbouring the target BAC or plasmid was used to 
inoculate 10 mL LB (plus appropriate antibiotics) and grown for ~3 hrs until OD600 reached 
0.5-0.6.  
For each recombineering experiment, once the initial culture has reached OD600 ~0.5-0.6, two 
1.5 mL aliquots of the cell suspension were taken, one to be induced (I) and one to act as an 
un-induced control (UI). Both I and UI were incubated at 30 °C for 5 mins to ensure that both 
aliquots were at temperature. I was then transferred to 42 °C to induce recombinase 
expression and both I and UI were incubated for a further 15 mins. Both aliquots are then 
transferred to an ice-water slurry.  
The protocol described in Section 2.4.3 General Recombineering Protocol was then followed.  
2.4.3 General Recombineering Protocol 
E.coli bacteria were induced as described for the specific system used (see Section 2.4.1 for 
Red/ET and 2.4.2 for SW102). The protocol in Section 2.2.5 Preparation and Transformation of 
Electrocompetent E.coli, was then followed from (§1), but with the following modifications:  
§2- 1 µL linear DNA suspended in ddH2O at 100 ng/µL, or, in the case of synthetic 
oligonucleotides, 200 ng/µL in TE, was transformed into the electrocompetent E.coli.  
§3- After the 90 min recovery period, samples were centrifuged in a room temperature bench 
top microfuge for 15 secs and supernatant tipped off. Cells were resuspended in the medium 
remaining in the tube and the entire suspension spread onto LB agar plates with antibiotics 
selective for the desired modification. Plates were incubated overnight at 30 °C.  
The number of colonies grown on each plate was counted, with the number on the un-induced 
control plate used as a guide for how many clones from the induced plate to screen. PCR 
screening was then carried out as described in Section 2.1.2.2.  
2.4.4 Preparation of Inserts and Subcloning Vectors for 
Recombineering 
Except in the case of synthetic oligonucleotides (where concentration is calculated based on 
details supplied by the manufacturers), concentration of inserts/vectors was calculated by 
nanodrop spectrophotometer and diluted to 100 ng/µL in ddH2O. Concentration was then 
checked by agarose gel electrophoresis using an appropriate quantitative DNA ladder (see 
Section 2.1.7).  
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2.4.4.1 PCR AMPLIFICATION  
A nested PCR strategy was used to amplify the insert or subcloning vectors used for 
recombineering.  
Touchdown PCR (see Section 2.1.2.1) was used to amplify the target fragment from plasmid 
DNA template. The first set of primers was designed to amplify the insert/subcloning vector, 
plus 10-20 bp flanking either side.  
Plasmid DNA template was then separated from the PCR product by RE digestion (where 
available) followed by agarose gel electrophoresis and gel extraction. The retrieved PCR 
product was then used as template for a further touchdown PCR with primers designed to 
amplify just the section required for recombineering. PCR products were purified using 
microCLEAN and resuspended in ddH2O.  
2.4.4.2 ADDITION OF HOMOLOGY ARMS BY PCR AMPLIFICATION  
The protocol described in Section 2.4.4.1, was used with the following modifications:  
1- The first set of primers is designed to amplify the target with no additional flanking 
sequence.  
2- The second pair of primers is identical to the first, but with 40-50 bp added to the 5’ 
end of the primer designed to act as homology arms for targeting during 
recombineering.  
2.4.4.3 LINEARIZATION BY RESTRICTION ENDONUCLEASE DIGESTION 
In some cases where it was not possible or desirable to amplify the insert or subcloning vector 
by PCR, RE digestion was used to extract the desired sequence from its resident plasmid.  
RE digestion was carried out as described in Section 2.1.4. The desired fragment was then 
separated from the unwanted portion by gel electrophoresis and gel extraction as described 
(see Section 2.1.7 and 2.1.1.5.1).  
2.4.4.4 OLIGONUCLEOTIDES 
For small insertions, deletions and base pair changes synthetic oligonucleotides (oligos) were 
used for recombineering.  
Synthetic oligos are designed with 50-60 bp of homology either side of the desired change. 
Lyophilised oligos were resuspended to a concentration of 200 ng/µL in TE.  
2.4.5 Sibling Selection 
For unselected recombineering modifications (without an addition of a new antibiotic 
selection cassette) or modifications with a low probability and/or high background, sibling-
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selection (sib-selection) was used to increase the likelihood of identifying a correctly modified 
clone by initially screening ~10 clones per screening PCR.  
A 96 well cell-culture plate was prepared with 200 µL LB plus antibiotics per well (leaving some 
empty wells to allow for controls when screening). Appropriate antibiotics are used for either 
maintenance of the plasmid or selection of the modified plasmid.  
At point (§3) in the recombineering protocol, rather than plating the recombineering 
experiment onto selective LB agar plates, the cell suspension was diluted to ~ 10 cells/µL and 1 
µL added to each well of the prepared 96-well cell-culture plate. The plate was grown 
overnight in a shaking incubator before screening.  
DNA was prepared as described in Section 2.1.1.4 Fast DNA Preparations for Plasmid Screening 
PCR and PCR screened for the desired recombination. For wells in which the correct 
recombination was detected, 1 µL culture was diluted and used to inoculate another 96 well 
cell-culture plate and re-screened. After the second screening, 10 µL from those wells 
screened positive was spread onto selective LB agar plates and individual colonies screened.  
2.5 MICE 
All animals were maintained and all animal experiments were carried out in accordance with 
the Animals (Scientific Procedures) Act 1986 and Home Office Project licence No. 30/2290.  
Within the text of this thesis, a shortened form of nomenclature will be used to describe the 
various genotypes of mice used. The nomenclature is explained below in Sections 2.5.2 - 2.5.6 
and for clarity presented here in Table 2.13 and repeated at the beginning of each relevant 
Results chapter.  
2.5.1 Housing and General Husbandry 
 Animals were housed in Tecniplast individually ventilated cages (IVCs) with grade 5 dust-free 
autoclaved wood bedding and had constant access to food and water, if mice appeared to 
start losing their ability to move freely around the cage or when weight loss started to become 
apparent, hydrogel was placed at ground level in the cage and paper bedding was removed to 
reduce possible impedance to their movement. The animal house was maintained at a 
constant temperature of 19-23 °C with 55±10% humidity in a 12 hr light:dark cycle. 
When animals were allocated to experimental groups (usually between 35-60-days of age) 
they were moved into standardised group housing (5 mice per cage) which in addition to equal 
quantities of wood bedding, all had paper bedding and a translucent red “mouse house” for 
nesting.  
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All weighing and behavioural assessments were carried out in class 2 animal handling cabinet.  
 
2.5.1.1 HUMANE ENDPOINTS 
Humane endpoints were defined as: 15% body weight loss, a loss of the righting reflex (ability 
to right itself when placed on its side), or paralysis which prevented the animal from moving 
about the cage. Other welfare issues were assessed on a case by case basis.  
2.5.2 Human SOD1G93A Transgenic Mice  
B6.Cg-Tg(SOD1*G93A)1Gur/J mice (Gurney et al., 1994; Chiu et al., 1995) (Jax stock code 
004435) were purchased from Jackson Laboratories. These mice were purchased already 
congenic on a C57CL/6J background. For general maintenance, the line was bred by 
backcrossing hemizygous transgenic males in trios with C57BL/6J females. Within the text of 
this thesis these animals will be referred to as TgG93A and non-transgenic littermates as NTg.  
Genotyping was carried out using the protocol as described in Section 2.1.2.4.  
For breeding stock, animals were killed at 120-days of age in order to avoid development of 
symptoms and unnecessary suffering.  
2.5.3 Human Wild-Type SOD1 Transgenic Mice  
B6SJL-Tg(SOD1)2Gur/J mice (Gurney et al., 1994) (Jax stock code 002297) were purchased 
from Jackson Laboratories. These mice were purchased on a C57BL/6J x SJL/J hybrid 
background. The F1 animals were backcrossed to C57BL/6J for at least 4 generations before 
being used in experimental crosses. Including the original F1 cross to C57BL/6J, 5 generations 
of crosses should theoretically result in offspring homozygous for BL/6J at ~96.9% of the 
genome, with ~3.1% in a BL/6J, SJL heterozygous state.  
Table 2.13 Short form nomenclature of mouse genotypes 
Transgene (Tg) allele Knockout (KO) allele Short form (used in text) 
Non-transgenic Sod1+/+ (WT) NTg;Sod1wt 
Non-transgenic Sod1+/- (heterozygous KO) NTg;Sod1het 
Non-transgenic Sod1-/- (homozygous KO) NTg;Sod1ko 
SOD1G93A Tg hemizygous Sod1+/+ (WT) TgG93A;Sod1wt 
SOD1G93A Tg hemizygous Sod1+/- (heterozygous KO) TgG93A;Sod1het 
SOD1G93A Tg hemizygous Sod1-/- (homozygous KO) TgG93A;Sod1ko 
SOD1WT Tg hemizygous Sod1+/+ (WT) TgWT;Sod1wt 
SOD1WT Tg hemizygous Sod1+/- (heterozygous KO) TgWT;Sod1het 
SOD1WT Tg hemizygous Sod1-/- (homozygous KO) TgWT;Sod1ko 
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For general maintenance, the line was bred by backcrossing hemizygous transgenic males in 
trios with C57BL/6J females. Within the text of this thesis these animals will be referred to as 
TgWT and non-transgenic littermates as NTg. 
Genotyping was carried out using the protocol as described in Section 2.1.2.4.  
2.5.4 Sod1 Knockout Mice  
B6;129S-Sod1tm1Leb/J mice (Matzuk et al., 1998) (Jax stock number 002972) were purchased 
from Jackson laboratory. These mice were purchased on a C57BL/6J x 129S hybrid background. 
The F1 animals were backcrossed to C57BL/6J for at least 4 generations before being used in 
experimental crosses. Including the original F1 cross to C57BL/6J, 5 generations of crosses 
should theoretically result in offspring homozygous for BL/6J at ~96.9% of the genome, with 
~3.1% in a BL/6J, 129S heterozygous state.  
Within the text of this thesis these animals will be referred to as Sod1wt (homozygous for the 
wild-type Sod1 allele), Sod1het (heterozygous for the Sod1 KO allele) and Sod1ko (homozygous 
for the Sod1 KO allele).  
Genotyping was carried out using the protocol described in Section 2.1.2.5.  
Sod1het males were mated in trios with two Sod1het females in order to produce Sod1ko 
males for further breeding. Sod1ko males were bred in trios with two C57BL/6J females in 
order to produce Sod1het females needed for breeding of the transgene x KO crossed 
colonies.  
2.5.5 TgG93A, Sod1ko Cross 
This line of mice was produced by crossing TgG93A with Sod1ko mice. A two-step cross was 
used to initiate the line as illustrated in  
Figure 2.7. TgG93A males (from the SOD1G93A transgenic colony) were mated to Sod1het 
females (from the Sod1 KO colony), producing both NTg and TgG93A offspring with either 
Sod1het or Sod1wt genotypes, as illustrated in  
Figure 2.7a, resulting in 4 possible genotype combinations: NTg;Sod1wt, NTg;Sod1het, 
TgG93A;Sod1wt and TgG93A;Sod1het.  
For the second step, shown in  
Figure 2.7b, male TgG93A;Sod1het offspring were mated to Sod1het females (from the Sod1 
KO colony), producing 6 genotype combinations: NTg;Sod1wt, NTg;Sod1het, NTg;Sod1ko, 
TgG93A;Sod1wt, TgG93A;Sod1het, TgG93A;Sod1ko). For on-going maintenance of the colony, 
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and production of mice for use in the cross characterisation project (described in Chapter 4) 
this is the breeding scheme that was used.  
 
  
 
Figure 2.7 Breeding scheme for producing transgenic KO cross colonies 
The figure shows the 2-step cross (a and b) used to produce the TgG93A;Sod1ko and 
TgWT;Sod1ko cross colonies.  
At step (a), a Tg male (either TgG93A or TgWT) is mated to a Sod1het female, producing 4 
genotypes, as shown.  
At step (b), a Tg.Sod1het male, produced from cross (a) is mated to Sod1het female, 
producing all 6 of the possible genotypes produced from this cross, as shown.  
In order to reduce wastage and speed breeding, the third step, (c), can be used if mice 
with a Sod1wt genotype are not required.  
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For the Transmission project (described in Chapter 3), a third level of the crossing scheme was 
used, as illustrated in  
Figure 2.7 c. TgG93A;Sod1ko males were mated to Sod1het females (from the Sod1 KO colony) 
producing 4 possible genotype combinations: NTg;Sod1het, NTg;Sod1ko, TgG93A;Sod1het and 
TgG93A;Sod1ko. Female offspring with a TgG93A;Sod1ko genotype were used in the 
experiment.  
Genotyping was carried out using the protocols described in Sections 2.1.2.4 and 2.1.2.5. For 
animals with TgG93A;Sod1ko genotype result, the PCRs were repeated to confirm the 
genotype.  
2.5.6 TgWT, Sod1ko Cross 
This line of mice was produced by crossing TgWT with the Sod1ko mice. The same 2-step cross 
was used to produce the line, as described for the TgG93A Sod1ko cross. As is shown in  
Figure 2.7 a, in the first step, TgWT males (from the WT SOD1 transgenic colony) were mated 
to Sod1het females (from the Sod1 KO colony), producing 4 possible genotype combinations: 
NTg;Sod1wt, NTg;Sod1het, TgWT;Sod1wt, TgWT;Sod1het.  
For the second step, illustrated in  
Figure 2.7 b, male TgWT;Sod1het offspring from the first step were mated to Sod1het females 
(from the Sod1 KO colony), producing 6 possible genotype combinations: NTg;Sod1wt, 
NTg;Sod1het, NTg;Sod1ko, TgWT;Sod1wt, TgWT;Sod1het, TgWT;Sod1ko. This is the mating 
scheme that was used for on-going colony maintenance.  
In order to produce animals for use in the Transmission project (described in Chapter 3) a third 
level of the crossing scheme was used, as is shown in  
Figure 2.7c. TgWT;Sod1ko males were mated to Sod1het females (from the Sod1 KO colony) 
producing 4 possible genotype combinations: NTg;Sod1het, NTg;Sod1ko, TgWT;Sod1het and 
TgWT;Sod1ko. Female offspring with a TgWT;Sod1ko genotype were used in the experiment.  
Genotyping was carried out using the protocols described in Sections 2.1.2.4 and 2.1.2.5. For 
animals with TgWT;Sod1ko genotype result, the PCRs were repeated to confirm the genotype.  
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2.6 MOUSE EXPERIMENTAL PROCEDURES 
2.6.1 Mouse Experimental Procedures Specific to the 
Transmission Project 
All experiments were carried out using female mice. Animals were allocated to experimental 
groups sequentially with longer incubation periods allocated first and each inoculation group 
being filled one at a time.  
2.6.1.1 NEUROLOGICAL CHECKS 
Weekly neurological checks were carried out by technical staff at the MRC Prion Unit Biological 
Services Facility. Once a week, each animal was lifted out of its cage by its tail and observed for 
signs of onset defined as: tremor in the rear limbs when suspended up the tail, rear limbs 
moving toward the midline of the body rather than being held out in a splayed position as is 
normal. Observations were carried out by an animal technician and whenever possible, the 
same technician carried out all observations.  
2.6.2 Inoculation of Mice 
2.6.2.1 INOCULANT PREPARATION 
Details of the tissues used are given in Table 2.14. Tissues were stored at -70 °C until being 
defrosted on ice for preparation of inocula. Inocula were prepared in a class 1 microbiological 
safety cabinet by Dr Graham Jackson.  
A stock 10% (w/v) homogenate of tissue was prepared in Dulbecco’s Phosphate Buffered 
Saline, minus CaCl2 and MgCl2 (DPBS. Gibco). Tissue and DPBS were measured into a sterile 
bijou tube. A sterile 19G needle was then attached to a syringe and used to disrupt the tissue. 
Once the tissue was disrupted, the sample was aspirated at least 5 times through the needle. 
Aspiration was then repeated using a 21G needle and then a 23G needle. The 10% 
homogenate was then transferred to a cryotube for storage at 70 °C.  
For preparation of 1% homogenates to be used as inocula, the 10% homogenate was 
thoroughly defrosted on ice and mixed by shaking. An appropriate volume of DPBS was 
dispensed into a sterile bijou tube followed by an appropriate volume of the 10% homogenate. 
A syringe fitted with a 26G needle was then used to aspirate the sample at least 5 times. 
Aliquots were then dispensed into cryotubes for storage at -70 °C.  
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2.6.2.2 INOCULATION PROTOCOL 
Inoculations were carried out by technical staff at the MRC Prion Unit Biological Services 
Facility.  
Inocula were removed from the -70 °C freezer and allowed to thaw completely and return to 
room temperature.  
Animals were anaesthetised by inhalation of a mixture of oxygen and isoflurane within an 
induction chamber. Oxygen flow was set to 2-4 L/min and the isoflurane vaporiser was set to 
5% for anaesthetic induction. Five animals were placed in the induction chamber at a time and 
were monitored by the anaesthetist.  
Once anaesthetised, one animal at a time was removed from the chamber and depth of 
anaesthesia was checked by pedal reflex and blink reflex. The mouse’s head was held stable 
using a pair of forceps. A 25G needle fitted to a 1 mL syringe was used for intra-cerebral 
inoculations. The needle was positioned in the right front quadrant of the head (see Figure 2.8) 
and inserted through the skull into the cerebrum and 30 µL inoculum dispensed. The animal 
was then taken by the anaesthetist back to the home cage which was rested on a heat mat. 
The animal was placed on a tissue at the front of the cage and observed until fully recovered 
and mobile.  
Table 2.14 Details of inocula 
Name ID Species Genotype Age at 
death 
Sex Tissue used 
m-TgG93A I12250 mouse TgG93A;Sod1ko 
100 
days female spinal cord 
m-TgWT I12251 mouse TgWT;Sod1ko 
100 
days female spinal cord 
m-NTg I12252 mouse NTg;Sod1ko 
100 
days female spinal cord 
h-D101G I13029 human SOD1+/D101G 
46 
years female 
motor 
cortex 
h-I113T I13031 human SOD1+/I113T 
47 
years male 
motor 
cortex 
h-cntrl1 I13033 human SOD1+/+ 
52 
years female 
motor 
cortex 
h-cntrl2 I13035 human SOD1+/+ 
40 
years male 
motor 
cortex 
DPBS I56 n/a 
DPBS only 
control       
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2.6.2.3 TGG93A TRANSMISSION INOCULATION SCHEDULE  
TgG93A;Sod1ko mice, were inoculated at 50-days of age ±1day. Four different inocula were 
used and there were two post-inoculation time-points for harvesting of tissues for histological 
analysis. There was also one group of non-inoculated controls. Table 2.15 details inoculum 
used and the number of animals per group.  
 
2.6.2.4 TGWT TRANSMISSION INOCULATION SCHEDULE  
TgWT;Sod1ko mice, were inoculated at 70-days of age ±15days. Eight different inocula were 
used. There were 5 time-points for harvesting of tissues for histological analysis. Non-
inoculated controls were also taken at each of the time-points. Table 2.16 details inoculum 
used and the number of animals per group.  
 
Figure 2.8 Location of intra-cerebral injection 
Marked with black dot. Image kindly provided by Gavin Graham 
Table 2.15 G93A inoculation schedule  
Table shows number of animals allocated to each group 
 Post-inoculation cull 
time-point (days) 
Inoculum 40 1 
m-TgG93A 11 3 
m-TgWT 10 3 
m-NTg 10 3 
DPBS 10 3 
non-inoculated 10 0 
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2.6.3 Mouse Experimental Procedures Specific to the 
Characterisation Project 
All experiments were carried out using female mice. One allocated to the experiment, animals 
were group house according to birth order and their genotypes blinded to both technical staff 
and the experimenter by censoring cage cards.  
2.6.3.1 WEEKLY WEIGHTS  
Mice were weighed by technical staff at the MRC Prion Unit Biological Services Facility.  
Once a week on a set day and at approximately the same time of day (between 8 and 21 am) 
all experimental animals were weighed using digital scales. When a mouse reached 10% 
weight loss as calculated from its maximum body weight, they were weighed on a daily basis 
and hydrogel was placed at ground level in the cages.  
2.6.3.2 GRIP STRENGTH  
Grip strength was measured twice a week (Monday and Thursday or Tuesday and Friday) 
between 1 pm and 4 pm using a Grip-strength meter bio-GS3 (Bioseb).  
The mouse was moved from its home cage into an empty tecniplast cage. The mouse was then 
lifted by the base of the tail and place with all 4 feet on the mesh of the grip strength meter 
and held for a moment to allow the mouse to settle on the grip. It was then drawn horizontally 
back away from the mesh in one smooth movement and replaced into the empty cage. Four 
measures were taken during each session. Grip-strength was measured in grams with 2 
decimal places. The empty cage was cleaned with 70% ethanol and allowed to dry between 
cages of animals.  
Table 2.16 WT inoculation schedule 
Table shows number of animals in each group 
 
 Post-inoculation cull time-
point (days) 
Inoculum 660 295 180 90 7 
m-TgG93A 20 10 10 10 10 
m-TgWT 20 10 10 10 10 
m-NTg 20 10 10 10 10 
h-D101G 20 10 10 10 10 
h-I113T 20 10 10 10 10 
h-cntrl1 20 10 10 10 10 
h-cntrl2 20 10 10 10 10 
DPBS 20 10 10 10 10 
non-inoculated 20 10 10 10 10 
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The 4 individual measurements were averaged and divided by the weight of the animal for 
that week. If the experimenter was not available to take the measurements none were taken 
as it was decided that missed measurements were more desirable that the inter-operator 
variability in measurements.  
Animals were measured from 50-52-days of age, with the first two measurements being taken 
as training. Measurements were then averaged into 2-week bins starting from the 57-59 day 
time-point, resulting in 6 bins: 57-70, 71-84, 85-98, 99-112, and 113-126-days of age. As the 
data were to be analysed by ANOVA, no higher age brackets were used to avoid excluding 
animals which died earlier.  
2.6.3.3 SURVIVAL 
The humane end points are defined in Section 2.5.1.1. All animals reached 15% weight loss 
before either losing righting reflex or severe paralysis. Animals which died or were culled for 
“non-ALS” causes, for example as a result of malocclusion or tumours, were not used for 
survival or any subsequent experimental measures.  
On reaching the humane end point, the animal was culled by exposure to a rising 
concentration of CO2 and both brain and spinal cord (SC) were harvested and snap frozen.  
2.6.4 Perfusion with Paraformaldehyde  
Animals were anaesthetised with 200 µL sodium pentobarbital (Euthatal) by intraperitoneal 
injection. Depth of anaesthesia was checked by blink reflex and paw pinch.  
When the animal was sufficiently anaesthetised it was pinned on its back by all 4 feet and the 
abdominal cavity opened exposing the sternum. The diaphragm was punctured and the 
sternum cut from the lower, outer edge of the ribs to the top, mid-sternum avoiding the blood 
vessels in the centre of the rib cage. The rib cage was inflected back to expose the heart and 
the pericardium removed. With the perfusion pump set to 0.3 mL/min pumping ice cold sterile 
0.9% NaCl, a 27G needle was inserted into the left ventricle and the right atrium cut to allow 
flow through. The pump was then switched to 3 mL/min and the limbs unpinned.  
Blood was first cleared by perfusing for 4 mins with 0.9% NaCl (~12 mL) before switching to ice 
cold 4% paraformaldehyde (PFA) in PBS Dulbecco A (PBS-DA. Oxoid) for 8 mins (~24 mL).  
2.7 HISTOLOGY OF PARAFFIN EMBEDDED TISSUES 
Sections were stained with haematoxylin and eosin to assess morphological characteristics. 
Immunostaining with SEDI and USOD was used to assess misfolded SOD1 load.  
110 
2.7.1 Harvesting of Tissues 
Tissues were harvested by technical staff at the MRC Prion Unit Biological Services Facility. At 
the predetermined time-points, mice were culled by C02 inhalation in batches of 5. Brains and 
spinal columns were dissected out fresh and post-fixed in 10% buffered formal saline (BFS) 
(Pioneer Research).  
2.7.2 Paraffin Embedding Samples and Sectioning  
Paraffin embedded histological samples were processed by the MRC Prion Unit Histology 
Group. Brains and SCs were fixed in 10% Buffered Formal Saline (BFS. Pioneer Research 
Chemicals). Brains were cut into two sagittal sections and SCs were cut into three sections: 
cervical, thoracic and sacral. These sections were processed and embedded into paraffin wax 
blocks on a tissue embedding machine using standard procedures. Serial sagittal sections from 
the central plane of the brain were cut at a thickness of 3 µm, placed on to Super-frost slides 
(VWR) and allowed to dry at 37 °C for a minimum of 2 hrs, before being transferred to a 60 °C 
oven overnight.  
2.7.3 Immunostaining  
All pre- and post-staining treatments and staining were carried out on a Ventana automated 
immunohistochemical staining machine using proprietary reagents. All sections were de-
waxed and rehydrated before staining and dehydrated after staining according to 
manufacturer’s instructions and using Ventana’s proprietary reagents. Antibodies were diluted 
in Antibody Diluent (Ventana). Colour development was carried out using a 3,3- 
diaminobenzidine tetrahydrochloride (DAB) detection system and counterstaining was carried 
out using Haematoxylin and Bluing Reagent (Ventana) according to the manufacturer’s 
instructions. After staining and dehydration, sections were mounted using Pertex, a xylene 
based mounting medium, and cover-slipped on a DIAPATH cover-slipping machine. All steps 
were carried out at room temperature unless specified.  
2.7.4 Immunostaining  
Section slides were incubated as follows: Pre-treatment in Discovery MCC1 (a proprietary 
antigen retrieval solution containing Tris/EDTA pH 8.0 Ventana), incubated in a proprietary 
citrate buffer (Ventana) at 96 °C for 30 mins. Blocking for 10 mins. SEDI rabbit antibody (Rakhit 
et al., 2007) at a 1:100 dilution for 5 hrs. Swine anti-rabbit biotinylated antibody at a 1:200 
dilution for 30 mins.  
2.7.5 Analysis 
Slides were scanned at 40X using a Leica SCN400F slide scanner. Definiens tissue Studio 
software was used to define regions of interest as described below. Within each region and 
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areas positive for brown DAB chromogen were highlighted by the software and manually 
curated to remove artefacts. The total area and stained area were then computed and the 
ratio of the two used as the output. All analysis of images was done blind to experimental 
group. Statistical analysis was by ANOVA.  
2.7.5.1 SPINAL CORD PATHOLOGY 
Five slides, averaging ~4 sections per slide, were analysed per animal and results from multiple 
sections averaged for analysis. Cord sections were categorised into the following regions: 
anterior horn, dorsal horn, white matter, ventral roots and dorsal roots and “other”, as shown 
in Figure 2.9. Regions were analysed as above.  
 
2.7.5.2 BRAIN PATHOLOGY 
One sagittal section was analysed per animal. Brain sections were categorised into the 
following regions: Cortex, olfactory bulb, corpus callosum, hippocampus, cerebellum, brain 
stem and “other”, as shown in Figure 2.10. Regions were analysed as above.  
 
Figure 2.9 Definition of spinal cord regions 
Blue= dorsal horns. Orange= ventral horns. yellow= white matter. Red= dorsal roots. 
Green= ventral roots. Grey= other 
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2.8 HISTOLOGY OF FROZEN TISSUES 
2.8.1 Neuromuscular Junction (NMJ) Staining 
2.8.1.1 SAMPLING AND EMBEDDING 
The extensor digitorum longus (EDL) of the left leg was dissected immediately after perfusing, 
pinned out in a gentle stretch and post fixed for 1-4 hrs in 4% PFA at 4 °C. Muscles were then 
transferred to 40% sucrose, 0.001% sodium azide in PBS to cryoprotect overnight at 4 °C.  
The following day muscles were frozen in OCT freezing medium (Sakura) in foil moulds on a 
sheet of aluminium pre-chilled in dry-ice. Muscles were stored at -20 °C.  
 
Figure 2.10 Definition of brain regions 
Blue= cortex. Dark green= olfactory bulb. Red= corpus callosum. yellow= hippocampus. 
Pale blue= cerebellum. Grey= brain stem. Orange= other 
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2.8.1.2 CUTTING AND STAINING 
20 µm longitudinal sections were cut in 2 series, using a BrightTM cryostat and collected onto 
poly-lysine coated slides (VWR) and air-dried for ~1 hr at room temp. One of the 2 series was 
stained for counting. As NMJs are ~40 µm in size, all NMJs should be captured, but repeated 
counting of the same NMJ avoided.  
Sections were circled with a PAP pen (Invitrogen) and allowed to dry for 30 mins. All 
subsequent steps were carried out in a humidified chamber. Staining was carried out using 
reagents from the Vector M.O.M. Immunodetection Kit BASIC (Vector Laboratories).  
Sections were washed 3 x 5 mins with PBS to remove OCT.  
Sections were blocked for 1 hr with 3.5% M.O.M. blocking reagent (Vector Labs) diluted in PBS 
with 0.2% Triton X-100 (PBS+tr).  
Sections were washed 2 x 2 mins with PBS+tr. 
Sections were incubated for 5 mins with M.O.M. diluent (7.5% M.O.M protein concentrate 
(Vector Labs) diluted in PBS+tr).  
Sections were incubated with primary antibodies for 30 mins at a 1:10 dilution in M.O.M. 
diluent. Antibodies used were Mouse monoclonal anti-synaptic vesicle (SV2, Developmental 
Studies Hybridoma Bank) and Mouse monoclonal anti-neurofilament (165 kDa) (2H3, 
Developmental Studies Hybridoma Bank) 
Sections were washed 2 x 2 mins PBS+tr. 
Sections were incubated with M.O.M. biotinylated anti-mouse secondary antibody diluted 
1:250 in M.O.M. diluent for 10 mins.  
Sections were washed 2 x 2 mins with PBS+tr.  
Fluorescent labelling was performed using Streptavidin-Alexafluor 488 (1:200 Invitrogen), 
α-Bungarotoxin-Rhodamine (1:500 Sigma) and DAPI (1:500 Sigma ) diluted in PBS+tr and 
incubated for 30 mins in darkened, humidified chamber. 
Sections were washed 3 x 5 mins with PBS (no Triton X-100). Slides were cover slipped using 
fluorescence mounting media (Dako), dried at room temperature for 24 hrs (light excluded) 
and stored at -20 °C.  
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2.8.1.3 ANALYSIS 
NMJs were visualised used a Leica DMR epifluorescent microscope. The total number of NMJs 
on each muscle were counted by methodically scanning the red fluorescence channel to 
identify end plates, the region on the muscle fibre which is populated by nicotinic 
acetylcholine receptors (AChR) and receives inputs from the MNs. α-Bungarotoxin (in the red 
channel) binds the AChR of the neuromuscular end plate. Once identified, the innervation 
status of the end plate was assessed by switching between the red and green channels to 
establish the level of co-localisation between the muscle fibre end plate (red), and the foot 
plate of the MN (green), the pre-synaptic region of the MN which synapses with the end plate. 
Anti-neurofilament (in the green channel) binds within the axons of the incoming MNs and 
anti-synaptic vesicle (also in the green channel) binds to the synaptic vesicles populating the 
pre-synaptic nerve terminals of the incoming MNs. In a normal, healthy, NMJ, the whole of the 
end plate (red) will co-localise with the foot plate (green), and are classified as “fully 
innervated”. When the red and the green channel were not aligned, or the alignment was very 
minimal, the NMJ was classified as “denervated”. When as intermediated level of co-
localisation was present, whereby it was clear that the two were not fully aligned, but a 
significant alignment was still present, the NMJ was classified as “partially innervated”. All 
analysis was carried out blind to genotype.  
2.8.2 Muscle Fibre Typing 
2.8.2.1 SAMPLING AND EMBEDDING 
Muscles harvested for fibre type analysis needed to be harvested fresh and unfixed. For this 
reason, the leg was removed at the beginning of the perfusion protocol while perfusing with 
0.9% NaCl; the right leg was partially skinned to aid visualisation and cut off close to the hip 
while avoiding damage to the surrounding structures. The remaining skin was then removed 
and the leg stored on ice in PBS for 1-3 hrs. The tibialis anterior (TA) and EDL and triceps surae 
(TS. a muscle group containing the medial and lateral gastrocnemius, soleus and plantaris 
muscles) dissected. The belly of the muscle was trimmed out and the muscles arranged 
vertically on a small cork board in OCT. The mount was then submerged in isopentane chilled 
in liquid nitrogen for ~1 min to freeze and the transferred to liquid nitrogen for 10 mins-1 hr 
before being stored at -80 °C.  
2.8.2.2 CUTTING AND STAINING 
Transverse sections of 12 µm were cut using a BrightTM cryostat. Six serial sections were 
collected per poly-lysine coated slides (VWR) and air-dried for ~1 hr at room temperature. 
Sections were circled with PAP pen as shown in and allowed to dry for 30 mins. All subsequent 
steps were carried out in a humidified chamber. 
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Sections were stained as follows: 
Wash 5 mins in PBS.  
Block 30 mins in 5% normal goat serum (NGS) diluted in PBS+tr. 
Sections were washed 3X 2 mins PBS+tr.  
Sections were incubated with primary antibodies (detailed below) diluted in PBS+tr 2% NGS for 
1 hr.  
Sections were then washed 3X 2 mins in PBS+tr.  
Secondary antibodies, Alexa Fluor 488 goat anti-mouse IgM (µ chain) (Invitrogen) and Alexa 
Fluor 568 goat anti-mouse IgG (H+L) (Invitrogen) and DAPI, were diluted in PBS+tr with 2% 
normal goat serum at 1:500 dilution and incubated for 2 hrs with light excluded.  
Sections were washed 3X 2 mins in PBS (no Triton X-100). Slides were cover slipped using 
fluorescence mounting media (Dako), dried at room temperature for 24 hrs (light excluded) 
and stored at -20 °C.  
To differentiate different fibre types, three primary antibody combinations (all from 
Developmental Studies Hybridoma Bank) were used to stain serial sections as follows: 
Protocol A: BF-F3 (IgM, anti-myosin heavy chain 2B) 1:5 dilution and SC-71 (IgG1, anti-myosin 
heavy chain 2A) 1:10 dilution.  
Protocol B: BF-F3 (IgM, anti-myosin heavy chain 2B) 1:5 dilution and BF-35 (IgG1, anti-myosin 
heavy chain all but 2X) 1:5 dilution.  
Protocol C: BF-F3 (IgM, anti-myosin heavy chain 2B) 1:5 dilution and BA-D5 (IgM, anti-myosin 
heavy chain, slow, alpha- and beta-) 1:10 dilution.  
2.8.2.3 ANALYSIS 
Type 2A fibres were quantified using staining protocol A. Type 1 fibres were quantified using 
staining protocol C.  
The entire muscle was imaged by sequential imaging at 10X magnification on a Zeiss 710 
confocal microscope using the same settings. Captured images were montaged in Adobe 
Photoshop. Volocity Image Analysis Software was used for semi-automated quantitation of the 
area containing myosin heavy chain 2B and 2A or 1, and the proportion of staining (2A/2B or 1/ 
2B) was calculated for the TA and EDL. A qualitative assessment of the TS was also carried out 
with the help of Dr Barney Bryson. All analysis was carried out blind to genotype.  
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2.8.3 Motor Neuron Counts 
2.8.3.1 SAMPLING AND EMBEDDING 
After perfusion, the spinal column was dissected and post fixed in 4% PFA overnight. The 
following day, the SC was dissected from the column and submerged in 40% sucrose, 0.001% 
sodium azide in PBS to cryoprotect and stored at 4 °C for a minimum of 24 hrs.  
The SC ventral roots were pinned out in order to identify the lumbar SC region from L2-L5 
roots, inclusive, and this region (referred to hereafter as the lumbar cord) was excised. The 
lumbar cord was mounted directly onto the cryostat chuck by cooling the chuck in liquid 
nitrogen and embedding the cord in situ in OCT medium. The mount was then left to 
equilibrate in the cryostat for a minimum of 30 mins before cutting.  
2.8.3.2 CUTTING AND STAINING 
20 µm serial sections were cut in 3 series, using a BrightTM cryostat. 24 sections were collected 
onto each poly-lysine coated slides (VWR), air-dried for ~1 hr at room temperature and stored 
at -20 °C. One of the 3 series was stained for counting per animal to avoid re-counting the 
same MN twice.  
The nissl stain, gallocyanine, was used. Sections were air dried for 15 mins before staining and 
were stained by submerging the slides as follows: 
Gallocyanine stain (see Section 7.2.7, Appendix 2) 20 mins. 2X ddH2O 10 secs. 70% ethanol 1 
min. 90% ethanol 1 min. 2X 100% ethanol 1 min. 2X Histo-clear (National Diagnostics) 2 mins. 
Slides were then cover slipped with DPX mounting medium.  
2.8.3.3 ANALYSIS 
A minimum of 40 sections were counted per SC, and where more than 40 sections were 
counted, numbers were standardised to 40 sections.  
Motor neurons were identified as greater than 20 µm, polygonal cells with a visible nucleus 
and nucleolus. Cells within the sciatic pool in every third section were counted. All analysis was 
carried out blind to genotype.  
2.9 STATISTICAL ANALYSES  
Statistics were carried out using IBM SPSS, except Chi Square test for inheritance ratios which 
was carried out using GraphPad online tool (http://graphpad.com/quickcalcs/chisquared1/).  
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Chapter 3. SOD1 Transmission Project  
The work described in this Chapter was carried out in conjunction with Dr Anny Devoy, Dr 
Pietro Fratta and Mr Luc Masset (UCL Department of Neurodegenerative Disease) and with the 
assistance of technical staff of the MRC Prion Unit.  
3.1 AIMS  
SOD1 displays prion-like properties in vitro and in cellular models. The main aim of the work 
described in this chapter was to examine whether SOD1 can act in a prion-like way, seeding 
aggregation in a mouse model.  
Transgenic mice expressing huSOD1 were intracerebrally inoculated with tissue homogenates 
containing mutant huSOD1 species, or with control homogenates or a vehicle only control. 
After a period of incubation, misfolded SOD1 aggregate pathology was assessed.  
For experiments investigating self-seeded aggregation potential, mice transgenically 
expressing G93A mutant huSOD1 were inoculated with spinal cord (SC) homogenates from the 
same mouse line; seeding mutant huSOD1 with mutant huSOD1. To assess cross-seeded 
aggregation potential, mice transgenically expressing WT huSOD1 were inoculated with either 
mutant SOD1 transgenic mouse SC homogenate, or human SOD1-fALS motor cortex 
homogenates; seeding WT huSOD1 with mutant huSOD1. Premature deaths, potentially 
caused by toxicity of the mutant huSOD1 species in the inocula, were also monitored.  
All of the mice used in these experiments were bred on to an endogenous Sod1 null 
background. This is common practice in the Prion field, where the endogenous Prnp can 
perturb the transmission of non-mouse PrPSc species (Telling et al., 1995; Collinge et al., 1995). 
Breeding the mice for use in these experiments also allowed us to examine whether the 
inheritance patterns of the WT and G93A mutant transgenes, and the Sod1 null allele followed 
Mendelian ratios.  
3.2 INTRODUCTION 
Misfolded SOD1 histopathology is used in this Chapter to assess differences between 
experimental conditions. Both WT and mutant SOD1 transgenic mice have high levels of SOD1 
detectable by histopathology (Jaarsma et al., 2000). Our aim was to specifically measure the 
misfolded portion of the transgenic protein, therefore misfolded SOD1 antibodies were used.  
Several conformation specific SOD1 antibodies have been produced that can detect misfolded 
SOD1 species present in SOD1-fALS and mutant SOD1 transgenic mice (e.g. (Rakhit et al., 2007; 
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Kerman et al., 2010; Prudencio et al., 2011; Jonsson et al., 2004)). In this Chapter two of these 
antibodies are used: SEDI and USOD.  
The SEDI (SOD1 exposed dimer interface) antibody recognises aa 143-151 of the SOD1 protein 
which, in the correctly folded SOD1 dimer, are hidden within the dimer interface (Figure 3.1) 
(Rakhit et al., 2007).The SEDI antibody was shown to specifically detect monomeric misfolded 
SOD1 species by immunoprecipitation (IP) and immunohistochemistry of spinal cords of 3 
mutant huSOD1 transgenic mouse lines (G37R, G85R and G93A). In G37R transgenic mice, the 
area of SEDI staining was further defined as being within the MNs and astrocytes of the ventral 
horn with particularly high abundance in the axons and white matter tracts. Lower level 
staining of spinal cords from mice transgenically expressing WT huSOD1 was detected, with 
staining particularly prevalent in the white matter tracts. Neuronal SEDI staining was also 
reported in the spinal cord of an A4V SOD1-fALS case (Rakhit et al., 2007).  
 
SEDI has subsequently identified, via immunohistochemistry, monomeric misfolded SOD1 in 
the periphery of vacuoles and in intraneuronal inclusions in the SC of SOD1-fALS patients with 
a number of different mutations (A4T, A4V, V14M, ΔG27/P28, I113T) (Zinman et al., 2009; Liu 
et al., 2009; Kerman et al., 2010). However, in non-SOD1-fALS and sALS similar SEDI pathology 
is reported as absent (Liu et al., 2009).  
SEDI has also shown specificity for recombinant non-amyloid aggregated WT huSOD1, but not 
non-aggregated WT huSOD1 by competition enzyme-linked immunosorbent assay (ELISA) 
(Hwang et al., 2010) and a higher affinity to A4V mutant huSOD1, as compared to WT huSOD1, 
by immunocytochemistry in a cell culture model (Prudencio et al., 2011). Monomer misfolded 
 
Figure 3.1 SEDI and USOD epitopes 
The 3D structure of SOD1 is shown. SEDI epitope (aa 143-153) is highlighted in cyan. The 
USOD epitope (aa 42-48) is highlighted in purple. Copper atoms are shown in orange.  
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huSOD1 was also detected in the cerebrospinal fluid of G93A and G37R transgenic mice by 
SEDI IP, and immunisation with the SEDI peptide delayed onset of disease in both of these 
models, suggesting that the epitope targeted by SEDI is disease relevant (Liu et al., 2012).  
USOD (unfolded SOD1) detects a region of the SOD1 protein, involved in copper binding, which 
is buried within the correctly folded dimer and monomer (Figure 3.1) (Kerman et al., 2010). 
USOD also reacts with recombinant misfolded WT huSOD1 which had been destabilised by 
various chemical compounds, but not correctly folded holo (metalated) SOD1. This antibody 
detected misfolded huSOD1, by immunohistochemistry and IP, in SOD1-fALS SC (A4V and 
ΔG27/P28 mutations) but not sALS, and labelled similar structures to SEDI when used in 
immunohistochemistry on an A4V SOD1-fALS SC. In a G93A mutant SOD1 transgenic mouse, 
USOD immunohistochemistry revealed vacuolated structures in the ventral horns and roots; a 
similar pattern to that described by Rakhit et al., (2007) with SEDI. To our knowledge no other 
groups have reported the use of USOD in other patient or mouse tissues, although Linares et 
al., (2013) used USOD IP to detect a reduction in misfolded SOD1 in the spinal cords of G93A 
SOD1 transgenic rats in response to pharmacological treatment.  
Weichert et al., (2014) used IP with both SEDI and USOD to assess misfolding of a recombinant 
huSOD1 which had polypeptide linkers to produce homo and hetero WT and/or mutant 
dimers. Both SEDI and USOD showed a similar pattern, with high affinity to recombinant 
mutant (A4V, G37R, G41D, G41S, G85R and G93C) homodimers, reduced affinity for 
mutant:WT heterodimers and low affinity for WT homodimers. The fact that SEDI was able to 
precipitate these forms of SOD1 suggests that although described as “obligate dimers” the 
polypeptide linker actually allowed the dimer to dissociate, but presumably limited the 
dimerisation of the protein to the subunit that it was linked to.  
In this Chapter SEDI and USOD were used in immunohistochemistry to assess misfolded 
huSOD1 pathology in WT and G93A mutant transgenic huSOD1 mice. Both of these antibodies 
have been validated as identifying misfolded huSOD1 in SOD1-fALS and mutant huSOD1 
transgenic mice, while reactivity to WT huSOD1 is more limited in transgenic mice and absent 
in non-SOD1 patient tissue.  
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3.3 RESULTS  
The nomenclature used to refer to different mouse lines within the text of this chapter is 
summarised in Table 3.1.  
 
3.3.1 Inheritance Patterns of SOD1 Tg and KO Allele 
To produce mice with the genotypes needed for the projects presented in this Thesis and 
other work in our laboratory, we used two breeding strategies (Figure 3.2).  
The first is a cross between male Tg (WT or G93A);Sod1het mice and female NTg;Sod1het mice 
which can give rise to offspring of 6 possible genotypes as summarised in Figure 3.2a. This 
scheme was used when transgenic mice with both Sod1wt and Sod1ko genotypes were 
required.  
The second is a cross between male Tg (WT or G93A);Sod1ko mice and females NTg;Sod1het 
mice, which can give rise to offspring of 4 potential genotypes as summarised in Figure 3.2b. 
This breeding scheme was used when only transgenic mice with a Sod1ko genotype were 
needed.  
The number of offspring with different genotypes was monitored for each breeding scheme 
for both WT and G93A transgenic mice, using trio matings of 1 male mated to 2 female mice.  
Table 3.1 Mutant mouse nomenclature used within text 
Both the WT and G93A mutant SOD1 transgenes are human  
Tg allele KO allele Short form (used in text) 
Non-transgenic Sod1+/+ (WT) NTg;Sod1wt 
Non-transgenic Sod1+/- (heterozygous KO) NTg;Sod1het 
Non-transgenic Sod1-/- (homozygous KO) NTg;Sod1ko 
SOD1WT Tg hemizygous Sod1+/+ (WT) TgWT;Sod1wt 
SOD1WT Tg hemizygous Sod1+/- (heterozygous KO) TgWT;Sod1het 
SOD1WT Tg hemizygous Sod1-/- (homozygous KO) TgWT;Sod1ko 
SOD1G93A Tg hemizygous Sod1+/+ (WT) TgG93A;Sod1wt 
SOD1G93A Tg hemizygous Sod1+/- (heterozygous KO) TgG93A;Sod1het 
SOD1G93A Tg hemizygous Sod1-/- (homozygous KO) TgG93A;Sod1ko 
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3.3.1.1 INHERITANCE PATTERNS IN MALE TGWT;SOD1HET X FEMALE 
NTG;SOD1HET MATINGS 
The number of offspring of the 6 potential genotypes was monitored from 17 trios. Results are 
summarised in Table 3.2. The observed ratios did not differ significantly from the expected 
ratios. χ2(5)= 4.599, p>0.05.  
 
 
Figure 3.2 Breeding scheme 
Table 3.2 Observed genotype ratios of offspring from TgWT;Sod1het X NTg;Sod1het 
matings 
The omnibus χ2 showed that observed ratios did not differ from the expected Mendelian 
ratios. 
Genotype 
Number of 
animals born 
Observed 
ratio 
Expected 
Mendelian 
ratio 
NTg;Sod1wt 62 0.1480 0.125 
NTg;Sod1het 91 0.2172 0.25 
NTg;Sod1ko 48 0.1146 0.125 
TgWT;Sod1wt 52 0.1241 0.125 
TgWT;Sod1het 113 0.2697 0.25 
TgWT;Sod1ko 53 0.1265 0.125 
TOTAL 419 1 1 
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3.3.1.2 INHERITANCE PATTERNS IN MALE TGWT;SOD1HOM X FEMALE 
NTG;SOD1HET MATINGS 
The number of offspring of the 4 potential genotypes was monitored from 81 trios. Results are 
summarised in Table 3.3. The observed ratios differed significantly from the expected ratios. 
χ2(3)= 12.402, p<0.01.  
Eight post-hoc χ2 comparisons were carried out using a Bonferroni adjusted significance 
threshold of p=0.00625. The results, including χ2 statistics are summarised in Table 3.4 
The ratio of NTg;Sod1het offspring compared to NTg;Sod1ko offspring was significantly higher 
than the expected ratio. All other observed ratios did not differ significantly from the expected 
ratios.  
Table 3.3 Observed genotype ratios of offspring from TgWT;Sod1hom X NTg;Sod1het 
matings 
The omnibus χ2 showed that observed ratios were significantly different from the expected 
Mendelian ratios. 
Genotype 
Number of 
animals born 
Observed 
ratio 
Expected 
Mendelian 
ratio 
NTg;Sod1het 535 0.2761 0.25 
NTg;Sod1ko 426 0.2198 0.25 
TgWT;Sod1het 487 0.2513 0.25 
TgWT;Sod1ko 490 0.2528 0.25 
TOTAL 1938 1 1 
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Table 3.4 Pair-wise comparisons for TgWT;Sod1hom X NTg;Sod1het matings 
Significant comparisons are highlighted in green. Significance relative to non-adjusted 
levels : ** p<0.01.  
Genotype 
Mice 
born 
Observed 
Ratio 
Expected 
Mendelian 
Ratio 
Comparison 1- χ2(1)=0.132, p>0.00625 
NTg 961 0.4959 0.5 
TgWT 977 0.5041 0.5 
TOTAL 1938 1   
Comparison 2- χ2(1)=5.798, p>0.00625 
Sod1het 1022 0.5273 0.5 
Sod1ko 916 0.4727 0.5 
TOTAL 1938 1 1 
Comparison 3- χ2(1)=12.363, p<0.00125 ** 
NTg;Sod1het 535 0.5567 0.5 
NTg;Sod1ko 426 0.4433 0.5 
TOTAL 961     
Comparison 4- χ2(1)=2.254, p>0.00625 
NTg;Sod1het 535 0.5235 0.5 
TgWT;Sod1het 487 0.4765 0.5 
TOTAL 1022 1 1 
Comparison 5- χ2(1)=1.976, p>0.00625 
NTg;Sod1het 535 0.5220 0.5 
TgWT;Sod1ko 490 0.4780 0.5 
TOTAL 1025 1 1 
Comparison 6- χ2(1)=4.076, p>0.00625 
NTg;Sod1ko 426 0.4666 0.5 
TgWT;Sod1het 487 0.5334 0.5 
TOTAL 913 1 1 
Comparison 7- χ2(1)=4.472, p>0.00625 
NTg;Sod1ko 426 0.4651 0.5 
TgWT;Sod1ko 490 0.5349 0.5 
TOTAL 916 1 1 
Comparison 8- χ2(1)=0.009, p>0.00625 
TgWT;Sod1het 487 0.4985 0.5 
TgWT;Sod1ko 490 0.5015 0.5 
TOTAL 977 1 1 
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3.3.1.3 INHERITANCE PATTERNS IN MALE TGG93A;SOD1HET X FEMALE 
NTG;SOD1HET MATINGS 
The number of offspring of the 6 potential genotypes was measured from 106 trios. Results 
are summarised in Table 3.5. The observed ratios differed significantly from the expected 
ratios. χ2(5)= 47.858, p<0.001.  
Eighteen post-hoc χ2 comparisons were carried out using a Bonferroni adjusted significance 
level of p=0.002778. The comparisons and their χ2 statistics are summarised in Table 3.6.  
The observed ratio of NTg offspring compared to TgG93A offspring was significantly higher 
than the expected ratio.  
The observed ratio of NTg;Sod1wt offspring compared to NTg;Sod1ko, TgG93A;Sod1wt and 
TgG93A;Sod1het offspring was significantly higher than the expected ratio.  
The observed ratio of NTg;Sod1het offspring compared to NTg;Sod1ko, TgG93A;Sod1wt, 
TgG93A;Sod1het and TgG93A;Sod1ko was significantly higher than the expected ratio. None of 
the other comparisons were significantly different.  
Table 3.5 Observed genotype ratios of offspring from TgG93A;Sod1het X NTg;Sod1het 
matings 
The omnibus χ2 showed that observed ratios differed significantly from the expected 
Mendelian ratios.  
  
Number of 
animals born 
Observed 
ratio 
Expected 
Mendelian 
ratio 
NTg;Sod1wt 225 0.1530 0.125 
NTg;Sod1het 453 0.3080 0.25 
NTg;Sod1ko 148 0.1006 0.125 
TgG93A;Sod1wt 161 0.1094 0.125 
TgG93A;Sod1het 313 0.2128 0.25 
TgG93A;Sod1ko 171 0.1162 0.125 
TOTAL 1471 1 1 
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3.3.1.4 INHERITANCE PATTERNS IN MALE TGG93A;SOD1HOM X FEMALE 
NTG;SOD1HET MATINGS 
The number of offspring of the 4 potential genotypes was measured from 77 trios. Results are 
summarised in Table 3.7. The observed ratios differed significantly from the expected ratios. 
χ2(3)= 17.453, p<0.001.  
Eight post-hoc χ2 comparisons were carried out using a Bonferroni corrected significance level 
of p=0.00625. These comparisons and the χ2 statistics are summarised in Table 3.8.  
Table 3.6 Pair-wise comparisons for TgG93A;Sod1het X NTg;Sod1het matings 
Significant comparisons are highlighted in green. Significance relative to non-adjusted 
levels: * p<0.05. ** p<0.01. ***p<0.001. 
Genotype 
Mice 
born 
Observ-
ed Ratio 
Expect-
ed Ratio 
 
Genotype 
Mice 
born 
Observ-
ed Ratio 
Expect-
ed Ratio 
Comparison 1- χ
2
(1)=22.271, p<0.000056 *** 
 
Comparison 10- χ
2
(1)=13.975, p<0.000556 ** 
NTg 826 0.5615 0.5 
 
NTg;Sod1het 453 0.7378 0.6667 
Tg 645 0.4385 0.5 
 
TgG93A;Sod1wt 161 0.2622 0.3333 
TOTAL 1471 1 1 
 
TOTAL 614 1 1 
Comparison 2- χ
2
(1)=0.016, p>0.002778 
 
Comparison 11- χ
2
(1)=25.587, p<0.000056 *** 
Sod1wt 386 0.3351 0.3333 
 
NTg;Sod1het 453 0.5914 0.5 
Sod1het 766 0.6649 0.6667 
 
TgG93A;Sod1het 313 0.4086 0.5 
TOTAL 1152 1 1 
 
TOTAL 766 1 1 
Comparison 3- χ
2
(1)=6.367, p>0.002778 
 
Comparison 12- χ
2
(1)=9.873, p<0.002778 * 
Sod1wt 386 0.5475 0.5 
 
NTg;Sod1het 453 0.7260 0.6667 
Sod1ko 319 0.4525 0.5 
 
TgG93A;Sod1ko 171 0.2740 0.3333 
TOTAL 705 1 1 
 
TOTAL 624 1 1 
Comparison 4- χ
2
(1)=0.007, p>0.002778 
 
Comparison 13- χ
2
(1)=0.547, p>0.002778 
NTg;Sod1wt 225 0.3319 0.3333 
 
NTg;Sod1ko 148 0.4790 0.5 
NTg;Sod1het 453 0.6681 0.6667 
 
TgG93A;Sod1wt 161 0.5210 0.5 
TOTAL 678 1 1 
 
TOTAL 309 1 1 
Comparison 5- χ
2
(1)=15.895, p<0.000556 ** 
 
Comparison 14- χ
2
(1)=0.313, p>0.002778 
NTg;Sod1wt 225 0.6032 0.5 
 
NTg;Sod1ko 148 0.3210 0.3333 
NTg;Sod1ko 148 0.3968 0.5 
 
TgG93A;Sod1het 313 0.6790 0.6667 
TOTAL 373 1 1 
 
TOTAL 461 1 1 
Comparison 6- χ
2
(1)=10.611, p<0.002778 * 
 
Comparison 15- χ
2
(1)=1.658, p>0.002778 
NTg;Sod1wt 225 0.5829 0.5 
 
NTg;Sod1ko 148 0.4639 0.5 
TgG93A;Sod1wt 161 0.4171 0.5 
 
TgG93A;Sod1ko 171 0.5361 0.5 
TOTAL 386 1 1 
 
TOTAL 319 1 1 
Comparison 7- χ
2
(1)=17.444, p<0.000056 *** 
 
Comparison 16- χ
2
(1)=0.085, p>0.002778 
NTg;Sod1wt 225 0.4182 0.3333 
 
TgG93A;Sod1wt 161 0.3397 0.3333 
TgG93A;Sod1het 313 0.5818 0.6667 
 
TgG93A;Sod1het 313 0.6603 0.6667 
TOTAL 538 1 1 
 
TOTAL 474 1 1 
Comparison 8- χ
2
(1)=7.364, p>0.002778 
 
Comparison 17- χ
2
(1)=0.301, p>0.002778 
NTg;Sod1wt 225 0.5682 0.5 
 
TgG93A;Sod1wt 161 0.4849 0.5 
TgG93A;Sod1ko 171 0.4318 0.5 
 
TgG93A;Sod1ko 171 0.5151 0.5 
TOTAL 396 1 1 
 
TOTAL 332 1 1 
Comparison 9- χ
2
(1)=20.506, p<0.000056 *** 
 
Comparison 18- χ
2
(1)=0.869, p>0.002778 
NTg;Sod1het 453 0.7537 0.6667 
 
TgG93A;Sod1het 313 0.6467 0.6667 
NTg;Sod1ko 148 0.2463 0.3333 
 
TgG93A;Sod1ko 171 0.3533 0.3333 
TOTAL 601 1 1 
 
TOTAL 484 1 1 
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The observed ratio of NTg;Sod1het offspring compared to NTg;Sod1ko and TgG93A;Sod1het 
offspring was significantly higher than the expected ratio. No of the other comparisons was 
significant.  
These results will be discussed in Section 3.4.1.  
Table 3.7 Observed genotype ratios of offspring from TgG93A;Sod1hom X NTg;Sod1het 
matings 
The omnibus χ2 showed that observed ratios were significantly different to the expected 
Mendelian ratios.  
 Genotype 
Number of 
animals born 
Observed 
ratio 
Expected 
Mendelian 
ratio 
NTg;Sod1het 330 0.2992 0.25 
NTg;Sod1ko 252 0.2285 0.25 
TgG93A;Sod1het 240 0.2176 0.25 
TgG93A;Sod1ko 281 0.2548 0.25 
TOTAL 1103 1 1 
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Table 3.8 Pair-wise comparisons for TgG93A;Sod1hom X NTg;Sod1het matings 
Significant comparisons are highlighted in green. Significance relative to non-adjusted 
levels: * p<0.05. ** p<0.01.  
Genotype 
Mice 
born 
Observed 
ratio 
Expected 
Mendelian 
ratio 
Comparison 1- χ2(1)=, p>0.00625 
NTg 582 0.5277 0.5 
Tg 521 0.4723 0.5 
TOTAL 1103 1.0000 1.0000 
Comparison 2- χ2(1)=, p>0.00625 
Sod1het 570 0.5168 0.5 
Sod1ko 533 0.4832 0.5 
TOTAL 1103 1 1 
Comparison 3- χ2(1)=10.454, p<0.00625 * 
NTg;Sod1het 330 0.5670 0.5 
NTg;Sod1ko 252 0.4330 0.5 
TOTAL 582 1 1 
Comparison 4- χ2(1)=14.211, p<0.00125 ** 
NTg;Sod1het 330 0.5789 0.5 
TgG93A;Sod1het 240 0.4211 0.5 
TOTAL 570 1 1 
Comparison 5- χ2(1)=3.930, p>0.00625 
NTg;Sod1het 330 0.5401 0.5 
TgG93A;Sod1ko 281 0.4599 0.5 
TOTAL 611 1 1 
Comparison 6- χ2(1)=0.293, p>0.00625 
NTg;Sod1ko 252 0.5122 0.5 
TgG93A;Sod1het 240 0.4878 0.5 
TOTAL 492 1 1 
Comparison 7- χ2(1)=1.578, p>0.00625 
NTg;Sod1ko 252 0.4728 0.5 
TgG93A;Sod1ko 281 0.5272 0.5 
TOTAL 533 1 1 
Comparison 8- χ2(1)=3.226, p>0.00625 
TgG93A;Sod1het 240 0.4607 0.5 
TgG93A;Sod1ko 281 0.5393 0.5 
TOTAL 521 1 1 
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3.3.2 Transmission in SOD1G93A Transgenic Mice 
In cellular models of prion-like seeded aggregation, self-seeding is consistently reported 
(Munch et al., 2011; Furukawa et al., 2013; Grad et al., 2011; Grad et al., 2014; 
Sundaramoorthy et al., 2013). Cross-seeded aggregation of WT SOD1 by mutant SOD1 is also 
reported in some cellular models (Grad et al., 2011; Grad et al., 2014; Sundaramoorthy et al., 
2013), however, this is not consistent (Munch et al., 2011). We therefore first tested whether 
self-seeded aggregation could be detected in a mutant huSOD1 transgenic mouse.  
Fifty day old TgG93A;Sod1ko mice were inoculated with SC homogenate from 100-days old 
TgG93A;Sod1ko mice (as described in Section 2.6.2). Several control inocula were also used as 
summarised in Table 3.9. Animals were culled at either 24 hours or 40-days post-inoculation 
and the misfolded SOD1 burden in the brain was assayed.  
Where pair-wise comparisons are carried out between inoculum groups, comparison is to the 
m-NTg inoculated animals; because this inoculum has no human or mouse SOD1, if an effect is 
due to prion-like properties of SOD1 they should be absent in this group, however non-specific 
effects due to inoculation with CNS homogenate with be controlled for. 
 
3.3.2.1 PREMATURE DEATH AND EXCLUSIONS  
Only 1 animal was culled before its pre-defined cull date and this was due to malocclusion and 
not related to any experimental procedure. One animal, from the m-TgG93A 40 day time-point 
was found dead after the inoculation procedure. Both of these animals were excluded from 
the data set.  
3.3.2.2 AGE DIFFERENCES BETWEEN GROUPS 
The average age of mice at their scheduled cull date, split by inoculum group, is shown in Table 
3.10. Two one-way ANOVAS were carried out, one for each time-point, to check for variance in 
age between inoculum groups. There was no difference in the age at cull between inoculum 
groups in either the 24 hour (F(3,11)=0.40, p>0.05) or 40 day (F(4,50)=1.503, p>0.05) 
time-points.  
Table 3.9 Inoculum used for TgG93A transmission experiment 
The experimental inoculum is highlighted in blue, control inocula are in white 
Name Species Genotype 
Age at 
death Sex 
Tissue 
used 
m-TgG93A mouse TgG93A;Sod1ko 100 days female spinal cord 
m-TgWT mouse TgWT;Sod1ko  100 days female spinal cord 
m-NTg mouse NTg;Sod1ko 100 days female spinal cord 
PBS n/a PBS only controls  
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3.3.2.3 SEDI BRAIN PATHOLOGY  
The brain was divided into regions as shown in Figure 3.3 and analysed using Definiens tissue 
Studio software, as described in Section 2.7.5, to give the proportion of each region stained. 
Because the proportions were very small, the numbers presented have been multiplied by 
1000.  
Analyses for this project are on-going and at present, data are available for inoculated 
TgG93A;Sod1ko mice, but not for non-inoculated controls or for NTg;Sod1ko mice inoculated 
with m-TgG93A.  
 
Table 3.10 Average age at scheduled cull 
Table shows number of animals inoculated per group and their mean (and SEM) age in 
days 
 
24 hour time-point 40 day time-point 
Inoculum n= mean SEM n= mean SEM 
NI 0 -  -  10 89.900 0.100 
PBS 3 52.333 0.667 10 89.700 0.335 
m-NTg 3 51.000 1.000 10 89.200 0.389 
m-TgWT 3 51.333 0.333 10 89.900 0.180 
m-TgG93A 3 51.333 1.333 11 90.636 0.730 
 
 
Figure 3.3 Brain region division 
Blue= cortex. Green= olfactory bulb. Red= corpus callosum. Yellow= hippocampus. Cyan= 
cerebellum. Grey= brain stem. Orange= other 
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3.3.2.3.1 Twenty-four Hours Post-Inoculation  
Figure 3.4 shows examples of SEDI staining of sagittal brain sections 24 hours post-inoculation. 
Data were analysed by one-way ANOVA with planned comparisons to the m-NTg control 
inoculated group. The results for each region analysed are summarised in Figure 3.5 
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Figure 3.4 SEDI stained TgG93A;Sod1ko sagittal brain sections 24 hours post-inoculation 
Representative examples of sagittal brain sections ofTgG93A;Sod1ko mice 24 hours after 
inoculation (51-days of age) inoculated with (a) PBS only, (b) m-NTg, (c) m-TgWT, or (d) 
m-TgG93A.  
Scale bar= 1mm. SEDI staining is brown, and sections were counterstained with 
haematoxylin  
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In the brain stem there was a significant difference in the area of SEDI staining between 
inoculum groups: F(3,7)=6.328, p<0.05. A larger proportion of the brain stem stained positive 
for SEDI in mice inoculated with m-NTg than mice inoculated with either PBS (t(7)=3.943, 
p<0.01), or m-TgG93A (t(7)=2.452, p<0.05), but did not differ from mice inoculated with m-
TgWT (t(7)=0.392, p>0.05) 
In the hippocampus there was a significant difference in the area of SEDI staining between 
inoculum groups: F(3,7)=6.497, p<0.05. Mice inoculated with m-NTg had a significantly smaller 
proportion of the hippocampus stained with SEDI than did mice inoculated with m-TgG93A 
(t(7)=-3.738, p<0.01), but did not differ from either mice inoculated with PBS (t(7)=-0.124, 
p>0.05) or m-TgWT (t(7)=-0.118, p>0.05).  
In the “other” region there was a significant difference in the area of SEDI staining between 
inoculum groups: F(3,7)=23.784, p<0.001. Mice inoculated with m-NTg had a significantly 
smaller proportion of the “other” region stained positive for SEDI than mice inoculated with m-
TgG93A (t(7)=-6.436, p<0.001), but did not differ from mice inoculated with PBS (t(7)=1.143, 
p>0.05) or m-TgWT (t(7)=0.254), p>0.05).  
 
Figure 3.5 Quantification of SEDI stained TgG93A;Sod1ko brains at 24 hours post-
inoculation 
Graphs show the mean (and SEM) proportion of SEDI stained area for each brain region.  
ANOVA found significant differences between inoculation group for the brain stem, 
hippocampus and “other” regions. Significance values of planned comparisons to mice 
inoculated with m-NTg are indicated.  
* p<0.05. ** p<0.01. ***p<0.001. n.s.= not significant.  
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There was no significant difference in the area of SEDI staining between inoculum groups in 
the cerebellum (F(3,7)=3.889, p>0.05), corpus callosum (F(3,7)=1.373, p>0.05), cortex 
(F(3,7)=3.483, p>0.05) or olfactory bulb (F(3,7)=3.765, p>0.05). Although the differences in 
these regions did not reach statistical significance, a non-significant trend of mice inoculated 
with m-TgG93A having increased SEDI staining can be seen (Figure 3.5).  
3.3.2.3.2 Forty-Days Post-Inoculation  
Figure 3.6 shows examples of SEDI staining in sagittal brain sections 40-days post-inoculation. 
Data were analysed by one-way ANOVA with planned comparisons to the m-NTg control 
inoculated group. Results for each region analysed as summarised in Figure 3.7.  
There was no significant difference in the area of SEDI staining between inoculum groups for 
any of the brain regions (brain stem: F(3,34)=0.973, p>0.05, cerebellum: F(3,33)=0.333, p>0.05, 
corpus callosum: F(3,34)=1.078, p>0.05, cortex: F(3,34)=1.432, p>0.05, hippocampus: 
F(3,34)=0.756, p>0.05, olfactory bulb: F(3,33)=0.063, p>0.05, “other” F=3,34)=1.558, p>0.05).  
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(continued…) 
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Figure 3.6 SEDI stained TgG93A;Sod1ko sagittal brain sections 40 days post-inoculation 
Representative examples of sagittal brain sections ofTgG93A;Sod1ko mice 40-days after 
inoculation (91-days of age) inoculated with (a) PBS only, (b) m-NTg, (c) m-TgWT or (d) 
m-TgG93A.  
Scale bar= 1mm. SEDI staining is brown, and sections were counterstained with 
haematoxylin 
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3.3.3 Transmission in Wild-Type SOD1 Transgenic Mice 
Cross-seeded misfolding of WT SOD1, by mutant misfolded SOD1, has been reported in some 
(Grad et al., 2011; Sundaramoorthy et al., 2013) but not all (Munch et al., 2011) cellular models 
of prion-like SOD1. We next tested whether cross-seeded aggregation could be detected in a 
WT huSOD1 transgenic mouse.  
Seventy day old TgWT;Sod1ko mice were intracerebrally inoculated with SC homogenate from 
100-days old TgG93A;Sod1ko mice, or motor cortex homogenate from SOD1-fALS patients (as 
described in Section 2.6.2). Several control inocula were also used as summarised in Table 
3.11.  
 
 
Figure 3.7 Quantification of SEDI stained TgG93A;Sod1ko brains at 40 days post-
inoculation 
Graphs show the mean (and SEM) proportion of SEDI stained area for each brain region. 
ANOVA found no differences between inoculation groups for any brain region.  
 
Table 3.11 Inoculum used for TgWT transmission experiment 
Experimental inocula, containing mutant SOD1, are highlighted in blue, control inocula are 
white.  
Name Species Genotype Age at death Sex Tissue used 
m-TgG93A mouse TgG93A,Sod1ko 100 days female spinal cord 
m-TgWT mouse TgWT,Sod1ko 100 days female spinal cord 
m-NTg mouse NTg,Sod1ko 100 days female spinal cord 
h-D101G human SOD1+/D101G 46 years female motor cortex 
h-I113T human SOD1+/I113T 47 years male motor cortex 
h-cntrl1 human SOD1+/+ 52 years female motor cortex 
h-cntrl2 human SOD1+/+ 40 years male motor cortex 
PBS n/a PBS only control       
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Where pair-wise comparisons are carried out between inoculum groups, comparison is to the 
m-NTg inoculated animals; as this inoculum is devoid of either human or mouse SOD1, if an 
effect is due to prion-like properties of SOD1 they should be absent in this group, however 
non-specific effects due to the inoculation with CNS material will be controlled for. 
3.3.3.1 PREMATURE DEATH AND EXCLUSION  
During the experiment a number of animals died or were culled before their scheduled cull 
date. Table 3.12 shows causes of premature death split between inoculum groups. A full list of 
all animals that died prematurely, broken down by inoculum and time-point group, can be 
found in Section 7.3, Appendix 3.  
In total 211 animals, or 37.7% of all animals entering the experiment, were excluded from the 
final data set due to premature death. Table 3.13 shows the number of animals in each inocula 
and time-point group to survive to its scheduled cull date.  
The most common causes of premature death/cull were weight loss and self-inflicted injury 
due to over-grooming and scratching which accounted for 34.6% and 30.8% of the 211 
premature deaths, respectively. The next most common cause of death was intolerance to the 
inoculation/anaesthetic procedure, which accounted for 20.9% of premature deaths. Other 
individual causes were responsible for the death/cull of very small numbers of animals (all less 
that 4% of premature deaths).  
Of the 211 cases that were culled prior to their scheduled cull date, 184 were from the 2 
longest time-points of 365 and 660-days post-inoculation. Kaplan-Meier survival analysis was 
used to compare the survival of animals in the 2 longest time-points for the most common 
causes of premature death (weight loss and scratching) and other disease relevant causes 
(hind limb paralysis and impaired righting reflex). Figure 3.8 shows the Kaplan-Meier survival 
graph (for increased clarity, the same data is displayed in Section 7.4, Appendix 4 with data 
split onto 2 graphs, one showing data for mice inoculated with mouse tissues, and another 
showing data from mice inoculated with human tissues). There was a significant effect of 
inoculum group on survival (χ2(8)=40.246, p<0.001).  
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Table 3.12 Causes of premature death 
Inoculum 
Inocula-
tion / 
anaesthe-
tic 
Scratch
-ing 
Weight 
loss 
Found 
dead 
Abdom-
inal 
swelling 
Ab-
normal 
breath-
ing 
Hind 
limb 
paralysis 
Righting 
reflex 
Missing 
presumed 
dead 
Culled 
in 
error 
Pro-
lapsed 
rectum Tumour 
TOTAL 
(pre-
mature 
/ total) 
Non-
inoculated 0 2 7 1 0 0 0 0 3 1 0 2 16/61 
PBS 4 7 3 1 1 0 0 0 1 1 1 0 19/65 
m-NTg 5 6 9 0 1 0 1 0 0 1 0 0 23/63 
m-TgWT 2 11 8 2 0 0 0 1 0 0 0 0 24/60 
m-TgG93A 1 9 10 0 0 0 0 0 0 1 0 0 21/62 
h-cntrl1 8 3 14 0 1 1 0 0 1 0 0 0 28/63 
h-cntrl2 9 7 6 1 0 0 0 0 0 0 0 0 23/60 
h-D101G 6 11 6 1 0 0 0 1 0 0 0 0 25/62 
h-I113T 9 9 10 2 1 0 0 1 0 0 0 0 32/64 
TOTAL 44 65 73 8 4 1 1 3 5 4 1 2 211/560 
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Figure 3.8 Kaplan-Meier survival graph of TgWT;Sod1ko mice 
Mice from the 2 longest time-points (365 and 660-days post-inoculation) that were culled 
before their scheduled cull date due to weight loss, self-inflicted scratching wounds, hind 
limb paralysis and impaired righting reflex were included in the analysis. There was a 
significant effect of inoculation group on likelihood of survival χ2(8)=40.246, p<0.001. Pair-
wise comparisons to m-NTg inoculated mice did not reveal any significant differences.  
This data is also presented in 2 graphs in Section 7.4, Appendix 4, spilt between mouse and 
human inocula.  
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Eight further pair-wise comparisons were carried out to compare the survival of each inoculum 
group to mice inoculated with m-NTg. A Bonferroni adjusted significance level of 0.00625 was 
used. There was no significant difference between survival of the m-NTg inoculated mice 
compared to the survival of non-inoculated mice (χ2(1)=5.654, p>0.00625) or mice inoculated 
with PBS (χ2(1)=7.292, p>0.00625), m-TgWT (χ2(1)=0.952, p>0.00625), m-TgG93A (χ2(1)=0.02, 
p>0.00625), h-cntrl1 (χ2(1)=1.233, p>0.00625), h-cntrl2 (χ2(1)=0.263, p>0.00625), h-D101G 
(χ2(1)=3.232, p>0.00625) or h-I113T (χ2(1)=3.437, p>0.00625). Comparisons of m-NTg 
inoculated to both non-inoculated and PBS inoculated animals had p values below the un-
correct cut-off of p=0.05 (p=0.017 and p=0.007, respectively), suggesting that the significant 
omnibus χ2 could be due to differences between animals inoculated with tissue homogenates 
and those non-inoculated or inoculated with PBS.  
3.3.3.2 AGE DIFFERENCES BETWEEN GROUPS 
3.3.3.2.1 Age at Cull - 7 Day Time-Point 
Figure 3.9 shows the average age at cull date for animals in the 7 day post-inoculation time-
point. A one-way ANOVA revealed significant differences in the age at cull date between 
inoculation groups: F(8,84)=13.621, p<0.001. Bonferroni post-hoc comparisons were carried 
out to identify pair-wise differences.  
PBS inoculated animals had a significantly higher age at cull than animals inoculated with m-
NTg (p<0.001), m-TgG93A (p<0.05), h-cntrl2 (p<0.001) and h-D101G (p<0.001) and non-
inoculated animals (p<0.01).  
Table 3.13 Number of animals surviving to scheduled cull date 
Table shows the number of animals surviving to the scheduled cull date / the number of 
animals allocate to the group  
  Time-point (days post-inoculation) 
Inoculum 7 90 180 365 660 
Non-inoculated 8/11 10/10 10/10 9/10 8/20 
PBS 10/10 9/10 9/10 9/15 9/20 
m-NTg 10/10 10/10 9/13 7/10 4/20 
m-TgWT 10/10 10/10 10/10 4/10 2/20 
m-TgG93A 10/10 10/10 10/10 8/10 3/22 
h-cntrl1 9/10 9/13 9/10 8/10 0/20 
h-cntrl2 9/10 9/10 10/15 7/10 2/15 
h-D101G 9/10 10/10 10/12 8/10 0/20 
h-I113T 10/10 9/10 9/10 3/10 1/24 
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Mice inoculated with m-TgWT were significantly older at cull than mice inoculated with m-NTg 
(p<0.01) h-cntrl2 (p<0.01) and h-D101G (p<0.01).  
Mice inoculated with h-I113T were significantly older at cull than mice inoculated with m-NTg 
(p<0.001), m-TgWT (p<0.05), m-TgG93A (p<0.001), h-cntrl1 (p<0.01) h-cntrl2 (p<0.001) and h-
D101G (p<0.001) and non-inoculated mice (p<0.001).  
 
3.3.3.2.2 Age at Cull - 90 Day Time-Point 
Figure 3.10 shows the average age at cull date for animals in the 90 day post-inoculation time-
point. A one-way ANOVA revealed significant differences in the age at cull date between 
inoculation groups at the 90 day time-point: F(8,85)=3.722, P<0.01. Bonferroni post-hoc 
comparisons were carried out to identify pair-wise differences.  
Mice inoculated with h-cntrl2 had significantly higher age at cull than mice inoculated with PBS 
(p<0.01) or h-D101G (p<0.05) or non-inoculated animals (p<0.01).  
 
Figure 3.9 Average age at cull- 7 day time-point 
The mean (and SEM) age at scheduled cull is plotted. ANOVA found a significant difference 
in the age at scheduled cull between inoculation groups. Significance levels of post-hoc 
Bonferroni t-tests pair-wise comparisons are indicated: * p<0.05. ** p<0.01. ***p<0.001. 
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3.3.3.2.3 Age at Cull - 180 Day Time-Point 
Figure 3.11 shows the average age at cull date for animals in the 180 day post-inoculation 
time-point. A one-way ANOVA revealed significant differences in the age at cull date between 
inoculation groups at the 180 day time-point: F(8,85)=6.244, p<0.001. Bonferroni post-hoc 
comparisons were carried out to identify pair-wise differences.  
Mice inoculated with m-TgG93A had significantly lower age at cull date than mice inoculated 
with m-NTg (p<0.001), h-cntrl1 (p<0.001), h-cntrl2 (p<0.01), h-D101G (p<0.05) or h-I113T 
(p<0.01) or non-inoculated animals (p<001).  
 
Figure 3.10 Average age at cull- 90 day time-point 
The mean (and SEM) age at scheduled cull is plotted. ANOVA found a significant difference 
in the age at scheduled cull between inoculation groups. Significance levels of post-hoc 
Bonferroni t-tests pair-wise comparisons are indicated: * p<0.05. ** p<0.01.  
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3.3.3.2.4 Age at Cull - 365 Day Time-Point 
Figure 3.12 shows the average age at cull date for animals in the 365 day post-inoculation 
time-point. A one-way ANOVA revealed significant differences in the age at cull date between 
inoculation groups at the 365 day time-point: F(8,62)=5.546, p<0.001. Bonferroni post-hoc 
comparisons were carried out to identify pair-wise differences.  
Mice inoculated with m-TgWT were significantly older at their cull date than mice inoculated 
with m-TgG93A (p<0.05), h-cntrl2 (p<0.001), h-D101G (p<0.01) or h-I113T (p<0.01) or non-
inoculated animals (p<0.01). Mice inoculated with h-cntrl2 were significantly younger at their 
cull date than mice inoculated with PBS (p<0.05) or h-cntrl1 (p<0.01).  
 
Figure 3.11 Average age at cull- 180 day time-point 
The mean (and SEM) age at scheduled cull is plotted. ANOVA found a significant difference 
in the age at scheduled cull between inoculation groups. Significance levels of post-hoc 
Bonferroni t-tests pair-wise comparisons are indicated: * p<0.05. ** p<0.01. ***p<0.001. 
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3.3.3.2.5 Age at Cull - 660 Day Time-Point 
Figure 3.13 shows the average age at cull date for animals in the 660 day post-inoculation 
time-point. Because only one mouse in the h-I113T inoculum group survived until its allocated 
cull date, and no mice from either the h-cntrl1 or h-D101G inoculum groups survived, these 
groups were excluded from the analyses. A one-way ANOVA revealed significant differences in 
the age at cull date between inoculation groups at the 660 day time-point: F(5,27)=18.877, 
p<0.001. Bonferroni post-hoc comparisons were carried out to identify pair-wise differences.  
Non-inoculated mice had significantly lower ages at their cull date than did mice inoculated 
with PBS (p<0.001) and m-TgG93A (p<0.05). Mice inoculated with m-NTg had significantly 
lower ages at their cull date than did mice inoculated with PBS (p<0.001), m-TgWT (p<0.05), 
m-TgG93A (p<0.001) or h-cntrl2 (p<0.01).  
 
Figure 3.12 Average age at cull- 365 day time-point 
The mean (and SEM) age at scheduled cull is plotted. ANOVA found a significant difference 
in the age at scheduled cull between inoculation groups. Significance levels of post-hoc 
Bonferroni t-tests pair-wise comparisons are indicated: * p<0.05. ** p<0.01. ***p<0.001. 
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3.3.3.3 MISFOLDED SOD1 PATHOLOGY 
Initial testing of SEDI staining of spinal cords of mice culled at 180-days post-inoculation 
revealed very high levels of staining even in mice inoculated with PBS and m-NTg as shown in 
Figure 3.14. For this reason, the USOD antibody was tested for analysis at an earlier time-point 
of 90-days post-inoculation. Data collection and analysis is on-going for this project. At this 
time data are available for USOD stained spinal cords of mice in the 90 day time-point, 
inoculated with PBS, m-NTg, m-TgWT and m-TgG93A. Five animals have been analysed per 
inoculum group except for the m-NTg group where only 4 animals have been analysed.  
 
Figure 3.13 Average age at cull- 660 day time-point 
The mean (and SEM) age at scheduled cull is plotted. ANOVA found a significant difference 
in the age at scheduled cull between inoculation groups. Significance levels of post-hoc 
Bonferroni t-tests pair-wise comparisons are indicated: * p<0.05. ** p<0.01. ***p<0.001. 
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Figure 3.14 SEDI staining of TgWT;Sod1ko cords at 90 days post-inoculation 
Examples of SEDI stained spinal cords of TgG93A;Sod1ko mice inoculated with (a) PBS or 
(b) m-NTg. High staining can be seen in both cases, particularly in the ventral horns and 
white matter tracts. Inset shown higher magnification of ventral horn.  
Scale bar= 100µm. SEDI staining is brown, and sections were counterstained with 
haematoxylin 
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3.3.3.3.1 USOD Spinal Cord Pathology 
The cords were divided into regions as shown in Figure 3.15 and analysed using Definiens 
tissue Studio software, as described in Section 2.7.5, to give the proportion of each region 
stained. Because the proportions were very small the numbers presented in Figures and Tables 
have been multiplied by 1000.  
 
Figure 3.16 shows examples of USOD stained spinal cord sections at 90-days post-inoculation. 
Data were analysed by one-way ANOVA with planned comparisons to the m-NTg control 
inoculated group. Results for each region analysed as summarised in Figure 3.17.  
There was no difference in the area of USOD staining between inoculum groups for the ventral 
horns (F(3,18)=1.761, p>0.05), dorsal horns (F(3,16)=0.585, p>0.05), white matter 
(F(3,16)=0.675, p>0.05) or the dorsal roots (F(3,16)=1.068, p>0.05).  
There was a significant difference in the proportion of USOD staining between inoculum 
groups in the ventral roots (F(3,16)=3.735, p<0.05). As shown in Figure 3.17, mice inoculated 
with m-NTg had a significantly smaller proportion of USOD staining within the ventral roots 
compared to mice inoculated with m-TgG93A (t(13)=-2.311, p<0.05) but did not differ to 
animals inoculated with PBS (t(13)=0.002, p>0.05) or m-TgWT (t(13)=-0.620, p>0.05).  
 
Figure 3.15 Division of spinal cord regions 
Blue= dorsal horns. Orange= ventral horns. Yellow= white matter. Red= dorsal roots. 
Green= ventral roots.  
150 
 
 
(continued…) 
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Figure 3.16 USOD stained TgWT;Sod1ko spinal cord sections 90 days post-inoculation 
Representative examples of USOD stained spinal cords of TgWT;Sod1ko mice ninety-days 
post-inoculation (160-days of age), inoculated with (a) PBS only, (b) m-NTg, (c) m-TgWT or 
(d) m-TgG93A. Inset shows higher magnification of ventral horn white matter and roots.  
Scale bar= 100µm. USOD staining is brown, and sections were counterstained with 
haematoxylin 
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Figure 3.17 Quantification of USOD stained TgWT;Sod1ko spinal cords at 90 days post-
inoculation 
Graphs show the mean (and SEM) proportion of USOD stained area for each spinal cord 
region. ANOVA found a significant difference in the proportion of USOD stained area 
between inoculation groups in the ventral roots only. Significance values of planned 
comparisons to mice inoculated with m-NTg are indicated. n.s.= not significant; * p<0.05 
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3.4 CONCLUSIONS  
3.4.1 Inheritance Patterns of Human WT and G93A Transgenes 
and a Sod1 KO Allele 
The inheritance of the WT SOD1 transgene appears to follow Mendelian ratios as its 
inheritance did not differ from the expected ratio in either of the breeding schemes examined.  
In our breeding scheme crossing TgG93A;Sod1het males to NTg;Sod1het females, the ratio of 
NTg to TgG93A offspring was significantly higher than the expected ratio, with a p value of less 
than 0.0001. Pair-wise comparisons also identified significantly fewer TgG93A;Sod1wt and 
TgG93A;Sod1het offspring compared to NTg;Sod1wt offspring. There were also fewer 
TgG93A;Sod1ko compared to NTg;Sod1wt offspring, however this was not significantly 
different from the Mendelian ratio; the p value was 0.0067, which although low, was above 
the corrected significance cut off for multiple comparisons. The ratio of the number of 
offspring with any of the 3 TgG93A genotypes compared to NTg;Sod1het offspring was also 
significantly lower than the expected ratio. These results show that in matings between 
TgG93A;Sod1het males and NTg;Sod1het females, the G93A mutant SOD1 transgene is 
inherited at a lower frequency than would be expected according to Mendelian inheritance. 
The overall inheritance of the Sod1 KO allele was not significantly different from the expected 
Mendelian ratio. Within the NTg offspring there were significantly fewer NTg;Sod1ko offspring 
compared to NTg;Sod1wt offspring, but within the TgG93A offspring, neither the number of 
TgG93A;Sod1het nor TgG93A;Sod1ko offspring was different from the expected number as 
compared to TgG93A;Sod1wt offspring. This suggests that in NTg animals, Sod1ko pups are less 
common than expected, but in TgG93A animals, inheritance is Mendelian.  
In our mating scheme crossing TgG93A;Sod1ko males to NTg;Sod1het females, the ratio of NTg 
to TgG93A offspring did not differ from the expected ratio, even at an uncorrected significance 
threshold. However the ratio of NTg;Sod1het mice compared to TgG93A;Sod1het mice was 
higher than expected, although this did not hold true in those animals with a Sod1ko genotype. 
The inheritance of the Sod1 null allele showed a similar pattern as in offspring of matings with 
TgG93A;Sod1het males, the overall ratio was not different from the Mendelian ratio, but 
within NTg offspring more Sod1het animals were born than Sod1ko.  
Inheritance of the Sod1 null allele showed the same pattern in offspring of TgWT;Sod1ko 
males. Because the omnibus χ2 for matings using TgWT;Sod1het males was not significant, no 
pairwise comparisons were carried out.  
The fact that the omnibus χ2 for matings using TgWT;Sod1het males was not significant and 
that for matings using TgWT;Sod1ko males was, is most likely due to the sample size. Over 4 
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times more animals were born from matings using TgWT;Sodko males as compared to those 
using TgWT;Sod1het males. All matings for which full data were available were used in the 
analysis and the discrepancy is because animals of the TgWT;Sod1ko genotype were most 
commonly required for experiments and so more matings were set up using TgWT;Sod1ko 
males as these were least wasteful for their production. If the n number is artificially increased 
for inheritance from TgWT;Sod1het matings to match that of TgWT;Sod1ko matings, then a 
highly significant omnibus χ2 results. This suggests that an error has been made either due to 
under-powering the analysis of matings using TgWT;Sod1het males, or over-powering for 
matings using TgWT;Sod1ko males. Under-powering analysis is commonly caused by having a 
smaller sample size than is appropriate and can result in a type 2 error, where the null 
hypothesis is accepted, even though the experimental hypothesis is actually correct. Similarly, 
over-powering analysis can occur when an inappropriately large sample size is used; as the 
sample size increases, relative error decreases, making a type 1 error, where the experimental 
hypothesis is accepted erroneously, more likely (Coolican, 1999).  
The consistent finding across the 3 mating schemes for which pairwise comparisons were 
carried out is that overall there is no difference between expected and observed ratio when 
comparing Sod1ko offspring to either Sod1het (in the case of matings using Sod1ko males) or 
Sod1wt (in the case of matings using Sod1het males). However, when only NTg offspring are 
considered, the ratios are significantly different, with fewer NTg;Sod1ko offspring than 
expected. 
In summary, these results suggest a tendency towards less TgG93A offspring being born than 
Mendelian inheritance would predict, but for normal Mendelian inheritance of the WT 
huSOD1 transgene.  
The Sod1ko genotype appears to be less common than expected within a NTg population, 
however this does not hold true within either WT or G93A huSOD1 transgenic populations. 
Sod1 null sperm are known to have reduced fertilising ability (Tsunoda et al., 2012; Garratt et 
al., 2013) which could be responsible for a lower number of Sod1ko pups born to Sod1het 
males as Sod1- sperm would be less viable than Sod1+ sperm. In the case of Sod1ko males, all 
sperm would be Sod1- and so any difference would likely be maternal; either reduced 
inheritance of the Sod1 null allele from the mother, or reduced viability of the zygote/embryo. 
Sod1 null females are known to have reduced fertility (Matzuk et al., 1998) with increased 
levels of oxidative stress in the uterus (Noda et al., 2012). However Sod1 null oocytes are just 
as viable for in vitro fertilisation as WT oocytes and transplanted Sod1ko embryos survive 
normally within WT surrogate mothers (Noda et al., 2012). To our knowledge, similar 
examination has not been made of Sod1het female fertility, although we may speculate that 
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Sod1het females also have increased levels of oxidative stress in the uterus due to reduced 
SOD1 activity. The reduced number of Sod1ko offspring could therefore, be as a result of Sod1 
null oocytes/zygotes being more sensitive than WT oocytes/zygotes to the increased oxidative 
stress of the Sod1ko or Sod1het uterus. The lack of a difference in frequency of the Sod1 null 
allele in SOD1 transgenic mice could be due to the restoration of SOD1 activity by the huSOD1 
transgene, thus reducing in utero oxidative stress.  
3.4.2 Does Mutant SOD1 Display Prion-Like Properties In Vivo?  
3.4.2.1 NO EVIDENCE FOR SELF-SEEDED AGGREGATION IN TGG93A;SOD1KO MICE 
TgG93A mice have a limited lifespan surviving to around 152-days (average on C57BL/6J 
background. See Figure 1.14) limiting the incubation time available in this line of mice. It is 
currently unknown whether self-seeded transmission of misfolded SOD1 species occurs in vivo 
and if it does, what timescale is required for misfolded SOD1 pathology to spread through the 
CNS. For these reasons we decided to examine the misfolded SOD1 pathology in the brains of 
our animals in the first instance rather than the spinal cords, as the inoculations were 
intracerebral.  
An examination of the brains from animals 24 hours post-inoculation was carried out to assess 
the penetration of the inoculum into different brain regions. At this time-point significantly 
higher levels of misfolded SOD1, as detected using the SEDI antibody, were apparent in the 
hippocampus and the region defined as “other” in mice inoculated with m-TgG93A compared 
to mice inoculated with m-NTg. A similar, but non-significant, trend was also seen in the 
cerebellum, corpus callosum, cortex and olfactory bulb (Figure 3.5). Levels of misfolded SOD1 
in the brain stem were lower in animals inoculated with both PBS and m-TgG93A, compared to 
mice inoculated with m-NTg, but there was no difference between m-NTg and m-TgWT 
inoculated animals. Because we do not have data for non-inoculated control mice at this 
time-point, it is not clear whether these lower levels are due to a decrease from baseline, or a 
smaller relative increase in response to inoculation. The meaning of this result is not clear at 
this time; as the m-NTg inoculum does not contain any SOD1 species, misfolded or otherwise, 
it is unlikely that an increase in SEDI staining would have occurred in animals inoculated with 
m-NTg as compared to those inoculated with m-TgG93A, which contains mutant SOD1. Neither 
does it seem likely that intracerebral inoculation with PBS and m-TgG93A could cause a 
decrease in the area of misfolded SOD1, particularly over such a short timescale. The 
differences in SEDI staining in the brain stem at this time-point could be indicative of baseline 
differences between the groups as the brain stem is the structure furthest from the site of 
inoculation, and so the inocula may not have penetrated to this region.  
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Data from all other brain regions suggest that at 24 hours post-inoculation the inoculum is 
present throughout the brain (with the exception of the brain stem) and that the mutant 
misfolded SOD1 present in the m-TgG93A inoculum is detectable using the SEDI antibody. 
Tissues from NTg;Sod1ko mice, inoculated with m-TgG93A have also been collected at 40-days 
post-inoculation to determine whether the inoculum is still detectable at this time-point 
however these tissues have not yet been processed.  
We examined the accumulation of misfolded SOD1 at 40-days post-inoculation when mice 
were 90-days old. SEDI staining has been shown to increase in TgG93A mice between 20 and 
63-days of age; however a decrease is seen between 100 and 120-days, presumed to be due to 
MN death (Rakhit et al., 2007). Ninety-days of age was therefore chosen as an appropriate age 
to maximise the length of incubation time while minimising the chances of missing an increase 
in the accumulation of misfolded SOD1 due to MN loss.  
At 40-days post-inoculation there was no detectable difference in the area of SEDI staining 
between inocula in any brain region, suggesting that self-seeded propagation of misfolded 
SOD1 does not occur in this model, at least over the time scale of this experiment. This also 
suggests that if any of the original inoculum is still present by this time, it is not present at a 
detectable level. The TgG93A mouse has one of the most aggressive degenerative processes of 
the published mutant SOD1 mice (see Table 1.3). Although it has not been possible to detect 
self-seeded transmission of misfolded SOD1 in this model, it is still possible that in an 
alternative model, with a less aggressive phenotype, a longer incubation time could reveal the 
presence of such a phenomenon. Alternatively a line such as the A4V mutant SOD1 transgenic 
mouse, which expresses an ALS mutant SOD1 but does not display clinical characteristics could 
have been used to examine whether conversion to a disease phenotype and pathology could 
be caused by intra-cerebral inoculation with misfolded species, as it is when this line is crossed 
to a WT SOD1 transgenic line.  
3.4.2.2 CROSS-SEEDED AGGREGATION OF SOD1 IN TGWT;SOD1KO MICE 
Many of the animals in this experiment died before their scheduled cull dates, particularly 
those in the longer time-point groups. We examined whether these premature deaths were 
related to the inoculation group of the animal. The omnibus Kaplan-Meier analysis showed a 
highly significant effect of inocula group on survival, however pair-wise comparisons did not 
reveal any differences between mice inoculated with m-NTg and any of the other inoculated or 
the non-inoculated mice. This suggests that the effect of inoculum group was not due to the 
presence of misfolded SOD1 species in some of the inocula. A more likely explanation is that 
non-inoculated or PBS inoculated mice survive longer than those inoculated with CNS 
homogenates; the pair-wise comparison between m-NTg inoculated and both PBS and non-
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inoculated mice were below the non-adjusted significance threshold and visual inspection of 
the Kaplan-Meier graph is also suggestive of this trend.  
The area of misfolded SOD1 in the brain of TgG93A;Sod1ko mice was not affected by 
inoculation with m-TgG93A, however the potential incubation period was limited by the 
lifespan of these mice and the baseline burden of misfolded SOD1 may make detection of 
potentially small increases within this timescale problematic. TgWT mice can live to at least 
2-years of age (Jaarsma et al., 2000) and so allow a much larger timescale for incubation. As a 
longer incubation time was possible in this line of mice, we decided to first look at the spinal 
cord to see if we could identify transmission of misfolded SOD1 and spread from the initial site 
of inoculation in the brain down into the spinal cord in response to inoculation with m-TgG93A 
homogenate. Our initial qualitative assessment of spinal cords of mice inoculated with PBS or 
m-NTg in the 180 day time-point was that the SEDI staining was already high at this time and 
was particularly abundant in the ventral white matter tracts as described by Rakhit et al., 
(2007). As an alternative, we decided to use the USOD antibody to stain sections from mice at 
the earlier, 90 day time-point. This antibody at the earlier time-point produced a lower 
baseline level of staining in both PBS and m-NTg inoculated animals and so we chose this 
method to continue our analysis. Significant differences in the ages between the different 
inoculum groups within this time-point were identified, however these differences were all in 
relation to mice inoculated with h-cntrl2, and so should not have a bearing on these results. 
For future analyses however, in which this other inoculum group is included, it may be 
appropriate to include age at death as a potential covariate.  
Five spinal cord regions were examined. Significant differences were found between inoculum 
groups for USOD staining area in the ventral roots; mice inoculated with m-TgG93A were 
found to have a significantly larger area of USOD staining than mice inoculated with m-NTg. 
This result suggests that a cross-seeded increase in misfolding of WT SOD1 may occur in mice 
inoculated with m-TgG93A. It is possibly relevant that this difference is seen in the ventral 
roots, as the ventral roots contain the axons of the LMNs. This suggests that the effect may be 
MN specific making it particularly relevant to ALS, or that the passage of cell-to-cell 
transmission favours descending tracts away from the site of initial misfolding, or in this case 
inoculation. It is however important to note that the ventral roots of only 2 mice inoculated 
with m-NTg were used for the comparisons. The 2 mice inoculated with m-NTg that are 
missing from the ventral root analysis had much higher USOD staining in the ventral horns 
than did the 2 animals that were included in the analysis (4.909 and 2.765 compared to 0.625 
and 0.982 proportion stained (x1000) respectively). Re-sectioning and analysis of the spinal 
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cords from these animals and completion of the analysis for rest of the animals in these 
cohorts will be required to have confidence in this finding.  
Experiments using monkeys have provided evidence that a pathogenic species (thought then 
to be viral and now postulated to be proteinaceous) might be present within CNS tissue of ALS 
patients which is able to “infect” WT monkeys (Zil'ber et al., 1963). The genotype of the 
patients whose tissues were used is unknown and histopathological evidence for the presence 
of inclusions composed of SOD1 or other ALS proteins such as TDP43 are also not available. For 
these reasons it is only possible to speculate as to whether misfolded ALS proteins could have 
been responsible for this apparent transmission of disease. Despite the multiple passages of 
disease described by Zil’ber et al., (1963) attempts by subsequent groups to replicate these 
findings, in monkeys and other laboratory species, failed (Gajdusek et al., 1964; Gibbs et al., 
1972).  
More recent experiments have used transgenic mice which express mutant and WT forms of 
the respective proteins to examine prion-like properties of at least 3 hallmark 
neurodegenerative disease proteins (see Table 1.6). Such experiments have successfully 
demonstrated prion-like transmission of misfolded protein pathology and even phenotypic 
neurological degeneration in mice expressing mutant proteins. These have often used 
stereotactic injections allowing targeting of specific disease relevant brain regions and tight 
control over the amount of inoculum introduced. Luk et al., (2012), for example, inoculated a 
mutant α-synuclein transgenic mouse model of Parkinson’s Disease with amyloid misfolded 
α-synuclein in the form of tissue homogenates or recombinant proteins. Inoculations were 
stereotactic and specifically targeted the neocortex and striatum, allowing them to map the 
spread of pathology from the site of inoculation along connective neuronal pathways.  
One potential criticism of the work presented here is that we have little control over the 
specific brain region or regions which are targeted by the inoculation protocol used. However, 
results from our 24 hour time-point in TgG93A;Sod1ko mice suggest that in fact the inocula 
penetrated throughout the brain and thus should contact relevant structures such as the 
motor cortex with its descending tracts to the spinal cord. This project was carried out in 
collaboration with the MRC Prion Unit and the methodology borrows from that commonly 
used in the prion field. Prion-like transmission of α-synuclein has also been demonstrated 
using a similar methodology to that used here, for example by Watts et al., (2013) who 
successfully induced both misfolded α-synuclein pathology and symptomatic “disease” in 
inoculated mutant α-synuclein transgenic mice. In this paper self-seeding was demonstrated 
by inoculating mice with homogenates prepared from “sick” mutant mouse tissue, and cross-
seeding by inoculation with patient tissue that had been neuropathologically confirmed as 
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containing misfolded/aggregated α-synuclein but was not from patients with known 
α-synuclein mutations. Both types of inocula induced a similar pattern of pathology and 
disease phenotype, however, mice inoculated with human tissues had a shorter incubation 
period, despite containing WT and not mutant α-synuclein and at a much lower concentration 
than in the transgenic mouse tissue. This lends increased impetus to the analysis of our mice 
inoculated with SOD1-fALS patient tissue homogenates to compare the levels of SOD1 
misfolding between human and mouse inocula.  
3.4.3 Future Work  
The primary goal at present is to complete the analysis of the USOD stained spinal cords at the 
90 day time-point for our cross-seeding transmission experiment in all inoculated and non-
inoculated control groups. This work is underway. Once completed, and depending on the 
results an appropriate second time-point and set of inocula can be chosen on for the next step 
of the analysis.  
A question that we have not yet addressed is whether our chosen outcome measures of SEDI 
and USOD can reliably detect increasing misfolded SOD1 pathology. As previously described, in 
TgG93A mice, Rakhit et al., (2007) found that SEDI staining increased between 20 and 63-days 
of age, but then a decline from 100 to 120-days. The fact that SEDI staining decreases during 
the later stages of degeneration makes the task of choosing an appropriate time-point in our 
self-seeding transmission experiment particularly difficult; it is important that our outcome 
measure is able to pick up potentially small differences at earlier time-points in order to avoid 
the drop in staining area due to loss of MNs. The USOD antibody was shown to be 
immunoreactive in G93A mutant SOD1 transgenic mice by Kerman et al., (2010) however only 
1 time-point was assessed and, to our knowledge, no other examples of USOD pathology in the 
G93A SOD1, or similar, transgenic mice have been published. In addition to our 90 day old non-
inoculated mice, we have now collected tissue from TgG93A;Sod1ko mice at 70 and 120-days 
of age in order to assess whether we can indeed detect changes in SEDI and USOD staining in 
this line over time. Potential alternative outcome measures will be discussed briefly in Section 
6.1.  
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Chapter 4. The Effect of Wild-Type Endogenous 
Sod1 in the G93A Mutant SOD1 Mouse 
4.1 INTRODUCTION 
It is well established that the presence of WT huSOD1 has an exacerbating effect on the 
degenerative process seen in SOD1-fALS transgenic mice (Deng et al., 2006; Prudencio et al., 
2010; Wang et al., 2009b; Jaarsma et al., 2000; Jaarsma et al., 2008), however a similar effect is 
not apparent when the mutant SOD1 being expressed is mouse rather than human (Audet et 
al., 2010). Previous attempts to address the question of whether the endogenous WT moSOD1 
protein affects the phenotype of SOD1-fALS mouse models have provided limited and mixed 
results suggesting that its presence may worsen disease (Bruijn et al., 1998; Deng et al., 2006). 
In this Chapter I aim to more thoroughly characterise differences between G93A mutant 
huSOD1 transgenic mice with and without endogenous moSOD1 expression.  
Although the ultimate result of mutant SOD1 toxicity in SOD1-fALS mouse models, and in ALS, 
is MN loss (e.g. (Chiu et al., 1995; Mendonça et al., 2005)) the earliest evidence of neuronal 
degeneration is detected at the distal axon, for example by examining NMJs, and this has led 
to the suggestion that the process is one of die-back rather than forward (Fischer et al., 2004).  
Evidence of axonal degeneration can also be detected within muscle; the motor unit (MU) is 
the functional unit of a single MN and the group of muscle fibres it innervates. Each MU can be 
categorised according to the type of MN and muscle fibres it is composed of, as summarised in 
Table 4.1 (Gordon et al., 2004; Augusto et al., 2004). Remodelling of the MU occurs in 
response to both mechanical and degenerative nerve damage, with surviving MN axons 
reinnervating the NMJ end-plates of muscle fibres which have lost their neuronal connection. 
This compensatory reinnervation results in an increased size of the MU as extra muscle fibres 
are recruited. Reinnervation of a muscle fibre by a MN of a type distinct to that which 
originally innervated it can cause conversion of the fibre to match that of the incoming MU (as 
reviewed by (Gordon et al., 2004).  
In ALS and SOD1-fALS mice the fastest, type 2B, MUs are affected earlier in the degenerative 
process with slower MUs affected later (Schmied et al., 1999; Frey et al., 2000; Pun et al., 
2006). Thus, it is possible to monitor the progression of MN degeneration by examining 
changes in muscle fibre type composition indicative of reinnervation by slower type MNs.  
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4.2 AIMS  
The aim of the work described in this Chapter was to examine the effect of endogenous 
moSOD1 protein on ALS disease related phenotypes in a SOD1-fALS mouse model. Behavioural 
measures of disease progression were: 
 Survival 
 Body weight  
 Grip-strength  
Histological examination also evaluated: 
 Motor neuron survival in the sciatic pool of the spinal cord (SC) 
 NMJ integrity in the extensor digitorum longus (EDL), as a measure of MN 
axonal/muscle health 
 Muscle fibre type changes as a measure of denervation and re-innervation by motor 
neurons  
4.3 RESULTS  
Only female mice were used in this study in order to minimise the variability within and 
between groups due to gender differences. Females were chosen because, 1) female 
transgenic mice were not used for breeding and so were more freely available and 2) reduced 
variability in disease related measures has been reported in female mice as compared to males 
(Mead et al., 2011). 
Table 4.1 Motor unit characteristics 
Motor 
neuron 
properties 
Muscle fibre properties 
Motor 
neuron 
size 
Muscle fibre 
type 
Myosin heavy 
chain isoform 
Histochemical 
classification 
Fibre 
diameter Fatigue index 
Small Type 1 Type 1 
slow-oxidative 
(SO) small slow (S) 
↕ 
Type 2a Type 2A 
fast-oxidative/ 
glycolic (FOG) intermediate 
fast- fatigue-
resistant (FR) 
Type 2x (also 
referred to as 
2d) Type 2X   intermediate 
fast- fatigue-
intermediate 
(FI) 
Large Type 2b Type 2B 
fast-glycolic 
(FG) large 
fastest- 
fatigable (FF) 
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Four genotypes were used in the experiments described. These are listed in Table 4.2 including 
the short form nomenclature used within the text.  
 
Ideally littermate matching would have been carried out, particularly between TgG93A;Sod1wt 
and TgG93A;Sod1ko mice, however this was not feasible due to the inheritance ratios; the 
mice used in this experiment were bred as described in Figure 2.7 in Section 2.5.5, by crossing 
TgG93A;Sod1het males to NTg;Sod1het females, producing 6 possible genotypes. The 
inheritance ratios of these genotypes (which were described in more detail in Section 3.3.1) 
are presented in Table 4.3. Over 50% of all pups born were Sod1het and so not required for 
experiments. Furthermore, as only female mice were used, another ~50% from each litter 
would be discounted due to gender. This left ~25% of animals per litter of the correct sex and 
of one of the required genotypes. As an average C57BL/6J litter is ~7 pups (Brady et al., 2012) 
litter matching was not feasible.  
 
  
Table 4.2 Experimental genotypes 
Tg allele KO allele 
Short form (used in 
text) 
Non-transgenic Sod1+/+ (WT) NTg;Sod1wt 
Non-transgenic Sod1-/- (homozygous KO) NTg;Sod1ko 
SOD1G93A Tg hemizygous Sod1+/+ (WT) TgG93A;Sod1wt 
SOD1G93A Tg hemizygous Sod1-/- (homozygous KO) TgG93A;Sod1ko 
 
Table 4.3 Genotype ratios 
Ratio of each genotype according to Mendelian inheritance ratios  
Genotype Expected Observed 
NTg;Sod1wt 0.125 0.1530 
NTg;Sod1het 0.25 0.3080 
NTg;Sod1ko 0.125 0.1006 
TgG93A;Sod1wt 0.125 0.1094 
TgG93A;Sod1het 0.25 0.2128 
TgG93A;Sod1ko 0.125 0.1162 
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4.3.1 Transgene Copy Number  
Because there is a correlation between the copy number of the G93A transgene array and the 
phenotypes displayed by the mice (Alexander et al., 2004) it was important to control for 
differences in copy number between experimental genotypes.  
Quantitative real time PCR (qPCR) was used to obtain the relative copy number of the 
transgene array as described in Section 2.1.3. Mice with a relative copy number of 0.8 or below 
(20% below the reference sample obtained from Jackson Laboratories) were excluded from 
the experiment. Twelve TgG93A;Sod1wt and 7 TgG93A;Sod1ko animals were excluded, as 
summarised in Table 4.4. Data for individuals is presented in Section 7.5, Appendix 5.  
Figure 4.1 shows the average relative copy number for TgG93A;Sod1wt and TgG93A;Sod1ko 
animals included in the experimental groups. There is no difference in transgene copy number 
between the 2 genotypes; t(23,688)=0.508, p>0.05.  
 
 
Table 4.4 Relative transgene copy number for excluded animals 
Genotype n= Mean SEM 
TgG39A;Sod1wt 12 0.65986 0.01567 
TgG93A;Sod1ko 7 0.57513 0.78955 
 
 
Figure 4.1 Average relative transgene copy number for Sod1wt and Sod1ko mice 
Average relative transgene copy number of mice included in experimental groups. There is 
no statistically significant difference in transgene copy number between the 2 genotypes. 
Graph shows mean and SEM.  
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4.3.2 Behavioural Characterisation  
4.3.2.1 STARTING WEIGHT 
Sod1 null mice have decreased body weight from an early age, as compared to WT mice 
(Kostrominova et al., 2007; Muller et al., 2006; Noda et al., 2012) however, evidence of early 
body weight deficits in TgG93A mice is mixed (e.g. (Chiu et al., 1995; Smittkamp et al., 2008) 
c.f. (Teuchert et al., 2006)). I sought to examine whether early body weight deficits were 
apparent in our TgG93A colony and whether the mutant human SOD1 transgene was able to 
attenuate the decreased body weight reported in Sod1 KO mice. Results are summarised in 
Figure 4.2. A one-way analysis of variance (ANOVA) with planned pair-wise comparisons was 
used to analyse differences in body weight at 57-70-days of age between the 4 genotypes. The 
overall ANOVA was significant (F(3)=12.942, p<0.001).  
The first two planned pair-wise comparisons sought to answer the question of whether, in our 
colony, the G93A SOD1 transgene and/or the Sod1ko genotype reduced the body weight of 
mice.  
The first planned comparison (marked (1) in Figure 4.2) found that in our colony the body 
weight of TgG93A;Sod1wt mice was significantly lower than NTg;Sod1wt mice 
(t(39.302)=3.479, p<0.01). The second planned pair-wise comparison (marked (2) in Figure 4.2) 
confirmed previous findings that Sod1 null mice have significantly reduced body weight as 
compared to WT mice at this age (t(60.784)=5.296, p<0.001).  
To evaluate whether the G93A SOD1 transgene was able to attenuate the early reduced body 
weight of NTg;Sod1ko mice, a set of pair-wise comparisons were required; the first comparison 
(marked (3a) in Figure 4.2) found that, unlike in NTg mice, in those mice with the G93A SOD1 
transgene, there was no difference in body weight between mice with either the Sod1wt or 
Sod1ko genotypes (t(29.987)=0.086, p>0.05). The second comparison (marked (3b) in Figure 
4.2) found that, similar to TgG93A;Sod1wt mice, TgG93A;Sod1ko mice have significantly lower 
body weight than NTg;Sod1wt mice (t(64.705)=4.134, p<0.001). The final comparison (marked 
(3c) in Figure 4.2) found that TgG93A;Sod1ko mice had significantly higher body weight than 
NTg;Sod1ko mice (t(49.086)=-2.16, p<0.05). Together, these comparisons suggest that mutant 
huSOD1 can compensate for the reduction in body weight seen in NTg;Sod1ko, but only insofar 
as to increase the body weight to the level of TgG93A;Sod1wt mice.  
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Figure 4.2 Body weight at 57-70 days of age 
Average (mean and SEM) body weight of mice at 57-70 days of age. Transgenic 
expression of G93A mutant human SOD1 rescues the reduced body weight of NTg;Sod1ko 
mice to levels of the TgG93A;Sod1wt mouse. * p<0.05. ** p<0.01. ***p<0.001.  
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4.3.2.2 DISEASE ONSET 
Age at peak body weight before weight loss was used as a marker for disease onset. There was 
no significant difference in disease onset between TgG93A;Sod1wt and TgG93A;Sod1ko mice 
(Log-rank χ2(1)=0.0278, p>0.05) as shown in Figure 4.3.  
 
  
 
Figure 4.3 Onset 
Kaplan-Meier graph showing likelihood of onset, defined as the age at maximum weight 
before weight loss. There is no difference in onset between TgG93A;Sod1wt and 
TgG93A;Sod1ko mice.  
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4.3.2.3 SURVIVAL 
Survival was measured using the humane end points defined in Section 2.5.1. All mice reached 
15% weight loss first before any of the other end points. Twenty nine TgG93A;Sod1wt animals 
and 16 TgG93A;Sod1ko were assessed. Two animals of each genotype were excluded because 
they were not weighed daily from the time they reached 10% weight loss and so accurate time 
to death could not be assessed. Another 8 from each genotype were excluded due to loss of 
transgene copy number.  
Figure 4.4 shows the Kaplan-Meier survival curves for the 2 genotypes. There was no 
significant difference in survival time between the 2 genotypes: Log-rank χ2(1)=1.769, p>0.05 
 
  
 
Figure 4.4 Survival 
Kaplan-Meier survival graph. The humane end-point used to delineate survival was 15% 
body weight loss. There was no difference in survival between TgG93A;Sod1wt and 
TgG93A;Sod1ko mice.  
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4.3.2.4 GRIP-STRENGTH  
Grip-strength was measured in order to monitor potential differences in disease progression 
between TgG93A;Sod1wt and TgG93A;Sod1ko mice. Grip-strength was measured twice a 
week, and corrected for body weight as described in Section 2.6.3. Data were grouped into 
bins: 57-70 days; 71-84 days; 85-98 days; 99-112 days; 113-124 days. Five cases were excluded 
due to missing data (2 TgG93A;Sod1wt and 3 TgG93A;Sod1ko) and 43 due to loss of transgene 
copy number (16 TgG93A;Sod1wt and 27 TgG93A;Sod1ko). Data are summarised in Figure 4.5.  
Bonferroni corrected independent t-tests were used to compare grip-strength of the 2 
genotypes at each time-point. The grip-strength of the 2 genotypes was found to significantly 
differ at the 71-84 day time-point only, with TgG93A;Sod1wt mice having significantly lower 
grip-strength than the TgG93A;Sod1ko mice (t(36)=-3.146, p<0.05). There was no difference at 
the other 4 time-points. This suggests that TgG93A;Sod1ko mice maintain muscle strength for 
longer than the TgG93A;Sod1wt mice during the initial stages of degeneration, but that this 
difference is not sustained.  
 
  
 
Figure 4.5 Grip-strength 
Grip-strength was measured twice weekly, corrected for body weight and averaged into 2-
week bins. Although TgG93A;Sod1ko had consistently higher grip-strength than 
TgG93A;Sod1wt, they only differed significantly at the 71-84 day time-point. * p<0.05. 
Graph shows man and SEM are plotted.  
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4.3.3 Histological Characterisation  
4.3.3.1 MOTOR NEURON COUNTS 
The number of MNs within the sciatic pool was counted for TgG93A;Sod1wt and 
TgG93A;Sod1ko mice at 120-days of age as described in Section 2.8.3. Data are summarised in 
Figure 4.6 and representative examples from each genotype are shown in Figure 4.7. There 
was no significant difference in the number of MNs between the 2 genotypes. t(6)=0.844, 
p>0.05.  
MNs from the earlier 75 day time-point were not counted as loss at this age was not 
anticipated (Gould et al., 2006; Fischer et al., 2004; Chiu et al., 1995; Kong et al., 1998).  
 
 
 
Figure 4.6 Spinal cord motor neuron counts 
The graph shows the number of motor neurons counted within the sciatic pool of the 
lumbar spinal cord, standardised to 40 sections per animal. The mean and SEM are 
plotted.  
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Figure 4.7 Lumbar spinal cord motor neurons 
Representative lumbar spinal cord sections of TgG93A;Sod1wt (a and c) and TgG93A;Sod1ko (b and d) mice at 120-days old, stained with nissl stain, 
gallocyanine. In (c) and (d) arrow heads indicate motor neurons displaying the defining features: dense staining, polygonal shape and greater than 20µm. 
Scale bars: (a) and (c) 500µm. (b) and (d) 20µm 
171 
4.3.3.2 NEUROMUSCULAR JUNCTIONS  
Next I examined neuromuscular junction (NMJ) innervation in the EDL hind limb muscle, 
comparing TgG93A animals of either Sod1wt or Sod1ko genotype. As shown in Figure 1.1, 
when the axons of the LMNs degenerate they retract away from muscle fibre. This can be 
detected histologically by examining co-localisation between the axonal foot-plate and the 
post-synaptic motor end-plate on the muscle fibre. NMJs on the EDL were counted and 
classified as fully innervated, partially innervated, or fully denervated, as shown in Figure 4.8.  
Two time-points were examined for each genotype, an early disease time-point of 75 (±1) days 
of age and a late disease time-point of 120 (±1) days. The two genotypes were compared by 
t-test at each time-point for four measures: 1) total number of NMJs, 2) proportion of fully 
innervated NMJs, 3) proportion of intermediately innervated NMJs and 4) proportion of fully 
denervated NMJs. Results are summarised in Figure 4.9. The only significant difference was in 
the total number of NMJs at 75-days of age; TgG93A;Sod1ko animals had significantly more 
NMJs than TgG93A;Sod1wt animals (t(7)=-3.056) p<0.05).  
To explore this difference further I next examine NMJs of NTg;Sod1wt mice compared to 
NTg;Sod1ko mice at 120 (±1) days of age. Results are summarised in Figure 4.10. Again, the 
total number of NMJs was significantly different between the 2 groups, however the direction 
was different; NTg;Sod1wt animals had significantly more NMJs than did NTg;Sod1ko animals 
genotypes (t(5)=2.897, p<0.05). The proportions of fully innervated, intermediately innervated 
and fully denervated were not statistically different between the 2 genotypes.  
These data suggests that although TgG93A;Sod1ko animals start off with more NMJs compared 
to TgG93A;Sod1wt mice, they show the same pattern of NMJ degeneration as the 
TgG93A;Sod1wt mice, and any advantage is not maintained. These results mirror the results of 
the grip-strength analysis, where TgG93A;Sod1ko mice were found to maintain muscle 
strength, as compared to TgG93A;Sod1wt mice at 71-84-days, but lose this advantage at later 
ages.  
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Figure 4.8 Neuromuscular junctions in the EDL hind limb muscle 
Examples of neuromuscular junctions (NMJs) exhibiting different levels of innervation. 
Extensor digitorum longus (EDL) muscles were longitudinally sectioned into 2 series and 1 
whole series was quantified. NMJs were identified by α-bungarotoxin labelled post-
synaptic end-plates. Once identified, NMJs were categorised according to co-localisation 
with the pre-synaptic foot-plate labelled with anti-synaptic vesicle 2, and anti-
neurofilament, as shown:  
A= Fully innervated. Complete overlap between end-plate and foot-plate; B= Intermediate 
innervation. Partial overlap between end-plate and foot-plate; C= Fully denervated. No, or 
very limited, co-localisation between end-plate and foot-plate.  
Scale bar shows 50µm 
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Figure 4.9 Neuromuscular junction quantification 
NMJs were identified and categorised as shown in Figure 4.8. The total number of NMJs 
was significantly higher in TgG93A;Sod1ko mice at 75-days of age as compared to 
TgG93A;Sod1wt mice at the same age. * p<0.05. Graphs plot the mean and SEM. 
174 
 
  
 
Figure 4.10 Neuromuscular junction quantification for non-transgenic mice 
NMJs were identified and categorised as shown in Figure 4.8. The total number of NMJs 
was significantly higher in NTg;Sod1wt mice than in NTg;Sod1ko mice. * p<0.05. Graphs 
plot the mean and SEM. 
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4.3.3.3 MUSCLE FIBRE TYPING 
Although the total number of MNs did not differ between TgG93A;Sod1wt and TgG93A;Sod1ko 
mice at 75-days of age, the TgG93A;Sod1wt mice had fewer NMJs in total.  
Next I examined the pattern of expression of different myosin heavy chain (MHC) proteins in 
the skeletal muscles of TgG93A;Sod1wt and TgG93A;Sod1ko mice.  
Large fast-firing MNs are preferentially affected in SOD1-fALS mouse models, with 
reinnervation of the skeletal muscle by the slower-firing surviving MNs (Frey et al., 2000; Pun 
et al., 2006). To address whether this pattern of denervation/reinnervation differed between 
the TgG93A;Sod1wt and TgG93A;Sod1ko mice by examining the expression of different MHC 
proteins in skeletal muscle fibres. Muscle sections were prepared and analysed as described in 
Section 2.8.2. Antibody combinations (summarised in Table 4.5) labelled type 2B (fastest-
glycolic) fibres on all sections in combination with either type 1 (slow-oxidative) or type 2A 
(fast-oxidative/glycolic) fibres.  
The originally planned method of analysis was to categorise and count individual muscle fibres. 
However, due to difficulty in identifying individual fibres (example shown in Figure 4.11a) this 
method was not possible. An alternative was to use image analysis software to quantify the 
area of staining. However, calculation of the area stained as a proportion of the total area of 
the section was not possible due to freezing artefacts in many of the tissue sections (as shown 
in Figure 4.11b). For these reasons, analysis was carried out by quantifying the area stained in 
each channel and calculating the ratio of slower fibre type MHC area (type 1 or 2A) divided by 
the fastest fibre type MHC area (type 2B). The higher the ratio, the higher the proportion of 
slower fibre MHC area as compared to fastest fibre MHC area, indicating a conversion from 
fast to slow fibres as degeneration progresses.  
 
Table 4.5 Fibre type antibody summary 
Antibody Antigen 
Fibre 
type Fatigue index Type 2A /2B Type 1 /2B  
BA-D5 
myosin heavy 
chain slow (type 
1) Type 1 slow (S) unstained red 
SC-71 
myosin heavy 
chain type 2A Type 2a 
fast- fatigue-
resistant (FR) red unstained 
    Type 2x  
fast- fatigue-
intermediate (FI) unstained unstained 
BF-F3 
myosin heavy 
chain type 2B Type 2b 
fastest- fatigable 
(FF) green green 
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Figure 4.11 Indistinct fibre boundaries and freezing artefacts 
Transverse muscle sections were immunostained for different myosin heavy chain isoforms in order to identify muscle fibre type composition. a- arrow head 
indicates area in which discrimination of individual muscle fibre boundaries was not possible. b- arrows indicate freezing artefacts that cause wholes within the 
muscle fibres precluding accurate calculation of area stained as a proportion of the total area of the muscle section.  
Scale bar 500µm.  
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4.3.3.3.1 Fibre Types in the Extensor Digitorum Longus 
Data are summarised in Figure 4.12 and representative images of EDL muscles from the 2 
genotypes, stained for MHC 2A / 2B and for MHC 1 / 2B are shown in Figure 4.13 and Figure 
4.14, respectively (see Section 7.6, Appendix 6 for images from all animals). There was no 
significant difference between TgG93A;Sod1wt and TgG93A;Sod1ko for either the proportion 
of MHC 2A / 2B area (t(8)=1.1254. p>0.05) or MHC 1 / 2B area (t(8)=0.950, p>0.05).  
 
 
 
Figure 4.12 EDL fibre typing quantification 
Area ratios of myosin heavy chain (MHC) types were quantified for extensor digitorum 
longus (EDL) muscles of 75 day old TgG93A;Sod1wt and TgG93A;Sod1ko mice. There was 
no significant difference between genotypes. Graphs show mean and SEM.  
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Figure 4.13 EDL fibre typing: Myosin heavy chain type 2A and 2B 
Representative transverse sections of extensor digitorum longus (EDL) muscles of TgG93A;Sod1wt and TgG93A;Sod1ko immunostained for myosin heavy chain 
type 2B and type 2A. Scale bar 500µm.  
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Figure 4.14 EDL fibre typing: Myosin heavy chain type 1 and 2B 
Representative transverse sections of extensor digitorum longus (EDL) muscles of TgG93A;Sod1wt and TgG93A;Sod1ko immunostained for myosin heavy chain 
type 2B and type 1. Scale bar 500µm.  
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4.3.3.3.2 Fibre Types in the Tibialis Anterior 
Data are summarised in Figure 4.15 and representative images of tibialis anterior (TA) muscles 
from the 2 genotypes, stained for MHC 2A / 2B and for MHC 1 / 2B are shown in Figure 4.16 
and Figure 4.17, respectively (see Section 7.6, Appendix 6 for images from all animals). No 
significant difference was found between TgG93A;Sod1wt and TgG93A;Sod1ko for either the 
proportion of MHC 2A / 2B area (t(3.132)=1.888, p>0.05) or MHC 1 / 2B area (t(8)=0.814, 
p>0.05).  
 
 
Figure 4.15 TA fibre typing quantification 
Area ratios of myosin heavy chain (MHC) types were quantified for tibialis anterior (TA) 
muscles of 75 day old TgG93A;Sod1wt and TgG93A;Sod1ko mice. There was no significant 
difference between genotypes. Graphs show mean and SEM.  
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Figure 4.16 TA fibre typing: Myosin heavy chain type 2A and 2B 
Representative transverse sections of tibialis anterior (TA) muscles of TgG93A;Sod1wt and TgG93A;Sod1ko immunostained for myosin heavy chain type 2B and 
type 2A. Scale bar 500µm.  
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Figure 4.17 TA fibre typing. Myosin heavy chain type 1and 2B 
Representative transverse sections of tibialis anterior (TA) muscles of TgG93A;Sod1wt and TgG93A;Sod1ko immunostained for myosin heavy chain type 2B and 
type 1. Scale bar 500µm.  
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4.3.4 Can Transgenically Expressed Human SOD1 Compensate for 
Sod1ko Female Subfertility?  
To examine whether transgenically expressed WT huSOD1 could save the subfertility reported 
in female Sod1ko mice (Ishii et al., 2005; Matzuk et al., 1998; Noda et al., 2012; Tsunoda et al., 
2012), female mice of 4 genotypes (NTg;Sod1wt, NTg;Sod1ko, TgWT;Sod1wt and 
TgWT;Sod1ko) were mated to WT males, with proven fertility, for 6-months and the number of 
litters, total number of pups and the number of pups surviving to weaning (~40-days of age) 
were counted. Data were analysed by multivariate ANCOVA with Bonferroni post-hoc 
comparisons, with the age of male and female mice at the start of the matings as co-variants. 
The results are summarised in Table 4.6 and Figure 4.18 and the co-variants are summarised in 
Table 4.7.  
Both TgWT;Sod1wt and TgWT;Sod1ko mice were severely subfertile; only 3/12 TgWT;Sod1wt 
and 2/12 TgWT;Sod1ko females produced any litters, with a maximum litter size of 2 pups and 
no pups survived to weaning for either maternal genotype.  
The maternal age covariate did not significantly co-vary with the number of litters, total pups 
born or pups surviving to weaning (p>0.05). The paternal age covariate was found significantly 
co-vary with the number of litters (F(1)=4.307, p<0.05), total pups born (F(1)=7.339, p<0.05) 
and for pups surviving to weaning(F(1)=8.148, p<0.01). Therefore paternal age must be 
considered as a potential affecter of differences in these measures.  
 
 
Table 4.6 Fertility of Sod1 KO and WT SOD1 transgenic mice 
    Litters Pups born 
Pups survived 
to weaning Pups/litter 
Maternal 
genotype n= Mean SEM Mean SEM Mean SEM Mean SEM 
NTg;Sod1wt 12 4.583 0.267 28.833 1.551 22.917 0.480 6.437 0.359 
NTg;Sod1ko 14 3.714 0.255 14.500 0.822 10.571 0.581 3.987 0.17 
TgWT;Sod1wt 12 0.250 0.115 0.167 0.112 0 0     
TgWT;Sod1ko 12 0.167 0.112 0.333 0.225 0 0   
  
Table 4.7 Age at start of mating 
  Female age  Male age  
Maternal genotype Mean SEM n= Mean SEM n= 
NTg;Sod1wt 49.167 2.011 12 52.000 2.791 6 
NTg;Sod1ko 58.286 2.971 14 94.571 7.885 7 
TgWT;Sod1wt 39.833 2.332 12 81.667 1.504 6 
TgWT;Sod1ko 53.750 3.429 12 83.333 4.249 6 
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Figure 4.18 Fertility of human WT SOD1 transgenic and Sod1 KO mice 
Female mice of 4 genotypes (NTg;Sod1wt, NTg;Sod1ko, TgWT;Sod1wt and TgWT;Sod1ko) 
were mated to WT males, of proven fertility, for 6-months and the number of litters and 
pups were counted. * p<0.05. ** p<0.01. ***p<0.001. Graphs shown mean and SEM.  
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The main effect of maternal genotype had a significant effect on the number of litters 
(F(3)=119.832, p<0.001). Post-hoc Bonferroni comparisons found no significant difference 
between TgWT;Sod1wt and TgWT;Sod1ko females for the number of litters. Both NTg;Sod1wt 
and NTg;Sod1ko females produced significantly more litters than both TgWT;Sod1wt and 
TgWT;Sod1ko females (p<0.001). Compared to NTg;Sod1wt females, NTg;Sod1ko females 
produced significantly fewer litters (p<0.001), with NTg;Sod1ko producing 0.81 times as many. 
The main effect of maternal genotype had a significant effect on the total number of pups 
born (F(3)=220.192, p<0.001. Post-hoc Bonferroni comparisons identified no significant 
difference between TgWT;Sod1wt and TgWT;Sod1ko females (p>0.05) for the total number of 
pups born. Both NTg;Sod1wt and NTg;Sod1ko females produced significantly more pups than 
both TgWT;Sod1wt and TgWT;Sod1ko females (p<0.001). Compared to NTg;Sod1wt females, 
NTg;Sod1ko females produced significantly fewer pups (p<0.001), with NTg;Sod1ko producing 
0.5 times as many.  
The main effect of maternal genotype had a significant effect of the number of pups surviving 
to weaning (F(3)=669.184, p<0.001. Post-hoc Bonferroni comparisons identified no significant 
difference between TgWT;Sod1wt and TgWT;Sod1ko females for the number of pups surviving 
to weaning. Both NTg;Sod1wt and NTg;Sod1ko females produced significantly more pups 
which survived to weaning than both TgWT;Sod1wt and TgWT;Sod1ko females (p<0.001). 
Compared to NTg;Sod1wt females, NTg;Sod1ko mice produced significantly fewer pups that 
survived to weaning (p<0.001), with NTg;Sod1ko producing 0.46 times as many.  
Because so few litters were produced by females of both TgWT genotypes, a separate ANCOVA 
was carried out to examine whether the number of pups produced per litter differed between 
females of the two NTg genotypes, data are summarised in Table 4.6. Neither maternal nor 
paternal age was a significant covariate with the number of pups produced per litter (p>0.05). 
The main effect of maternal genotype had a significant effect on the number of pups produced 
per litter (F(1)=26.391, p>0.001). Compared to NTg;Sod1wt females, NTg;Sod1ko females 
produced significantly fewer pups per litter, 0.62 as many.  
4.4 DISCUSSION 
4.4.1 Does Endogenous Mouse SOD1 Effect the Disease Phenotype 
of the TgG93A Mouse?  
The data presented here suggest that endogenous moSOD1 does not affect the onset or 
survival of the TgG93A mouse. Grip-strength was similar for TgG93A;Sod1wt and 
TgG93A;Sod1ko mice at our earliest time-point (57-70-days) but differed at 71-84-days with 
TgG93A;Sod1ko mice having higher grip-strength than TgG93A;Sod1wt mice. This early 
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advantage of the Sod1ko genotype in maintaining muscle strength in TgG93A mice is lost at 
later time-points; although the average grip-strength of TgG93A;Sod1ko mice is higher than 
the TgG93A;Sod1wt mice at all time-points the difference is only statistically significant at 
71-84-days of age.  
Neither MN number nor NMJ number or innervation status differed between TgG93A;Sod1wt 
and TgG93A;Sod1ko mice at the later time-point (120-days). The earlier histological time-point 
of 75-days of age was chosen based on the difference in grip-strength seen at this age. At 
75-days of age TgG93A;Sod1ko mice have on significantly more (~14% on average) NMJs on 
the EDL than TgG93A;Sod1wt mice (1082.2 vs 946.38 respectively) however the pattern of 
innervation/denervation does not differ significantly between genotypes. Loss of the 
acetylcholine receptors (AchR) that form the post-synaptic end-plate of the NMJ can result 
from prolonged denervation (Rich et al., 1989) and a progressive loss of NMJs is reported in 
SOD1-fALS mice (Seijffers et al., 2014) so one possible explanation of a lower total number of 
NMJs in the TgG93A;Sod1wt mice is that an early pre-symptomatic degeneration of the MN 
axons, which is absent or less profound in the TgG93A;Sod1ko mice, leads to their loss. A 
reduction in the number of functional motor units (MU) can be detected from as early as 
45-days of age in G93A-SOD1-fALS mice compared to WT mice (Hegedus et al., 2007), along 
with reductions in end-plate size (Kalmar et al., 2012). This is before denervation of NMJs is 
usually reported by histological examination, and is unlikely due to a reduced number of MNs 
as TgG93A;Sod1wt mice have a normal compliment of MNs until at least 100-days of age 
(Gould et al., 2006; Fischer et al., 2004; Chiu et al., 1995; Kong et al., 1998). Together this is 
suggestive of an early, pre-symptomatic denervation of the skeletal muscles in the TgG93A 
mouse. Differences in this process between TgG93A;Sod1wt and TgG93A;Sod1ko mice, could 
therefore be the cause of the distinction in number of NMJs reported here. However, because 
earlier time-points were not investigated here it is also possible that the lower number of 
NMJs seen in the TgG93A;Sod1wt compared to the TgG93A;Sod1ko mice, rather than being 
due to a degenerative process, could be due to a developmental difference; the formation of 
the neuromuscular network could be less robust in the TgG93A;Sod1wt mice resulting in fewer 
NMJs. Alternatively, the muscles of the TgG93A;Sod1wt mice could contain fewer fibres than 
the TgG93A;Sod1ko mice resulting in fewer NMJs.  
To address the question of whether differences in NMJ number are due to a degenerative or 
developmental difference, neural cell adhesion molecule (NCAM) staining of muscle sections 
could be used for the detection of denervated muscle fibres (Gordon et al., 2009) to see if 
there is also a higher level of denervated muscle fibres in TgG93A;Sod1wt mice compared to 
the TgG93A;Sod1ko mice.  
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The pattern of decline apparent in the grip-strength measured in our TgG93A;Sod1wt mice is 
similar to that seen by other investigators (e.g. (Kong et al., 1998)) and also mirrors a pattern 
of MU loss reported in the TA and medial gastrocnemius (MG. Part of the triceps surea (TS) 
hind limb muscles (Hegedus et al., 2007), that of an initial decline in function plateauing at 
around 70-days, before another decline later. Several lines of evidence suggest that the MN 
populations that are most vulnerable to degeneration at early diseases stages are the large-
fast fatigable MNs that innervate the fastest, type 2B muscle fibres; Pathological signs of 
degeneration are seen specifically within the large MNs of the SC of SOD1-fALS mice from 
56-days of age (Bendotti et al., 2001) and the large calibre MN axons of the ventral roots are 
the first to degenerate, from 80-days of age (Fischer et al., 2004). At the distal axon, both Pun 
et al., (2006) and Frey et al., (2000) have identified those MNs that innervate the fastest 
muscle fibres as the earliest to degenerate, with Frey et al., (2000) mapping this to a similar 
time frame of 45-80-days of age.  
The attenuation of the initial fast decline stage seen in our TgG93A;Sod1ko mice could 
therefore be due to improved maintenance of the neuromuscular connections between large 
fast firing MNs and fast type 2b muscle fibres. Alternatively, an increased capacity of 
reinnervation by slower firing MNs could be the cause. We sought to assess this by examining 
the fibre type composition of hind limb muscles. As previously described, the planned analysis 
of classifying and counting individual muscle fibres was not possible and so alternative analysis 
based on the ratio of areas of staining was used. Although this analysis did not yield significant 
differences between TgG93A;Sod1wt and TgG93A;Sod1ko in the muscles assessed, there was a 
consistent non-significant trend of lower ratios of slow:fast MHC staining for the 
TgG93A;Sod1ko compared to the TgG93A;Sod1wt mice for all measures. This is suggestive of 
improved maintenance of the fastest, type 2b fibres in the TgG93A;Sod1ko mice compared to 
the TgG93A;Sod1wt. A lower level of reinnervation and consequent fibre type conversion by 
slower MNs in the TgG93A;Sod1ko mice could also account for the difference in ratios of MHC 
expression, however this would most likely be accompanied by a decrease in innervated NMJs 
and lower muscle strength. In this context of increased relative muscle strength and a higher 
number of total NMJs, with no difference in the pattern of innervation, this is the less likely 
explanation. That the difference between genotypes lies within the more vulnerable, fast-
fatigable MNs is also consistent with the absence of a difference at later ages in our mice; as 
this population is the first to be lost, at later ages they will not be present to affect a difference 
between the two genotypes.  
It is important to keep in mind that this analysis was based on the area of staining, rather than 
the number of fibres. Cross sectional area of muscle fibres can change in response to fibre type 
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conversion produced by changes in innervation or activity (Gordon et al., 2009; Hegedus et al., 
2008). This means that another explanation for the difference in ratios of slow:fast MHC types 
is that the TgG93A;Sod1ko mice maintain type 2b fibres with a larger cross sectional area 
whereas, in TgG93A;Sod1wt there is a relative reduction in the size/area of the type 2b muscle 
fibres, without a reduction in their number. However, either explanation – a difference in 
number or cross sectional area –indicates a lower level of degeneration of type 2b fibres in 
TgG93A;Sod1ko mice at 75-days of age. In order to overcome the problem of quantification, an 
alternative staining protocol has now been identified which uses anti-laminin antibodies to 
delineate the boarders of the fibres (Li et al., 2007). This may aid in identification of individual 
fibres for counting and classification. Total quantification of muscle fibres may also aid in 
delineating whether the difference in the total number of NMJs is due to denervation or 
differences in the number of muscle fibres.  
Hegedus et al., (2007) has questioned whether compensatory reinnervation of muscle fibres 
occurs in SOD1-fALS mice, particularly in muscles composed of fast fibres; they find a direct 
relationship between MU number and muscle force, precluding the possibility of surviving 
MUs increasing their force producing capacity as a result of sprouting. However, 
immunohistochemical evaluation of the neuromuscular network provides direct evidence for 
reinnervation, including increased MU size concomitant with decreasing numbers of MUs and 
in vivo longitudinal imaging of reinnervation of unoccupied end-plates, although, in agreement 
with Hegedus et al., (2007) reinnervation does appear to be limited to the longer surviving 
slower MNs (Frey et al., 2000; Schaefer et al., 2005; Pun et al., 2006). If the increased grip-
strength at 75-days of age seen in our TgG93A;Sod1ko mice, relative to the TgG93A;Sod1wt 
mice, were due to increased capacity for reinnervation by surviving MNs, a concomitant 
increase in the proportion of slower muscle fibre types, signifying reinnervation by surviving 
slower-MNs, might be expected as a result. This is not the case, instead an increased 
proportion of the fastest fibre type is apparent, and there is also no difference in the 
proportion of innervated, intermediate or denervated NMJs. These results are more 
compatible with improved maintenance of existing fast MUs, a difference which is not 
sustained as degeneration progresses.  
Discussion of how huSOD1 and moSOD1 may interact to produce these effects can be found in 
Section 6.2.  
4.4.2 Can Transgenic Human SOD1 Compensate for Sod1 KO 
Phenotypes? 
Our NTg;Sod1ko mice had significantly lower body weight at 57-70-days of age compared to 
our NTg;Sod1wt mice. Our TgG93A;Sod1wt and TgG93A;Sod1ko weighed similar amounts at 
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the same age and the TgG93A;Sod1ko mice weighed significantly more than the NTg;Sod1ko 
mice. This suggests that expression of the mutant G93A huSOD1 protein is able to attenuate 
for the reduced body weight seen in the NTg;Sod1ko mice, at least increasing the weight to 
equal that of TgG93A;Sod1wt mice.  
We sought to further evaluate whether transgenically expressed huSOD1 was able to rescue 
Sod1ko phenotypes by examining the subfertility reported in female Sod1ko mice (Matzuk et 
al., 1998; Noda et al., 2012). For this experiment we used TgWT dams because TgG93A females 
are reported as poor breeders by Jackson Laboratories 
(http://jaxmice.jax.org/strain/004435.html accessed March 2014) whereas no such issue is 
reported for TgWT mice (http://jaxmice.jax.org/strain/002298.html accessed March 2014). In 
fact, our results were that both TgWT;Sod1wt and TgWT;Sod1ko females are profoundly 
subfertile; over a 6 month mating period only 2 out of 12 females of each genotype produced 
any litters, the maximum litter size being 2 and none of the pups survived to weaning age. Due 
to the severe subfertility of TgWT;Sod1wt mice, it is apparent that transgenically expressed WT 
huSOD1 is not able to compensate for the reduced fertility of Sod1ko mice. The reduced 
fertility of Sod1ko mice may be due to increased oxidative stress either via effects on 
gonadotropin hormone in the pituitary or by direct effects in the tissue of the ovaries (Matzuk 
et al., 1998; Noda et al., 2012). Although somewhat counterintuitive, mice transgenically 
expressing high levels of G93A mutant huSOD1, which has increased SOD1 activity, actually 
display increased oxidative stress in multiple tissues (as reviewed by (Hensley et al., 2006)) and 
have oxidative damage to various cellular components (e.g. (Ferrante et al., 1997b; Andrus et 
al., 1998; Poon et al., 2005; Liu et al., 1998; Liu et al., 1999; Casoni et al., 2005; Liu et al., 2007; 
Cha et al., 2000; Lee et al., 2009)). However, transgenic overexpression of WT huSOD1 has 
been found to reduce sensitivity to chemically induced oxidative stress (Mele et al., 2006; 
Pérez et al., 2009) and oxidative lipid damage resulting from a high fat diet (Liu et al., 2013) 
suggesting that increased oxidative stress may not be a feature of TgWT mice and may not 
account for the subfertility seen in these mice.  
Similar to previously published data, our NTg;Sod1ko mice displayed reduced fertility 
compared to NTg;Sod1wt mice when assessed over a 6-month mating period, although our 
mice appear to be more fertile than previous reports; Matzuk et al., (1998) reported 2.7 pups 
per litter and a figure equating to an average of 1.38 litters over 6-months, compared to our 
data of 3.99 and 3.71 respectively. One female in their cohort died at 2-months. It is not 
reported whether this female had a significantly different number of litters to the remaining 
15 mice examined. The males used in the present experiments were initially placed in matings 
with WT C57BL/6J females to ensure that they were themselves fertile. It is possible that the 
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increased fertility apparent in our data is in part due to this precaution to exclude infertile stud 
males. A possible confound in our data is that the age of males when entering the matings was 
identified as a significant covariate with number of litters, number of pups and number of pups 
surviving to weaning (but not when pups/litter was analysed for NTg dams) and was lower in 
matings with NTg;Sod1wt females than any of the other genotypes and may therefore be 
partially responsible for the difference found between NTg;Sod1wt and NTg;Sod1ko females.  
4.4.2.1 TRANSGENICALLY EXPRESSED WT HUMAN SOD1 RESCUES MN 
AXONOPATHY IN SOD1 KO ANIMALS 
Another phenotype of the Sod1ko mice of more relevance to SOD1-fALS is the degenerative 
muscle denervation and associated reduction in skeletal muscle contractile force, as described 
in Section 1.4.2. In order to assess whether transgenic expression of WT huSOD1 can attenuate 
the functional denervation of skeletal muscles seen in Sod1ko mice, a neurophysiological 
assessment was carried out by Dr Philip McGoldrick (unpublished data). Female mice at 
105-days of age and of 3 genotypes (5X NTg;Sod1wt; 5X NTg;Sod1ko and 4X TgWT;Sod1ko) 
were assessed by measuring the weight and maximum tetanic force produced by the TA in 
response to electrical stimulation of the sciatic nerve. As illustrated in Figure 4.19, both TA 
weight and tetanic force are reduced in the NTg;Sod1ko mice compared to both the 
NTg;Sod1wt mice and the TgWT;Sod1ko mice suggesting that transgenic WT huSOD1 
expression can rescue at least some of the neuromuscular deficits of the Sod1ko mouse. This 
work complements an earlier publication by Fischer et al., (2011) who used 
immunohistochemistry to show that NMJ innervation of the TA muscles in Sod1ko mice at 
~120-days of age was restored to WT like levels by transgenic expression of a SOD1-mitoﬁlin 
fusion protein which is targeted specifically to the mitochondrial intermembrane space. NMJ 
integrity was maintained for up to 1 year and a measure of muscle strength at 1-year of age 
also showed that the mitochondrially targeted WT huSOD1 maintained the motor 
performance of Sod1ko mice at WT like levels.  
Together these data suggest that transgenically expressed huSOD1 can compensate for some 
of the Sod1ko phenotypes, such as early reduced body weight and functional denervation of 
the TA. However this compensation is not universal, as reduced fertility of Sod1ko mice cannot 
be alleviated by transgenic WT huSOD1 expression as this causes a profound loss of fertility 
itself.  
Of note, the MN specific toxic effects of ubiquitous WT huSOD1 expression, such as signs of 
MN axonal degeneration from as early as 30-weeks (210-days) of age and mild motor deficits 
from 58-weeks of age (Jaarsma et al., 2000; Dal Canto et al., 1995) mean that the early 
compensation for Sod1ko may not be sustained at later ages and, in conjunction with the data 
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from Fischer et al., (2011), suggest that such toxicity is affected in cellular compartments other 
than the mitochondria.  
 
4.4.3 Future Work 
Work is underway to increase the number of animals in our onset and survival cohorts to make 
up for mice excluded due to reduced transgene array copy number and incomplete data.  
Further examination of the muscle fibre type composition is required, including testing 
alternative staining protocols to include laminin to discern fibre boarders, as described by Li et 
al., (2007). This would help us to delineate, 1) whether differences in NMJ number between 
TgG93A;Sod1wt and TgG93A;Sod1ko mice is due to denervation or differences in the number 
of muscle fibres and 2) whether an increase in type 2B MHC staining area in TgG93A;Sod1ko 
mice compared to TgG93A;Sod1wt mice is apparent when quantified using the more usual 
 
Figure 4.19 Neurophysiological assessment of TA functional innervation 
Neurophysiological assessment of tibialis anterior (TA) weight and maximal force (tetanic 
force) produce in response to electrical stimulation of the sciatic nerve were carried out by 
Dr Philip McGoldrick. Transgenic WT human SOD1 expression rescues the decreased 
weight and muscle force of the Sod1ko mouse at 105-days of age. ** p<0.01. ***p<0.001. 
Graph shows mean and SEM.  
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technique of counting the number of fibres expressing different MHC isoforms. Similar 
histological staining of transverse muscle section for NCAM could also provide an alternative 
measure of fibre denervation which, if the laminin staining protocol proves successful, could 
be applied alongside fibre type staining of serial sections to allow discernment of which fibre 
types are denervated.  
193 
Chapter 5. Towards Making a Humanised SOD1 
Mouse 
5.1 AIMS  
The aim of the work described in this chapter is to make a new mouse model of SOD1-fALS by 
genomically humanising the mouse Sod1 locus with a conditional, Cre dependent, switch from 
expression of mutant to wild-type (WT) SOD1.  
This chapter will describe the design and cloning of the targeting construct which will be used 
to make the new mouse line.  
5.2 RESULTS  
5.2.1 Construct Design  
The targeting construct and primary cloning strategy were designed by Dr Anny Devoy. This 
project is part of a larger body of work being undertaken by Dr Devoy to produce a series of 
new models of fALS using similarly strategies to genomically humanise two ALS causative 
genes: SOD1 and FUS.  
Overview 
The full targeting construct is show in Figure 5.1a, with an expanded view of the engineered 
region in Figure 5.1b. The region of the mouse genome to be replaced is ~5.5 kb from the ATG 
start codon to the end of the 3’ UTR of exon 5 (the final exon) of Sod1. This region will be 
replaced with ~14.9 kb of engineered sequence, including:  
 the human SOD1 genomic locus from start codon, to the end of the 3’ UTR of exon 5 
(~9 kb) 
 one kb mouse genomic sequence 3’ of the Sod1 locus (1 kb terminator)  
 a kanamycin/neomycin selection cassette (neo. Gene Bridges) (~1 kb) 
 a repeat cassette which includes SOD1 genomic sequence from intron 3 to the end of 
exon 5 (~2 kb) 
 other engineered elements comprising the conditional Cre dependent mutant/WT 
“machinery”, described in more detail below 
 large (> 10 kb) homology arms: regions of flanking sequence homologous to the region 
of mouse chromosome that the construct is targeted to 
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Figure 5.1 SOD1 humanising construct 
(a) Whole construct in situ within the O19 C57BL/6N BAC 
(b) Close up of the engineered sequence 
(c) Close up of the engineered sequence after FLP excision  
(d) Close up of the engineered sequence after FLP and Cre excision  
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The large homology arms are designed to facilitate efficient targeting in mouse embryonic 
stem cells (mESCs). The neo cassette allows selection of targeted mESCs.  
The conditional allele allows expression of an exon 4 or 5 mutant human SOD1 (huSOD1) to be 
switched to expression of WT huSOD1. The human SOD1 sequence in the allele’s starting 
configuration will include an ALS mutation in either exon 4-5 (Figure 5.1c). Upon expression of 
Cre, the LoxP flanked (floxed) region is excised and the WT repeat moves into frame, switching 
the transcript from mutant to WT (Figure 5.1c-d transition). 
Neomycin/Kanamycin Selection Cassette 
The neo cassette is positioned 1 kb downstream from the end of the 3’ UTR of SOD1. The 
cassette has 2 promoters; transcription of the neo gene from a prokaryotic gb2 promoter 
confers kanamycin resistance in E.coli and transcription from the eukaryotic PGK promoter 
confers neomycin resistance in mammalian cells. It is included in the construct so that 
neomycin selection can be used in mESC targeting. The inclusion of this exogenous sequence 
has the potential to cause undesired/off-target effects on SOD1 or surrounding genes. The 
retention of such cassettes in knock-out (KO) alleles can cause perturbation of the expression 
of the surrounding genes which can lead to phenotypes, including embryonic lethality, which 
are caused by the cassette and not the KO itself (e.g.(Hug et al., 1996; Pham et al., 1996; Olson 
et al., 1996; Fiering et al., 1995)). Novel fusion transcripts have also been reported (Scacheri et 
al., 2001).  
To reduce the likelihood of this occurring, several precautions have been taken; firstly, the 
selection cassette has been positioned 1 kb downstream from the end of the 3’ UTR of 
humanised SOD1 to allow a run off for the transcription machinery without any exogenous 
sequence interfering with correct transcription termination. Scaf4 is 2.6 kb downstream of 
Sod1 and in the reverse orientation. The positioning of the selection cassette, 1 kb 
downstream of Sod1, also allows over 1.5 kb uninterrupted run off for transcription of Scaf4. 
The cassette is also flanked by Flippase Recognition Target (FRT) sites to allow excision of the 
cassette by expression of Flippase site-specific recombinase (FLP), leaving a single FRT “scar” 
(Figure 5.1, transition from b-c). This excision would usually be done once germ-line 
transmission of the modification has been achieved in mice, by crossing to a FLP transgenic 
mouse line.  
The positioning of the neo cassette here also aids cloning of the targeting construct; a repeat 
cassette must be inserted downstream of the 1 kb terminator. Having the neo cassette in this 
location provides a unique region of sequence for targeting by recombineering.  
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Conditional Mutant/WT Allele 
The conditional allele allows a switch from expression of mutant to WT huSOD1 by Cre excision 
of the floxed mutant exon 4-5 cassette (Figure 5.1c-d). The floxed cassette contains a ~3 kb 
region spanning from within intron 3 to 1 kb downstream of the 3’ UTR, with an ALS mutation 
in either exon 4 or exon 5. The downstream WT repeat cassette contains sequence almost 
identical but with the exception that there is no ALS mutation.  
In its starting configuration (Figure 5.1c) the allele directs expression of huSOD1 with an ALS 
mutation in either exon 4 or 5. Expression of Cre excised the floxed cassette, moving the WT 
repeat cassette into frame, changing expression to WT huSOD1 (Figure 5.1d). Expression of Cre 
can be achieved by crossing to a Cre transgenic mouse line. Many conditional and inducible 
Cre transgenic mouse lines are now available (e.g. (Heffner et al., 2012)).  
Homology Arms 
As is shown in Figure 5.1a, by engineering the construct into a BAC containing the mouse Sod1 
locus, large homology arms are provided to facilitate more efficient mESC targeting. Several 
BACs containing the required mouse genomic region with Sod1 in a relatively central position 
are available (described later in Section 5.2.3) and the size of the homology arms is dependent 
on which BAC is used. In the example shown in Figure 5.1a, the construct is shown in a 
B6Ng01-068O19 BAC which provides homology arms of 51.9 kb and 99 kb.  
5.2.2 Selection of Mutations 
The design of the conditional allele allows the use of any mutation within the repeat region 
encompassing exons 4 and 5. The starting point for selection of a mutation was to identify all 
the disease causative mutations within these exons by searching the ALS online database 
(http://alsod.iop.kcl.ac.uk/) and PubMed (http://www.ncbi.nlm.nih.gov/pubmed/). These 
mutations are shown in graphical format in Figure 1.2. It was decided that in the first instance 
two mutant constructs would be made, one with a wild-type like enzymatically active mutation 
and one highly destabilised mutation . A literature search was carried out and two mutations 
were chosen based upon:  
 Causality- many mutations have been reported in only single cases. The chosen 
mutation should have been reported in multiple probands and where familial 
pedigrees are available, segregation with disease should be apparent.  
 High penetrance- based on the pedigrees available a high level of penetrance should 
be apparent.  
 Absence of evidence for unusually long disease course or late onset.  
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In addition to these criteria, mutations for which biochemical or biophysical information was 
also available were viewed favourably. The 2 mutations chosen were the stable WT-like E100G 
mutation and the highly destabilising L126delTT mutation. Information presented below 
includes details of the patient literature available and a brief summary of the in vitro 
experimental and mouse data, where available.  
5.2.2.1 SOD1E100G 
The first mutation chosen was an adenine to guanine (GAA to GGA) mutation in the 101st 
codon residing in exon 4 of SOD1 causing a substitution from glutamic acid to glycine (E100G) 
(Figure 5.2). This is one of the mutations to have been reported in the paper that first 
identified SOD1 mutation as causative of ALS (Rosen et al., 1993). Further details of this 
particular cohort are not detailed in this paper.  
5.2.2.1.1 Patient Literature for the SOD1E100G Mutation 
The patient data described in this section are summarised in Table 5.1 where individual data 
are available and in Table 5.2, where averages are presented.  
From a literature search, a possible 9 independent probands/pedigrees have been identified. 
Each will be briefly described.  
Pedigree 1 
The first case identified by Rosen et al., (1993) was also examined in Deng et al., (1993) who 
measured dismutase activity from RBCs from 2 patients from the same family. Dismutase 
activity was less than 50% that of WT control levels. A third paper (Yulug et al., 1995) identifies 
an individual with this mutation but gives no further information. The samples used for 
mutation identification were supplied by Professor Guy Rouleau, a co-author on the original 
Rosen paper. The samples are described as being of “unknown etiology”. It is not clear 
whether this is one of the cases identified by Rosen et al., (1993) and Deng et al., (1993), from 
the same pedigree, or an independent case.  
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Figure 5.2 Schematic representations of selected SOD1 humanisation mutations 
Amino acid sequence of SOD1 shown with key protein regions highlighted (see key). 
Numbering refers to mature protein sequence with initial methionine removed.  
The mutated amino acid sequences are shown, and the DNA mutations are annotated.  
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Table 5.1 Summary of clinical data for E100G individuals 
Reference ID 
Onset 
age 
(years) 
Site 
of 
onset 
Duration 
(years) 
Age at 
death 
(years) Sex 
Mutation 
confirmed Comments 
Calder et al., (1995) III-2 46 legs 4.75 51 m   
Mutation identified in a cousin and offspring. Appears as female in the 
pedigree chart 
Calder et al., (1995) III-3 49 legs 5.5 54 f   
Mutation identified in a cousin and offspring. Appears as male in the 
pedigree chart 
Ince et al., (1996)   36 legs 3.25   f y 4 relatives died aged 46, 42, 52 and unknown 
Aggarwal (2012)   48 legs 0.3   f y   
Aggarwal (2012)   44 legs 0.17   m y Treated with Riluzole. Alive on ventilation with tube feeding 
Vucic et al., (2008)   34       m y   
Vucic et al., (2008)   49   1.17   f y   
AVERAGE   43.71   2.5 52.5       
 
Table 5.2 Summary of averaged clinical data for E100G cases 
Reference 
Mean 
onset age 
(years) 
Mean 
duration 
(years) 
Mean age 
at death 
(years) Comments 
Juneja et al., (1997) 48.5 5.1   23 individuals 
Orrell et al., (1999) 57-75 7   3 pedigrees 
Orrell et al., (1997) 47-50 6-8   2 pedigrees including same patients as Rosen et al., (1993) and Yulug et al., (1995) 
Aggarwal and Nicholson (2005)     54 .17 33 individuals from 1 pedigree  
Cudkowicz et al., (1997) 46 3/4  4   26 individuals from 2 pedigrees 
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Pedigree 2 
A four generation pedigree with 8 affected individuals was identified in New Zealand in 1995 
by Calder et al.,. An autosomal dominant pattern of inheritance was displayed, as shown in 
Figure 5.3a. One surviving affected case, III-5, was genotyped and found to have the E100G 
mutation. Seven individuals from generation four (not shown on the pedigree), who were 
offspring of the affected cousins of III-5 (III-1, 2 and 3), were also genotyped. Five out of the 7 
offspring were found to have the mutation. None of these generation four individuals were 
clinically affected, however no information is given as to their ages. Dismutase activity 
measured from RBCs found that in family members with the mutation, activity was between 
70-85% that of controls, higher than was reported in patients by Deng et al., (1993). The 
authors also note that when measured on multiple occasions, the dismutase activity of E100G 
cases was more variable than that of non-mutant family members or controls, and state that, 
from unpublished data, the E100G mutant is less heat stable than the wild-type. They suggest 
that the reduced activity may be due to decreased stability and that inconsistencies in 
measured activity between reports may be due to the more labile nature of the protein to 
differences in sample handing. Calder et al., (1995) also show that WT homodimers, mutant 
homodimers and WT:mutant heterodimers are present in the RBCs and that mutant 
homodimers and heterodimers have lower activity than the WT homodimers. However, what 
is not clear is whether this lower activity level is due to a lower number of including the 
mutant protein, or the reduced activity of the mutant protein. 
Two case studies of deceased members of generation three are presented by Calder et.al., 
(1995). There is some discrepancy in the nomenclature, as III-2 is referred to as male in the 
text but female in the pedigree chart and vice versa for case III-3. Here I will use the reference 
given in the text. Case III-2 was a male, with onset at age 46 in the lower limbs later spreading 
to the upper limbs. He survived 4.75-years. Case III-3 was a female, with lower limb onset at 
49-years of age. Symptoms spread to upper limbs and included, at later stages, bulbar 
symptoms in the jaw and neck. She survived 5.2-years. Cause of death is not described for 
either case. Although the mutation was not confirmed in either of these cases, it was identified 
in an affected cousin and offspring.  
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Figure 5.3 Humanisation mutation pedigrees 
(a) and (b) show the two available E100G pedigrees. (c) and (d) show the available L126delTT pedigrees  
Square= male, circle = female. Confirmed or suspected ALS cases are filled/half-filled in black. Deceased cases are struck through. Cases of ALS or suspected ALS 
for which details are reported in the literature are highlighted in red. Non-symptomatic carriers of the mutation are highlighted in blue. Cases in which the 
mutation has been confirmed are denoted by a yellow star. 
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Pedigree 3 
The next case was reported in 1996 by a UK based group (Ince et al., 1998) and is a single case 
report with autopsy. The proband was female with onset in the upper and lower limbs of the 
left-hand side, at age 36. At a late stage she became severely tetraplegic with only mild bulbar 
involvement. She survived 3.25-years from presentation due to respiratory failure.  
Post mortem diagnosis was “ALS with posterior column involvement”. Briefly, examination of 
the spinal cord (SC) showed severe astrocytosis in the cord and roots, microglial infiltration 
and loss of lower motor neurons (LMNs) with some of the remaining LMNs appearing atrophic. 
In several motor nuclei in the brain a similar pattern was reported. Few ubiquitin inclusions 
were identified, and no SOD1 inclusions were identified, neither was neurofilament pathology. 
Demyelination was apparent in the white matter of the SC.  
Four relatives of the same lineage suffered from “progressive motor disorders”, suggesting an 
autosomal dominant inheritance. They died at ages 46, 42, 52 and one at an unascertained 
age. None of her three siblings had signs of disease.  
The same case was also examined by Shaw et al., (1997) for the presence of somatic mutations 
in SOD1, which were not found.  
Pedigrees 4, 5 and 6 
Orrell et al., (1997) present data from two E100G families, both from the UK, with an 
autosomal dominant pattern of inheritance. Dismutase activity was assayed from RBCs as 
63.5% that of controls. Graphs show survival of around 6-8-years, onset between 
~47-50-years, and age at death between ~40-70-years of age. A later follow up in 1999 (Orrell 
et al., 1999) reports data including a 3rd family and graphs showing duration of ~7-years and 
age at death of ~57-75-years of age.  
Pedigree 7 and 8 
Cudkowicz et al., (1997) examined a very large group of 366 families with fALS based in 
America and Europe. Two E100G families were identified, encompassing 26 patients. These 
may include the same patients reported by Deng et al., (1993) and Rosen et al., (1993). The 
mean age of onset for the E100G cases was 46.9-years of age (matching the average across all 
SOD1 families), with a range of 21-72-years. The mean duration was 4-years (3.9 averaged for 
all SOD1 mutations), ranging from 1-10-years with a median of 4.  
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Pedigree 9 
Aggarawal et al., (2001; 2002; 2005; 2012) carried out a prospective study following an 
Australian family with the E100G mutation including 5 asymptomatic, E100G mutation carrying 
relatives of known ALS case. This first study examined whether the electrophysiological test of 
motor unit number estimation (MUNE) was able to detect pre-symptomatic loss of MUs. 
Eighteen asymptomatic carriers of 4 different mutations were followed, and specific data for 
the E100G cases are not given. No pre-symptomatic MU loss was detected, and neither was 
there in a 3-year follow up (Aggarwal et al., 2002; Aggarwal et al., 2001). In 2005 (Aggarwal, 
2012) Aggarwal and Nicholson, presented a large, 6 generation, E100G family tree (Figure 5.3b, 
presumed to be the same family reported in 2001), which includes 33 ALS cases showing an 
autosomal dominant pattern of inheritance. Details of which individuals within the pedigree 
were confirmed to have the E100G mutation are not given. The average age of ALS related 
death was 54.2-years, ranging from 26-78.  
In a 5 year follow up, 2 out of the 5 E100G carriers had gone on to develop ALS (Aggarwal, 
2012). The first case, a woman diagnosed at 48-years of age, died only 4-months later due to 
respiratory failure. The second case, a male and second cousin once removed from the first, 
had a longer disease course. Onset was at around 44-years of age, and within 3-months the 
patient was unable to stand unaided. He was treated with Riluzole and was still alive 
10-months later, but was dependent on ventilation at night and tube feeding.  
Pedigree 10?  
Another paper examining both asymptomatic and symptomatic E100G carriers gives brief 
details of one male case with upper and lower limb onset at age 34, and a second female case 
with lower limb onset at age 49, with a disease duration of 14-months. An asymptomatic 45 
year old female with the E100G mutation is also described (Vucic et al., 2008). Similar to the 
previous pedigree, this group was based in Australia, and a co-author (Garth Nicholson) is 
shared, so it is possible that the same individuals/pedigrees are presented. Later, Vucic et al., 
(2013) presented evidence of anticipation, which included at least one E100G family with a 
three generation, autosomal dominant, pedigree.  
Finally, Juneja et al., (1997), an American group, present averaged data for twenty-three 
E100G cases. The mean age of onset was 48.6-years and disease duration was 5.1-years. The 
cases are described as showing autosomal dominant inheritance. Whether the cases were 
from a single or multiple pedigrees is not stated.  
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5.2.2.1.2 In Vitro SOD1E100G Literature 
A number of papers have been published examining the in vitro properties of E100G mutant 
human SOD1 and shall be briefly reviewed here.  
Several papers use a “pseudo WT” protein in which cysteines 6 and 111 (the 2 free cysteines 
not involved in native disulphide bonding) are mutated to alanine and/or serine, respectively, 
to allow reversibility of unfolding. In this context and using holo proteins, the E100G mutant 
has been reported as the most stable of 4 mutants (G85R, G93R, E100G, I113T), in regards its 
thermal unfolding kinetics, in the presence of chemical denaturants (Rumfeldt et al., 2006; 
Rumfeldt et al., 2009). Contrary to this, in the context of a normal WT sequence, and using apo 
proteins, Rodriguez et al., (2005), identified E100G as having the lowest thermal stability of 20 
SOD1 recombinant mutants examined.  
A number of other papers examining a variety of properties have compared mutant to WT 
SOD1, and reported no particular distinguishing features of the E100G mutant protein. Such 
properties include: the aggregation propensity of holo and apo proteins in vitro in response to 
chemical denaturants or heat (Stathopulos et al., 2003); aggregation propensity in mammalian 
cell expression assay (Prudencio et al., 2009b); the effect of mutation on the kinetics of dimer 
dissociation and monomer unfolding of the apo and holo protein in pseudo WT contexts 
(Vassall et al., 2006; Rumfeldt et al., 2009; Lindberg et al., 2005); post-translational folding and 
modifications (Bruns et al., 2007).  
5.2.2.2 SOD1L126DELTT 
The second mutation selected, referred to here as L126delTT, is a deletion of two thymines in 
the 127th codon (TTG to ΔΔG) of the SOD1 gene. This mutation results in a frame shift, as 
shown in Figure 5.2, deleting the last 28 amino acids (aa), introducing 5 alternative C-terminal 
aa and producing a truncated protein totalling 130 aa (including the initial methionine) and 
lacking a region important for dimer contact (Watanabe et al., 1997a).  
5.2.2.2.1 Patient Literature for the SOD1L126delTT Mutation 
All the patient data described in this section are summarised in Table 5.3. 
Pedigree 1. The Oki family 
The earliest reference for this mutation is from Pramatarova et al., (1994) who, identified the 
mutation in all 3 of the living ALS sufferers from a large pedigree from Japan, referred to as the 
Oki family. This pedigree has been well documented with at least 7 papers published which 
include details of members of the family. The pedigree (Watanabe et al., 2001b) is shown in 
Figure 5.1c, where cases referred to here are highlighted. The first published account of a 
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member of the Oki family is from 1972 (Takahashi et al., ) and describes an autosomal 
dominant pattern of inheritance through 3 generations including 5 cases of ALS. A case report 
described a woman (referred to as III-5 in this paper and as IV-5 in later papers) with onset in 
the right arm at 45-years of age who was diagnosed with fALS with posterior column 
involvement. Her symptoms progress to include all 4 limbs and the pelvic girdle. The patient 
died of respiratory failure 1.5-years after onset. Post mortem examination of the cervical and 
thoracic cord reveal MN loss, astrocytosis, hyaline inclusions and some demyelination. This 
case was further examined at a later date by Kato et al., (1996) who highlighted the presence 
of Lewy body hyaline inclusions (LBHI) in the MNs which were positive for SOD1, ubiquitin and 
phosphorylated neurofilament, along with SOD1 and ubiquitin positive glial inclusions which 
were negative for phosphorylated neurofilament.  
In 1995 (Nakashima et al., ) the mutation was identified in 2 affected and 3 unaffected family 
members from generations IV, V and VI of the Oki family. The 2 affected family members, V-2 
and IV-4, were aged 26 and 53 and had been on ventilatory support for 2 and 10-years 
respectively. The unaffected carriers, cases V-5, V-6 and VI-4, were aged 26, 23 and 33, 
respectively, at the time. All mutation carriers had reduced dismutase activity as assayed from 
RBCs, with affected cases having a reduction of 65-70% and unaffected carriers a reduction of 
around 35%.  
Case IV-4 was described in some detail after his death, at age 65, caused by "accidental 
intraperitoneal hemorrhage" (Kato et al., 1996). This male patient had onset initially affecting 
the pelvic girdle, at 54-years of age. Within 6-months he was unable to walk and was 
dependent upon respiratory support within 2-years of diagnosis. He had a long disease 
duration once utilising respiratory support, surviving 11-years from diagnosis. Unusually, he 
experienced eye movement disturbance after 5-years of the disease. Pathology was similar to 
case IV-5; there was a loss of SC MNs and LBHIs were positive for SOD1, ubiquitin and 
phosphorylated neurofilament, however unlike case IV-5, such inclusions were present not 
only in the MNs but also in neurons outside of the motor regions. SOD1 and ubiquitin positive, 
phosphorylated neurofilament negative inclusion were also present in SC astrocytes and some 
demyelination was reported. SOD1 inclusions were negative for Congo red and thioflavin S 
suggesting a non-amyloid form. As well as degeneration and loss of SC MNs, severe 
degeneration was also noted in the dorsal horns (Kato et al., 1996). When assessed by western 
blot and in gel activity assay, the truncated mutant SOD1 protein was not detected in post 
mortem tissue obtained from case IV-4. Instead, western blot revealed only the WT sized 
protein which was at 50% the intensity of control WT samples, although RT-PCR from mRNA 
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confirmed that the mutant allele was being transcribed at normal levels (Watanabe et al., 
1997a). 
Two review papers from Watanabe et al., (2000; 2001b), present some more information on 
case V-2 who had a slightly unusual disease progression. This male proband had onset in the 
lower legs predominating on the left side, at an early age of 22-years. Symptoms spread to 
include the upper limbs and 14-months after onset bulbar symptoms developed. 1.5-years 
after onset the patient received a tracheotomy and respiratory support. The patient died 
3-years and 8-months after diagnosis at which time eye movement and urinary disturbance 
were also noted.  
The average age of onset for the Oki family is 42, ranging from 22 to 54-years of age, with an 
average duration to death, or dependence on respiratory support, of 2-years from onset 
(Watanabe et al., 2001b).  
SOD1 activity and expression levels were examined in 10 non-specified Oki family members. 
Activity was found to be reduced by ~40% in non-affected carriers of the L126delTT mutation 
and by ~70% in affected carriers, as compared to WT family members. A positive correlation 
between SOD1 activity and quantity in RBCs suggests that the reduced activity is due to a lack 
of protein (Watanabe et al., 1997a).  
Also of note is a case briefly presented by Bruijn et al., (1998). The case is only described as 
being a 2 bp deletion in codon 126 leading to a truncated protein, however, one of the co-
authors is also a co-author in many of the Oki family papers, and so it is likely that the case 
presented is an Oki family member. A figure shows marked SOD1 pathology detected using an 
antibody specific to a region of SOD1 which is absent in the truncated protein, and so 
presumably detecting WT SOD1 aggregation in the absence of the mutant protein.  
Pedigree 2 
At least two other pedigrees of the L126delTT mutation, both from Japan, have been reported. 
The first, reported in 1996 (Kawamata et al., ) is a brief case report of a male with onset in the 
right arm at 44-years of age. He was still alive 2-years after onset, when symptoms had spread 
to all 4 limbs. His father was suspected of having died of ALS and was confirmed as carrying the 
mutation from analysis of a muscle biopsy sample. The father had onset in the left arm at 
66-years of age. His symptoms spread to include both arms and the intercostal muscles 
causing shortness of breath. He died at 68 from pneumonia and was still able to walk at this 
time. The paternal uncle also died of ALS, predominating in the lower limbs, 2-3-years after 
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onset. The proband’s younger sister was also suspected as suffering from ALS. The pedigree 
chart is shown in Figure 5.3d.  
 
Pedigree 3 
Kadekawa et al., (1997) present an autopsy case of a female who was diagnosed with ALS at 
42-years of age with onset in the lower left leg spreading into the right. Within 1.5-years of 
diagnosis, the patient had developed bulbar signs and was dependent on a respirator. She died 
of pneumonia after 2-years and had also suffered 2 heart attacks during the later stages due to 
asphyxiation. Her older brother, father and paternal uncle had also died following a similar 
clinical disease course. The proband’s details are summarised in Table 5.3, but her relatives are 
not included as no details are available. SOD1 activity from RBCs was reduced by ~70% and the 
truncated mutant protein was not evident by western blot. Post mortem examination of the 
brain and SC revealed MN loss and astrocytosis, with no dorsal horn involvement. MN LBHIs 
were also found and were positive for ubiquitin, phosphorylated neurofilament, but unlike 
those cases from the Oki family, were found to be negative for SOD1. Different tissue 
processing protocols and antibodies were used by the two groups and may explain this 
difference.  
Three further papers have been published examining various aspects of this case. Ogawa et al., 
(1997) used immunoprecipitation followed by high performance liquid chromatography (HPLC) 
and /electrospray ionization mass spectrometry (ESIMS) to quantify levels of WT and mutant 
protein from patient erythrocytes, but failed to detected any L126delTT SOD1 in the case 
described by Kadekawa et al., (1997). Similar to previous findings in sALS patients, 14-3-3 
proteins, which are involved in apoptotic and cell proliferation signalling pathways, were found 
to localise in the LBHIs of this patient (Kawamoto et al., 2005). Markers of increased oxidative 
stress were also identified in MNs and glia in SC sections from this patient (Shibata et al., 
2007). 
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Table 5.3 Summary of clinical data for L126delTT individuals 
* figure in brackets is years to dependence on respirator 
Pedigree ID 
Onset 
(years) 
Site of 
onset 
Duration 
(years)* 
Age at 
death 
(years) Sex 
Mutation 
confirmed 
Cause of death 
(where cited) Comments Ref 
Oki II-1 ?     50 m     
Died of progressive muscular wasting disease 
(referred to as I-4 in Takashi et al., 1972) 
1,6 
Oki III-1 36 legs 2 38 m     
Died of progressive neuromuscular disease (referred 
to as II-4 in Takashi et al., 1972) 
1,6 
Oki III-3 52 legs 3 55 f     
Died of progressive neuromuscular disease (referred 
to as II-5 in Takashi et al., 1972) 
1,6 
Oki IV-4 54 
pelvic 
girdle 
11 (1) 65 m y 
"accidental 
intraperitoneal 
haemorrhage" 
Reduced dismutase activity in RBCs. Extraocular 
involvement (referred to as 839 in Pramatarova et 
al., 1994)  
2,3,4,
5,6,7 
Oki IV-5 45 
right 
arm 
1.5 47 f y asphyxiation   1,4,6 
Oki IV-7 ? arms     f     Alive at 54 (referred to as III-8 in Takashi et al., 1972) 1,6 
Oki IV-9 54 
right 
thigh 
3 57 f       6 
Oki V-2 22 left leg 1.6 (1.5) 25 m y   
Reduced dismutase activity in RBCs. Extraocular and 
urinary involvement (referred to as 859 in 
Pramatarova et al., 1994) 
2,3,6,
7 
Oki V-5 n/a       f y   Non-symptomatic at age 26 3 
Oki V-6 n/a       f y   Non-symptomatic at age 23 3 
Oki V-7 ?       m y   
Clinically affected, but no details given (Referred to 
as 847 in Pramatarova et al., 1994) 
2 
209 
Pedigree ID 
Onset 
(years) 
Site of 
onset 
Duration 
(years)* 
Age at 
death 
(years) Sex 
Mutation 
confirmed 
Cause of death 
(where cited) Comments Ref 
Oki 
V-
14 
42 
right 
shoulder 
girdle 
3 (1) 45 f     V-14 respirator at 2 years 6 
Oki VI-4 n/a         y   VI-4 non-symptomatic at age 33 3 
2 III-1 44 
Right 
arm 
Still alive 
at 2 
years 
  m y     8 
2 II-3     2-3   m n   Gait disturbance 8 
2 II-6 66 Left arm 2 68 m y Pneumonia 
Main symptoms in upper body (arms and trunk) still 
able to walk before death 
8 
2 III-2 <46       f n   
Younger sister of proband "suspected clinically of 
having ALS" 
8 
3 n/a 42 right leg 2 (1.5)   f y Pneumonia 
Brother, father and paternal uncle also died of ALS 
like disease 
9 
1- (Takahashi et al., 1972); 2- (Pramatarova et al., 1994); 3- (Nakashima et al., 1995); 4- (Kato et al., 1996); 5- (Watanabe et al., 1997a); 6- (Watanabe et al., 2000); 
7- (Watanabe et al., 2001b); 8- (Kawamata et al., 1996); 9- (Kadekawa et al., 1997) 
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5.2.2.2.2 In Vitro SOD1L126delTT Literature 
At least 2 papers have been published in which the in vitro properties of recombinant 
L126delTT mutant SOD1 have been examined.  
The lack of dismutase activity of L126delTT SOD1 was confirmed in recombinant SOD1 fused to 
an N-terminal maltose binding domain (MBD) produced in E.coli by Watanabe et al., (1997b). 
Protein yield was ~3 times lower for the L126delTT mutant as compared to the WT within this 
expression system. Both the MBD fusion and cleaved versions of the WT protein displayed 
dismutase activity whereas neither MBD fusion nor cleaved L126delTT SOD1 did. The mutant 
protein also showed a much lower resistance to proteolysis by proteinase K. When expressed 
in mammalian cells (COS1) without the MBD, the mutant protein was not detectable by either 
western blot, or activity assay despite confirmation of its mRNA species.  
Koide et al., (1998) expressed a number of FLAG tagged mutants and WT SOD1 in COS7 cells to 
examine their aggregation propensity. At 24 hours after transfection, cells expressing 
L126delTT were the only in which aggregates were detected and at 48 hours post-transfection 
~30% of cells expressing L126delTT had SOD1 positive aggregates as compared to 3-9% of cells 
expressing A4V, G85R and G93A mutant SOD1 and none in those expressing WT SOD1.  
5.2.2.2.3 SOD1L126delTT Transgenic Mouse Literature 
Transgenic mice harbouring L126delTT mutant SOD1 were published in 2005 by the same 
group who originally identified the mutation in the Oki family (Watanabe et al., 2005). The 
mice were made using the same human genomic SOD1 plasmid as was used for the Gurney et 
al., (1994) WT and G93A mice. Mice with transgenic WT and L126delTT mutant and FLAG 
tagged versions of both were produced and 2 founder lines for each were phenotyped.  
Neither the WT nor WT-FLAG lines developed ALS like disease during their life span. Those 
mice with the L126delTT mutant SOD1 transgene (either with or without the FLAG tag) with 
the highest number of copies did develop ALS like symptoms with hind limb paralysis, muscle 
atrophy, weakness and weight loss. As summarised in Table 5.4, mice homozygous for the 
transgene developed symptoms earlier and died earlier than hemizygous mice. Mice with the 
L126delTT-FLAG transgene had an earlier onset and death despite having a lower transgene 
copy number, however, while western blots detected small quantities of the mutant SOD1 in 
the L126delTT-FLAG mouse, immunoprecipitation followed by western blot was needed to 
detect the very low quantities of mutant SOD1 present in the L126delTT line without the FLAG 
tag. SOD1 activity was no different to non-transgenic mice when assayed from the L126delTT 
or L126delTT-FLAG hemizygous lines which develop disease, but was increased 3-4 times in a 
WT line (summarised in Table 5.4). Northern blot of mRNA isolated from fibroblasts from the 
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mice confirmed that the transgenes were being transcribed at the levels expected by their 
copy number and so the low level of protein in the mutant lines was either due to reduced 
protein translation or increased degradation. Histological examination of the SC of the mutant 
lines revealed loss of MNs of the ventral horn and gliosis. Inclusions resembling LBHIs were 
also present in the remaining MNs and these were positive for SOD1 and for FLAG in the FLAG 
tagged lines. At least 4 subsequent papers have been published using the homozygous 
L126delTT-FLAG mice as models of ALS.  
Fukada et al., (2007) found that the L126delTT-FLAG mice, as compared to WT-FLAG mice, 
displayed differential expression of a number of genes, including heat shock proteins and 
genes related to inflammation and autophagy and found some parallels with similar work 
carried out in the G93A mutant SOD1 transgenic mouse. Doi et al., (2008) found low level 
SOD1 deposits in vacuolated mitochondria of the SC neurons of pre-symptomatic L126delTT-
FLAG mice, along with fibrillar inclusion in the ventral horns with high levels of SOD1. This was 
similar to observations in other mutant SOD1 transgenic mice, however the quantity of SOD1 
deposited in vacuolated mitochondria was lower than in other models; this may not be 
surprising considering that the L126delTT-FLAG mice have been shown to have only a very low 
level of mutant SOD1 protein.  
 
Table 5.4 Summary of L126delTT mutant SOD1 transgenic mices phenotypes 
Data from Watanabe et al., (2005) is summarised. The human end point was defined as 
being unable to right themselves within 30 seconds of being placed on their side.  
SOD1 activity assayed from brain and liver 
Hemi= hemizygous; Hom=homozygous; n.d.= not determined 
Genotype 
Transgene 
copy 
number 
Hemi 
or 
hom? 
Develops 
symptoms? 
Onset 
(days) 
Death 
(days) 
SOD1 
activity 
(relative to 
non-
transgenic) 
WT 1 Hemi no     n.d. 
WT 3 Hemi no     3-4 
WT-FLAG 2 Hemi no     n.d. 
WT-FLAG 3 Hemi no     n.d. 
L126delTT 1 Hemi no     n.d. 
L126delTT 5 Hemi yes 445 480 1 
L126delTT 10 Hom yes 239 251 n.d. 
L126delTT-FLAG 3 Hemi no     n.d. 
L126delTT-FLAG 4 Hemi yes 341 372 1 
L126delTT-FLAG 8 Hom yes 121 127 n.d. 
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Finally, Watanabe et al., (2008) carried out a proteomic analysis comparing binding partners of 
mutant and WT SOD1 in the SC of L126delTT-FLAG and WT-FLAG mice. They found 34 proteins 
interacting with L126delTT-FLAG SOD1 and only 3 with WT-FLAG SOD1. Among the binding 
partners of L126delTT-FLAG were ATPases, ATP synthases and heat shock proteins which had 
been detected in their earlier work carried out with G93A mutant SOD1 mice.  
5.2.3 BACs Sequence Confirmation  
5.2.3.1 HUMAN SOD1 BAC  
A SOD1 containing human BAC clone, RP11-535E10 (E10), was selected as described in Section 
2.3.1. This BAC was sequenced from PCR amplified sections of between 1,500-2,300 bp, using a 
proof reading polymerase, Pfx, in the touchdown PCR protocol (Section 2.1.2.1). Amplicons 
covered whole entire SOD1 gene plus at least 200 bp upstream and downstream (~9.7 kb 
total).  
Four mismatches were found between the sequence of the E10 BAC and the reference 
sequence (GRCh37.p6, Feb 2009), all in intronic regions, detailed in Table 5.5 
 
Later re-checking of the mismatches using the latest genome reference build (GRch37.p12) in 
the Ensembl genome browser (www.ensembl.org) to identify known sequence variants (tracks 
checked: all dbSNP, HapMap, all 1000 Genomes, all phenotype and curated variants, all LSDB-
associated variants, all phenotype annotations, all individual genomes, all failed variants, all 
external variant data) revealed that the C>T mismatch at ch21: 33,032,287 has an average 
frequency of 0.035 (ranging from 0.002 in East Asia to 0.107 in Iberian population in Spain) and 
Table 5.5 Mismatches between E10 BAC and reference sequence (GRCh37.p6) 
Chromosomal 
location 
Region 
description 
bp 
down- 
stream 
from 
exon 1 
bp up- 
stream 
from 
exon 2 
Reference 
(GRCh37. 
p6) 
E10 
BAC 
base 
Identified in 
GRch37.p12 
Ch21: 
33,032,287 
SOD1 
intron 1 134bp > 3.5 kb C T 
SNP ID 
rs17881180 
Ch21: 
33,033,782- 
33,033,783 
SOD1 
intron 1 > 1.5 kb > 2 kb TT TTT no 
Ch21: 
33,033,786-
33,033,787 
SOD1 
intron 1 > 1.5 kb > 2 kb CC CCC no 
Ch21: 
33,033,805-
33,033,806 
SOD1 
intron 1 > 1.5 kb > 2 kb TA TAA no 
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has been given the SNP ID rs17881180. This SNP has been found to be associated with the 
development of severe nephropathy in people with type 1 diabetes (Al Kateb et al., 2008).  
The remaining 3 mismatches, which were not identified as know variants, were single bp 
expansions, increasing either a double to a triple, or a triple to a quadruple single bp repeat 
(see Table 5.5). The Ensembl genome browser was used to examine the 25 bp region in which 
these 3 mismatches were found and the flanking 500 bp upstream and downstream (Chr21: 
33,033,282-33,034,306 in reference build GRch37.p12) to check for the presence of known 
regulatory or binding regions or transcribed sequences etc. Features checked were: CpG 
islands, tRNAs, GENCODE genes, all mRNA alignments, ncRNAs, all structural variants, all 
external variation data, all regulatory features, all other regulatory regions. The only feature 
identified within this region, an exon from a putative alternative transcript of SOD1, is over 50 
bp away. This transcript (Ensembl ID ENST00000476106), which lacks an open reading frame, is 
a manual annotation from the Havana Project based on ab initio examination of the genome 
sequence and is not based on experimental data of an actual transcript. Based on this 
evidence, these discrepancies were deemed acceptable.  
5.2.3.2 MOUSE SOD1 BACS 
Two Sod1 containing C57BL/6J mouse BAC clones, RP24-363N21 (N21) and RP24-238L18 (L18), 
were selected as described in Section 2.3.1. These BACs were sequenced in the same manner 
as the E10 BAC. The initial cloning plan involved subcloning a large region from the mouse BAC 
to include ~13 kb 5’ and ~15 kb 3’ homology arms for targeting, and so these two regions were 
sequenced in entirety. As the region to be used from the mouse BAC is several times larger 
than that of the human BAC, the chances of finding mutations/mismatches between the BAC 
and the reference sequence is also higher and so two BACs were selected for sequencing with 
the best match to be used for construct synthesis.  
The first region spanned 13,284 bp 5’ of the Sod1 gene and included the 5’ UTR and the start of 
exon 1. The second region spanned 15,357 bp 3’ of Sod1 and included 106 bp of exon 5.  
Two mismatches between the BAC sequences and the reference sequence (NCBIM37) were 
found. The first was in an intergenic region between Sod1 and Scaf4, was present in both L18 
and N21 and the second was within intron 19 of Scaf4, and was present on L18 only. These are 
detailed in Table 5.6. 
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The Ensembl genome browser (www.ensembl.org) was used to check if these were known 
sequence variants in build GRCm38. Tracks checked were: all sequence variants, all variation 
sets, all structural variants, phenotype annotations. The first mismatch, a single additional T in 
a 9 bp T repeat was identified as a known deletion/insertion variation with no overlap to 
Ensembl regulatory or motif sequences. The second mismatch, a 2 bp increase of a stretch of 
12 As, was not identified, although a single bp increase was recorded as a known variant (see 
Table 5.6) and again there was no overlap to Ensembl regulatory sequences. The region 
surrounding the second mutation, 500 bp up and downstream, was manually checked for the 
presence of known regulatory or binding regions or transcribed sequences, etc. using the 
Ensembl genome browser with the following features checked: all genes, all external gene and 
transcript data, prediction transcripts, all mRNA alignments, all regulatory features, all other 
regulatory regions. The only feature found within this region, other than the intronic Scaf4 
transcript, was a predicted exon, >250 bp downstream, identified by gene prediction software. 
Clone N21 was therefore selected for use as it most closely matched the reference sequence.  
After starting this project, a new BAC library constructed from C57BL/6N (BL/6N) DNA was 
made available from Riken. Using this library rather than the C57BL/6J library was desirable as 
currently mESCs used for gene targeting are derived from BL/6N mice and to increase targeting 
efficiency the ESC and targeting construct should ideally be isogenic. A Sod1 containing 
C57BL/6N BAC, B6Ng01-068O19 (O19), was selected as described in Section 2.3.1.  
The O19 BAC was directly sequenced rather than being sequenced from amplified PCR 
sections. This was desirable for 2 reasons: first it reduced the possibility of PCR introduced 
mutations being detected, and second, it reduced the number of steps required, making the 
Table 5.6 Mismatches between L18 and N21 BACs and reference sequence (NCBIM37) 
BAC 
Chromo- 
somal 
location 
(build 
NCBIM37) Region  
Reference 
base BAC base 
Chromo- 
somal 
location 
(build 
GRCm38) 
Identified in 
GRCm38 
L18 
& 
N21 
Ch16: 
90,229,075- 
90,229,083 
Intergenic 
between 
Sod1 and 
Scaf4 
TTTTTTTTT 
(9) 
TTTTTTTT
TT (10) 
Ch16: 
90,228,831-
90,228,838 rs262788338 
L18 
Ch16: 
90,240,240- 
90,240,251 
Intron 19 
Scaf4 
AAAAAAA
AAAAA 
(12) 
AAAAAA
AAAAAA
AA (14) 
Ch16: 
90,239,996 
-90,240,006 
rs387178423 
and 
rs214928959 
are both single 
bp adenine 
insertions 
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protocol faster and without the potential need for optimising PCR amplification steps. The 
protocol was optimised for sequencing directly from BACS by increasing the annealing 
temperature thus making annealing more specific, and increasing the extensions time (see 
Section 2.1.6).  
As a reference sequence is not currently available for the C57BL/6N mouse line, it was not 
possible to tell whether any discrepancies found between the BAC and the available reference 
sequence, for C57BL/6J, were due to mutation of the BAC clone or strain differences. 
Therefore, only those regions which would be targeted for homologous recombination during 
the cloning process were sequenced. No mismatches between the C57BL/6J reference 
sequence (GRCm38) and the O19 (C57BL/6N) BAC were found.  
5.2.4 Cloning 
Unless otherwise specified, screening PCRs were carried out using the General Plasmid 
Screening PCR protocol described in Section 2.1.2.2 using plasmid DNA prepared using the Fast 
protocol described in Section 2.1.1.4, and PCR amplified recombineering vectors were purified 
for use in recombineering experiments using the QIAprep Spin Miniprep Kit (Qiagen) (Section 
2.1.1.2) and resuspended in ddH2O.  
5.2.4.1 SUBCLONING SOD1 INTO SOD1_HSUBARMS_PMS  
The first step towards making the humanising construct was to subclone the genomic human 
SOD1 sequence from the E10 BAC into the SOD1_hSUBarms_pMS plasmid (described in 
Section 2.3.3.1). The subcloning plan is summarise in Figure 5.4. The SOD1_hSUBarms_pMS 
plasmid was PCR amplified to produce a linear product to be used as a subcloning vector 
(Figure 5.4a-b). The vector includes a 151 bp, 5’ homology arm, matching the human SOD1 
sequence spanning from the ATG in exon 1 into intron 1. A 3’ homology arm, 494 bp in size 
maps to a region of SOD1 starting within intron 4 and extending to the end of the 3’ UTR of 
exon 5 (Figure 5.4b). 
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Figure 5.4 Subcloning SOD1 into SOD1_hSUBarms_pMS 
Schematic shows cloning plan. SOD1_hSUBarms_pMS (a) is PCR amplified to produce the 
SOD1_hSUBarms subcloning vector (b). The genomic SOD1 sequence is then subcloned 
from the E10 BAC (c) producing hSOD1_SC_pMS (d).  
fE= fusion exon. hE= human exon. MCS= multiple cloning site. SpcR= spectinomycin 
resistance cassette. CmR= chloramphenicol resistance cassette. 
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5.2.4.1.1 Preparation of the Subcloning Vector 
The SOD1_hSUBarms vector was PCR amplified using the touchdown PCR protocol (Section 
2.1.2.1), using SOD1_hSUBarms_pMS as the template with the primers listed in Table 5.7 to 
amplify the 5,200 bp product. The PCR product was purified using Qiagen PCR purification kit 
before digestion with DpnI (NEB). DpnI cuts at a common 4 bp motif (GA/TC) which appears 17 
times in SOD1_hSUBarms_pMS. The enzyme cuts only methylated DNA so should digest only 
the parental plasmid template leaving the PCR product intact.  
5.2.4.1.2 Recombineering and Screening 
The linear SOD1_hSUBarms PCR product was used to subclone the SOD1 sequence from the 
E10 BAC, to produce hSOD1_SC_pMS, using RedET recombineering as described in Section 
2.4.1.  
After selection on spectinomycin LB (LB-Spc) agar plates, an equal number of colonies formed 
on both the induced and un-induced plates. This suggested that plasmid template from the 
PCR was still present and able to confer resistance to spectinomycin without the need of 
recombination to circularise the plasmid.  
To test this, 1 µL of the SOD1_hSUBarms PCR product that was used in the recombineering 
experiment was transformed into electroMAX electro-competent DH10B E.coli (Invitrogen) 
and a control transformation was also carried out but with the omission of the PCR product. As 
suspected, transformation of the PCR product resulted in growth on LB-Spc plates, whereas 
control cells failed to grow. PCR screening of the clones obtained from the transformation 
experiment were carried out to further confirm the presence of the SOD1_hSUBarms_pMS 
using primers detailed in Table 5.8, SOD1_SC screening PCR D. This screening PCR amplifies a 
357 bp region spanning the multiple cloning site (MCS) of the SOD1_hSUMarms_pMS plasmid 
and, as shown in Figure 5.5, confirmed the presence of circular plasmid despite DpnI digestion 
of the PCR product.  
An alternative DpnI enzyme (Roche) was also tested, but gave the same results.  
 
Table 5.7 Primers for amplification of SOD1_hSUBarms subcloning vector 
  Sequence Product size 
SOD1_hSUB_R ACCCGCTCCTAGCAAAGG 5,200bp amplified from 
SOD1_hSUBarms_pMS  SOD1_hSUB_L GCCCAAAGTTATCTTCTTAAAATTTTTTAC 
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Table 5.8 Primer pairs for SOD1 subcloning screening PCRs 
SOD1_SC  
screen A Sequence Binding site Product size 
SOD1_mE1_FOR 
GTCGGCTTCTCGT
CTTGCTC start mE1 
314bp amplified from 5' 
side of correctly 
recombined 
hSOD1_SC_pMS 
hSOD_SC_Scr1_R CACTTGGGCACCG
CACC 
hI1 within subcloned 
BAC sequence 
SOD1_SC  
screen B Sequence Binding site Product size 
hSOD_SC_Scr1.2_F GAAGCTGTTGTCC
CAAGTTATCCTGG 
hI4 within subcloned 
BAC sequence 1,194bp amplified from 
3' side of correctly 
recombined 
hSOD1_SC_pMS 
hSOD_SC_Scr1.3_R CAGTCTCCATCAG
CTGTCATTGC 
downstream of mouse 
Sod1 within 1kb 
terminator 
SOD1_SC  
screen C Sequence Binding site Product size 
SOD1_hE1_FOR 
GAGGTCTGGCCTA
TAAAGTAGTCG hE1 5’ UTR 193bp amplified from 
human SOD1 exon1 
within the E10 BAC 
SOD1_hE1_REV 
CTTCTGCTCGAAA
TTGATGATG hE1 
SOD1_SC  
screen D Sequence Binding site Product size 
hSOD_SC_Scr1_F 
GCATCATCAATTT
CGAGCAGAAGGC 
end of hE1 in 
SOD1_hSUBarms_pMS 
357bp amplified from 
SOD1_hSUBarms_pMS 
across the MCS OR 
1,439bp amplified from 
SOD1_hSUBarms_pMS+
rpsL across the 
rpsL_Gen cassette 
hSOD_SC_Scr1.2_R CGATCCCAATTAC
ACCACAAGCC 
hE5 in 
SOD1_hSUBarms_pMS 
SOD1_SC  
screen E Sequence Binding site Product size 
SOD1_hSUBarms_L4 GCAGATATCCAGC
ACAGTGGC 
MCS of 
hSOD_SUBarms_pMS 
186bp amplified from 
SOD1_hSUBarms_pMS 
hSOD_SC_Scr1.2_R CGATCCCAATTAC
ACCACAAGCC 
hE5 in 
SOD1_hSUBarms_pMS 
 
 
Figure 5.5 PCR screen D of E.coli transformed with SOD1_hSUBarms PCR 
Screening PCR to check for the presence of SOD1_hSUBarms_pMS. PCR D amplifies a 
357bp product across the MCS in the presence of SOD1_hSUBarms_pMS PCR template.  
ntc= no template PCR control. SUBarms= SOD1_hSUBarms_pMS. HLIV= HyperLadder IV 
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5.2.4.1.3 Using Nested PCR and Gel Extraction to Reduce 
SOD1_hSUBarms_pMS Background Contamination 
As DpnI digestion did not appear to be efficiently removing the plasmid template from the 
SOD1_hSUBarms vector PCR, a nested PCR strategy was employed. This reduces the amount of 
template DNA in the final PCR product as only a very small proportion of the first step PCR 
product is used as template for the second step. Size separation by agarose gel electrophoresis 
followed by gel extraction was also carried out in order to separate the PCR product from the 
template plasmid.  
5.2.4.1.4 Preparation of the Subcloning Vector 
The nested PCR strategy is schematically depicted in Figure 5.6. The first amplification used 
new primers which bind within MCS of the SOD1_hSUBarms_pMS plasmid (depicted in blue in 
the Figure 5.6 and presented in Table 5.9) using the touchdown PCR protocol (Section 2.1.2.1). 
The primers amplify a 5,219 bp product which includes the linear vector needed for subcloning 
SOD1 from the E10 BAC (green in Figure 5.6) but with extra, unrequired sequence, which is not 
amplified in the second amplification step. The PCR product was gel purified to separate 
plasmid template from linear product (Section 2.1.1.5). Two µL of pre-gel purified and 2 µl of 
post-gel purified PCR were electrophoresed to check that the product had been successfully 
purified. The second PCR step amplifies just the 5.2 kb SOD1_hSUBarms vector using 10 ng of 
the first step PCR product as template and the original primers (Table 5.7. Shown in green in 
Figure 5.6).  
 
 
Figure 5.6 Nested PCR 
Schematic diagram showing nested PCR scheme.  
Step 1- amplification with blue primers includes extra sequence.  
Step 2- amplification with green primers amplify only required sequence 
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5.2.4.1.5 Recombineering and Screening  
SW102 recombineering (Section 2.4.2) was used to subclone SOD1 from the E10 BAC using the 
nested PCR and gel purified SOD1_hSUBarms subcloning vector.  
After selection on LB-Spc plates, a similar number of colonies grew on both the induced and 
un-induced plates. Two screening PCRs to detect the presence of the SOD1_hSUBarms_pMS 
were carried out on 26 clones: SOD1_SC screening PCR D, as above, amplifies a 357 bp product 
across the MCS of SOD1_hSUBarms_pMS. SOD1_SC screening PCR E amplifies a 186 bp 
product from SOD1_hSUBarms_pMS with primers binding within the MCS and within human 
exon 5, in the 3’ human homology arm of the plasmid. Primers are detailed in Table 5.8 
Screening PCR results, examples of which are shown in Figure 5.7, show that all colonies 
screened contained background contamination from SOD1_hSUBarms_pMS.  
 
 
Table 5.9 Primers pair for amplification step 1 of SOD1_hSUBarms nested PCR 
  Sequence 
SOD1_hSUBarms_L4 GCAGATATCCAGCACAGTGGC 
SOD1_hSUBarms_R4 GCTCGGTACCAAGCTTGGC 
 
 
Figure 5.7 Screening PCR D and E of hSOD1_SC_pMS with nested PCR strategy 
Example of screening PCR results to check for the presence of SOD1_hSUBarms_pMS after 
a recombineering experiment to subclone SOD1 from the E10 BAC into SOD1_hSUBarms 
vector, to produce hSOD1_SC_pMS, using a nested PCR strategy for vector amplification. 
PCR D amplifies a 357bp product and PCR E amplifies a 186bp product in the presence of 
SOD1_hSUBarms_pMS 
ntc= no template PCR control. E10= human SOD1 containing BAC. SUBarms= 
SOD1_hSUBarms_pMS. HLIV= HyperLadder IV 
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5.2.4.2 SUBCLONING SOD1 USING SOD1_HSUBARMS_PMS+RPSL AS VECTOR 
TEMPLATE  
In a further attempt to overcome the problem of contamination from SOD1_hSUBarms_pMS 
during recombineering experiments, a new strategy was devised and is shown in Figure 5.8. 
The rpsL_gen positive/negative selection cassette (see Section 2.3.2.2) was cloned into the 
MCS of the SOD1_hSUBarms_pMS plasmid using restriction endonuclease (RE) cloning with 
BamHI, and this modified plasmid, SOD1_hSUBarms_pMS+rpsL (Figure 5.8a) used as template 
to PCR amplify the subcloning vector. Inclusion of the rpsL_gen cassette allows selection 
against the presence of template plasmid DNA after recombineering.  
5.2.4.2.1 Cloning the rpsL_gen Cassette into SOD1_hSUBarms_pMS 
BamHI sites were first added onto the 5’ and 3’ ends of the rpsL_gen cassette by PCR 
amplification with modifying primers (Table 5.10) using the touchdown PCR protocol (Section 
2.1.2.1). These primers amplified a 1,098 bp product using rpsL_gen cassette PCR (Section 
2.3.2.2) as template. The PCR product included the rpsL_gen cassette (1,077 bp) plus BamHI 
sites (highlighted in red on the primer sequence in Table 5.10) and 5 extra additional bp 
(underlined in the primer sequence). These extra bp were added to ensure integrity of the RE 
site and because many REs require additional bases flanking the recognition site to allow 
efficient binding and cleavage.  
 
 
Table 5.10 Primer pair for amplification of rpsL_gen+BamHI 
  Sequence Product size 
rpsL-ge_BamHI_F GATTAGGATCCGAGCATGTTTCTGCGTAGTGTCAGC 
1,098bp 
rpsL-ge_BamHI_R GTTATGGATCCATCCTGTAGGTGTAGACGACGACG 
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Figure 5.8 Subcloning SOD1 into SOD1_hSUBarms_pMS+rpsL 
Schematic shows cloning plan. SOD1_hSUBarms_pMS+rpsL (a) is PCR amplified to produce 
SOD1_hSUBarms linear vector (b). The genomic SOD1 sequence is then subcloned from 
the E10 BAC into the vector (c) producing hSOD1_SC_pMS (d).  
The presence of the rpsL_gen cassette in the PCR template allows for counter selection 
against the presence of the PCR template.  
fE= fusion exon. hE= human exon. MCS= multiple cloning site. SpcR= spectinomycin 
resistance cassette. CmR= chloramphenicol resistance cassette. hSOD1= human SOD1 
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The rpsL_gen+BamHI cassette was introduced into SOD1_hSUBarms_pMS using the BamHI site 
present in the MCS as described in Section 2.1.5. One µl of the ligation product, 
SOD1_hSUBarms_pMS+rpsL, was transformed into DH10B MAXefficiency chemically 
competent E.coli (Invitrogen) which were selected on gentamicin LB (LB-Gent) agar plates. Five 
colonies were screened by multiplex PCR using the primers detailed in Table 5.11. A 357 bp 
product is amplified with primers hSOD_SC_Scr1_F and hSOD_SC_Scr1.2_R in the presence of 
the original SOD1_hSUBarms_pMS plasmid. In the presence of SOD1_hSUBarms_pMS+rpsL a 
1,445 bp product would be amplified. As the smaller PCR product would be preferentially 
amplified in the case of both modified and unmodified plasmid being present, a third primer, 
binding within the rpsL_gen cassette (rpsL-gen_IntScrn_F) was also included. Primers rpsL-
gen_IntScrn_F and hSOD_SC_Scr1.2_R amplified a 555 bp or 486 bp product from 
SOD1_hSUBarms+pMS+rpsL depending on the orientation of the insert. Screening PCR results 
(Figure 5.9) show that all 5 clones screened were positive for the modified plasmid and 
negative for the unmodified plasmid.  
Plasmid DNA prepared from SOD1_hSUBarms_pMS+rpsL clone A was used as template for PCR 
amplification of the SOD1_hSUBarms vector (primer details as above in Table 5.7).  
5.2.4.2.2 Recombineering and Screening 
Both SW102 and pRed/ET recombineering (Sections 2.4.1 and 2.4.2) were used in parallel to 
subclone SOD1 from the E10 BAC using subcloning vector amplified from 
SOD1_hSUBarms_pMS+rpsL.  
 
 
Table 5.11 Primers for SOD1_hSUBarms_pMS+rpsL screening PCR 
  Sequence Binding site Product size 
hSOD_SC_Scr1_F 
GCATCATCA
ATTTCGAGC
AGAAGGC 
The end of hE1 in 
SOD1_hSUBarms_pMS 
357bp amplified from 
SOD1_hSUBarms_pMS across 
the MCS OR 1,439bp 
amplified from 
SOD1_hSUBarms_pMS+rpsL 
across the rpsL_Gen cassette 
rpsL-gen_IntScrn_F 
CGCTTGCTG
CCTTCGACC 
Within rpsL_Gen 
cassette 
486bp or 555 bp amplified 
from 
SOD1_hSUBarms_pMS+rpsL, 
depending on orientation of 
the insert 
hSOD_SC_Scr1.2_R 
CGATCCCAA
TTACACCAC
AAGCC 
hE5 in 
SOD1_hSUBamrs_pMS   
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The recombineering experiments were plated out with both single (spectinomycin) and double 
(spectinomycin and streptomycin) selection. Spectinomycin selects for the recombined 
subclone, hSOD1_SC_pMS, and streptomycin selects against the parental template plasmid, 
SOD1_hSUBarms_pMS+rpsL.  
With single selection, 32 colonies grew on the SW102 plate and 33 on the pRed/ET plate. With 
double selection 35 colonies grew on the SW102 plate and 70 on the pRed/ET plate. On the 
un-induced plates, 1 single colony formed on the SW102 single selection plate and on the 
double selection pRed/ET plate, suggesting that background contamination from the parental 
plasmid was not present.  
Twenty-three colonies from each induced plate were picked and three PCR screens were 
carried out using the primers listed in Table 5.8 above. PCR A and PCR B amplify products of 
314 bp and 1,194 bp at the 3’ and 5’ sides, respectively, from the correctly recombined SOD1 
subclone (hSOD1_SC_pMS). PCR C amplifies a product of 193 bp, from exon 1 of the 
unmodified E10 BAC.  
Results from PCR A and B (Figure 5.10, and summarised in Table 5.12) show that most clones 
were positive for correct recombination. PCR B also amplified a non-specific product of around 
400 bp which was also amplified from SOD1_hSUBarms_pMS+rpsL. PCR C showed that the 
unmodified BAC was also present in all of the clones in which PCR amplification was successful.  
 
Figure 5.9 PCR screen of SOD1_hSUBarms_pMS+rpsL 
Screening PCR to identify clones with successful insertion of the rpsL_gen cassette into the 
MCS of SOD1_hSUBarms_pMS to produce SOD1_hSUBarms_pMS+rpsL.  
A 555 bp or 486 bp product is amplified in the presence of SOD1_hSUBarms_pMS+rpsL. A 
357 bp product is amplified in the presence of SOD1_hSUBarms+pMS 
ntc= no template PCR control. SUBarms= SOD1_hSUBarms_pMS. HLI=HyperLadder I 
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Figure 5.10 Screening PCRs for SOD1 subcloning recombineering experiment using 
SOD1_hSUBarms_pMS+rpsL as vector template 
PCR A amplifies a 314 bp product from 5’ recombination of hSOD1_SC_pMS.  
PCR B amplified a 1,194 bp product from 3’ recombination of hSOD1_SC_pMS. A non-
specific product of ~400bp is also amplified.  
PCR C amplifies a 193 bp product from exon 1 of human SOD1 in the E10 BAC 
ntc= no template PCR control. E10= E10 BAC. SUBrpsL= SOD1_hSUBarms_pMS+rpsL. HLI= 
HyperLadder I. HLIV= HyperLadder IV 
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To separate the unmodified BAC from the subclone, plasmid DNA was prepared using the rapid 
protocol (Section 2.1.1.3) from 4 clones which were positive for both 5’ and 3’ recombination, 
one for each of the experimental conditions. The plasmid DNA was transformed into SW102 
E.coli and spread onto spectinomycin and streptomycin LB (LB-Scp+Strep) agar plates.  
Retransformed clone p#ss4 (pRed/ET double selection clone 4) did not form distinct colonies, 
but grew as a smear. Ten 10 colonies each were picked from the other 3 retransformations 
(p#s2 (pRed/ET single selection clone 2), s#s1 (SW102 single selection clone 1), s#ss2 (SW102 
double selection clone 2). Colonies were re-screened using PCRs A, B and C and also the 
SOD1_hSUBarms_pMS+rpsL screening PCR, which amplifies a 486 bp product from 
SOD1_hSUBarms_pMS+rpsL or a 357 bp product from SOD1_hSUBarms_pMS (as above, Table 
5.8 Table 5.11). PCR B was carried out with an increased annealing temperature of 60°C in 
order to increase specificity of the primer binding and reduce non-specific amplification.  
Screening PCRs results are shown in Figure 5.11, and summarised in Table 5.13.  
The 2 clones, highlighted with a star in Figure 5.11, were selected for sequence confirmation.  
Table 5.12 Results of SOD1 subcloning screening PCRs A, B and C 
Table summarises the results of three screening PCRs between the four conditions of the 
subcloning recombineering experiment. PCR results in brackets e.g. “(B)”, indicate faint a 
PCR product.  
PCR A indicates correct 5’ recombination. PCR B indicates correct 3’ recombination. PCR C 
indicates presence of un-recombined E10 BAC.  
  Positive pRed/ET pRed/ET SW102 SW102 
  
PCRs Single 
selection 
Double 
selection 
Single 
selection 
Double 
selection 
5' and 3' 
recombination,  ABC 8 6 13 8 
plus E10 BAC 
contamination A(B)C   3 4 5 
E10 BAC only C 1   1   
E10 BAC and  AC 10 11 5 10 
partial  (A)C 1 3     
recombination (A)C 2       
All PCRs failed none 1       
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Figure 5.11 Screening PCRs of retransformation of SOD1 subcloning recombineering 
experiment using SOD1_hSUBarms_pMS+rpsL as vector template 
Screening PCRs of retransformation of SOD1 subcloning recombineering experiment using 
SOD1_hSUBarms_pMS+rpsL as vector template 
PCR A amplifies a 314 bp product from 5’ recombination of hSOD1_SC_pMS.  
PCR B amplified a 1,194 bp product from 3’ recombination of hSOD1_SC_pMS. A non-
specific product of ~400 bp is also amplified.  
PCR C amplifies a 193 bp product from exon 1 of human SOD1 in the E10 BAC 
PCR screen SOD1_hSUBarms_pMS+rpsL amplifies a 486 bp product in the presence of 
SOD1_hSUBarms_pMS+rpsL 
ntc= no template PCR control. E10= E10 BAC. SUBrpsL= SOD1_hSUBarms_pMS+rpsL. HLI= 
HyperLadder I. HLIV= HyperLadder IV 
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Plasmid DNA was prepared by Plasmid Maxi Kit (Qiagen) for sequencing, and sequenced 
directly from plasmid DNA as described in Section 2.1.6. One clone was found to have an 84 bp 
deletion within the spectinomycin selection cassette of the plasmid backbone. Visual 
inspection of this region revealed an 8 bp repeat (TGCGGTGG) which may have acted as a site 
for recombination, as shown in Figure 5.12. This clone was rejected because of the possibility 
of reduced spectinomycin resistance due to the deletion in the cassette. The second clone had 
no errors between the plasmid sequence and the reference sequence, other than the original 
C>T base change in intron 1 which was present in the E10 BAC.  
 
 
Table 5.13 Results of SOD1_SC screening for retransformations PCRs A, B, C and 
SOD1_hSUBarms_pMS+rpsL 
Table summarises the results of three screening PCRs on retransformed clones 
PCR A indicates correct 5’ recombination. PCR B indicates correct 3’ recombination. PCR C 
indicates presence of un-recombined E10 BAC. PCR screen SOD1_hSUBarms_pMS+rpsL 
indicates the presence of SOD1_hSUBarms_pMS+rpsL 
  
Positive 
PCRs 
pRed/ET SW102 SW102 
  
Single 
selection 
Single 
selection 
Double 
selection 
5' and 3' recombination AB 7 5 2 
5' and 3' 
recombination, plus 
E10 BAC contamination AB(C)     3 
5' recombination only A 2 5 4 
5' recombination and 
E10 BAC A(C)     1 
 
 
Figure 5.12 Deletion within the spectinomycin resistance cassette of an hSOD1_SC_pMS 
clone 
Red bar highlights deleted region. Purple bars highlight the 8bp repeat believed to be the 
site of recombination. Upper sequence is reference; lower sequence was obtained from 
sequencing.  
SpcR= spectinomycin resistance cassette. Image created in Geneious (Drummond et al., 
2010) 
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5.2.4.3 CLONING THE NEOMYCIN CASSETTE INTO HSOD1_SC_PMS  
The next step in the cloning plan was to insert the neo selection cassette, in reverse 
orientation, into hSOD1_SC_pMS at the end of the 1 kb mouse terminator, as shown in Figure 
5.13, to produce hSOD1_SC+neo_pMS.  
5.2.4.3.1 Preparation of the Targeting Vector 
The FRT flanked neo cassette (FRT-PGK-gb2-neo-FRT, Gene Bridges. Section 2.3.2.1) was 
amplified by PCR as described in Section 2.3.2.1. The PCR product was then used as template 
in a second PCR using the modifying primers in Table 5.14 to add homology arms for targeting 
of the cassette to hSOD1_SC_pMS by recombineering. The 1,701 bp product, 
FRT_Neo_SC_Targ, was amplified using the touchdown PCR protocol (Section 2.1.2.1) and 
included the cassette (1,601 bp) flanked by 50 bp homology arms on each end (highlighted in 
red on the primer sequences) targeting the cassette in reverse orientation. 
 
 
 
Figure 5.13 Insertion of neomycin resistance cassette into hSOD1_SC_pMS 
Insertion of neomycin resistance cassette into hSOD1_SC_pMS 
Schematic shows location of the insertion of the FRT flanked prokaryotic/eukaryotic 
neomycin selection cassette into hSOD1_SC_pMS, creating hSOD1_SC+neo_pMS 
fE= fusion exon. hE= human exon. SpcR= spectinomycin resistance cassette 
Table 5.14 Primers for amplification of FRT_Neo_SC_targ 
  Sequence 
Product 
size 
FRT_hSOD_Targ_F 
CATTTAGTGGCTCACGATAACTTCGTATAATGTATGCTATACGAAGTTAT
CTATAGGGCTCGAGGAAGTTC 
1,107bp 
FRT_hSOD_Targ_R 
GATTCCAAGGACAGACTTGCAGCTTGTCTTTCCAACTAAAAATACTGAG
ACGCGAAGTTCCTATTCTCTAGAAAG 
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5.2.4.3.2 Recombineering and Screening 
SW102 recombineering (Section 2.4.2) was used to insert FRT_Neo_SC_Targ into 
SOD1_SC_pMS and clones were selected on kanamycin LB (LB-Kana) agar plates. Over 200 
colonies grew on the induced plate and none grew on the un-induced plate. Multiplex PCR 
screening was carried out using the primers in Table 5.15. The PCR screen was designed to 
amplify a 223 bp product from the unmodified hSOD1_SC_pMS (primers Neo_Scrn_F and 
Neo_Scrn_R2 which flank either side of the target site) and a 337 bp product following correct 
targeting (primers Neo_Scrn_R1, which binds within the cassette and Neo_Scrn_F). All clones 
screened positive for both the modified and unmodified target plasmid (Figure 5.14).  
 
 
Table 5.15 Primers for screening PCR for hSOD1_SC+Neo_pMS 
  Sequence Binding site Product size 
Neo_Scrn_F 
GATGACTCAATGC
GGATTAACTTGG 5' of target site   
Neo_Scrn_R1 
CGCTTCCTCGTGCT
TTACGG 
Within Neo 
cassette 
337bp amplified from 
hSOD1_SC+Neo_pMS 
Neo_Scrn_R2 
GGCTTCAGCTTTCT
GGTGACC 3' of target site 
223bp amplified from 
hSOD1_SC_pMS OR 1,824 
amplified from 
hSOD1_SC+Neo_pMS 
 
 
Figure 5.14 PCR screen of hSOD1_SC+Neo_pMS recombineering experiment 
PCR screen of hSOD1_SC+Neo_pMS recombineering experiment 
A 337 bp product is amplified from hSOD1_SC+Neo_pMS; a 223 bp product is amplified 
from hSOD1+SC_pMS. 
ntc= No template PCR control. SOD1_SC= hSOD1_SC_pMS. HLIV= HyperLadder IV 
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To separate hSOD1_SC_pMS from hSOD1_SC+Neo_pMS, 4 clones were selected (highlighted in 
Figure 5.14 with a star, and labelled A-D) and DNA was prepared using the rapid protocol 
(Section 2.1.1.3). The plasmid preparations were retransformed into SW102 E.coli and spread 
onto LB-Kana agar plates. Five clones from each of the 4 retransformations (A-D) were 
screened using the same screening PCR. As can be seen in Figure 5.15, 16 of these were pure 
positives with no background hSOD1_SC_pMS contamination. DNA was prepared from 4 of the 
pure clones (highlighted in Figure 5.15 with a star) using the rapid protocol (Section 2.1.1.3). 
The inserted neo cassette, homology arms, and at least 30 bp flanking was sequenced directly 
from the plasmids (Section 2.1.6) to confirm the absence of mutations and correct targeting.  
5.2.4.4 INTRON 3 LOXP INSERTION USING OLIGONUCLEOTIDE RECOMBINEERING 
To allow the human SOD1 gene to function as a conditional mutant allele, a LoxP site was 
introduced into intron 3 of hSOD1_SC+neo_pMS to produce hSOD1_SC_N_L_pMS.  
This step used oligonucleotide recombineering, in which single stranded synthetic 
oligonucleotides (oligos) are used to mutate, insert or delete short stretches of DNA. As 
described in Section 1.3.2.2, ssDNA oligo recombineering is more efficient than 
recombineering using a dsDNA donor, particularly when the oligo is designed to act as an 
Okazaki fragment, annealing to the lagging strand of the replication fork. For this reason it is 
often possible to produce mutations in a single step, without antibiotic selection, by using 
sibling selection (see Section 2.4.5) to increase the number of clones screened.  
 
 
Figure 5.15 PCR Screen of retransformation of hSOD1_SC+Neo_pMS recombineering 
experiment 
A 337 bp product is amplified from hSOD1_SC+Neo_pMS; a 223 bp product is amplified 
from hSOD1+SC_pMS. Five colonies from each of 4 retransformed clones (A-D) were 
screened 
ntc= no template PCR control. SOD1_SC= hSOD1_SC_pMS. HLIV= HyperLadder IV 
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5.2.4.4.1 Recombineering and Screening 
The oligo, 3-4_LoxP_R (see Table 5.16) was used to target the hSOD1_SC+neo_pMS plasmid 
using SW102 recombineering (Section 2.4.2). The LoxP site is highlighted in red in the oligo 
sequence, and is flanked on either side by 40 bp homology arms.  
After recovery, a 1/10,000 dilution of the recombineering experiment was made in LB-Kana 
and 10 µl aliquots were dispensed into 200 µL LB-Kana, in a 96-well cell culture plate. To 
estimate the number of cells dispensed into each well, 50 µl each of a 1/1,000 and 1/5,000 
dilution were spread into LB-Kana agar plates. After overnight growth, 2 and 31 colonies grew 
on the 1/1,000 and 1/5,000 dilution plates, respectively, giving an estimate of 0.04-0.62 cells 
per well. This was much lower than intended; ideally this number would be close to 10, as this 
allows multiple clones to be screened at once while keeping the number low enough to allow 
clones to be separated at subsequent screening steps.  
PCR screening of sibling pools was carried out using the primers in Table 5.17. The multiplex 
screening PCR amplifies a 361 bp product in the absence of the LoxP site, by primers binding 
on either side of the target location (primers LoxP_scrn_F and LoxP_scrn_R). In the presence of 
the LoxP site, a 395 bp product is amplified across the targeting site and a second product of 
140 bp is amplified by binding of an additional forward primer (LoxP_scrn_F2) which binds 
within the inserted LoxP site.  
A PCR product was amplified from almost all of the sibling pools suggesting that more cells 
were aliquoted into each well of the cell culture plate than had been estimated according to 
the numbers which grew on the LB-Kana agar plates.  
 
 
Table 5.16 LoxP targeting oligonucleotide 
  Sequence 
3-4_LoxP_R 
TTTTCTGAAAGGCTTTCAGAAAACATACACATATAAATGGATAACTTCGTATAGCA 
TACATTATACGAAGTTATAGTCTCGACTAGTTTTCAGTATCAATTTTTTTTTTTATCT 
 
Table 5.17 Screening primers for LoxP insertion 
  Sequence Binding site Product size 
LoxP_scrn_F 
 CTTGCTGACTCATCTAAACC
CCTGC 5' of target site 
361bp amplified from 
SOD1_SC+neo_pMS 
LoxP_scrn_F2 
 CTAGTCGAGACTATAACTTC
G 
5' into targeted 
LoxP site 
395bp and 140bp 
amplified from 
hSOD1_N_L_pMS 
LoxP_scrn_R 
 CAAAGCTATGTCCCAAGGC
CTCTG 3' of target site   
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Because the wells of some of the PCR gels were uneven (Figure 5.16) and the size difference 
between products being relatively small, differentiating a 361 bp and 395 bp band might not 
have been possible. Based on the migration of the negative control PCR, which used the 
unmodified hSOD1_SC+neo_pMS as template, none of the sibling pools showed an obviously 
larger product size. The internal primer (LoxP_scrn_F2), required for amplification of the 
140 bp positive product, had a very low melting temperature (52.6°C), due to the low G/C 
content of the LoxP site and had moderate secondary structure. This was unavoidable as the 
primer needed to at least partially bind within the LoxP site in order to differentiate the 
targeted and untargeted plasmid. Due to the lack of an available positive control for the PCR, it 
was not clear whether all clones were, indeed negative, or if the PCR screen had failed to 
differentiate positive from negative clones.  
To identify whether the screening PCR was able to detect a correctly targeted clone, plasmid 
DNA was extracted from the entire remaining volume of the recombineering experiment 
(~1 mL) to use as template DNA for an optimisation of the screening PCR protocol on the 
assumption that at least some correctly recombined plasmid would be present for 
amplification. PCR screening should be able to detect correct transformants if the frequency is 
above ~1/1,000-10,000 (Capecchi, 1989).  
5.2.4.4.2 Optimisation of the LoxP Insertion Screening PCR 
A gradient PCR was set up to test a range of lower annealing temperatures, using the same 
screening primers. Plasmid DNA template was prepared from the entire remaining volume of 
the experiment using the rapid protocol (Section 2.1.1.3. Referred to as “full experiment”). A 
gradient PCR was used as described in Section 2.1.2.3. Annealing temperatures and results are 
shown in Figure 5.17. A clear 361 bp product was amplified, along with a fainter band at 
approximately ~140 bp. There is also a very faint third band of ~395 bp. With the gel run for 
longer (Figure 5.17b) the distinction between the 361 bp band and the 395 bp band is clearer, 
however, the band intensity is reduced (a section of the gel containing the strongest bands is 
shown). The optimisation showed all further screening PCRs should be carried out with a 55°C 
annealing temperature, as originally specified in the Screening PCR protocol (Section 2.1.2.2) 
with the 140 bp band being the primary amplicon for indicating correct recombination.  
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Figure 5.16 Screening PCR sibling pools of LoxP site insertion into SOD1_SC+neo_pMS 
Examples of 3 gels. In the first gel, uneven wells produced by the el comb can be seen. In 
the second and third gel, uneven running due to a crooked electrode can be seen.  
A 361bp product is amplified from hSOD1_SC+neo_pMS. When the LoxP site has been 
inserted, a 395bp and a 140bp product is amplified from hSOD1_N_L_pMS 
ntc= no template control. SC+n= hSOD1_SC+neo_pMS. HLIV= HyperLadder IV 
 
 
Figure 5.17 Optimisation of LoxP insertion screening PCR 
Amplification of products across a range of annealing temperatures is shown. Template 
used was plasmid DNA extracted from the entire remaining volume (~1 mL) of the 
recombineering experiment to insert the LoxP site into hSOD1_SC+neo_pMS to make 
hSOD1_SC_N_L_pMS  
A 361bp product is amplified from hSOD1_SC+neo_pMS. When the LoxP site has been 
inserted, a 395 bp and a 140bp product is amplified from hSOD1_N_L_pMS 
(b) shows gel (a) electrophoresed further to separate bands of 361bp and 395bp.  
HLIV= HyperLadder IV 
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5.2.4.4.3 Recombineering and Screening 
The whole experiment was repeated, but this time, dilutions of 1/1,000, 1/10,000 and 
1/50,000 were made in a 5 mL total volume LB-Kana. These dilutions were inoculated into 
96-well plates and 50 µl spread onto LB-Kana agar plates as above. Additionally, the dilutions 
themselves were also kept and cultured overnight. The number of colonies which grew on the 
LB-Kana agar plates were 17, 3 and 3 for the 1/1,000, 1/10,000 and 1/50,000 dilutions 
respectively.  
This number was much lower than expected. Recombineering experiments were started when 
the OD600 of the E.coli culture was between 0.5 and 0.6. An OD600=1 is equivalent of ~8 x 10
8 
cells/mL, therefore a 1.5 mL aliquot of OD600=0.5 should contain ~4 x 10
8 (400,000,000) E.coli. 
A 1/1,000 dilution of would yield 400,000 cells/mL, 50 µL of which should contain 20,000 cells. 
This means that less than 0.1% of the cells were surviving the recombineering experiment.  
The 5 mL dilution cultures were screened and, as shown in Figure 5.18, all appeared to be 
negative for recombination. Another gradient PCR was set up to screen the 1/1,000 dilution 
and the remaining full concentration recombineering experiment. Results, shown is Figure 
5.19, show that at least some correctly targeted clones were produced during the experiment, 
but at a frequency too low to detect within the sibling pools.  
 
 
 
Figure 5.18 PCR screen of 5 mL cultures of second LoxP insertion recombineering 
experiment 
Five mL cultures made from the second LoxP insertion recombineering experiment at 3 
dilutions: 1/1k, 1/10k and 1/50k, were screened for the presence of hSOD1_SC_N_L_pMS.  
A 337bp product is amplified from hSOD1_SC+Neo_pMS; a 223bp product is amplified 
from hSOD1+SC_pMS. Five colonies from each of 4 retransformed clones (A-D) were 
screened 
ntc= no template PCR control. SC+n= hSOD1_SC+neo_pMS. HLIV= HyperLadder IV 
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5.2.4.4.4 Recombineering and Screening: Is the Oligo Toxic?  
To check whether the oligo recombineering was having a toxic effect on the E.coli, beyond any 
effects of induction of the recombineering proteins and electroporation, the experiment was 
repeated again, this time including a “no-oligo” control in which the cells were treated 
identically except that no oligo was added before electroporation. The E10 BAC was also used 
as an additional target for the oligo, as a recombineering positive control. The BAC is at a lower 
copy number than the hSOD1_SC+neo_pMS plasmid within the E.coli and so if correct 
targeting occurs, it should be easier to identify as the signal to noise ratio would be reduced. 
 
Figure 5.19 Screening PCR of 1/1k dilution and full concentration of second LoxP 
insertion recombineering experiment 
Amplification of products across a range of annealing temperatures is shown. Template 
used was a 5 mL overnight culture at a 1/1k dilution (first row) and the entire remaining 
volume (~1 mL) of the recombineering experiment (second row).  
A 361bp product is amplified from hSOD1_SC+neo_pMS. When the LoxP site has been 
inserted, a 395bp and a 140bp product is amplified from hSOD1_N_L_pMS 
ntc= no template PCR control. SC+n= hSOD1_SC+neo_pMS. Full expt=DNA extracted 
from the entire remaining volume (1 mL) of this recombineering experiment. First full 
expt= plasmid DNA extracted from the entire remaining volume (1 mL) of the first LoxP 
insertion experiment. HLIV= HyperLadder IV 
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As a further check, two 5 mL cultures at a 1/50 dilution were prepared using LB-Kana and LB 
with no antibiotics, to see if the oligo recombineering was effecting the ability of the E.coli to 
survive antibiotic selection and if its removal would increase detection of correct 
recombinants.  
The number of colonies that grew on each plate is given in Table 5.18. Nearly 20 times more 
cells survived the experiment when the oligo was omitted, suggesting that it had some toxic 
effect on the E.coli above the effect of the recombineering experiment itself.  
Screening PCRs of DNA prepared from the full 5 mL volume of the liquid cultures, shown in 
Figure 5.20 , failed to reveal any correctly targeted clones, including in those in which 
antibiotic selection was omitted. PCR screening of the remaining full concentration 
experiments, shown in Figure 5.21 suggest that some correctly targeted clones were present. 
It appears that although recombination is occurring, the efficiency is too low for recovery in a 
non-selected experiment. An alternative targeting strategy using 2-step positive/negative 
selection cassette targeting followed by replacement with the LoxP site will be required to 
isolate correctly recombined clones.  
 
 
Table 5.18 Growth profiles 
Target Oligo? 
Dilution 
factor 
Number 
of 
colonies 
Surviving cells 
per ul (full 
concentration) 
Average 
surviving 
cells 
hSOD1_SC+neo_pMS y 1/1,000 114 2,280 2,626.67 
hSOD1_SC+neo_pMS y 1/10,000 18 3,600   
hSOD1_SC+neo_pMS y 1/50,000 2 2,000   
hSOD1_SC+neo_pMS n 1/1,000 1,334 26,680 52,026.67 
hSOD1_SC+neo_pMS n 1/10,000 347 69,400   
hSOD1_SC+neo_pMS n 1/50,000 60 60,000   
E10 y 1/1,000 480 9,600 28,666.67 
E10 y 1/10,000 252 50,400   
E10 y 1/50,000 26 26,000   
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Figure 5.20 PCR screen of 5 mL cultures of the third LoxP insertion recombineering 
experiment 
PCR screen of 5 mL cultures of the third LoxP insertion recombineering experiment 
5 mL cultures at varying dilution factors, as shown, of the recombineering experiment to 
insert a LoxP site into hSOD1_SC+neo_pMS (SC+n) and the E10 BAC (E10) were screened. 
1/50 dilutions were cultured overnight with (+) or without (-) kanamycin selection to see 
whether removing selection pressure increased the chance of seeing correct 
recombinants.  
A 361bp product is amplified from hSOD1_SC+neo_pMS. When the LoxP site has been 
inserted, a 395bp and a 140bp product is amplified from hSOD1_N_L_pMS 
ntc= no template PCR control. First full expt= plasmid DNA extracted from the entire 
remaining volume (1 mL) of the first LoxP insertion experiment. SC+n= 
hSOD1_SC+neo_pMS. E10= E10 BAC.HLI= HyperLadder I 
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5.3 GENE BRIDGES CONSTRUCT COMPLETION 
Due to increasing time constraints it was decided that the remainder of the cloning of the 
targeting construct would be outsourced to Gene Bridges. The custom made plasmid, 
SOD1_Exon4-5_pMA (see Section 2.3.3.2), along with hSOD1_SC+neo_pMS and the O19 
mouse BAC were sent to Gene Bridges. The remaining steps to complete the construct, as 
carried out by Gene Bridges, are briefly described below and presented in Figure 5.22.  
First, the LoxP site was introduced into intron 3 of hSOD1_SC+neo_pMS to produce 
hSOD1_SC_N_L_pMS (Figure 5.22a), using a 2-step strategy, as described above.  
Next, the engineered insert from hSOD1_SC_N_L_pMS was subcloned into the O19 BAC, to 
produce O19_hSOD1_pBAC_Cm. This was done by linearlisation of the hSOD1_SC_N_L_pMS 
insert by digestion with NaeI (Figure 5.22b). The linearised product was then used as the donor 
vector to insert the sequence into the O19 mouse BAC with kanamycin selection (Figure 5.22c).  
In our original cloning plan, the next step was adding the ALS mutations, creating 2 separate 
mutant humanised BACs, to which the repeat exon cassettes would be added subsequently. 
This was in order to avoid subsequent recombineering steps once the repeat cassette was in 
place, as the ~3 kb repeat that this would introduce would be liable to recombine during 
subsequent steps.  
 
Figure 5.21 PCR screen of ~1 mL full concentration of the third LoxP insertion 
recombineering experiment 
The remaining ~1 mL of the recombineering experiments to add insert a LoxP site into 
both the E10 BAC and hSOD1_SC_N_pMS (SC+n) were screened for the presence of the 
correctly recombined hSOD1_SC_N_L_pMS.  
A 361bp product is amplified from hSOD1_SC+neo_pMS. When the LoxP site has been 
inserted, a 395bp and a 140bp product is amplified from hSOD1_N_L_pMS 
ntc= no template PCR control. First full expt= plasmid DNA extracted from the entire 
remaining volume (1 mL) of the first LoxP insertion experiment. SC+n= 
hSOD1_SC+neo_pMS. E10= E10 BAC.HLI= HyperLadder I 
240 
 
 
 
241 
 
 
 
Figure 5.22 Remaining steps for construction of the humanising SOD1 targeting construct 
(a) Insertion of LoxP site into intron 3 
(b) Linearised hSOD1_SC_N_L_pMS, producing donor vector for insertion into O19 
C57BL/6N BAC 
(c) SOD1 humanised O19 C57BL/6N BAC 
(d) Introduction of mutation into exons 4 or 5 (location indicated by yellow star) 
(e) Linearised WT repeat exon cassette with 200bp homology arms for targeting  
(f) Insertion of the WT repeat cassette into the humanised SOD1 mouse BAC.  
(g) Close up view of the engineered sequence of the targeting construct.  
fE= fusion exon. hE= human exon. SpcR= spectinomycin resistance cassette. CmR= 
chloramphenicol resistance cassette. 
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According to the information supplied to us by Gene Bridges, they first inserted the repeat 
cassette (Figure 5.22d-e). This would have been done using a 2 step process, inserting a 
positive/negative selection cassette and then replacing it with the SOD1_Exon4-5 targeting 
vector, PCR amplified from the SOD1_Exon4-5_pMA plasmid. After this, the mutations would 
be targeted using oligo recombineering, resulting in the final targeting constructs Figure 5.22f 
E100G _O19_hSOD1_+repEx_BAC_Cm and L126delTT_O19_hSOD1_+repEx_BAC_Cm.  
5.4 FUTURE WORK  
5.4.1 Confirmation of Gene Bridges Finalised Construct 
Gene Bridges supplied the finished constructs to us and PCR screening was carried out by Dr 
Anny Devoy. PCR screening revealed that the humanised BAC clones appeared to be a mixed 
population, containing BACs both with and without the repeat exon cassette. This suggests 
that the construct is unstable and possibly liable to unwanted recombination events between 
the initial and repeat exon regions.  
In our original plan, the mutations were to be introduced into O19_hSOD1_pBAC_Cm before 
carrying out 2 independent recombineering experiments to insert the repeat cassette into the 
2 mutant humanised mouse BACs. The repeat cassette has 88% homology to the floxed exon 
4-5 region of humanised mouse BACs, with 200 bp homology arms targeting it downstream of 
the FRT flanked neo cassette. This high level of off-target homology would likely result in a low 
efficiency of correct targeting of the repeat cassette, however it was deemed desirable due to 
the very high homology between the initial floxed exon 4-5 cassette, and repeat exon 4-5 
cassette, differing by only 1 bp across a ~3 kb region. This high level of homology is likely to 
result in decreased stability of this region and a high chance of recombination events between 
the 2 regions. Once the repeat cassette has been inserted, it is therefore desirable to move the 
construct into a more stable E.coli host with reduced recombinase activities as repeat 
associated deletions can occur when propagating BAC clones in E.coli even without the 
induced expression of recombinases during recombineering experiments (Song et al., 2001; 
Westenberg et al., 2010). It is therefore highly undesirable to carry out further recombineering 
experiments once the repeat cassette has been inserted into the humanised BAC.  
Further work is needed to obtain pure clonal populations from the material provided by Gene 
Bridges for further screening. The first step for this will be preparing BAC DNA and 
retransforming it into an E.coli line which has been modified to reduce recombination events 
to provide a more stable host for propagating unstable plasmid DNAs. Transformation should 
be done using a low concentration of DNA to increase the chance of obtaining single copy 
transformation and include kanamycin as well as chloramphenicol selection as deletions due to 
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recombination between the initial floxed and repeat exon 4-5 cassette may cause deletion of 
the neo cassette.  
Although the final construct was confirmed by sequencing by Gene Bridges, once clonal 
populations of the humanised BAC have been achieved, re-sequencing will be required 
particularly for regions which are as risk of recombination. For example, the initial floxed and 
repeat exon 5-4 regions will need to be screened and re-sequences to confirm that the WT and 
mutant exons have not undergone recombination, potentially swapping or replacing the 
WT/mutant alleles. Similarly, the region around the LoxP site of the initial intron 3 and the 
repeat intron 3, and the end of both the initial and repeat 1 kb terminator region are at risk of 
sequence swapping due to unwanted recombination events.  
5.4.2 Using the Targeting Construct to Derive Humanised SOD1 
Mice  
As is described in Section 1.3.2.2, gene targeting will be achieved by electroporation of the 
linearised targeting construct into C57BL/6N mESCs followed by selection with neomycin to 
identify those cells which have incorporated the construct into their genome (in either in a 
targeted fashion or by random integration).  
After neomycin selection qPCR will be used to quantify the copy number of the humanised 
SOD1 and endogenous Sod1 alleles. Two autosomal genes (Tfrc and Tert copy number control 
assays, Life Technologies) will be used as standards for gene copy number quantification (each 
should be present at 2 copies). Correctly targeted ESCs should have 1 copy each of the 
endogenous and humanised SOD1 sequence, and if the conditional cassette has inserted 
correctly, the humanised allele should have an extra copy of the 3’ region contained within the 
repeat cassette. Other genes both upstream and downstream of the targeting site will also be 
quantified to ensure they remain present in two copies only, as it has previously been reported 
that extensions of the targeting construct can take place within the targeted genomic region 
followed by ectopic insertion (Mangerich et al., 2009).  
Once correctly targeted mESCs have been confirmed, the mESCs will be used in blastocyst 
injection followed by embryo implantation and coat colour selection. High coat colour pups 
will then be used for breeding and their offspring genotyped by PCR specific to the human 
SOD1 sequence to identify germ-line transmission of the humanised allele. Once germ line 
transmission has been achieved, offspring can be mated to an appropriate C57BL/6 transgenic 
line with ubiquitous FLP expression in order to excise the FRT flanked neo cassette. Screening 
of offspring can be carried out using the screening PCR described in Section 5.2.4.3. Once the 
cassette is excised, breeding can be carried out by either backcrossing to the parental 
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C57BL/6N strain, or heterozygotes could be inter-crossed to produce homozygous humanised 
SOD1 mice. Alternatively, the conditional/inducible allele can be utilised by crossing to an 
appropriate Cre transgenic mouse line.  
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Chapter 6. Discussion  
The work described in this Thesis has focussed on the roles of different types of SOD1 – WT, 
mutant, human (huSOD1) and mouse (moSOD1) – in SOD1-fALS mouse models. In particular, I 
have examined whether mutant or WT huSOD1 can be induced to aggregate via prion-like 
mechanisms in vivo and have found some limited evidence that this may occur, although 
further work is needed to confirm, or otherwise, this result. Next I looked at whether 
endogenous moSOD1 affects the degenerative phenotype of G93A mutant SOD1 transgenic 
mouse. These data suggest that endogenous WT moSOD1 has an exacerbating effect on the 
disease phenotype in the earlier stages of degeneration, but that the difference is lost as 
degeneration progresses. Finally I have carried out molecular cloning towards the production 
of a targeting construct for use in the genomic humanisation of the endogenous mouse Sod1 
locus. The construct has been designed as a conditional allele with a Cre-dependent switch 
from mutant to WT huSOD1 expression, and will provide a tool suitable for further dissection 
of the interaction between WT and mutant SOD1, and huSOD1 and moSOD1.  
6.1 MISFOLDING OF SOD1 WITHIN THE PRION PARADIGM  
The concept of a prion-like spread of pathogenically misfolded protein within 
neurodegenerative disease is gaining increasing interest. Seeded aggregation and spread of 
pathology from the initial site of inoculation with recombinant aggregated proteins has been 
demonstrated in vivo in transgenic mice expressing proteins associated with 
neurodegenerative diseases, such as tau, Aβ, and α-synuclein (e.g. (Iba et al., 2013; Masuda-
Suzukake et al., 2013; Stöhr et al., 2012) see also Table 1.6). This work, along with experiments 
in vitro and in cell models demonstrating seeded-aggregation and cell-to-cell aggregate spread, 
and experiments in vivo using transgenic mouse models which are inoculated with “seeds” 
derived from patient or mouse model CNS tissue, strongly suggest that a prion-like spread of 
pathologically misfolded proteins may be at play in several neurodegenerative disease. The 
idea of prion-like spread is particularly compelling in ALS due to the stereotypical pattern of 
symptomatic spread often reported, whereby onset is focal and spreads through contiguous 
regions of the body along the axis of spinal cord innervation (Fujimura-Kiyono et al., 2011).  
In the case of SOD1, it has been established that huSOD1 forms aggregates in vitro and that 
the process of aggregation can be hastened by both self-seeding and cross-seeding with pre-
formed aggregates or with spinal cord homogenates from SOD1-fALS transgenic mice (Chia et 
al., 2010). Other experiments have also established that misfolded SOD1 is transferred 
between cultured cells and can act as a seed for misfolding and aggregation in naïve cells 
(Munch et al., 2011). Cross-culture experiments have also provided evidence that cell-to-cell 
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transmission may be involved in non-cell autonomous mechanisms of SOD1 toxicity, for 
example astrocytes of SOD1-fALS or sALS patients, or SOD1-fALS mice, are toxic to naïve MNs 
in co-culture, however SOD1 knock-down attenuates this toxicity, hinting that prion-like 
mechanisms may be at play here too (Haidet-Phillips et al., 2011; Kunze et al., 2013). Unlike 
several other neurodegenerative hallmark proteins however, an in vivo role for transmission of 
misfolded/aggregated protein has not previously been reported for SOD1.  
Here we found no evidence that self-seeded-aggregation occurs in vivo in our experiments 
inoculating G93A mutant SOD1 transgenic mice with tissue homogenates derived from the 
same mouse line at a later, symptomatic age. There was no difference in the area of misfolded 
SOD1 pathology in any brain region between mice inoculated with SC homogenates from G93A 
mutant SOD1 mice, or those inoculated with homogenates prepared from Sod1 null mouse SC.  
The preliminary results of our cross-seeding experiment, in which mice expressing WT huSOD1 
were inoculated with material containing mutant SOD1 species, have not provided conclusive 
evidence of a difference in misfolded SOD1 pathology between inocula groups. The area of 
misfolded SOD1 staining in the ventral roots only is larger in those mice inoculated with spinal 
cord homogenates derived from G93A mutant transgenic mouse as compared to Sod1 null 
mouse, however, because the data set is incomplete at this time, a firm conclusion cannot yet 
be drawn.  
6.1.1 SEDI/USOD Outcome Measures 
Our outcome measure for experiments examining prion-like properties of SOD1 and the 
potential for transmission of pathogenically misfolded species in vivo, was the extent of 
misfolded SOD1 burden measured histopathologically by conformation specific antibodies. The 
first antibody that we used, SEDI, has previously been reported to detect a progressive 
increase in histopathological staining, and later a decrease presumed to be due to loss of MNs, 
in the G93A SOD1-fALS mouse as degeneration proceeds (Rakhit et al., 2007). The USOD 
antibody has also been used to identify misfolded SOD1 pathology in a G93A SOD1-fALS mouse 
(Kerman et al., 2010). Although no time-course of pathology has been described so far with 
the USOD antibody, it was reported that similar structures were stained when the 2 antibodies 
were used on sequential sections of the same tissue samples (Kerman et al., 2010), and so one 
could infer that a similar pattern of staining may also occur through the course of 
degeneration. It should be noted, however, that the epitopes that the 2 antibodies detect are 
distinct (see Figure 3.1); SEDI recognises amino acids 143-153 and is expected to be exposed in 
natively folded but monomeric SOD1 (Rakhit et al., 2007). USOD, on the other hand, was raised 
against amino acids 42-48 and is expected to require unfolding of the monomer to expose the 
epitope (Kerman et al., 2010). We have not yet validated that we can use these antibodies to 
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differentiate stages of degeneration in SOD1 transgenic mice. This work needs to be 
completed before we can be confident in our interpretation of our results.  
There are several alternative misfolded SOD1 antibodies which have been used to show 
changes in the level of misfolded SOD1 pathology over time, or in response to pharmacological 
treatment or genetic manipulation; a DSE2 antibody (disease specific epitope 2) detected 
reduced levels of misfolded SOD1 in 3 mutant SOD1-fALS mice (G37R, G85R and G93A) when 
crossed to a CypD KO line (Parone et al., 2013) and a progressive increase in motor neuronal 
and non-neuronal misfolded SOD1 in the spinal cords of SOD1-fALS transgenic rats as 
degeneration proceeded (Israelson et al., 2010). Three other antibodies, D3H5, B8H10 and 
A5C3, which recognise epitopes in exons 2, 3 and 4, respectively, were also used by Parone et 
al., (2013) and revealed similar patterns of a reduction in misfolded SOD1 pathology in G37R 
mutant SOD1 transgenic mice when crossed to a CypD (Cyclophilin D) KO. This same panel of 3 
antibodies was also used by Gros-Louis et al., (2010) revealing a pattern of developing 
pathology in a G93A mutant SOD1 transgenic mice; immunofluorescence revealed an initially 
diffuse staining of MNs in the ventral horns that became more concentrated with time and 
eventually condensed into a punctate inclusion like pattern by 130-days of age. In WT SOD1 
transgenic mice, on the other hand, an almost complete absence of staining was apparent, at 
least at 80-days of age. These antibodies represent potential alternatives for measuring 
differences in misfolded SOD1 pathology as they have been previously shown to differentiate 
different stages of degeneration in at least 2 different transgenic mouse lines. They also 
appear to have low reactivity to the spinal cords of WT SOD1 transgenic mice, although the 
specific WT transgenic line is not defined by Gros-Louis et al., (2010) so it is not possible to tell 
whether the expression level is comparable to the line used in the work described in this 
Thesis.  
While both SEDI and USOD have been reported as histopathologically negative in cases of sALS 
and non-SOD1-fALS (Liu et al., 2009; Kerman et al., 2010) some other misfolded SOD1 
antibodies have produced positive results in such cases; Pokrishevsky et al., (2012) found that 
the 10E11C11 antibody stained both the cytoplasm and axons of MNs in the cervical spinal 
cord of SOD1-fALS patients, and also the axons of some sALS and non-SOD1-fALS patients, but 
not in non-ALS control tissue. The C4F6 antibody is reported as staining MN of the ventral horn 
in 4 out of 9 sALS cases examined by Bosco et al., (2010) while no non-ALS control tissues were 
positive. Later, however, Brotherton et al., (2012) found that while the C4F6 antibody detected 
skein-like inclusions in the MNs of SOD1-fALS cases, in sALS and non-SOD1-fALS only a diffuse 
reactivity was present in MNs, which was also present in the majority of both neurological and 
non-neurological controls. This range of misfolded SOD1 antibodies represent potential 
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alternative neuropathological tools for detecting changes in the levels of misfolded SOD1 as a 
result of transmission of misfolded SOD1 species. As different misfolded SOD1 antibodies may 
detect different forms of SOD1 and it is not clear which of these are pathogenic (Prudencio et 
al., 2011) it may be appropriate to also test our tissue sample with a range of such antibodies, 
in particularly those which have been described as reactive to non-SOD1-fALS and sALS tissues 
which may contain pathogenically misfolded WT SOD1 species.  
6.1.2 SOD1 Aggregation and Pathogenicity  
Although the aggregation of WT SOD1 has been implicated in disease pathogenesis by 
experiments crossing WT and mutant SOD1 transgenic mice (Deng et al., 2006; Prudencio et 
al., 2010; Wang et al., 2009b; Jaarsma et al., 2000; Fukada et al., 2001; Jaarsma et al., 2008), a 
direct correlation between aggregation and disease is not consistently reported and it is 
becoming increasingly recognised that a non-aggregated misfolded protein species is more 
likely responsible for disease pathogenesis; in WT:mutant double transgenic huSOD1 mice, 
aggregation of WT huSOD1 can occur with no effect on disease phenotype (Prudencio et al., 
2010), while the disease phenotype can be exacerbated by the expression of WT huSOD1 
without it becoming aggregated (Witan et al., 2009). A lack of correlation between aggregation 
of mutant huSOD1 and toxicity was also reported when a L126Z mutant SOD1 transgenic 
mouse line was crossed to 2 different WT SOD1 transgenics; one cross resulted in increased 
mutant aggregation with no change to the disease phenotype while the other produced a 
more aggressive disease phenotype with no increase in mutant aggregation (Prudencio et al., 
2010).  
A distinction between mutant SOD1 aggregation and disease have also been described as 
resulting from other genetic crosses. In one such example, genetic ablation of CypD in several 
SOD1-fALS mouse lines caused a reduction of SOD1 aggregation and improved other ALS 
related features such as gliosis, mitochondrial function and morphology and even MN death, 
however, axonal degeneration, onset and survival were left unchanged (Parone et al., 2013). In 
another example crossing a mutant SOD1 transgenic to a CCS transgenic reduced the SOD1 
aggregate burden while actually exacerbating the disease phenotype (Son et al., 2007). These 
studies strongly suggest that aggregation of SOD1 is a secondary effect of disease which may 
not be necessary for the initiation of muscle denervation or behavioural disease. Indeed it has 
been suggested that aggregation load may be related to disease duration rather than disease 
onset (Prudencio et al., 2009b).  
Furthermore, we also show here, as has previously been reported (Rakhit et al., 2007), that WT 
SOD1 transgenic mice have SEDI inclusion pathology in the spinal cord, particularly focused in 
the ventral horns and roots, despite having no overt motor phenotype at similar ages (Chiu et 
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al., 1995; Dal Canto et al., 1995; Tu et al., 1996; Jaarsma et al., 2000). Interestingly, a 
disconnect between aggregate pathology and disease phenotypes has also been described in 
infectious prion disease (Sandberg et al., 2011). Infectious prion diseases have been described 
as the prototypical protein misfolding disease due to the tight causal link between misfolded 
PrP and disease state (Goold et al., 2013). That such a differentiation between aggregate 
pathology and disease can be made in prion disease lends further weight to the notion that a 
non-aggregated, but misfolded form of SOD1 may be the primary cause of disease, while 
aggregates may be a secondary consequence of misfolding and also possibly responsible for 
secondary effects for example by causing deficits in proteostasis (Bence et al., 2001).  
As previously discussed in Section 1.5.4, pre-aggregate species have been implicated as the 
toxic species using a number of different in vitro and in vivo models. If a pre-aggregate 
misfolded species is responsible for disease, an alternative outcome measure to misfolded 
aggregate pathology, could be to investigate whether pre-aggregate soluble misfolded SOD1 
species are transmissible via prion-like template misfolding. Although SEDI has been reported 
as reactive to soluble SOD1 species, the assessment was qualitative and based on 
immunofluorescence intensity in transfected cells in culture (Prudencio et al., 2011). We have 
used SEDI to analyse animals with a high baseline level of immunoreactivity and our analysis 
was more suited to detecting changes in the area of inclusion type pathology, rather than 
diffuse staining or changes in intensity of misfolded SOD1 staining. The USOD antibody detects 
histopathological structures which are similar to those detected with SEDI (Kerman et al., 
2010), although whether this would include both soluble and insoluble misfolded SOD1 has not 
been determined.  
An alternative to histopathology for the detection of pre-aggregate misfolded SOD1 species 
would have been using biochemical methods, such as differential detergent extraction. 
Suitable samples were not collected during our experiments and so it has not been possible for 
us to carry out such analysis. These techniques have been used by other groups to quantify the 
levels of soluble, insoluble and aggregated SOD1 to differentiate mouse lines or stages of 
degeneration (e.g. (Karch et al., 2009; Prudencio et al., 2010; Wang et al., 2009b; Witan et al., 
2009)). Such techniques can be used to differentiate and quantify multiple different species of 
SOD1 from the same sample based on their biochemical/biophysical behaviour. Unlike 
histopathology with misfolded SOD1 antibodies, they are not necessarily limited to the 
exposure of a particular epitope. However, just as with misfolded SOD1 antibody detection, it 
is not known which specific fraction or form of SOD1 is causal of disease (Koyama et al., 2006). 
Similarly, it would therefore not be possible to draw conclusions about potential pathogenic 
consequences of perturbations of a particular fraction measured using such techniques.  
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6.1.3 Alternative Outcome Measures  
At present it is not clear which species of misfolded SOD1 is responsible for the pathogenic 
effects of mutant/misfolded SOD1. The mouse models that we have used have high baseline 
levels of total SOD1 and appreciable levels of misfolded SOD1 even without a potential further 
induction of misfolding by prion-like mechanisms, which may confound our ability to 
differentiate variation in misfolded SOD1 staining.  
Rather than directly assaying misfolded forms of SOD1, an alternative could be to look at other 
histopathological markers of disease progression as evidence for toxicity resulting from 
misfolded SOD1 transmission caused by inoculation with pathogenic SOD1 inoculation. 
Histopathological markers of gliosis (Jaarsma et al., 2000; McGeer et al., 2002), ubiquitin and 
p62 (Mackenzie et al., 2007; Gal et al., 2007), or caspase activation (Pasinelli et al., 2000) are 
all potential markers of disease progression in SOD1-fALS mice with relevance to patient ALS 
pathology. Although this methodology would not provide a direct measurement of prion-like 
transmission of SOD1 misfolding, if the phenomenon does occur and is relevant to disease, 
then it may provide a measure of its effect, which is accessible to us using the tissues we have 
available.  
6.1.4 Wild-type SOD1 Toxicity Outside the Prion Paradigm  
Our data do not provide strong support for the hypothesis that misfolding of SOD1 can be 
induced by prion-like mechanisms and spread through the CNS by cell-to-cell transmission. 
Previous evidence however, in particular that from double transgenic mice with both WT and 
mutant SOD1 transgenes, strongly indicates that WT SOD1 can contribute to the disease 
process, at least in SOD1-fALS mouse models (Deng et al., 2006; Prudencio et al., 2010; Wang 
et al., 2009b; Jaarsma et al., 2000; Jaarsma et al., 2008). If prion-like misfolding is not the cause 
of the synergistic relationship between WT and mutant SOD1, what alternative mechanisms 
could be responsible?  
In double transgenic WT:mutant huSOD1 mice, cellular protein homeostasis may be 
antagonised purely due to the increase protein expression resulting from double, as compared 
to single, transgenic mice and this could have a detrimental effect on disease progression 
(Bence et al., 2001). However, the fact that double transgenic mice expressing mutant 
moSOD1 and WT huSOD1 do not display the disease exacerbation commonly reported in 
huSOD1 WT:mutant double transgenics (Audet et al., 2010) argues against this being a major 
cause of toxicity.  
WT huSOD1 can become misfolded in vivo as a result of non-prion-like mechanisms, for 
example as a result of a lack or loss of structural metal ions or by oxidisation (Ezzi et al., 2007; 
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Redler et al., 2011; Proctor et al., 2011; Rakhit et al., 2004; Lindberg et al., 2004; Urushitani et 
al., 2006; Estévez et al., 1999). Such forms of misfolded WT SOD1 have been detected in 
tissues and cultured cells derived from both SOD1-fALS and some sALS patients, and moreover, 
they share some toxic properties with mutant SOD1 (e.g. (Bosco et al., 2010; Guareschi et al., 
2012)). As discussed in Section 1.5.3.1, although many SOD1 mutants retain full or partial 
dismutase activity, markers of increased oxidative stress are reported in both patient tissue 
and in SOD1-fALS mouse models, and SOD1 itself is highly oxidised in SOD1-fALS mice (Andrus 
et al., 1998). The misfolding of WT huSOD1, and the potentially toxic consequences of this, in 
double WT:mutant SOD1 transgenic mice could therefore be the result of the highly oxidative 
environment caused by mutant huSOD1 expression.  
Another way in which WT SOD1 has been proposed to exacerbate the toxicity of mutant SOD1 
is via stabilisation of the mutant protein. Rather than increasing the level of aggregated SOD1, 
co-expression of both WT and mutant SOD1 has been shown to reduce aggregation relative to 
expression of mutant SOD1 alone in cellular models (Witan et al., 2008; Witan et al., 2009; 
Prudencio et al., 2009a; Prudencio et al., 2010; Brotherton et al., 2013). Compared to mutant 
homodimers, WT:mutant heterodimers not only have a lower propensity to aggregate but also 
higher cellular toxicity, while heterodimerisation appears to increase the stability of the 
mutant monomer, protecting it from degradation and/or aggregation (Witan et al., 2008; 
Witan et al., 2009; Weichert et al., 2014). However, heterodimerisation does not appear to be 
essential for stabilisation of pre-aggregate species; the L126Z SOD1 mutant is a truncation 
mutant incapable of dimerising which is highly labile with a short half-life in vivo and when 
expressed in a cell model it is primarily found in the insoluble fraction due to degradation of 
the soluble protein. When co-expressed with WT SOD1 its levels are reduced to below 
detectable levels in both soluble and insoluble fractions (Prudencio et al., 2010). Because of 
the short half-life of this mutant protein, this is likely explained by a shift from an insoluble to a 
soluble state, but that the soluble population is degraded too quickly to be measured. The fact 
that this reduction in aggregated protein occurs without heterodimerisation or an increase in 
the soluble levels suggests that the process may be better characterised as blocking the 
aggregation pathway rather than stabilising a pre-aggregate form.  
WT SOD1 may exert toxicity due to a combination of these mechanisms; by heightening the 
toxicity of mutant SOD1 by increasing the availability of the toxic species, possibly through 
stabilisation and/or blocking its sequestration into aggregates; by becoming toxic itself via 
post-translational modification and misfolding, thereby taking on characteristic of mutant 
misfolded SOD1. From the data presented in this Thesis, it does not appear that seeded-
aggregation of huSOD1 plays a significant role in the formation of misfolded SOD1 aggregate 
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pathology in TgG93A mice. Further analysis is needed for strong conclusions to be drawn in the 
case of TgWT mice. Future analysis is also planned to examine whether markers of neuronal 
degeneration are selectively increased in those mice inoculated with pathogenic mutant 
species to investigate potential functional consequences of templated misfolding.  
6.2 HUMAN:MOUSE SOD1 INTERACTION IN SOD1-FALS MICE 
From the data presented in this Thesis the endogenous moSOD1 appears to have an 
exacerbating effect on the early degenerative process of the G93A mutant SOD1 transgenic 
mouse. At a later stage this difference is lost. In TgG93A;Sod1ko mice, grip-strength and total 
number of NMJs are significantly higher than in TgG93A;Sod1wt mice at around 75-days of age 
and there is a non-significant trend suggesting increased preservation of the most vulnerable, 
fast firing, motor units innervating the hind limb muscles.  
The effect of WT moSOD1 appears to be similar in quality to the effect of WT huSOD1 in that 
both have a negative impact on the degenerative process in the TgG93A mouse. Endogenous 
moSOD1 has previously been reported as having little or no effect on SOD1-fALS mouse 
models (Deng et al., 2006; Bruijn et al., 1998), although the small effect reported by Deng et 
al., (2006), is in agreement with the data presented here, in that the disease phenotype of a 
low copy G93A mutant SOD1 transgenic mice was less severe on a Sod1 null background. If the 
interaction between WT huSOD1 or moSOD1 and mutant huSOD1 are the same, or of a similar 
nature, then the effect size might be expected to be smaller here as compared to in double 
WT:mutant transgenic mice; although the ratio of transgenic to endogenous SOD1 is not 
known for either of the papers which have previously examined the effect of endogenous 
moSOD1 on SOD1-fALS transgenic mice, in the mouse line used in this Thesis the level of 
transgenic huSOD1 is several times higher than that of the endogenous (Chiu et al., 1995). In 
double transgenic mice in which an exacerbation of the phenotype is seen, the amount of WT 
huSOD1 tends to be at least equal, if not substantially higher than the mutant huSOD1 
transgene expression (e.g. (Shibata et al., 1996b; Wang et al., 2009b; Jaarsma et al., 2000)) and 
the effect of WT huSOD1 in double transgenic mice appears to be dose dependent with higher 
levels of expression resulting in more profound exacerbation of the phenotype (Prudencio et 
al., 2010). It would therefore follow that the effect of endogenous WT moSOD1 would be 
smaller than that of transgenically expressed WT huSOD1. This would make it more difficult to 
detect, particularly with small sample sizes and high intra-group variability.  
In addition to a simple dose effect, evidence suggests that there are differences between 
huSOD1 and moSOD1 limiting their interaction which could also impact the effect of 
endogenous moSOD1 in SOD1-fALS mouse models. Unlike transgenically expressed WT 
huSOD1, the endogenous WT moSOD1 is usually reported as absent from transgenic mutant 
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huSOD1 aggregates (Deng et al., 2006; Jonsson et al., 2004; Bruijn et al., 1998), although there 
is at least one case in which co-aggregation is reported and the lack of detected co-aggregation 
could be at least partially due to the relatively smaller amount of moSOD1 as compared to 
huSOD1 (Wang et al., 2002a). It is unlikely that the discrepancy in co-aggregation of WT 
huSOD1 or moSOD1 with mutant huSOD1 is due to a baseline difference in the propensity to 
form aggregates as cellular assay suggests that both WT huSOD1 and moSOD1 have similarly 
high resistance to aggregation (Karch et al., 2010).  
The most obvious example of a functional consequence of the differences in the interactions 
of huSOD1 and moSOD1 was seen when a transgenic mouse expressing a G86R mutant 
moSOD1 was crossed to a WT SOD1 transgenic line. Unlike crosses between mutant and WT 
SOD1 transgenic mice where both transgenes are human, in which the disease tends to be 
exacerbated, co-expression of WT huSOD1 with G86R moSOD1 had no effect on the motor 
phenotype or survival of the G86R mouse line and co-aggregation of WT huSOD1 and mutant 
moSOD1 was not detected (Audet et al., 2010). This suggests that the disease exacerbating 
interaction between WT huSOD1 and mutant huSOD1 does not occur between WT huSOD1 
and mutant moSOD1. However the data presented in this Thesis suggest a functional genetic 
interaction between WT moSOD1 and mutant huSOD1 does occur. Although behavioural 
phenotyping was carried out by Audet et al., (2010) the ages at which measures were taken 
are not described. It is therefore possible that early differences did occur, but that measures 
were taken at later ages when differences were no longer apparent. It should also be noted 
that in some cases of WT:mutant huSOD1 double transgenic mice, no disease exacerbation is 
reported, possibly due to differences in expression levels of WT SOD1 transgenes (Bruijn et al., 
1998; Prudencio et al., 2010). 
A potential explanation for the apparent difference between the interaction of WT 
huSOD1:mutant moSOD1 and WT moSOD1:mutant huSOD1, described here and by Audet et 
al., (2010), could lie in the differential effect of mutation on huSOD1 and moSOD1. Although 
the WT proteins are similarly aggregate resistant, in the context of ALS mutation mutant 
huSOD1 has been reported as more aggregation prone than the corresponding mouse mutant 
(Karch et al., 2010).  
Cellular assays of co-aggregation have revealed that when huSOD1 mutants are expressed in 
either human or mouse cell lines, WT endogenous huSOD1, but not endogenous moSOD1, co-
aggregates with the human mutant protein. When the 32nd tryptophan (W32) residue of 
mutant huSOD1 was itself substituted for the mouse equivalent, serine, and expressed in 
human cells, a significant reduction in the co-aggregation of the endogenous huSOD1 resulted. 
This suggests that this residue is important for limiting co-aggregation between mutant and 
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WT huSOD1 (Grad et al., 2011). The effect of the W32S substitution on the co-aggregation of 
mutant huSOD1 and WT moSOD1 was not examined. It is possible that the W32 residue is 
necessary for the mutant protein to elicit co-aggregation of WT SOD1 generally, and could be 
linked to the increased aggregation propensity of mutant huSOD1 as compared to mutant 
moSOD1 described by Karch and Borchelt (2010). This would mean that WT moSOD1 would 
not have co-aggregated with the W32S substituted mutant huSOD1. Another explanation 
could be that this residue is important for limiting the interaction of human and mouse SOD1, 
and that the W32S substitution could increase the ability of mutant huSOD1 to recruit WT 
moSOD1 to co-aggregate. In other work using transfection driven expression of both WT and 
mutant SOD1, WT huSOD1, but not WT moSOD1, was found to co-aggregate with mutant 
huSOD1 (Prudencio et al., 2009a), while WT moSOD1, but not WT huSOD1, co-aggregates with 
mutant moSOD1 (Qualls et al., 2013). Together this suggests that the tryptophan/serine at 
residue 32 is important for limiting the co-aggregation of human and mouse SOD1 rather than 
causing a difference in the ability of the mutant protein to elicit co-aggregation more 
generally.  
These assays specifically examine co-aggregation and, as discussed above, it is not clear that 
aggregation per se is primarily responsible for causing disease. I have presented evidence for a 
toxic interaction between transgenic mutant SOD1 and the endogenous WT Sod1. This 
suggests that this interaction is not dependent on co-aggregation of these two proteins. There 
are several other possibilities; the interaction could be a physical interaction between the two 
proteins, but one that does not result in co-aggregation, such as a prion-like template 
misfolding interaction. A second possibility is an indirect interaction between the proteins. For 
example, the increased oxidative environment reported in SOD1-fALS mouse tissues (e.g. 
(Andrus et al., 1998; Liu et al., 1999)) may lead to the oxidisation of WT moSOD1, which could 
potentially cause misfolding and toxicity as has been reported to result from the oxidisation of 
WT huSOD1 (Bosco et al., 2010; Guareschi et al., 2012). A third possibility is that the 
interaction is genetic. As we have seen, transgenically expressed human SOD1 can rescue 
some, but not all phenotypes of Sod1 null mice (see Section 4.4.2), suggesting that an 
interaction between genetic phenotypes could occur. This is considered a less likely 
explanation as the Sod1 null phenotypes tend to be detrimental to neuronal health, rather 
than protective, as described in Section 1.4.2. If the interaction between mutant huSOD1 and 
WT moSOD1 involves the augmentation of the aggregation of the transgenically expressed 
G93A huSOD1, it may be possible to detect this by histological methods on our samples 
collected from 75 day old animals, either using pan-SOD1 of misfolded SOD1 antibodies. A 
biochemical technique to evaluate differentially fractions may be a more suitable technique as 
255 
it could allow the examination of a wider array of species, however, at this time, suitable 
samples are not available.  
6.3 MECHANISMS OF WT SOD1 PATHOGENICITY 
WT SOD1 appears to have 3 main potential modes of toxicity in SOD1-fALS; the most obvious, 
is the aggregation of WT SOD1, often co-aggregated with mutant SOD1 (e.g. (Bruijn et al., 
1998; Jaarsma et al., 2000; Fukada et al., 2001; Deng et al., 2006; Jaarsma et al., 2008; Wang et 
al., 2009b; Prudencio et al., 2010)). Although it is still not clear whether protein aggregates are 
a primary cause of disease, they are likely responsible for secondary cellular toxicity, thereby 
exacerbating the disease process (Pasinelli et al., 2004; Ligon et al., 2005; Zhang et al., 2007; 
Bergemalm et al., 2010; Sau et al., 2011; Weisberg et al., 2012; Mulligan et al., 2013). The 
evidence presented in this Thesis suggests that in transgenic mouse models the prion-like 
process of seeded-aggregation is not likely to be a primary cause of aggregation of either 
mutant or WT transgenically expressed huSOD1. Prion-like seeded aggregation is also unlikely 
to be involved in the effect of the endogenous moSOD1 on mutant huSOD1 in SOD1-fALS mice, 
as evidence from other groups described above suggests that human and mouse SOD1 do not 
easily co-aggregate.  
The second route by which WT SOD1 may exert toxicity is to become misfolded itself, thereby 
taking on properties which mimic the toxic mutant species (Bosco et al., 2010; 
Sundaramoorthy et al., 2013; Pasinelli et al., 2004; Guareschi et al., 2012). Misfolding of WT 
SOD1 could be caused by prion-like templated misfolding as has been demonstrated in vitro 
and in cellular models (Chia et al., 2010; Hwang et al., 2010; Grad et al., 2011; Grad et al., 
2014). Our current method may not be able to assess whether the level of pre-aggregated 
soluble misfolded SOD1 species is affected by intracerebral inoculation with mutant SOD1 
species and thus whether prion-like templated misfolded is at play. Behavioural assessment 
was not carried out and so we cannot determine whether the disease phenotype of TgG93A 
mice was affected, or whether any disease phenotype was elicited in TgWT mice by our 
inoculation protocol. However, from analysis of the premature deaths occurring in our TgWT 
mice in our longest time-point group, it does not appear that inoculation with mutant SOD1 
species had any specific effect on survival, as survival times of animals inoculated with such 
material did not differ from control inoculated mice. Rather than being due to prion-like 
mechanisms, the misfolding of WT huSOD1, as is reported in double transgenic mouse models 
and in some ALS cases, could be caused by other factors, such as oxidisation or demetalation, 
which can destabilise this typically highly stable protein (e.g. (Estévez et al., 1999; Urushitani et 
al., 2006; Lindberg et al., 2004; Rakhit et al., 2004; Ezzi et al., 2007; Rumfeldt et al., 2009; 
Proctor et al., 2011; Redler et al., 2011)).  
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The third mechanism by which WT SOD1 may exert toxicity is by augmenting the 
aggregation/misfolding of mutant SOD1. The reduced or slowed aggregation of mutant 
huSOD1 that results from co-expression with WT SOD1 (human or mouse) could lead to 
increased toxicity by maintaining the levels of a toxic pre-aggregate species, blocking its 
sequestration into aggregates (Brotherton et al., 2012; Prudencio et al., 2009a; Prudencio et 
al., 2010; Witan et al., 2008; Witan et al., 2009). This mode of toxicity is not dependent on a 
prion-like mechanism. It is not clear at this time whether misfolded WT moSOD1 is capable of 
taking on toxic conformers and contributing directly to the disease process of SOD1-fALS mice. 
Until there is a consensus as to the identity of the ALS pathogenic SOD1 species (singular or 
plural) or epitope, answering this question will be challenging. In cellular models the 
aggregation of mutant huSOD1 is augmented by both WT huSOD1 and WT moSOD1 
(Brotherton et al., 2012; Prudencio et al., 2009a; Prudencio et al., 2010); whether this 
augmentation is relevant to the ALS like disease seen in SOD1-fALS mouse models is also not 
yet clear. Further investigation of the time course of aggregation in such models will be 
required to answer this question.  
6.4 THE SOD1 HUMANISED MOUSE  
I have presented the initial stages of the production of a new type of mouse model of SOD1-
fALS in which the endogenous Sod1 locus will be genomically humanised with a conditional 
switch of expression from ALS mutant huSOD1 to WT huSOD1. By genomically humanising the 
endogenous Sod1 locus, physiological levels of protein expression should be achieved under 
the control of the endogenous cis and trans acting transcriptional regulators. By developing 
such a model, using targeted genomic humanisation rather than the more traditional 
insertional transgenic techniques, we aim to produce a model of the disease process and 
mechanisms which more closely mimic that seen in humans with SOD1-fALS. For example, by 
removing the very common feature of over-expression of the transgenic SOD1, a more 
accurate picture of the role of protein homeostasis systems, such as the ER and UPR, should be 
presented.  
One major risk of producing a mouse model of SOD1-fALS with only endogenous expression 
levels is that expression may not be high enough to produce an overt disease phenotype 
within the lifespan of a mouse; the disease phenotype of SOD1-fALS mice is known to be 
tightly correlated to the expression level of the transgene. Of note on this matter, an ENU 
induced mutation in the endogenous Sod1 locus, equivalent to a mutation seen in SOD1-fALS 
cases, has been reported as displaying some features in common with transgenic SOD1-fALS 
mice (McGoldrick et al., 2012). However, even if no overt motor phenotype does occur, this 
may still be a useful model by allowing a more detailed examination of the very early stages of 
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disease and the interactions of SOD1. As degeneration progresses, more secondary and 
tertiary processes and pathways become activated as a response to the primary degeneration. 
Opening the window on the earliest stages of degeneration may facilitate the identification of 
the root causes of disease, something which has remained elusive despite 20 years of research 
on transgenic SOD1-fALS mouse models.  
By crossing the humanised SOD1 mouse to a suitable Cre expressing line, more questions can 
be explored using the conditional mutant-WT switch; for example, by using an inducible Cre 
expresser, this model could be used to further investigate whether prion-like mechanisms are 
involved in the pathogenesis of SOD1-fALS; switching from expression of mutant huSOD1 to 
WT huSOD1 either before the initial signs of, or at time-points during, degeneration would 
allow investigation of whether continued expression of mutant huSOD1 is necessary for the 
disease progression. Such investigation could have important implications for potential 
therapeutic interventions which aim to reduce the level of mutant SOD1 expression using 
technologies such as antisense oligonucleotides or RNA interference (e.g. (Miller et al., 2005; 
Raoul et al., 2005; Smith et al., 2006; Miller et al., 2013)).  
6.5 CONCLUSIONS  
In this Thesis preliminary evidence is presented suggesting that prion-like seeded aggregation 
does not play a role in the aggregate pathology of transgenic SOD1 mice, although further 
analysis is required to confirm these results. A high copy G93A mutant SOD1 transgenic line 
was used in the first set of experiments to investigate whether SOD1 displays the prion-like 
property of self-seeded aggregation in vivo. This mouse line may not have been ideal as the 
disease progression is aggressive, leaving only a limited time window between inoculation and 
harvesting of tissues. This also means that is has a high baseline level of aggregate pathology 
which may hamper the detection of potentially subtle changes in pathology. In the second set 
of experiments we investigated cross-seeded aggregation in WT SOD1 transgenic mice. 
Although a significant difference in misfolded SOD1 aggregate pathology was detected for one 
of the spinal cord regions analysed, because of a low sample size of analysed animals in the 
control group, we cannot draw any strong conclusions based on this result until the remaining 
cases have been processed and analysed. Alternative outcome measures could still provide 
evidence for prion-like mechanisms in vivo in SOD1 pathogenicity. For example 
histopathological markers of degeneration could act as a surrogate, indicating changes in the 
levels of the pathogenic form of SOD1.  
I also present evidence that the endogenous moSOD1 plays an augmenting role in the disease 
phenotype of the G93A mutant SOD1 transgenic mouse at an early stage of the degenerative 
process. A functional advantage is found in mice null for the endogenous Sod1 allele at 75-days 
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of age. I also present data that at the same age, compared to TgG93A;Sod1wt mice, 
TgG93A;Sod1ko mice have more neuromuscular junctions in hind limb muscles and a non-
significant trend towards better maintenance of innervation by the most vulnerable, fast-firing 
MNs. It is well established, from double transgenic mice, that WT huSOD1 interacts with 
mutant huSOD1 to exacerbate the disease phenotype, however previous examination of 
whether WT endogenous moSOD1 effects the phenotype produced by mutant huSOD1 have 
not been fully conclusive (Bruijn et al., 1998; Fukada et al., 2001; Jaarsma et al., 2000; Deng et 
al., 2006; Jaarsma et al., 2008; Wang et al., 2009b; Prudencio et al., 2010). Here I provide 
evidence that the degenerative process in the TgG93A mouse is indeed affected by the 
endogenous WT moSOD1 however, just as is the case with WT and mutant huSOD1, further 
research will be required to delineate the mechanism of this interaction.  
Finally I have presented the construction of a targeting vector for the production of a new type 
of mouse model of SOD1-fALS; a genomically humanised SOD1 mouse with a conditional 
switch from mutant expression to WT. Further work is needed to ready the construct for 
genome targeting in mESCs but it is hoped that the resultant mouse model will be a valuable 
new tool to help elucidate the early and primary disease processes relevant to the instigation 
of disease in SOD1-fALS.  
As has been discussed, it is becoming increasingly apparent that WT SOD1 is involved in SOD1-
fALS and also possibly non SOD1-fALS and sALS. Here I have tried to answer some questions 
related to this phenomenon, such as whether prion-like seeded aggregation may be involved 
in the development of WT SOD1 aggregation, and whether an interaction between WT and 
mutant SOD1 might be augmenting the phenotype of the most commonly used SOD1-fALS 
mouse model. I have also presented preliminary work in developing a new type of SOD1-fALS 
mouse model that has been designed to allow further exploration of this topic and to act as a 
new and complementary model of this disease. Ultimately, it is our hope that by improving our 
understanding of this ALS and improving on our ability to accurately model it, we will help 
towards the development of effective treatments for this devastating disease, something that 
despite decades of research has so far eluded us.  
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Chapter 7. Appendices 
7.1 APPENDIX 1 - FULL TABLE OF MUTANT SOD1 TRANSGENIC MICE 
Rows are arranged by the location of the mutation used. Lines used in the work presented in 
this Thesis are highlighted in yellow. Lines which failed to develop disease are highlighted in 
pink.  
All figures are for hemizygous mice unless specified. Protein expression and dismutase activity 
were assayed from spinal cord, unless specified.  
(*1)- Protein expression is expressed as fold increase relative to endogenous Sod1 level 
(*2) SOD1 activity is expressed as fold difference compared to NTg 
 
Tg= Transgene; Hom= homozygous; nr= not reported; nq= measured but not quantified; ($)= 
symptoms and survival shown for homozygotes; (#)= introduces a stop codon at position 133; 
¥=- promoter region 483 bp 3' of exon 1; ¤=- EcoRI-BamHI human gDNA fragment is 11.58 kb 
and included SOD1 gene plus 0.5 kb 5' & 1.8 kb 3'. 
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Mutation Promoter Tg fragment 
Tg 
copy Protein (*1) 
Activity 
(*2)  
Symptom 
onset 
(weeks) 
Survival 
(weeks) notes MGI Symbol Ref 
WT 
Human 
SOD1 (¥) gDNA E-B (¤) 7 
50 
(reported as 
24 fold in 
39) 8.6 36 (hom) 52 (hom)   
Tg(SOD1) 
2Gur (N1029) 
1, 
2, 
38 
A4V 
Human 
SOD1 (¥) gDNA E-B (¤) ~5 nr ~1.4 none     
Tg(SOD1* 
A4V) 
A1073Gur 2 
G37R (line 
106) 
Human 
SOD1 (¥) gDNA E-B (¤) nr 
4.2/5.3 
(brain/spina
l cord) 7.2 22-30 25–29   
Tg(SOD1* 
G37R) 
106Dpr 3 
G37R (line 
29 
Human 
SOD1 (¥) gDNA E-B (¤) nr 
4.0/5.0 
(brain/spina
l cord) 7 24-32     
Tg(SOD1* 
G37R)29Dpr 3 
G37R (line 
42) 
Human 
SOD1 (¥) gDNA E-B (¤) nr 
8.0/10.5 
(brain/spina
l cord) 14.5 14-16     
Tg(SOD1* 
G37R)42Dpr 3 
G37R (line 
9) 
Human 
SOD1 (¥) gDNA E-B (¤) nr 
5.4/6.2 
(brain/spina
l cord) 9 20-24     
Tg(SOD1* 
G37R)9Dpr 3 
G37R 
Neuro-
ﬁlament 
light chain 
promoter cDNA   
4.3 (line 
3156) and 
2.8 (line 
4012) nr 
none (up to 
1.5 years) 
none (up 
to 1.5 
years) 
Neuron specific expression. Two 
lines reported   4 
G37R (see 
notes) 
Mouse 
prion 
promoter  cDNA nr nq nq 28-36 (hom) 
onset 
+1-3 
weeks 
Co-integration of SOD1 transgene 
with construct encoding wild-type 
human presenilin 1 (hPS1)with PrP 
promoter) 
Tg(Prnp-
SOD1*G37R,-
PSEN1) 
110Dbo 5 
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Mutation Promoter Tg fragment 
Tg 
copy Protein (*1) 
Activity 
(*2)  
Symptom 
onset 
(weeks) 
Survival 
(weeks) notes MGI Symbol Ref 
G37R 
(floxed) 
nr (human 
SOD1?) 
gDNA 
unspecified 
fragment nr nq nr 26-30 37-48   
Tg(SOD1* 
G37R)1Dwc 6 
G37R and 
G93A (see 
notes) 
Chicken 
skeletal 
muscle αsk 
actin cDNA 1-8     32-40   
Two mutants (G37R and G93A, 
plus the WT) created, results do 
not specify which mutant. Muscle-
specific expression. 
Neuromuscular phenotype seen in 
both WT and mutant (G37R and 
G93A) mice. Mutants had reduced 
NMJ innervation and axonal 
degeneration and 50% MN loss by 
1-year   7 
H46R 
Human 
SOD1 (¥) gDNA E-B (¤) nr nr nr 22-26 
onset +4 
weeks     8 
H46R 
Human 
SOD1 (¥) gDNA E-B (¤) nr nr nr 20 24   
Tg(SOD1* 
H46R)#Maw 9 
H46R/ 
H48Q (line 
139) 
Human 
SOD1 (¥) gDNA E-B (¤) nr nq 1 nr 17-26   
Tg(SOD1* 
H46R*H48Q)
139Dbo 10 
H46R/ 
H48Q (line 
58) 
Human 
SOD1 (¥) gDNA E-B (¤) nr nq nr nr 12-14   
Tg(SOD1* 
H46R*H48Q)
58Dbo 
10, 
11 
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Mutation Promoter Tg fragment 
Tg 
copy Protein (*1) 
Activity 
(*2)  
Symptom 
onset 
(weeks) 
Survival 
(weeks) notes MGI Symbol Ref 
H46R/ 
H48Q/ 
H63G/ 
H120G 
(line 121) 
Human 
SOD1 (¥) gDNA E-B (¤) nr nq nr nr 
over 69 
weeks 
H46R/H48Q ALS mutations with 
H63G/H120G experimental 
mutations to disrupt copper 
binding   11 
H46R/ 
H48Q/ 
H63G/ 
H120G 
(line 125) 
Human 
SOD1 (¥) gDNA E-B (¤) nr nq 1 nr 39-52 
H46R/H48Q ALS mutations with 
H63G/H120G experimental 
mutations to disrupt copper 
binding 
Tg(SOD1*) 
125Dbo 11 
H46R/ 
H48Q/ 
H63G/ 
H120G 
(line 187) 
Human 
SOD1 (¥) gDNA E-B (¤) nr nq nr nr 35-48 
H46R/H48Q ALS mutations with 
H63G/H120G experimental 
mutations to disrupt copper 
binding   11 
E77X 
(stop) 
Human 
SOD1 (¥) gDNA E-B (¤) nq 
nr (RNA 
"barely 
detected") nr none normal 
Experimental (rather than ALS) 
mutation to examine whether 
truncated proteins are capable of 
causing disease   12 
L84V 
Human 
SOD1 (¥) gDNA E-B (¤) nr nr nr 22-26 26     
13, 
14 
G85R (line 
148) 
Human 
SOD1 (¥) gDNA E-B (¤) nr 1 1 33 35   
Tg(SOD1* 
G85R)148Dw
c 15 
G85R (line 
74) 
Human 
SOD1 (¥) gDNA E-B (¤) nr 0.2 nr 51-61 
onset +2 
weeks   
Tg(SOD1* 
G85R)74Dwc 15 
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Mutation Promoter Tg fragment 
Tg 
copy Protein (*1) 
Activity 
(*2)  
Symptom 
onset 
(weeks) 
Survival 
(weeks) notes MGI Symbol Ref 
G85R Thy1.2  cDNA   nq nq 
none (up to 
87)   
Bicistronic expression of SOD1 and 
EGFP in postnatal motor neurons   16 
G85R 
(floxed) nr 
A G85R 
genomic 
clone nr 1.5 1 44 50 LoxP flanked transgene 
Tg(SOD1* 
G85R)#Roos 17 
G85R (YFP 
fusion) 
(line 641) 
nr (but 
presumed 
to be 
Human 
SOD1 (¥)) gDNA E-B (¤)   nr nr 39 (hom)       18 
G86R 
(mouse) 
nr (mouse 
Sod1?) 
gDNA mouse 
SalI fragment 
(see notes) nr nr 1 13-17 13-17 
Reported as a SalI fragment of 
mouse gDNA, but SalI cuts within 
intron 3 
Tg(Sod1* 
G86R)M1Jwg 
19, 
4 
G86R 
(mouse) 
(line 2) 
Mouse 
GFAP 
cDNA from 
mouse brain nq nq   
none (up to 
70)   Astrocyte specific expression   20 
G86R 
(mouse) 
(line 29) 
Mouse 
GFAP 
cDNA from 
mouse brain 10 nq   
none (up to 
70)   Astrocyte specific expression   20 
D90A (line 
134) 
nr (but 
presumed 
to be 
Human 
SOD1 (¥)) gDNA E-B (¤) nr nr ~6-9  50 (hom) 58 (hom)     21 
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Mutation Promoter Tg fragment 
Tg 
copy Protein (*1) 
Activity 
(*2)  
Symptom 
onset 
(weeks) 
Survival 
(weeks) notes MGI Symbol Ref 
K91X 
(stop) 
Human 
SOD1 (¥) gDNA E-B (¤) nq 
nr (RNA 
"barely 
detected") nr none normal 
Experimental (rather than ALS) 
mutation to examine whether 
truncated proteins are capable of 
causing disease   12 
G93A (line 
G1) 
Human 
SOD1 (¥) gDNA E-B (¤) 18 nr ~4 12-16 20   
Tg(SOD1* 
G93A)2Gur 
(G1) 2 
G93A (line 
G20) 
Human 
SOD1 (¥) gDNA E-B (¤) 1.7 nr ~1.6 nr 49   
Tg(SOD1* 
G93A)G20Gu
r 
2, 
22 
G93A (line 
G1H) 
Human 
SOD1 (¥) gDNA E-B (¤) 25 
17 
(described 
as equal to 
the N1029 
line in 24) 
>4 
(reporte
d as 8.9 
in 26) 13 19.4 
High transgene copy number 
derived from G1 line 
Tg(SOD1* 
G93A)1Gur 
(subline of 
G1 with 
expansion) 
23, 
24 
G93A (line 
G1del) 
Human 
SOD1 (¥) gDNA E-B (¤) 8 nr nr 28 36 
Low transgene copy number 
derived from G1 line 
Tg(SOD1* 
G93A)dl1Gur 
25, 
26 
G93A 
Rat 
myosin 
light chain 
(MLC1) cDNA nr nq nq 
muscle 
atrophy 
from 4 
weeks nr 
Muscle specific expression, 
especially fast fibres 
Tg(Myl1-
SOD1*G93A)
#Amu 27 
G93A 
(T1xT3 see 
notes) Thy1.2 cDNA nr     77-104 84-104 
Compound hemizygote T1 and T3 
transgene. Postnatal motor 
neurons specific expression   28 
G93A (line 
T1) Thy1.2 cDNA nr     none normal 
Postnatal motor neurons specific 
expression 
Tg(Thy1-
SOD1*G93A)
T1Hgrd  28 
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Mutation Promoter Tg fragment 
Tg 
copy Protein (*1) 
Activity 
(*2)  
Symptom 
onset 
(weeks) 
Survival 
(weeks) notes MGI Symbol Ref 
G93A (line 
T3) Thy1.2 cDNA nr nq   
none (54-
104 for 
hom) 
62-104 
(hom) 
Postnatal motor neurons specific 
expression 
Tg(Thy1-
SOD1*G93A)
T3Hgrd  28 
G93A 
(with 
luciferase 
reporter) 
BiTetO 
(see 
notes) cDNA       none 
over 64 
weeks 
Conditional Cre expression in 
some subgroups of embryonic 
motor neurons and interneurons 
from transgene with Lhx3 
promoter. Cre expression allows 
transgenic expression of a 
tetracycline-repressible 
transactivator gene which 
activates transcription from a 
BiTetO (bicistronic tetracycline-
repressible transactivator) 
promoter expressing a SOD1-G93A 
and luciferase transgene. WT line 
also made 
Tg(tetO-
SOD1*G93A,-
luc)1Roos 29 
G93A MLC1f/3f cDNA       See notes   
Skeletal muscle specific 
expression, especially in fast 
fibres. Increasing muscle atrophy 
from 4 weeks. Decreased force by 
4 months. Lipid peroxidation and 
microglial activation in spinal cord. 
No MN loss or change in fibre 
composition of muscles   27 
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Mutation Promoter Tg fragment 
Tg 
copy Protein (*1) 
Activity 
(*2)  
Symptom 
onset 
(weeks) 
Survival 
(weeks) notes MGI Symbol Ref 
G93A 
TRE (See 
notes) cDNA       none   
Bidirectional 
tetracycline/doxycycline response 
(TRE) transgene, controlling 
expression of SOD1-G93A and 
EGFP with unexpected translation 
restricted to olfactory bulb   30 
I113T nr nr nr nr nr 52 nr     
31, 
32 
T116X 
(stop) 
Human 
SOD1 (¥) 
Minigene (see 
notes) nr nr nr 
survival 
minus 2 
weeks 
(hom) 43 (hom) 
EcoRI-BamHI gDNA fragment of 
SOD1 locus with engineered fusion 
exon 4-5.  
Experimental (rather than ALS) 
mutation to examine whether 
truncated proteins are capable of 
causing disease   12 
L126delTT 
(see 
notes) nr 
gDNA (11 kb 
fragment) nr nr nr 
none (ALS 
specific 
unto 52 
weeks)   
Mouse created to model ALS but 
resultant phenotype was due to 
insertional disruption of the Ssdp1 
(single stranded DNA binding 
protein 1) locus in homozygous 
transgenics 
Ssbp3Tg(SOD
1)1Hssk 33 
L126delTT 
(#) (line 
D1) 
Human 
SOD1 (¥) gDNA E-B (¤) 1 nr nr none       34 
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Mutation Promoter Tg fragment 
Tg 
copy Protein (*1) 
Activity 
(*2)  
Symptom 
onset 
(weeks) 
Survival 
(weeks) notes MGI Symbol Ref 
L126delTT 
(#) (line 
D2) 
Human 
SOD1 (¥) gDNA E-B (¤) 5 
“below 
western 
detection 
threshold” 1 
63 (34 for 
hom) 
68 (36 
for hom)     34 
L126delTT
-FLAG (#) 
(line DF2) 
Human 
SOD1 (¥) gDNA E-B (¤) 3 nr nr none   FLAG tagged SOD1   34 
L126delTT
-FLAG (#) 
(line DF7) 
Human 
SOD1 (¥) gDNA E-B (¤) 4 nq 1 
49 (17 for 
hom) 
53 (18 
for hom) FLAG tagged SOD1   34 
L126Z 
(stop) 
Human 
SOD1 (¥) 
Minigene (see 
notes) nr 0–0.5 nr 30-39 nq 
EcoRI-BamHI gDNA fragment of 
SOD1 locus with engineered fusion 
exon 3, 4 and 5    35 
L126Z 
(stop) 
nr (but 
presumed 
to be (¥)) gDNA E-B (¤) nr 0–1 nr 48 51   
Tg(SOD1*L12
6Z)#Deng 36 
SOD1G127
insTGGG 
(line 716) 
nr (but 
presumed 
to be 
Human 
SOD1 (¥)) gDNA E-B (¤) 19 0.45–0.97 1 
onset minus 
7-10 (hom) 
64 (36 
for hom)   
Tg(SOD1*G1
27X)716Mrkl 37 
SOD1G127
insTGGG 
(line 832) 
nr (but 
presumed 
to be (¥)) gDNA E-B (¤) 28 nr nr nr 
30 (18 
for hom)   
Tg(SOD1*G1
27X)832Mrkl 37 
1- (Graffmo et al., 2012); 2- (Gurney et al., 1994); 3- (Wong et al., 1995); 4- (Pramatarova et al., 2001); 5- (Wang et al., 2005b); 6- (Boillée et al., 2006); 7- (Wong et 
al., 2010); 8- (Nagai et al., 2000); 9- (Chang-Hong et al., 2005); 10- (Wang et al., 2002b); 11- (Wang et al., 2003); 12- (Deng et al., 2008); 13- (Kato et al., 2001a); 14- 
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(Tobisawa et al., 2003); 15- (Bruijn et al., 1997); 16- (Lino et al., 2002); 17- (Wang et al., 2009b); 18- (Wang et al., 2009a); 19- (Ripps et al., 1995); 20- (Gong et al., 
2000); 21- (Jonsson et al., 2006a); 22- (Dal Canto et al., 1995); 23- (Chiu et al., 1995); 24- (Tu et al., 1996); 25- (Zhang et al., 1997); 26- (Gurney, 1997); 27- 
(Dobrowolny et al., 2008); 28- (Jaarsma et al., 2008); 29- (Wang et al., 2008); 30- (Bao-Cutrona et al., 2009); 31- (Ryoichi et al., 2001); 32- (Kikugawa et al., 2000); 
33- (Nishioka et al., 2005); 34- (Watanabe et al., 2005); 35- (Wang et al., 2005a); 36- (Deng et al., 2006); 37- (Jonsson et al., 2004); 38- (Jaarsma et al., 2000); 39- 
(Jonsson et al., 2006b)
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7.2 APPENDIX 2 - DETAILED MATERIALS AND EQUIPMENT 
7.2.1 Molecular Biology 
7.2.1.1 REAGENTS 
Betaine solution 5 M, PCR Reagent Sigma B0300  
BetterBase Microzone 3BBR-5 
BetterBuffer Microzone  3BB-5 
Buffer P1 Qiagen 
19051 NB: RNase A added as per 
manufacturer’s instructions 
Buffer P2  Qiagen 19052 
Buffer P3 Qiagen 19053 
Crystal 5x DNA Loading Buffer Blue Bioline 
 DPBS 1X Dulbecco’s Phosphate Buffered 
Saline (Minus CaCl2 and MgCl2)  Gibco 14190 
EB  Qiagen 
 Ethidium bromide 500µg/ml in H2O Sigma Aldrich E1385-5ML 
Extraction Solution Sigma  E7526 
HyperLadder I Bioline BIO-33025 
HyperLadder IV Bioline BIO-33029 
MicroCLEAN  Microzone 
Neutralisation Solution B  Sigma  N3910 
PBS (phosphate buffered saline) solution 
10x DNase RNase and protease free 
Fisher 
BioReagents 10214733 
RNase A Qiagen 19101 
TaqMan Universal PCR Master Mix with 
passive internal reference, and AmpErase 
UNG Applied Biosystems 
Tissue Preparation Solution Sigma  T3073 
Tris-EDTA buffer solution pH 8.0 Sigma 93283 FLUKA 
UltraPure™ Agarose Invitrogen 
Quick & Easy BAC Modification Kit Gene Bridges     K001 
7.2.1.2 KITS 
QIAEX II Gel Extraction Kit Qiagen 20021 
QIAGEN Large-Construct Kit Qiagen  12462 
QIAGEN Plasmid Maxi Kit Qiagen  12162 
QIAprep Spin Miniprep Kit Qiagen  27104 
QIAquick Gel Extraction Kit  Qiagen 28704 
QIAquick PCR Purification Kit Qiagen 28104 
7.2.1.3 ENZYMES 
ABI PRISM® BigDye® Terminator v1.1 Ready Reaction mix Applied Biosystems 4337450 
AccuPrime™ Pfx SuperMix Invitrogen  12344-040 
Alkaline Phosphatise, Calf Intestinal (CIP) New England BioLabs M0290L 
REDTaq® ReadyMix™ PCR Reaction Mix Sigma-Aldrich R2523 
T4 DNA Ligase New England BioLabs M0202 
TaqMan(R) Universal PCR Master Mix Invitrogen  4304437 
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7.2.2 Bacterial Artificial Chromosomes 
7.2.2.1 HUMAN SOD1 BAC 
BACs were ordered from Children’s Hospital Oakland Research Institute (CHORI) BACPAC 
Resource Center (http://bacpac.chori.org/home.htm). 
Human SOD1 BAC (E10)   
Feature RP11-535E10 
Description Library: RP11 
Chromosome 21 
Chromosome position 32,928,199 – 33,097,333 
Contig NT_011512.11 
Contig position 18,590,070 - 18,759,204 
Span 169135 
Clone ends AZ301041.3 span: 467 
  AZ301042.2 span: 457 
Backbone pBACe3.6 at EcoRI sites  
5’ of SOD1 103,735bp 
3’ of SOD1 56,090bp 
7.2.2.1.1 Vector Map 
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7.2.2.2 C57BL/6J MOUSE SOD1 BACS  
BACs were ordered from Children’s Hospital Oakland Research Institute (CHORI) BACPAC 
Resource Center (http://bacpac.chori.org/home.htm). 
C57BL/6J Sod1 BAC 
(N21) 
  
Clone name RP24-363N21 
Library RP24 
Chromosome 16 
Chromosome 
position 
90,198,557 - 90,376,511 
Strain name C57BL/6J Male from Jackson Laboratory 
Contig NT_039625.7 
Contig position 24,903,634 - 25,081,588 
Span 177955 
Clone ends BH102801.1 span: 621 
  BH102799.1 span: 600 
Backbone pTARBAC1 at BamHI sites 
5’ of Sod1 22,431bp 
3’ of Sod1 149,943bp 
 
C57BL/6J Sod1 BAC (L18)   
Clone name RP24-238L18 
Library RP24 
Chromosome 16 
Chromosome position 90,078,076 - 90,243,716 
Strain name C57BL/6J Male from Jackson Laboratory 
Contig NT_039625.7 
Contig position 24,783,153 - 24,948,793 
Span 165641 
Clone ends BH111706.1 span: 310 
  BH111705.1 span: 511 
Backbone pTARBAC1 at BamHI sites 
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7.2.2.2.1 Vector Map 
 
7.2.2.3 C57BL/6N MOUSE SOD1 BAC  
Ordered from Riken Bioresource Center (http://dna.brc.riken.jp/en/NBRPB6Nbacen.html).  
C57BL/6N Sod1 BAC #1 (O19)   
Clone name B6Ng01-068O19 
Library B6Ng01 
Chromosome 16 
Strain name C57BL/6NCrlCrlj 
Chromosome position 90,169,050 - 90,326,628 
Contig   
Contig position   
Span 157579 
Clone ends DH887377.1 span: 964 
  DH887378.1 span: 1019 
Backbone pBACe3.6 at EcoRI sites 
5’ of Sod1 51,937bp 
3’ of Sod1 100,054bp 
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7.2.3 Bacterial Culture 
7.2.3.1 REAGENTS 
ElectroMAX DH10B Cells Invitrogen 18290-015 
Glycerol Sigma G5516 
L-arabinose Sigma A3256 
LB agar Sigma L3147 
Luria Broth (Miller’s Modification) Sigma L3397 
MAX Efficiency DH10B Competent Cells Invitrogen 18297.01 
7.2.3.2 ANTIBIOTICS 
Ampicillin (Amp) Sigma A0166 
Stock 100 mg/ml in 50% EtOH 
Working 50 ug/ml for BACs (2000x dilution) 
  100 ug/ml for high copy plasmid (1000 x dilution) 
Chloramphenicol (Cm) Sigma C7795 
Stock 30 mg/ml in 100% EtOH 
Working 15 ug/ml for BACs (2000x dilution) 
  50 ug/ml for high copy plasmid (600x dilution) 
Gentamicin (Gent) Sigma G1914 
Stock 10 mg/ml in H2O 
Working 10 ug/ml (1000x dilution) 
Kanamycin (Kana) Sigma K0254 
Stock 50 mg/ml in 0.9% NaCl (ready-made stock) 
Working 15 ug/ml for BACs (3300x dilution) 
  50 ug/ml for high copy plasmid (1000x dilution) 
Spectinomycin (Spc) Sigma S4014 
Stock 50 mg/mL in H2O 
Working 100 ug/mL for BACs and high copy plasmid (500x dilution) 
Streptomycin (Strep) Sigma S6501 
Stock 10 mg/ml in H2O 
Working 5 ug/ml (2000x dilution) 
Tetracycline (Tet) T7660 
Stock 5 mg/ml in 75% EtOH 
Working 3 ug/ml for pRedET (1650x dilution) 
  10 ug/ml for BACs and high copy plasmid (500x dilution) 
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7.2.4 Histology  
7.2.4.1 REAGENTS AND KITS 
0.5% eosin aqueous solution  Prolab 
 
10% Buffered Formal Saline 
Pioneer Research 
Chemicals PRC/R/2 
DPX mounting medium VWR 360292F 
Fluorescence mounting medium Dako S3023 
Harris’ haematoxylin for microscopy  Prolab  
 Histo-clear National Diagnostics HS-200  
Paraformaldehyde  Sigma-Aldrich  P6148-500g 
PBS-DA Phosphate Buffered Saline (Dulbecco A) 
tablets (no calcium of magnesium) pH7.3 Oxoid  BR0014G 
Pertex mounting medium Leica 3808706E 
Tissue-Tek® O.C.T. Compound Sakura 4583 
Vector M.O.M. Immunodetection Kit BASIC Vector Labs BMK-2202 
7.2.4.2 ANTIBODIES 
7.2.4.2.1 Primary Antibodies 
Anti-β-actin (mouse) Sigma A5441 
Mouse monoclonal anti-myosin heavy chain 2A  
Developmental Studies 
Hybridoma Bank  SC-71 
Mouse monoclonal anti-myosin heavy chain 2B  
Developmental Studies 
Hybridoma Bank  BF-F3 
Mouse monoclonal anti-myosin heavy chain, all 
but 2X  
Developmental Studies 
Hybridoma Bank  BF-35 
Mouse monoclonal anti-myosin heavy chain, 
slow, alpha and beta-  
Developmental Studies 
Hybridoma Bank  BA-D5 
Mouse monoclonal anti-neurofilament (165kDa)  
Developmental Studies 
Hybridoma Bank 2H3 
Mouse monoclonal anti-synaptic vesicle  
Developmental Studies 
Hybridoma Bank  SV2 
SOD100. Rabbit, pan-anti-SOD1 Enzo 
ADI-SOD-
100-D 
7.2.4.2.2 Secondary Antibodies 
Alexa Fluor 488 goat anti-mouse IgM (µ chain) 2mg/ml Invitrogen A21042 
Alexa Fluor 568 goat anti-mouse IgG (H+L) 2mg/ml Invitrogen A11004 
Alpha-bungarotoxin  Sigma T0195 
DAPI Sigma D8417 
Goat anti-mouse IgG-AP (alkaline phosphatase) Southern biotech 1070-04 
Poly-clonal goat anti-rabbit IgG-HRP Dako 
 Streptavidin Alexafluor 488 conjugated 2mg/ml  Invitrogen S32354 
 
7.2.5 Protein Biochemistry Reagents 
CDP-Star Roche 11685627001 
Pierce ECL Western Blotting Substrate Pierce  32106 
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Protease inhibitor cocktail Roache 05892791001 
Protein A agarose beads Sigma P3476 
RIPA Buffer Sigma R0278 
 
7.2.6 Equipment  
Bench top refrigerated microfuge. Heraeus Fresco 17 Thermo Fisher  
BrightTM cryostat 
  Electroporation cuvettes. 1mm black cap  Eurogentec CE-0001-50 
Electroporator. E.coli Pulser  Biorad  Model 1652104 
Grip-strength meter bio-GS3  Bioseb 
 MaxQ Mini 4450 compact bench top incubated shaker, 
analogue  Barnstead  SHKA4450-1CE 
PAP pen  VWR 72-0169 
Poly-lysine coated slides  VWR 631-0107 
polystyrene disposable cuvettes 1.6ml VWR  634-2501 
Standard bench top microfuge  Eppendorf Centrifuge 5424 
Thermomixer compact  Eppendorf 5350 000.013 
Ventana automated immunohistochemical staining machine using a basic diaminobenzidine 
detection system according to the manufacturer’s instructions (Ventana Medical Systems, 
Tucson, AZ)  
7.2.7 Prepared Solutions and Materials 
7.2.7.1 LB MEDIA 
For liquid bacterial cultures Luria Broth (LB) Miller’s Modification was made according to 
manufacturer’s instruction and autoclaved to sterilise. Once sterilised LB was stored 
indefinitely in sealed glass bottles as room temperature. Antibiotics were added only 
immediately before use and at concentrations give in table 7.1 above.  
7.2.7.2 LB AGAR PLATES 
LB agar was prepared according to manufacturer’s instructions and autoclaved to sterilise. 
Once cooled to around 50°C antibiotics were added using concentrations given in table 7.1 
above and agar was mixed thoroughly. 25ml was used per petri dish. Once set and dried at 
room temperature plates were stored at 4°C for up to 1 month.  
7.2.7.3 BACTERIAL FREEZING MEDIA 2X 
LB Miller’s Modification was made according to manufacturer’s instructions, but replacing 
ddH2O with 1:1 glycerol:ddH2O. Medium was autoclaved to sterilise and kept indefinitely in 
sealed glass bottles at room temperature.  
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7.2.7.4 TRIS-EDTA-CITRATE BUFFER PH 7.8 10X 
For a 10X stock solution: 55g EDTA, 2.5g Trizma Base, 3.2g Tri-sodium citrate was dissolve in 1 
litre ddH2O. pH to 7.8 using 2M hydrochloric acid to reduce pH and 2M sodium hydroxide to 
increase pH. Store at 4°C.  
7.2.7.5 TRIS (0.5M) BUFFERED SALINE (9%) 10X 
 
30.29g TRIS base, 45g Sodium chloride, 15ml ddH2O. pH to 7.8 using concentrated hydrochloric 
acid. Make upto 500ml with ddH2O 
7.2.7.6 4% PARAFORMALDEHYDE IN DULBECCO’S PHOSPHATE BUFFERED SALINE  
40g paraformaldehyde (PFA, Sigma-Aldrich) was dissolved in 1L ddH2O by heating to 60°C and 
stiring for 30mins. 5-15µl 5M NaHO was then added until PFA was completely dissolved. Ten 
PBS (Dulbecco A, pH 7.3) tablets (Oxoid) were then added and stirred until dissolved. The 
solution was then brought back down to room temperature and filter sterilised using a 0.45µM 
Stericup (Millipore). If not for use within 24 hours, sterilised PFA was aliquot and stored at -
20°C. Aliquots were defrosted at 4°C overnight.  
7.2.7.7 GALLOCYANINE STAIN 
1.5g gallocyanine (C.I. 51030) 
50g chromium potassium sulphate 
500mL ddH2O 
Dissolve chromium potassium sulphate in water by heating. Add gallocyanine and boil for 20-
30 mins. Cool to room temperature before filtering and adding ddH2O to return the volume to 
500mL.  
7.2.7.8 LAEMMLI SAMPLE BUFFER - 20 ML 
Final 1X concs:  
60 mM Tris-Cl pH 6.8, 2% SDS, 10% glycerol, 5% β-mercaptoethanol, 0.01% bromophenol blue 
2X sample buffer: 
1.6 ml 1.5 M Tris-Cl pH 6.8  
4 ml glycerol  
2 ml β-mercaptoethanol  
0.8 g SDS (sodium dodecyl sulfate / sodium lauryl sulfate)  
0.4 ml 1% bromophenol blue (Sigma 3-8026 
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** CAUTION ** β-mercaptoethanol and SDS powder are hazerdous. Prepare solution in a 
ventilated fume hood. 
1) Add 0.4 ml of 1% bromophenol blue to 1.6 ml of 1.5 M Tris-Cl pH 6.8. 
2) Add 4ml of glycerol and mix. 
3) Add 0.8 g of SDS and mix (the SDS will take a few minutes to dissolve). 
4) top uptp 18ml (11.2ml ddH20) 
5) Aliquot (450ul aliquots) and store at -20°C. 
Add β-mercaptoethanol to 10% when thawed (50ul per aliquot)  
7.2.7.9 1.5 M TRIS-CL PH 6.8 – 50ML  
Reagents: 
9.0825 g Tris base  
35 ml ddH2O  
6 ml Concentrated HCl (37.2% - 12.1M)  
** NOTE: Many electronic pH Meters are unable to accurately determine the pH of 
concentrated Tris solutions. Be sure to use an appropriate probe. ** 
Directions: 
1) Mix 9.0825 g of Tris base with 35 ml of ddH2O by stirring. 
2) Adjust the pH by adding the concentrated HCl. Begin by adding 5 ml and then fine adjust if 
needed. 
3) Add ddH2O until final volume is 50ml. 
4) Autoclave to sterilize. 
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7.3 APPENDIX 3 - PREMATURE DEATHS FOR THE CROSS-SEEDED SOD1 TRANSMISSION EXPERIMENT 
Full breakdown of premature deaths for the cross-seeded SOD1 transmission experiment split by inocula and time-point group 
Inocula 
Time- 
point 
(days 
post 
inoc’) 
Inoculation / 
anaesthetic Scratching 
weight 
loss 
Found 
dead 
Swollen 
abdomen 
Abnormal 
breath-
ing 
Hind- 
limb 
paralysis 
Impaired 
righting 
reflex 
Missing 
presumed 
dead 
Culled 
in 
error 
Pro- 
lapsed 
rectum Tumour 
TOTAL 
premature 
deaths 
Reached 
cull date 
Non-
inoculated 7                 3       3 8 
Non-
inoculated 90                         0 10 
Non-
inoculated 180                         0 10 
Non-
inoculated 365                   1     1 9 
Non-
inoculated 660   2 7 1               2 12 8 
PBS 7                         0 10 
PBS 90   1                     1 9 
PBS 180 1                       1 9 
PBS 365 2 2     1         1     6 9 
PBS 660 1 4 3 1         1   1   11 9 
m-NTg 7                         0 10 
m-NTg 90                         0 10 
m-NTg 180 4                       4 9 
m-NTg 365   2 1                   3 7 
m-NTg 660 1 4 8   1   1     1     16 4 
m-TgWT 7                         0 10 
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Inocula 
Time- 
point 
(days 
post 
inoc’) 
Inoculation / 
anaesthetic Scratching 
weight 
loss 
Found 
dead 
Swollen 
abdomen 
Abnormal 
breath-
ing 
Hind- 
limb 
paralysis 
Impaired 
righting 
reflex 
Missing 
presumed 
dead 
Culled 
in 
error 
Pro- 
lapsed 
rectum Tumour 
TOTAL 
premature 
deaths 
Reached 
cull date 
m-TgWT 90                         0 10 
m-TgWT 180                         0 10 
m-TgWT 365   5 1                   6 4 
m-TgWT 660 2 6 7 2       1         18 2 
m-TgG93A 7                         0 10 
m-TgG93A 90                         0 10 
m-TgG93A 180                         0 10 
m-TgG93A 365   2                     2 8 
m-TgG93A 660 1 7 10             1     19 3 
h-cntrl1 7 1                       1 9 
h-cntrl1 90 3               1       4 9 
h-cntrl1 180 1                       1 9 
h-cntrl1 365   1 1                   2 8 
h-cntrl1 660 3 2 13   1 1             20   
h-cntrl2 7 1                       1 9 
h-cntrl2 90 1                       1 9 
h-cntrl2 180 5                       5 10 
h-cntrl2 365 1   1 1                 3 7 
h-cntrl2 660 1 7 5                   13 2 
h-D101G 7 1                       1 9 
h-D101G 90                         0 10 
h-D101G 180 2                       2 10 
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Inocula 
Time- 
point 
(days 
post 
inoc’) 
Inoculation / 
anaesthetic Scratching 
weight 
loss 
Found 
dead 
Swollen 
abdomen 
Abnormal 
breath-
ing 
Hind- 
limb 
paralysis 
Impaired 
righting 
reflex 
Missing 
presumed 
dead 
Culled 
in 
error 
Pro- 
lapsed 
rectum Tumour 
TOTAL 
premature 
deaths 
Reached 
cull date 
h-D101G 365   2                     2 8 
h-D101G 660 3 9 6 1       1         20   
h-I113T 7                         0 10 
h-I113T 90 1                       1 9 
h-I113T 180 1                       1 9 
h-I113T 365 2 5                     7 3 
h-I113T 660 5 4 10 2 1     1         23 1 
TOTAL   44 65 73 8 4 1 1 3 5 4 1 2 211 349 
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7.4 APPENDIX 4 - KAPLAN-MEIER SURVIVAL GRAPHS OF TGWT;SOD1KO 
MICE SPLIT BETWEEN MOUSE AND HUMAN INOCULA  
 
Kaplan-Meier survival graph of TgWT;Sod1ko mice split between mouse and human inocula  
Mice from the 2 longest time-points (365 and 660-days post-inoculation) that were culled 
before their scheduled cull date due to weight loss, self-inflicted scratching wounds, hind limb 
paralysis and impaired righting reflex were included in the analysis.  
Data are split over 2 graphs to aid visualisation.  
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7.5 APPENDIX 5 - RELATIVE TRANSGENE COPY NUMBER AND OTHER 
EXCLUSION FOR INDIVIDUAL ANIMALS 
 
animal ID genotype 
mean 
ΔΔCT 
RQ 
std 
dev 
ΔΔCT 
RQ 
Other exclusions 
EF14/115.3d TgG93A;Sod1wt 1.3574 0.0514 excluded from weights and survival as wasn't weighed daily 
EF14/115.4b TgG93A;Sod1wt 1.1010 0.0973   
EF14/143.1b TgG93A;Sod1wt 1.1919 0.1031   
EF14/145.2g TgG93A;Sod1wt 1.2268 0.0973   
EF14/147.1b TgG93A;Sod1wt 1.2354 0.1276   
EF14/157.1b TgG93A;Sod1wt 1.0086 0.1230   
EF14/157.1e TgG93A;Sod1wt 1.4492 0.1083 excluded from weights and survival as wasn't weighed daily 
EF14/157.2c TgG93A;Sod1wt 1.0472 0.0850   
EF14/176.3b TgG93A;Sod1wt 2.0437 0.1044   
EF14/185.4f TgG93A;Sod1wt 1.5086 0.2259   
EF14/193.1b TgG93A;Sod1wt 1.2661 0.1127   
EF14/193.1d TgG93A;Sod1wt 0.9832 0.1325   
EF14/197.1a TgG93A;Sod1wt 1.3250 0.1031   
EF14/200.1b TgG93A;Sod1wt 1.3323 0.0417   
EF14/200.4g TgG93A;Sod1wt 0.9412 0.0930   
EF14/205.3c TgG93A;Sod1wt 0.9571 0.0604   
EF14/211.2a TgG93A;Sod1wt 1.0634 0.1038   
EF14/213.2a TgG93A;Sod1wt 0.9941 0.0743   
EF14/208.3c TgG93A;Sod1wt 1.0225 0.0498   
EF14/214.1b TgG93A;Sod1wt 0.8470 0.1604   
EF14/114.1a TgG93A;Sod1ko 1.3005 0.1075   
EF14/114.1c TgG93A;Sod1ko 1.0565 0.0572 excluded from weights and survival as wasn't weighed daily 
EF14/114.2b TgG93A;Sod1ko 1.2804 0.1829   
EF14/114.2c TgG93A;Sod1ko 1.1921 0.2298 excluded from weights and survival as wasn't weighed daily 
EF14/113.4c TgG93A;Sod1ko 1.1287 0.0345   
EF14/121.1b TgG93A;Sod1ko 1.0862 0.0598   
EF14/131.1e TgG93A;Sod1ko 1.2263 0.0409   
EF14/131.1g TgG93A;Sod1ko 1.2811 0.2507   
EF14/130.1a TgG93A;Sod1ko 1.1084 0.0717   
EF14/132.1c TgG93A;Sod1ko 1.3881 0.1810   
EF14/124.2a TgG93A;Sod1ko 1.1574 0.0459   
EF14/125.2b TgG93A;Sod1ko 1.0702 0.0939   
EF14/130.3d TgG93A;Sod1ko 1.0635 0.0374   
EF14/136.1b TgG93A;Sod1ko 1.0770 0.1205   
EF14/143.1a TgG93A;Sod1ko 1.1568 0.0642   
EF14/145.1a TgG93A;Sod1ko 1.2352 0.0757   
EF14/151.1c TgG93A;Sod1ko 1.1880 0.0960   
EF14/145.2b TgG93A;Sod1ko 1.1579 0.0818   
EF14/176.3a TgG93A;Sod1ko 1.1937 0.0433   
EF14/186.2a TgG93A;Sod1ko 1.2780 0.0813 excluded from weights- missing data 
EF14/186.2b TgG93A;Sod1ko 1.2890 0.0691 excluded from weights- missing data 
EF14/185.3b TgG93A;Sod1ko 1.4598 0.0604   
EF14/192.4d TgG93A;Sod1ko 1.1827 0.1258   
EF14/197.1c TgG93A;Sod1ko 1.2842 0.1079   
EF14/197.1d TgG93A;Sod1ko 1.2642 0.1156   
EF14/202.2c TgG93A;Sod1ko 1.0634 0.1251   
EF14/202.2d TgG93A;Sod1ko 1.0335 0.0789   
EF14/200.4h TgG93A;Sod1ko 1.0103 0.0310   
EF14/206.1a TgG93A;Sod1ko 1.1998 0.0860   
EF14/206.1d TgG93A;Sod1ko 1.3075 0.0862   
EF14/205.1a TgG93A;Sod1ko 1.2728 0.0253   
EF14/205.3f TgG93A;Sod1ko 0.9987 0.1361   
EF14/210.1a TgG93A;Sod1ko 0.8438 0.0323   
EF14/213.1d TgG93A;Sod1ko 1.1140 0.0834   
EF14/206.5b TgG93A;Sod1ko 1.0848 0.1147   
EF14/211.2d TgG93A;Sod1ko 1.0585 0.0796   
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animal ID genotype 
mean 
ΔΔCT 
RQ 
std 
dev 
ΔΔCT 
RQ 
Other exclusions 
EF14/210.3g TgG93A;Sod1ko 0.9206 0.0300   
Excluded 
    EF14/140.1a TgG93A;Sod1wt 0.6162 0.0549   
EF14/140.1e TgG93A;Sod1wt 0.6740 0.0176   
EF14/140.2a TgG93A;Sod1wt 0.7329 0.0274   
EF14/140.3b TgG93A;Sod1wt 0.6725 0.0470   
EF14/140.3e TgG93A;Sod1wt 0.7021 0.0185   
EF14/141.1b TgG93A;Sod1wt 0.6410 0.0850   
EF14/154.2a TgG93A;Sod1wt 0.6413 0.0624   
EF14/155.1a TgG93A;Sod1wt 0.5800 0.0383   
EF14/167.2d TgG93A;Sod1wt 0.6383 0.0475   
EF14/167.2f TgG93A;Sod1wt 0.6136 0.0243   
EF14/180.1a TgG93A;Sod1wt 0.6338 0.0546   
EF14/198.1c TgG93A;Sod1wt 0.7725 0.1376   
EF14/126.4d TgG93A;Sod1ko 0.1121 0.0090   
EF14/140.1d TgG93A;Sod1ko 0.6474 0.0815   
EF14/141.1e TgG93A;Sod1ko 0.6472 0.0548   
EF14/154.3a TgG93A;Sod1ko     Alive at 1 year. Not assayed for copy number 
EF14/154.4c TgG93A;Sod1ko     Alive at 1 year. Not assayed for copy number 
EF14/155.2a TgG93A;Sod1ko 0.6257 0.0088   
EF14/161.1d TgG93A;Sod1ko 0.7445 0.0753   
EF14/169.2e TgG93A;Sod1ko 0.6456 0.0290   
EF14/182.3c TgG93A;Sod1ko 0.6034 0.0802   
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7.6 APPENDIX 6 - FIBRE TYPING MONTAGES 
Transverse sections of hind limb muscles, extensor digitorum longus (EDL) and tibialis anterior 
(TA) were immunostained for myosin heavy chain isoforms as labelled. Antibodies are in 
brackets.  
Scale bars of all images are 500 µm 
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7.6.1 EDL Fibre Typing: Myosin Heavy Chain type 2A and 2B 
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7.6.2 EDL Fibre Typing: Myosin Heavy Chain Type 1 and 2B 
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7.6.3 TA Fibre Typing: Myosin Heavy Chain Type 2A and 2B 
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7.6.4 TA Fibre Typing: Myosin Heavy Chain Type 1 and 2B 
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